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Abstract  
 
Epidemiological studies in populations with a high burden of pulmonary 
tuberculosis (PTB), including the Burden of Obstructive Lung Disease (BOLD) 
survey performed in Cape Town, South Africa in 2005, have suggested an 
association between PTB and the development of chronic airflow obstruction 
(CAO). The nature of this association and mechanisms responsible for CAO 
has not been previously studied, but likely includes: airway narrowing (from 
bronchiolitis, bronchiectasis or persistent low-grade inflammation associated 
with healed PTB); and reduced lung elastic recoil from coexistent 
emphysema. The present study investigated the structure and function of the 
lung in subjects with tuberculosis-associated obstructive pulmonary disease 
(TOPD) identified in BOLD 2005, and aspects of its natural history and 
response to treatment. It also examined the diagnostic performance of the 
standardised and internationally accepted BOLD method for estimating the 
prevalence of COPD in community-based surveys, with specific reference to 
misdiagnosis that might lead to overestimates of prevalence.  
 The study of TOPD was based on 103 of 196 subjects identified with 
CAO from BOLD 2005, and re-examined in 2010. These were categorised by 
history and chest CT scan into three groups: no previous tuberculosis (NPTB, 
n=31, 30.1%); probable previous tuberculosis (PrPTB, n=33, 32.0%); or 
definite previous tuberculosis (DPTB, n=39, 37.8%). In spite of similar 
demographics, smoking history, symptoms (MRC Dyspnoea score), health 
status (St George’s Respiratory Questionnaire score) and severity of CAO 
(mean post-bronchodilator FEV1, FVC and FEV1:FVC), subjects with DPTB 
had 16.3% lower diffusing capacity (DLCO) and 22.2% lower IC, than NPTB 
subjects. Multivariate analysis of quantitative CT scan findings confirmed that 
DPTB subjects had 6.5% higher gas trapping scores, 0.3% higher fibrosis 
scores, and 3.5% higher emphysema scores than subjects with NPTB, while 
the Pi10 – a measure of airway wall thickness – was similar between groups. 
This pattern suggests that a major site of CAO in TOPD is the smaller airways 
and bronchioles. This may reflect widespread involvement of the bronchial 
mucosa in PTB, resulting in cicatricial narrowing and even obliteration of 
airways. Both ventilation:perfusion mismatch and attenuation of the 
pulmonary vasculature adjacent to the fibrosed bronchi may contribute to the 
reduced DLco. 
 Of the original cohort with CAO, 45 (23.0%) subjects died during the 
five-year follow-up period, and, on multivariate analysis, only age and GOLD 
stage 4 disease in 2005 predicted death. The rate of decline in FEV1 was 
similar in subjects with and without PPTB, as well as various severity stages 
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of COPD. Treatment responses were also similar in subjects with and without 
PPTB.  
 The study of the diagnostic performance of the BOLD method 
confirmed significant misdiagnosis. Although the questionnaires performed 
acceptably, CAO was not confirmed in 15.1% of the cohort at follow-up, and 
a similar proportion of the cohort were found to have chronic asthma, some 
of which had CAO. Studies of the handheld spirometer specified by BOLD 
(the EasyOne ndd), confirmed significant variation between tests performed 
on the same spirometer and in a same-day comparison with office-based 
spirometry. In the latter comparison, the FEV1 differed by ≥150 mL in 22.5%, 
resulting in reclassification of COPD status in 16.7% of subjects. Between-
visit variability of spirometry performed with the EasyOne ndd, less than one 
month apart, resulted in reclassification of 11 of 56 subjects (19.6%), and in 
16 (28.6%), the FEV1 differed by >150 mL between visits. These findings 
raise questions: Whether the BOLD method should base the diagnosis of 
COPD on one result and whether BOLD estimates of COPD prevalence 
should be corrected for an anticipated over-diagnosis resulting from the 
inclusion of subjects with asthma. 
 Overall, the results of the TOPD studies supported the hypothesis that 
chronic airflow obstruction in patients with a history of previous PTB differs in 
terms of pathophysiology and radiology from patients with COPD without 
this risk factor, and should be considered as a phenotype of COPD. This 
designation will ensure that it is identified and not simply passed off as a late 
complication of PTB, but will be the subject of further research examining 
aspects of its pathogenesis, prevention and effective treatment. It is hoped 
that this is recognised as further reason for renewed efforts to control 
tobacco use and tuberculosis worldwide.  
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Chapter 1. Introduction 
 
Chronic obstructive pulmonary disease (COPD) is now recognised as a 
leading cause of death worldwide; by 2030, it is predicted to rank third. In the 
developed world, it is closely associated with tobacco smoking and can, 
thus, be expected to decline as the prevalence of smoking declines. 
However, currently and in the future, the greatest burden of COPD is and will 
be experienced in low-income and middle-income countries, in part because 
of smoking rates but also because of the promotion of smoking by the 
tobacco industries in these countries. However, it is clear that other factors 
that are more prevalent in developing countries, either alone or together with 
smoking, influence both the development and severity of COPD. Recognised 
risk factors are: exposure to smoke from biomass-fueled fires; childhood 
infections; poor nutrition before birth and during infancy; and passive 
exposure to the smoke of parents and partners. In addition, epidemiologic 
studies have confirmed a link between pulmonary tuberculosis (TB) and the 
later development of COPD, but few studies have examined the mechanisms 
of disease and nature of this association, in what respects it differs from the 
usual form of COPD and whether it should be regarded as a distinct entity or 
phenotype of COPD, requiring different strategies for prevention and 
treatment. These questions form the basis of the present study.  
 The present study builds on the findings of two previous projects 
undertaken by researchers from the University of Cape Town Lung Institute 
and Desmond Tutu TB Centre (Stellenbosch University), in two predominantly 
low-income suburbs of Cape Town, South Africa – Ravensmead and Uitsig. 
 Three major observations of these projects were as follows: First, the 
prevalence of COPD estimated using the Burden of Obstructive Disease 
(BOLD) method, was higher in these suburbs than in any other of the 12 sites 
surveyed in other countries of the world. Second, that although the 
proportion of subjects reporting cigarette smoking was high, the mean total 
pack-year exposure of each subject was the lowest among the 12 sites, 
 2 
suggesting that factors other than tobacco smoke exposure are involved. 
Finally, there was a strong association between a reported history of previous 
TB and the presence of COPD. Almost half (49.2%) of all adults over 40 years 
of age who reported a previous history of TB, had spirometric evidence of 
airflow obstruction compatible with the diagnosis of COPD.  
 The association between chronic airflow obstruction (CAO) and 
previous pulmonary tuberculosis (PPTB) has become increasingly 
recognised. A number of recent well-designed epidemiological surveys have 
confirmed the strength of this association, and some authors have concluded 
that PPTB is more strongly associated with CAO than either smoking or 
biomass fuel exposure. However, there is a difference of opinion on whether 
CAO in people with PPTB should be regarded as a variant or phenotype of 
COPD, or whether the CAO is explained by major structural damage to a 
large portion of the lungs with the usual features of ‘fibro-cystic change’ 
comprising: bronchiectasis, volume loss, broad bands of fibrosis and 
abnormal air spaces (cysts).  
 The research described in the present study aimed to address some 
of the questions concerning the relationship between healed pulmonary TB 
and COPD. It comprised three main parts. The first was a follow-up study, 
performed in 2010, of subjects diagnosed with COPD in the BOLD 2005 
study, to identify those in whom features of PPTB were present, and, using 
detailed tests of lung physiology and high-resolution radiologic imaging of 
the lungs to compare and contrast features and potential mechanisms of 
CAO in subjects with and without PPTB. Secondly, the interval between 
surveys permitted a limited study of the natural history of CAO in those with 
and without PPTB. Finally, as there are no descriptions on how CAO 
associated with PPTB should be treated, and the efficacy of usual treatment 
for COPD, a limited trial of treatment compared responses to treatment in 
these groups of subjects. 
 The Follow-up study provided two other important and novel research 
opportunities. First, the opportunity to assess the diagnostic performance of 
the BOLD method in providing estimates of the prevalence of COPD in 
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community-based surveys, which is its primary use specifically to estimate 
the magnitude of misdiagnosis resulting from the presence of subjects with 
asthma in the sample. Second, to assess the performance (accuracy and 
repeatability) of the BOLD questionnaire and method of spirometry with the 
potential that this information would inform the use and interpretation of 
results obtained in BOLD surveys globally.  
 This dissertation begins with a Literature Review (Chapter 2) of COPD, 
specifically its prevalence, associations, phenotyping, mechanisms of 
disease and natural history relevant to the present study. The BOLD and 
other methods used in the present study are also reviewed. Chapter 3 
provides the hypothesis and objectives of the work, and Chapter 4 describes 
detailed methodology. Chapter 5 provides data from the Follow-up 2010 
study; mortality, demographics and lung physiology. The analysis of the 
BOLD method is provided in Chapter 6, including diagnostic accuracy and 
performance of the BOLD instruments. Chapter 7 is dedicated to the 
classification of subjects according to their PPTB status, and rationale for the 
final classification used. Chapters 8 and 9 present the comparison of lung 
physiology and imaging data, respectively, between subjects with and 
without PPTB. Chapter 10 provides the results of multivariate analysis of 
associations that point to the site of airflow obstruction in PPTB. The final 
chapter discusses the important findings of this study, their implications and 
application. 
Chapter 2. Literature Review 
 
2.1. Introduction 
 
This review provides the background to the work described in this study 
beginning with a current view of the definition of chronic obstructive 
pulmonary disease (COPD), epidemiologic data on risk factors for COPD and 
evidence supporting tuberculosis (TB) as a cause of chronic airflow 
obstruction (CAO). It also considers the evolving field of phenotyping in 
COPD, mechanisms of airflow obstruction in COPD and in post-tuberculosis 
lung disease; and new advances in lung imaging to identify and quantitate 
lung pathology in COPD and its relationship to lung physiology.  
 
2.2. Definitions of COPD 
 
Chronic obstructive pulmonary disease is a common respiratory disorder that 
presents in adult life and is characterised by airflow obstruction. Historically, 
a number of definitions for COPD have been proposed and these have 
evolved with new appreciation of facts about its causation, natural history 
and pathophysiology. 
 The position paper of the combined American Thoracic Society 
(ATS)/European Respiratory Society (ERS) taskforce published in 2004 
defined COPD as: ‘Chronic obstructive pulmonary disease (COPD) is a 
preventable and treatable disease state characterised by airflow limitation that 
is not fully reversible. The airflow limitation is usually progressive and is 
associated with an abnormal inflammatory response of the lungs to noxious 
particles or gases, primarily caused by cigarette smoking. Although COPD 
affects the lungs, it also produces significant systemic consequences.’1,2  
Literature Review  
 5 
 The NICE guidelines (UK) similarly stated: ‘Chronic obstructive 
pulmonary disease (COPD) is characterised by airflow obstruction. The airflow 
obstruction is usually progressive, not fully reversible and does not change 
markedly over several months. The disease is predominantly caused by 
smoking.’3 
 The South African Thoracic Society defined COPD as: ‘a disease state 
resulting from an abnormal inflammatory response of the lungs to irritant 
particles and gases, with resultant progressive airflow limitation that is 
partially reversible. It is associated with lung hyperinflation and systemic 
effects. The pathological correlates are chronic bronchitis and emphysema.’4 
 Finally, the most widely cited definition for COPD is that of the Global 
initiative for chronic Obstructive Lung Disease (GOLD), which, in 2013, 
defined COPD as: ‘a common preventable and treatable disease, 
characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways 
and the lungs to noxious particles or gases.’5 
 Common to all definitions is the presence of airflow ‘obstruction’ or, 
the more accurate term ‘airflow limitation’ measured by spirometry. The 
measure of airflow limitation required to define this is a reduced ratio of 
forced expiratory volume in one second (FEV1) to forced vital capacity (FVC), 
but there is controversy concerning the threshold value that defines 
impairment.6 Currently, there are two approaches to defining COPD using the 
FEV1:FVC ratio. 
 The first method (‘fixed-ratio’ method) defines irreversible airflow 
obstruction as FEV1:FVC <0.7, regardless of subject age. The alternative 
approach defines COPD using the lower limit of normal (LLN) cut-point based 
on predicted FEV1:FVC values from a reference population.7 For this 
definition, the fifth percentile for the subject’s age and gender is 
conventionally used as the LLN cut-point, corresponding to a standard 
deviation score of <–1.645 for the population. Both the fixed-ratio and LLN 
methods have limitations.  
Chapter 2 
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 First, as part of the normal aging process both FEV1 and FVC decline 
over time but as FEV1 declines more rapidly than the FVC, the FEV1:FVC 
decreases with age, even in the absence of disease. Thus, using a fixed ratio 
cut-point will result in under diagnosis in younger subjects (whose ratio 
should be higher, and for whom 0.7 is lower than the LLN), and over 
diagnosis of COPD in the elderly (especially those over 70 years of age). For 
example, in a study of 71 asymptomatic, Norwegian adults, aged 70 years 
and older, who had never smoked, 35% were reported to have a FEV1:FVC 
<0.7. In those over 80 years, 50% would have been classified as having 
‘COPD’, using the fixed-ratio method.8 In contrast, the LLN method is a more 
accurate measure for defining abnormality – the presence of airflow 
limitation. Thus, it is argued that for clinical purposes the LLN is the more 
relevant measure, and correlates better with the presence of disease. For 
example, Akkermans et al demonstrated that subjects who had an FEV1:FVC 
above the LLN but <0.7, did not show the same accelerated decline in FEV1 
observed in subjects with a ratio below the LLN. This finding supports the 
hypothesis that COPD is over-diagnosed when the fixed ratio method is 
employed, and may lead to unnecessary concern and overtreatment, 
particularly in the elderly.9  
 Use of the LLN definition is, however, limited by the requirement of 
population reference data to derive prediction equations. Such data are 
frequently unavailable for the population under study. Interpreting findings 
using reference equations from other ethnic groups may introduce 
inaccuracy. For example, use of the NHANES III reference equations derived 
from a US population, may lead to misclassification when applied to low 
socioeconomic African or Asian populations.  
 Concern about the lack of appropriate reference equations for specific 
populations and ethnic groups has led to recommendations for the use of the 
fixed-ratio definition, over the LLN definition. Organisations that have 
adopted this approach include: the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD); National Clinical Guideline Centre (NICE – UK); 
American Thoracic Society (ATS)/European Respiratory Society (ERS); and 
Literature Review  
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the South African Thoracic Society (SATS).2–5 Two additional benefits of using 
the fixed ratio are the ability to directly compare different populations and the 
simplicity of use for clinicians working in the field.6 
 Direct comparison between the fixed-ratio and LLN methods in cross-
sectional studies have yielded mixed results; with two studies demonstrating 
better correlation between the presence of COPD and the fixed FEV1:FVC 
definition,10,11 while in two other studies the LLN definition performed 
better.12,13 Unfortunately all four studies used self-reporting of COPD by 
questionnaire and not physician assessment as the basis for the COPD 
diagnosis. 
 Authors of the NICE guidelines have attempted to limit the number of 
‘normal’ subjects erroneously labelled as COPD (i.e. false positives), by 
stipulating that, in addition to an FEV1:FVC <0.7, the FEV1 must be less than 
80.0% predicted.3 This criteria is not included in the GOLD guidelines, and 
subjects with an FEV1:FVC <0.7 and FEV1 >80% predicted are labelled by 
GOLD as stage 1 disease.5 
 The choice of spirometric criteria used to define COPD has 
implications on clinical patient management, epidemiological research and 
health planning. In clinical practice, COPD has traditionally been under 
recognised and spirometry has been under utilised (discussed in more detail 
below). This has prompted GOLD to recommend using the simpler fixed-ratio 
method in an attempt to promote awareness and usability (with some 
success), while some commentators claim that the inevitable over diagnosis 
is ‘not a major problem’.6 However, GOLD are at pains to emphasise that in 
clinical practice the diagnosis of COPD in an individual is not solely based on 
spirometry, but requires both exposure to a risk factor and/or symptoms. 
Indeed, the latest GOLD guidelines recommend an assessment of three 
domains: impairment (exercise capacity and symptoms), frequency (risk) of 
COPD exacerbations and spirometry, emphasising a departure from previous 
over-reliance on spirometry alone.5  
 The majority of recent, large epidemiological studies (discussed in 
detail below) have used the fixed-ratio method to define airflow obstruction 
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without consideration of symptoms, exposure, or alternate diagnoses. Such 
methodology is likely to overestimate disease in the elderly and 
underestimate it in younger subjects.6 Additionally, diagnostic accuracy may 
be worsened by the inclusion of subjects with obstructive lung diseases 
other than COPD (e.g. asthma). Despite these criticisms, the use of the fixed 
ratio in epidemiological research has been defended, as above, in that it 
allows comparison between population groups, while the alternative use of 
the LLN definition requires reference ranges, which introduces potential for 
bias.14 However, health planners who base their calculations on epidemiology 
performed using the fixed ratio in surveys need to be aware that the 
estimates might be inflated.15 
  A further point of contention is the use of forced vital capacity (FVC) as 
the denominator in spirometry (i.e. FEV1:FVC). The ERS consensus 
statement in 1995 proposed using the greater of either the FVC or the slow 
vital capacity (SVC) to define airflow obstruction.16 Most modern guidelines – 
including GOLD, NICE, ATS/ERS and SATS – recommend only using FVC as 
the denominator to define airflow obstruction.2–5 In normal subjects, the FVC 
is generally greater than a SVC; but the converse is true in those with 
moderate or severe airflow limitation, particularly those with air trapping 
(dynamic hyperinflation).15 Thus, use of the FEV1:SVC ratio in normal subjects 
will under diagnose airflow obstruction, while the FEV1:FVC is associated 
with under diagnosis in subjects with COPD. The difference between FVC 
and SVC is reduced, but not abolished, by use of a bronchodilator prior to 
spirometry.15 
 It is debatable whether pre-bronchodilator (pre-BD) or post-
bronchodilator (post-BD) spirometry should be used to diagnose COPD. 
Most, but not all, recent epidemiological studies have used post-BD 
spirometry,14,17,18 which is recommended by GOLD and other major 
professional groups.2–5 The GOLD strategy recommends the use 
administration of either 400 mcg of beta2-agonist, 160 mcg anticholinergic or 
a combination thereof prior to testing. Post-BD spirometry has been shown 
to be more reproducible than pre-BD spirometry and a better predictor of 
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high-risk clinical disease (a likelihood ratio of 2.122 for pre-BD, and 1.899 for 
post-BD spirometry), as well as lowering the observed ‘prevalence’ of 
disease in epidemiological studies, compared with pre-BD spirometry.3 A 
disadvantage of the post-BD is operational issues such as the time and cost 
implications of administering and waiting for maximal bronchodilation. 
However, interpretation of results of studies must be cautious when 
diagnosis of COPD is based solely on pre-BD spirometry. 
 The GOLD classification is the most widely used system for grading 
the severity of lung function impairment. GOLD stage 1 (mild disease) is 
defined as an FEV1 >80% predicted, GOLD stage 2 (moderate disease) as 
50%≤ FEV1 <80% predicted, GOLD stage 3 (severe disease) as 30%≤ FEV1 
<50% predicted, and GOLD stage 4 (very severe disease) as FEV1 <30% 
predicted.5 Thus, by definition, GOLD staging requires the uses of reference 
equations. The Burden of Obstructive Lung Disease (BOLD) investigators 
elected to use this GOLD classification as well as NHANES III prediction 
equations to categorise severity of airflow limitation.  
 Vollmer et al have suggested an alternative to both the fixed-ratio and 
LLN methods for defining COPD. They proposed the adoption of a series of 
separate fixed-ratio cut points for different age groups. They thought that this 
would overcome some of the limitations of the fixed ratio definition, as well 
as abrogating the need for reference data. They argued that the advantage of 
simplicity for the fixed-ratio method is lost as soon as measurement of 
clinical severity or stage of disease is attempted (i.e. GOLD stage 2 or 
higher)19 This recommendation has not been widely acknowledged or 
adopted in the literature or guidelines.  
 
2.3. Global burden of COPD 
 
Much work has recently been performed in defining the global burden of 
disease. COPD is ranked third as a cause of mortality worldwide (after 
ischaemic heart disease and stroke), with age-standardised death rates of 
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43.8 per 100 000.20 The World Health Organization estimates that 64 million 
people suffered with COPD in 2004, with in excess of three million deaths 
occurring in 2005. Additionally, it is estimated that 90% of COPD deaths 
occur in low-income and middle-income countries.21 Apart from mortality, 
COPD is projected to rank fifth in terms of global disease burden by 2020. As 
a cause of disability-adjusted life years (DALYs), COPD will be the seventh 
leading cause by 2030, from a ranking of twelfth in 1990.22 Despite the high 
global disease burden, COPD remains a largely under-diagnosed and under-
recognised condition in the general population.23 
  In the last decade, several epidemiological studies have been 
performed to determine the prevalence rates of COPD in various population 
groups. These data show significant global and regional variation, which is in 
part due to differences in survey methods and criteria for diagnosis.22 
The large Burden of Obstructive Lung Disease (BOLD) initiative 
conducted a survey in 12 sites worldwide (n=9 425), and found the global 
prevalence of stage 2, or higher, COPD to be 10.1% (SE ±4.7%); 11.8% for 
men and 8.5% for women.14 This study showed marked heterogeneity in the 
prevalence and staging of COPD across sites and between the genders, 
which was unexplained by age differences or smoking status of the 
populations, nor by other risk factors like biomass fuel and occupational 
exposures and tuberculosis.24 
 The Latin American Project for the Investigation of Obstructive Lung 
Disease (PLATINO Study) was a population-based prevalence survey 
conducted in five major Latin American cities (n=5 315). Menezes et al found 
the prevalence of COPD ranging between 7.8% (Mexico City) and 19,7% 
(Montevideo), with rates ranging from 11.4% to 22.2% for men, and from 
6.5% to 14.5% for women.25 Caballero et al conducted a similar population-
based survey in five Colombian cities (n=5 539). This PREPOCOL 
(Prevalencia de EPOC en Colombia) study found an overall prevalence of 
COPD of 8.9%, ranging from 6.2% (Barranquilla) to 13.5% (Medellin), and 
men were found to have higher rates of COPD compared with women 
(13.6% vs. 6.6%). In addition to age and smoking status, a history of 
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tuberculosis, biomass exposure and low education were found to be 
associated with COPD.18 In China, Lam et al, using the large Guangzhou 
cohort (n=5 522), found the prevalence of airflow obstruction to be 6.5% 
overall, with similar rates in both men (6.4%) and women (6.5%).26 
Apart from the morbidity and mortality associated with COPD, the 
disease places a high burden upon society in terms of cost and healthcare 
utilisation. In the United States alone, the direct medical costs of COPD were 
estimated to be $15.5 billion in 1993.27 These estimates have risen and, 
currently in the USA, the direct costs of COPD are estimated to be $29.5 
billion and indirect costs $20.4 billion per year. In Europe, the direct costs of 
respiratory disease consumes 6% of the total healthcare budget, with COPD 
accounting for 56% (€38.6 billion) of this cost.5 In the United Kingdom, the 
disease is responsible for 24 million working days being lost annually, at an 
estimated cost of £600 million in social security costs and £1.5 billion in lost 
productivity per year, in addition to the direct costs of management. Hospital 
care, medication and oxygen therapy account for most of these direct costs 
of COPD, and correlate with disease severity, age and health status of the 
patient. In Spain, the annual cost per patient is $1 876 per annum, with 
hospital costs (43%) and drugs (40%) being the major contributors. In the 
United States, direct healthcare costs in one cohort ranged from $1 681 (in 
stage 1 disease) to $10 812 (in stage 3 disease), per annum.27 Comparative 
data on costs of COPD are not available for much of the developing world.  
 
2.4. Burden of COPD in South Africa 
 
There is also paucity of prevalence data for COPD in South and Sub-Saharan 
Africa. Despite this, a number of sources suggest a high burden of chronic 
lung diseases in the South African population. For example, according to the 
latest Statistics South Africa Report (2013), chronic lower respiratory 
diseases were the cause of 2.8% of deaths in men in 2010 (ranked eighth), 
and it is presumed that a significant proportion of these deaths were due to 
COPD. In adults between 50 and 64 years of age, chronic lower respiratory 
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diseases were responsible for 3.8% of deaths (ranked seventh), while in 
adults over 65 years they accounted for 4.4% of deaths (ranked seventh). 
The Western Cape had the highest rate of death due to chronic lower 
respiratory diseases (4.4%) when compared with the other provinces (range 
<1.8%-3.7%).28 
  The Lung Health Study was a community based population survey 
conducted in the Western Cape in 2002 that assessed the prevalence of 
respiratory symptoms among 3 483 people from two lower-income 
communities. Jithoo et al found that 38.3% of adults (over 15 years of age) 
had at least one respiratory symptom, while 18.2% of those over 40 years of 
age had Grade 2 dyspnoea or higher.29 Among 13 000 subjects in the South 
African Demographic and Health Survey of 2004, a history compatible with 
chronic bronchitis was reported in 2.3% of men and 2.8% of women 
surveyed.30 
  Jithoo et al were the first researchers to perform a community-based 
prevalence survey of COPD in an adult South African population using 
standardised spirometry. This group employed the BOLD methodology and 
examined 847 adult subjects from two low-to-middle income suburbs in 
Cape Town. They reported that 23.8% of all subjects had GOLD stage 1 or 
higher COPD (28.7% for men, 20.0% for women), with GOLD stage 2 or 
higher COPD found in 19.1% of adults (22.2% for men, 16.7% for women). 
This was the highest rate reported among the 12 BOLD global study sites.14,29 
The Cape Town site reported very high rates of smoking in the study 
population, with 83.0% of men and 59.0% of women being ‘ever-smokers’. 
These were the highest and second-highest rates, respectively, of the 12 
BOLD sites studied. However, there was a discrepancy between the total 
numbers of ‘ever-smokers’ and the number of cigarettes smoked. Despite 
the high number of smokers, the total burden of smoking was only 18.3 
pack-years for men and 15.1 for women. When compared to the other 11 
bold sites this was the lowest total burden for men (BOLD range 18.3-44.9 
pack-years) and the second lowest for women (BOLD range 9.3-35.5 pack-
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years). In addition to smoking, higher rates of previous tuberculosis as well 
as occupational exposures were found. 
 The study by Jithoo et al was included in a recent systematic review 
on the prevalence of COPD in Sub-Saharan Africa, performed according to 
MOOSE (Meta-Analyses and Systematic Review of Observational Studies) 
guidelines. Only nine studies met eligibility criteria, of which five were from 
South Africa.31 The authors reported a markedly varying prevalence of COPD 
between the nine studies, ranging from 4.1%-24.8%. Only the Jithoo et al 
study included a representative sample of the general population and 
internationally recognised case definitions. Others were either performed in a 
non-general population (e.g. in miners or brick-workers), or had inadequate 
case definitions. Varying prevalence rates are therefore attributable to 
differing patient populations, lack of consistent diagnostic criteria and 
varying quality of the methodology between the studies. The review was 
unable to include estimates of the economic burden of COPD in Africa, but 
reported marked differences in the smoking status between studies, 
highlighting differences in exposure risks. The current smoking rates varied 
between 11 and 71% for men, and 0% and 61% for women. 
 
2.5. Risk factors for developing COPD 
 
Cigarette smoking has long been considered the most important cause of 
COPD. The United States Surgeon General report in 1984 concluded that 
80%-90% of COPD in the United States was attributable to smoking. 
However, in the last two decades, there has been increasing recognition of 
risk factors other than smoking as a cause for chronic airflow obstruction, 
especially in developing nations.32 The increasing recognition of the 
heterogeneity of COPD, both in terms of risk factors and phenotypes, has 
opened a debate on whether or not only smoking-related disease should be 
termed COPD.  
 Those in favour of defining COPD as a purely smoking-related disease 
argue that although chronic airflow obstruction can undoubtedly be found in 
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non-smoking related disease (e.g. asthma), the mechanisms of disease and 
causes of airflow limitation are different from those caused by cigarette 
smoking. An example of this is the airflow obstruction related to domestic 
wood-smoke inhalation, which shows features more commonly associated 
with inorganic dust exposure (such as fibrosis, inflammatory focal thickening 
of the alveolar septae and diffuse anthracotic deposition), suggesting a 
possible different pathophysiology.33 They further argue that if the term 
COPD is restricted to disease associated with smoking, it will encourage 
more extensive diagnostic workup of patients with CAO who have never 
smoked, thereby reducing ‘misdiagnoses’ of COPD. Further, by confining the 
term COPD to smoking-related disease, the heterogeneity of the airflow 
obstruction would be reduced, allowing more specific research into disease 
mechanisms and treatment. This view appears to be predominantly held in 
the developed world where other causes of CAO are few. 
 Estimates of non-smoking related COPD in different populations vary 
widely, but might be as high as 25% or even 45% of patients with COPD 
having never smoked.34 The Third National Health and Nutrition Examination 
Survey showed that 42% of cases with airflow obstruction (defined by 
FEV1:FVC <0.70) were non-smokers.35 Several other studies have supported 
these findings. For example, Lamprecht et al assessed 4 291 ‘never smokers’ 
from 14 countries that participated in the BOLD study, and found 6.6% met 
criteria for GOLD stage 1 (mild) disease, and 5.6% for GOLD stage 2 or 
higher (moderate to severe COPD).36 Significantly, in Austria, which is a 
developed country, nearly a third of subjects with chronic airflow limitation 
had never smoked.37 There are a number of possible explanations for these 
findings: the first lies in the definition of COPD and methodology used to 
determine burden of disease. Some authors argue that using the fixed ratio 
(i.e. FEV1:FVC <0.70) to define COPD is in part to blame for the observation 
of COPD in non-smokers, especially the over-diagnosis of COPD in the 
elderly, as discussed above. Thus, epidemiological links between these ‘false 
positive’ subjects and non-smoking causes may be erroneously drawn.18 A 
second explanation is misdiagnosis, that is, CAO being caused by a disease 
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other than COPD. A third possibility is that risk factors other than tobacco 
smoke can cause a form of lung disease, which is either entirely or partially 
similar to smoking-related disease. Further research is required to test the 
latter hypothesis, as most current research has focused on the classical form 
of smoking-related COPD and there is limited evidence into mechanisms in 
well-characterised cohorts of non-smokers with COPD 
 In spite of the above uncertainties, most current COPD definitions, 
including that of GOLD, recognise the existence of aetiological risk factors 
other than smoking,22 and the American Thoracic Society (ATS) statement 
(2010) claims that it is erroneous to view cigarette smoking as the sole 
meaningful factor in the epidemiology and natural history of COPD,32 and that 
a substantial proportion of COPD cases can not be explained by smoking 
alone, especially among young persons, females and residents of developing 
countries. The document lists occupational exposure, traffic, outdoor 
pollution, second-hand smoke, biomass exposure, dietary factors and rare 
genetic syndromes (such as alpha-1-antitrypsin deficiency) as possible 
additional causes of COPD. In addition, chronic asthma and tuberculosis are 
also recognised causes of irreversible airflow obstruction, but uncertainty 
remains as to whether these are the same as COPD in terms of clinical 
features and natural history. 
 The evidence surrounding inclusion of these factors as potential 
causes of COPD are considered below, particularly that relating to 
tuberculosis and COPD. 
 
2.5.1. Non-tuberculosis risk factors 
2.5.1.1. Smoking 
It is not disputed that cigarette smoking is an important cause of COPD, and 
early estimates were that 15% of smokers would develop symptomatic 
disease.22 33 Buist et al showed a significant positive association between 
cigarette smoking and COPD in the multinational BOLD study, with odds 
ratios for COPD stage 2 or higher of 1.28 (95% CI 1.15-1.42) for women and 
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1.16 (95% CI 1.12-1.21) for men, for each 10-pack year increase in history of 
smoking.38 However, smoking-related damage might even be present in 
smokers with normal spirometry. Mastora et al, using CT-scan analysis, 
showed emphysema in 40% of 144 smokers with normal spirometry, 
compared with none in a control group of non-smokers.39 Eisner et al, in a 
review of studies, estimated the fraction of COPD mortality attributable to 
smoking to be 54% for men between the ages of 30-69 years and 52% for 
men aged 70 years or older. Corresponding rates for women were 24% and 
19%, respectively. Attributable fractions were higher in developed countries 
(84% and 77% for men, and 62% and 61% for women) compared with 
developing countries (49% and 45% for men, 20% and 12% for women).32 In 
2000, Groenwald et al estimated the population attributable fraction of COPD 
to smoking in South Africa to be 62% overall (69% for men, 51% for 
women).40 
 These mortality rates from COPD have continued to rise for both male 
and female smokers (which is not simply an effect of ageing), and recent 
cohorts now show similar relative risks for death from COPD for both 
genders who are current smokers (25.6 for men, 22.4 for women)41. It has 
been estimated that in South Africa in the year 2000, COPD accounted for 
18% of the 7 831 tobacco-attributable deaths.40 A more recent case-control, 
death-registry study conducted in South Africa found that smoking was 
responsible for 54.6% of deaths from COPD among Coloured men; with 
smoking-attributable rates of 47.0% for White men and 24.4% for African 
men. The corresponding attributable rates for women were: 48.1% for 
Coloured, 42.1% for White and 11.0% for African.42 [Smoking-attributed 
number of deaths was calculated as S(1-1/RR), where S was the total 
number of deaths in smokers.]  
Studies of passive or second-hand smoke exposure have confirmed 
an association with the development of COPD. Apart from a temporal 
relationship, an exposure-response gradient exists as well as biological 
plausibility for a causal relationship.32 
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2.5.1.2. Biomass 
It is estimated that about three billion people worldwide are exposed to 
smoke from biomass fuel, which represents 50% of all households and 90% 
of rural households. It is suggested that biomass exposure may be a more 
important global cause of COPD than cigarette smoking.34 Numerous studies 
from around the world have confirmed biomass smoke as a risk factor for 
COPD,43–46 with one systematic review estimating the odds ratio for the 
development of COPD in women to be 2.40 (95% CI 1.47-3.93).47 
  In 2007, Norman et al estimated that 20% of South African 
households were exposed to indoor smoke, with marked variations in 
different population groups. The attributable fraction of COPD from solid 
household fuels in South Africa was estimated to be 13.1% for men and 
31.1% for women, accounting for 304 deaths for men and 721 deaths for 
women, and 2 957 DALYs in men and 8 920 DALYs in women.48 
2.5.1.3. Genetic 
Apart from rare hereditary causes of COPD (e.g. alpha-1-antitrypsin 
deficiency), there is limited but plausible evidence that an individual’s 
response to inhaled substances (e.g. cigarette smoke) may be genetically 
determined and influence the development of COPD. These genetic factors 
are likely to be particularly important in non-smokers who develop COPD.32 
2.5.1.4. Outdoor air pollution 
 Although there is much evidence from longitudinal cohorts of an association 
between outdoor pollution and decreased lung function in childhood and 
adolescents, as well as more exacerbations of COPD with increasing 
concentrations of air pollution, the causal relationship between pollution and 
the development of COPD has not been well established. Biological 
plausibility exists for the association. However, further robust epidemiological 
data is required to establish causation between air pollution and COPD.49,34,32 
2.5.1.5. Occupational exposure 
There is good epidemiological evidence of a causal relationship between 
occupational exposures and the development of COPD. Occupations that 
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have been implicated include: farming; factory work with high levels of dust, 
fumes and toxic gases; coal mining; hard-rock mining; tunnel, concrete and 
construction workers.34 The estimated population attributable fraction for 
occupational exposure contributing to COPD is between 15 and 20%, 
depending on the population studied.32 
2.5.2. Tuberculosis 
There is increasing evidence of an association between a previous history of 
pulmonary tuberculosis (TB) and the development of chronic airflow 
obstruction (CAO). 
  Several large population-based epidemiological studies have 
confirmed the association between TB and CAO. The PLATINO study, 
conducted among 5 571 subjects in Latin America, found CAO in 30.7% of 
subjects with a history of TB, compared with 13.9% among those without 
such history.17 After adjusting for confounders, men with a history of TB were 
4.1 times more likely to have CAO than those without a history (adjusted 
odds ratio for women was 1.7). In a similar population-based study 
performed among 5 539 subjects in Colombia (PREPOCOL Study), 25.8% of 
subjects with a history of TB had CAO. This association between TB and 
airflow obstruction was greater than that for smoking after adjusting for 
confounders (OR 2.94, 95% CI 1.58-5.49).18 Additionally, in a large Chinese 
population study of 8 066 subjects that defined previous TB status using 
chest X-rays, TB was found to be independently associated with CAO, after 
adjustment for gender, age and smoking (OR 1.37, 95% CI 1.13-1.67).  
In contrast to these results, the multinational BOLD study was unable 
to find an association between previous TB and CAO. Although on univariate 
analysis a significantly higher prevalence of previous TB was found among 
never-smokers with airflow obstruction than in never-smokers without airflow 
obstruction, this association was not significant on multivariate analysis. The 
reported odds ratio among never-smokers was 1.47 (95% CI 0.69-3.12) in 
women, and 1.65 (95% CI 0.43-6.34) in men.14,36 The lack of a positive 
association in the above BOLD study is likely to be due to a dilution effect of 
pooling the odds ratios of all sites. Of the 14 countries included in the study, 
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the median prevalence for tuberculosis was only 10.45/100 000 population 
(range 2.4-782/100 000), compared with the global average prevalence of 
201/100 000 at that time. Only two of the countries included had a 
prevalence of TB higher than the global average.50 Jithoo et al, in the South 
African study that formed part of this analysis, found a strong association 
between previous TB and CAO. For GOLD stage 1 and 2, they reported an 
OR of 2.6 (95% CI 1.5-4.6), and for GOLD stage 3 and 4 an OR of 8.9 (95% 
CI 4.2-18.9).29 In the Philippines, the other high burden country included in 
the BOLD Study, Idolor et al performed a separate population-based survey 
among 1 188 subjects from two rural areas using the BOLD methodology. 
These investigators similarly found a strong association between previous TB 
and CAO (OR 6.31, 95% CI 2.67-15.0), which was stronger than that for 
smoking, farming or biomass exposure.51 
 A recent review of the English language peer-reviewed literature found 
19 studies addressing the association between TB and CAO (one case 
series, three case-control studies, four cohort studies, eight single-centre 
cross-sectional studies and three multi-centre cross-sectional studies).52  
Although the authors were unable to perform a meaningful meta-analysis due 
to the marked heterogeneity between studies, they found convincing 
confirmatory evidence of a positive association between a history of previous 
TB and CAO. Only two of the 19 included studies didn’t report a positive 
association.  
 In another review comprising only South African studies, Ehrlich et al 
concluded that chronic chest symptoms and loss of lung function were 
consistently associated with pulmonary TB, with an OR for chronic bronchitis 
between 1.5 and 7.2, and an OR for spirometrically defined COPD between 
2.6 and 8.9.53 Unfortunately, only one of the eight included studies (Jithoo et 
al) employed spirometric data and was performed in a community setting. 
The other seven were conducted in an occupational setting (e.g. miners, 
bakery workers). 
  This association between previous TB and the development of 
COPD is increasingly being accepted by the international community, as 
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evidenced by the inclusion of TB among the risk factors for COPD in the 
latest GOLD guidelines.5 However, many aspects of this association need to 
be studied: first, the magnitude and determinants of the risk; second, the 
pathophysiology, including the relationship between structural damage and 
lung function; and third, the natural history of PTB-associated CAO (whether 
CAO progresses over time) and its response to conventional treatments for 
COPD. 
There is a paucity of prospective population-based cohort studies 
following subjects longitudinally into the post-TB period. Snider et al 
performed a cross-sectional study of 1 403 patients who were discharged 
from a TB sanatorium between 1964-1966 following completion of treatment. 
He reported a reduced FEV1:FVC in 42% of patients (23% obstruction, 19% 
mixed obstruction/restriction) upon discharge.54 Similarly, Plit et al studied 74 
patients who were hospitalised for TB, and reported airflow obstruction in 21 
patients (28%) at completion of treatment. Thirteen of these 21 patients 
(62%) did not have airflow obstruction at the start of treatment.55 In a study 
performed in a tertiary centre in India, 46% of 100 patients fully treated for 
pulmonary TB developed airflow obstruction. The severity of obstruction was 
mild (FEV1 >60%) in 75%; moderate (FEV1 40%-59%) in 10%; and severe 
(FEV1 <40%) in 15%.56 And, in a retrospective cohort, Willcox et al found 
airflow obstruction in 68% of 71 patients treated for TB, followed up after an 
average of 5.6 years.57 
 It is also uncertain what fraction of COPD is attributable to previous 
TB. Since a large proportion of patients who develop PTB are also smokers 
and may have other risk factors, correction for these have been carried out. 
For example, Ehrlich et al estimated the population attributable fraction for 
TB in COPD to be 24.9%.53  
 Given the paucity of data, it is currently difficult to make accurate 
estimates as to the burden of CAO secondary to TB in South Africa; 
however, if extrapolation is made from the available cohort studies, it can be 
postulated that a significant proportion of subjects with previous TB may be 
affected.  
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2.6. Burden of pulmonary tuberculosis 
 
Assessment of the magnitude of the TB epidemic - both globally and locally – 
is required in order to inform estimates on future chronic lung disease related 
to incident tuberculosis.  
 In 2012, according to the World Health Organization (WHO), there 
were 8.6 million cases of TB with 1.3 million deaths worldwide. Over 95% of 
these deaths occurred in low-income and middle-income countries.58 The 
global incidence rate is estimated to be 122/100 000 population, with the 
average incidence rate for Africa being 255/100 000 population. Africa has 
the highest incidence rates of all WHO regions, with the lowest rates reported 
in the Americas (29/100 000 population). India, which has a population of 
1.24 billion, reported the highest number of TB cases in 2012 (1.47 million 
cases), with an incidence rate of 176/100 000 population. China, with its 
population of 1.38 billion, had the second highest number of cases in 2012 
(900 678 cases), with an incidence rate of 73/100 000 population.59 
 South Africa, with a population of 52 million, has a disproportionately 
high burden of TB. Tuberculosis was the leading cause of death in 2010, 
accounting for 12% of all deaths.28 In the 2012 report, South Africa had the 
third highest number of cases annually (349 582 cases), behind only India 
and China. Additionally, South Africa had the second highest incidence rate 
for TB (1 003/100 000 population).59 Only Swaziland has a higher rate  
(1 350/100 000 population).  
 In the Lung Health Study of 2002, performed in two low-income 
suburbs of Cape Town, 9.7% of 3 483 adults (>15 years of age) reported a 
previous episode of TB (12.0% for men, 8.0% for women).29 
 Based on these figures for pulmonary TB in South Africa and the 
association of PTB with the development of CAO, it should be anticipated 
that PTB might account for a heavy burden of chronic lung disease and 
particularly of COPD in South Africa. However, to date there are few studies 
that have adequately quantified this burden. 
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2.7. Natural history of COPD 
 
The present study will also explore the natural history of COPD, by examining 
the status of patients diagnosed with COPD in the BOLD 2005 study five or 
more years later. First, it is relevant to review current evidence and views on 
this topic. 
 
2.7.1. Lung function decline 
As COPD is a disease characterised by chronic airflow limitation, FEV1 
decline is the standard method for assessing deterioration in COPD. Obvious 
advantages of this method are its ease of measurement and reproducibility. 
The annual decline in normal subjects is estimated between 15-30 mL/yr.60 
Populations of normal subjects usually include smokers. A decline of 
approximately 35 mL/yr has been reported in a group comprising 30% 
current smokers.61 In a much-cited study, Fletcher and Peto studied lung 
function in 792 West London men, and hypothesised that many smokers 
would not develop airflow obstruction. For those that did (‘susceptible 
smokers’), the loss of lung function was greater than either non-smoking 
individuals or those that had ceased to smoke. They also claimed that large 
irreversible declines in FEV1 were very rare, and that FEV1 declined smoothly 
and continuously over an individual’s life.62 In the light of more recent work, 
the validity of these findings has been questioned. Criticisms of the Fletcher-
Peto study revolve around the lack of standardisation of spirometry, high 
rates of loss to follow-up (likely healthy subjects) and flawed statistical 
analysis.63  
 More recent studies have shown lung function decline in COPD to be 
heterogeneous. The ECLIPSE (Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints) study of 2 163 patients with COPD over 
three years showed a mean rate of FEV1 decline of 33 ± 2 mL/yr, with 
significant variation between patients (sd 59 mL/yr). A total of 38% had a 
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decline in FEV1 >40 mL/yr, 31% a decline between 21-40 mL/yr, 23% 
ranged from a decline of 20 mL to a gain of 20 mL, and 8% had an increase 
of >20 mL/yr.64 However, these results were possibly affected by treatment 
received during the course of the three-year follow-up.  In a second study of 
1 198 COPD patients followed for a median of 64 months and up to 10 years, 
Casanova et al showed that most (72%) showed no statistically significantly 
decline of FEV1. The remaining 18% showed a decline of  
–86 mL/yr (95% CI –32 to –278 mL/yr).65 In other longitudinal studies, rates of 
annual FEV1 decline of between 40 and 55 mL/yr have been reported.66–68 
Lung function decline appears to be more rapid in patients with mild 
COPD. This hypothesis is supported by study of the placebo-treated groups 
in the large TORCH and UPLIFT studies.68,69 In these studies, the decline was 
most rapid in heavy smokers with only mild airflow limitation at baseline. 
Findings in the ECLIPSE study were similar. The mean rate of decline was ± 
35 ± 1 mL/yr for GOLD stage 2 patients, ± 33 ± 1 mL/yr in GOLD stage 3, 
and ± 25 ± 2 mL/yr for GOLD stage 4. (p=0.170 for stage 2 vs. stage 3, and 
p<0.001 for stage 2 vs. stage 4).64 This ‘reverse racehorse’ phenomenon was 
also observed in a study of male smokers, the majority of whom had either 
mild or no COPD. The greatest decline of lung function occurred in those 
without airflow limitation (i.e. FEV1:FVC >0.70).63 
A number of factors may influence lung function decline. Smoking (in 
particular, current smoking) is most strongly associated with accelerated 
decline in FEV1. Vestbo et al estimated this to be an additional 21 ± 4 mL/yr 
for current smokers compared to former smokers, while cumulative tobacco 
exposure (i.e. pack-years) did not appear to increase the rate of decline.63,64 
In keeping with these findings, the Lung Health Study found less lung 
function decline in people who quit smoking compared with those who 
continued to smoke (30.2 mL/yr vs. 66.1 mL/yr of FEV1 for men).70  
Acute exacerbations of COPD have also been shown to accelerate the 
decline in FEV1. In the ECLIPSE study, subjects with frequent exacerbations 
had a mean loss of 2 ± 0.5 mL/yr per exacerbation. In the Lung Health Study, 
for each lower respiratory tract illness per year the FEV1 declined by an 
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additional 7 mL/yr,71 while Donaldson et al reported a decline of 2.9 mL/yr in 
frequent exacerbators, compared with 0.7 mL/yr for infrequent 
exacerbators.61 
Patients with chronic bronchitis have not been found to have a faster 
rate of decline in FEV1, but have a lower mean FEV1. An excess decline in 
FEV1 of 13 ± 4 mL/yr has also been found in COPD patients with more than 
10% emphysema on CT scan, while bronchodilator reversibility to salbutamol 
was associated with both an increased loss of 17 ± 4 mL/yr and a higher 
mean baseline FEV1. Vestbo et al additionally found neither age nor gender 
predicted accelerated decline in FEV1 in the ECLIPSE study.64 
However, it is argued that in COPD that monitoring change in FEV1 
may not be the best method of assessing disease progression. In longitudinal 
studies, there is high variability in the rate of change in FEV1 between 
individuals, with some patients changing between severity groupings (both 
upward and downward migration). Furthermore, FEV1 as a test demonstrates 
a high variance, estimated at approximately 55 mL.72 In COPD, spirometric 
values explain less than 10%-25% of patient symptoms, quality of life and 
exercise performance,73 and are only weakly correlated with dyspnoea and 
exercise limitation.74 Symptoms of dyspnoea and exercise limitation have 
also been shown to worsen over time in COPD patients, and the BODE (body 
mass index, obstruction, dyspnoea and exercise limitation) index 
demonstrated greater sensitivity in predicting mortality than FEV1 alone.74 In 
patients with an FEV1 <50.0% predicted, changes in exercise tolerance (e.g. 
six-minute walk distance) decline more over time than FEV1.65 It is argued 
that because dyspnoea worsens over time, predicts mortality and improves 
with therapy, it may be a better marker of disease progression in COPD than 
FEV1. However, there is no ‘gold-standard’ measurement/tool for following 
changes in dyspnoea. Multi-dimensional dyspnoea measurements (e.g. 
Transitional Dyspnoea Index (TDI), Chronic Respiratory Disease 
Questionnaire (CRQ), or UCSD shortness of breath questionnaire) have been 
shown to be better than other uni-dimensional measurements (e.g. modified 
Medical Research Council (mMRC) scale or Oxygen Cost Diagram (OCD)) in 
Literature Review  
 25 
COPD.75 In spite of this, the mMRC and, more recently, the CAT method 
(which combines dyspnoea and exercise limitation), have been proposed by 
GOLD for quantitating symptom progression. 
 
2.7.2 Predictors of mortality 
FEV1 correlates inversely with mortality,76 77 but compared to dyspnoea and 
health-status scores is a weak predictor of death.78 It performs better as a 
prognostic indicator when combined with other clinical data in a 
multidimensional index (e.g. BODE index). For every one point increase in 
BODE score, the hazard ratio for death from a respiratory cause is 1.62 (95% 
CI 1.48-1.77).78 Variations of the BODE index have also been found to be 
good predictors of mortality.73 
 Older age is also consistently associated with mortality in COPD 
76,77,79,80, as is chronic bronchitis, independent of the severity of obstruction.81 
Bronchiectasis in subjects with moderate-severe COPD has equally been 
associated with an increased risk of death, with one study of 201 subjects 
demonstrating a hazard ratio for death of 2.54 (95% CI 1.16-5.56) for 
bronchiectasis diagnosed on CT scan, after adjustment for confounders.82 
 Numerous studies have demonstrated a positive association between 
mortality rates and acute COPD exacerbations.83,79,80 There is excess 
mortality in the weeks following a COPD exacerbation, and every new 
exacerbation increases the risk of subsequent mortality. For example, the 
risk of death is five times increased following the tenth, compared with the 
first hospitalisation.83 
 Other physiological parameters have been shown to predict mortality 
in patients with COPD. These include the diffusion capacity for carbon 
monoxide (DLCO), and partial pressure of oxygen in the arterial blood (PaO2).77 
The DLCO is thought to represent gas transport across the alveolar–capillary 
membrane and is therefore influenced by the degree of emphysema, which 
causes parenchymal destruction and loss of the pulmonary capillary bed. 
Additionally, a lower total lung capacity (TLC) and raised residual volume (RV) 
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have been shown to predict mortality in the large NETT (National 
Emphysema Treatment Trial) study.76 
 A number of investigators have attempted to identify biomarkers that 
predict outcomes in COPD. The ECLIPSE investigators identified a subgroup 
of patients with persistently raised biomarkers (16% of 1 755 subjects). This 
‘inflamed’ subpopulation of COPD exhibited increased mortality and 
exacerbation frequency, despite having similar lung function, compared to 
‘non-inflamed’ subjects.84 Although many biomarkers have been assessed, it 
is still unclear as to which is most useful in predicting outcomes. An increase 
in highly sensitive C-reactive protein (CRP) is common in COPD, but results 
differ between studies.80 In the ECLIPSE Cohort, an association between 
white blood cell count (WBC), IL-6, IL-8, fibrinogen, CCL-18/PARC, CRP and 
SP-D and mortality was observed over three years. However, when added to 
clinical models, only IL-6 was found to improve the predictive power of the 
model. The other variables only added marginal improvement, and were not 
recommended for inclusion.80 
 
2.8. Phenotyping in COPD 
 
One of the hypotheses of the work reported in this thesis is that tuberculosis-
associated chronic airflow obstruction (TOPD) differs in terms of 
pathophysiology, natural history and responsiveness to treatment from 
COPD without this risk factor. In essence, it is proposed that TOPD should 
be considered a distinct phenotype of COPD. This literature review will 
review current thinking on phenotyping in COPD.  
 
 2.8.1. Need for phenotyping 
A phenotype is defined as a set of observable characteristics of an individual 
that result from an interaction of its genetic make up with the environment. It 
is now well recognised that COPD is a complex syndrome, exhibiting both 
pulmonary and extra-pulmonary disease.73 The clinical manifestations and 
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disease course are highly variable (as highlighted above), with severity of 
airflow obstruction unable to capture this heterogeneity.85 Heterogeneity of 
lung function decline was highlighted in the ECLIPSE study, and was 
discussed above. However, this heterogeneity with COPD is not merely in 
terms of lung function or survival but also in clinical presentation, physiology, 
imaging and response to therapy.73 This has prompted an intensive search 
for COPD phenotypes.  
 There is, however, little consensus on what constitutes a phenotype. 
Han et al have proposed the following definition: ‘a single or combination of 
disease that differ between individuals and that relate to clinically meaningful 
outcomes (symptoms, exacerbations, response to therapy, rate of disease 
progression or death)’.73 Individuals in the same phenotypes may have similar 
biological and physiological mechanisms, and respond similarly to the same 
therapy. According to these authors, placing the emphasis on ‘clinically 
meaningful outcomes’ will necessitate the prospective validation of 
candidate phenotypes, prior to their adoption.73,85 
 It is evident that not all patients with COPD respond equally to all 
therapies. Therefore, one of the central drivers of phenotyping in COPD is to 
identify subsets of patients who share a common mechanistic pathway. This 
may allow development and trial of therapies that may be effective for such a 
subset, but useless (or even detrimental) for other subsets of patients.72,86  
 Currently, there is no widely accepted classification of COPD 
phenotypes. Owing to the marked heterogeneity of disease and its 
comorbidities, some have proposed that there should be ‘328 million 
phenotypes’ (the number of estimated patients worldwide).86 Different 
approaches to phenotyping patients with COPD will be briefly reviewed.  
 
 2.8.2. Phenotyping by exposure  
COPD can be sub-classified according to the primary environmental agent 
deemed responsible for the airflow obstruction in the individual patient. It is 
likely that airflow limitation resulting from a similar cause will, to some 
degree, be mechanistically similar, with similar outcomes among individuals. 
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It is on this basis that Miravitlles and Morera argue that the term COPD 
should be reserved for smoking-related disease;33 this view is not widely 
held.  
 
 2.8.3. Clinical phenotyping 
A number of different clinical phenotypes have been proposed. A brief 
discussion of a number of these follows.  
  2.8.3.1. Chronic bronchitis 
Chronic bronchitis (CB) is defined as a chronic cough with sputum 
production for at least three months per year, in two consecutive years. It is 
common in COPD, occurring in 14%-74% of patients; the prevalence in the 
ECLIPSE study was 35%.64,81 Chronic bronchitis is also found in 4%-22% of 
never-smokers, suggesting causes other than smoking, including biomass 
exposure, as well as dust and chemical fume exposure.81 Evidence from 
many sources have confirmed that CB is associated with more respiratory 
symptoms, worse quality of life, increased risk of COPD exacerbations, faster 
decline in FEV1 and possibly an increased all-cause mortality.81,87–92 However, 
in the ECLIPSE study CB was not associated with a faster decline in FEV1, 
but patients with CB did have a lower mean FEV1  
(43 mL ± 20 mL),64 nor was CB associated with more frequent COPD 
exacerbations.93 However, the utility of the chronic bronchitis phenotype is 
supported by the finding that the PDE4 inhibitor roflumilast reduces 
exacerbation risk in COPD patients with chronic cough (CB), but not those 
without.94 
  2.8.3.2. Allergic phenotype 
An allergic phenotype of COPD has been proposed, comprising smokers (or 
ex-smokers) with airflow obstruction and no previous diagnosis of asthma, 
who have either hay fever or allergic upper respiratory symptoms, or allergic 
sensitisation to perennial allergens. In a recent study, using two separate 
cohorts (NHANES III, and COPD and domestic endotoxin (CODE) cohorts), 
Jamieson et al found an increased risk of COPD exacerbations and increased 
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respiratory symptoms in such subjects.95 Additionally, bronchodilator 
reversibility (defined as a change in FEV1), although more commonly thought 
of in the context of asthma, has been reported in a significant proportion of 
COPD patients. In the NETT cohort, 22.2% of patients were found to have 
bronchodilator reversibility on at least one occasion. Airway hyper-
responsiveness is associated with a greater decline in lung function, while 
subjects with greater radiological emphysema exhibit less bronchodilator 
reversibility. However, use of both bronchodilator reversibility and airway 
hyper-responsiveness in diagnosing this phenotype is limited by their high 
degree of variability, which have both been observed to change over time 
within individual patients.73,96  
2.8.3.3. COPD/asthma overlap 
Many patients with chronic airflow limitation exhibit characteristics of both 
asthma and COPD, and present a challenge to clinicians in both diagnosis 
and management. Various definitions have been proposed, one example is: 
the COPD/asthma overlap where ‘the diagnosis of COPD (is made) in a 
patient with a history of previously diagnosed asthma before the age of 40 
years.’86 In a recent consensus document from Spain, this diagnosis requires 
two major and two minor criteria to be present. Major criteria are: very 
positive bronchodilator test (increase in FEV1 ≥15.0% and ≥400 mL); 
eosinophilia in sputum; and a personal history of asthma. Minor criteria are: 
high total IgE; a personal history of atopy; and a positive bronchodilator test 
(increase in FEV1 ≥12% and ≥200 mL) on two or more occasions.97 In 
contrast, the recent combined GINA/GOLD statement on asthma-COPD 
overlap syndrome (ACOS), promotes a stepwise approach where clinicians 
weigh evidence for and against both diagnoses of asthma and COPD. If there 
is similar evidence for both asthma and COPD, a diagnosis of ACOS should 
be considered, however rigid diagnostic criteria in diagnosing ACOS are not 
promoted.98 Because of a lack of a consensus definition, the true prevalence 
of this overlap phenotype is not known, but estimates range from 13% 
(COPDGene cohort)99 to 23% of patients in their sixth decade, with the 
prevalence increasing with age.100 Importantly, for this phenotype, experts 
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recommend that inhaled corticosteroids be started early, and that caution be 
exercised when withdrawing inhaled corticosteroids abruptly.97 
2.8.3.4. Rapid and slow progression of COPD 
Patients with a greater than average decline in FEV1 have been proposed as 
an additional phenotype. These ‘rapid progressors’ have higher rates of 
morbidity, mortality and hospitalisation. Additionally, they have been shown 
to have a distinct biomarker signature. What is uncertain is the absolute level 
of FEV1 decline that denotes a rapid progressor. Moreover, it is unclear 
whether the observed ‘rapid decline’ is merely the observable outcome of 
another occult process, rather than being a distinct phenotype in its own 
right. Rapid progressors require close monitoring of lung function over a 
prolonged period (at least three years); no specific treatment is currently 
available for these patients.64,73,74,86 
2.8.3.5. Frequent exacerbators  
There is increasing appreciation of the ‘frequent exacerbator’ phenotype, 
which refers to a patient with two or more exacerbations per year.86 The 
diagnosis is usually made on self-reporting (recall) by the patients, which has 
been shown to be reliable. In the large ECLIPSE study, Hurst et al, found that 
some patients were susceptible to exacerbations, irrespective of disease 
severity. Self-reporting of previous exacerbations identified these individuals, 
and susceptibility of exacerbations was relatively stable over the three-year 
study period. Of their cohort, 22% of patients with stage 2 disease had 
frequent exacerbations, while 33% and 47% of stage 3 and 4 disease, 
respectively, had frequent exacerbations.93 Frequent exacerbators 
demonstrate: a greater decline in FEV1; worsening health status; more 
frequent admissions to hospital; and a longer duration of stay once 
admitted.61,73,83 Exacerbations are additionally associated with severity in 
COPD, being more frequent and severe in those with advanced disease. 
Moreover, a history of exacerbations appears to be the best predictor of 
future exacerbations, leading to the proposal of a specific ‘frequent 
exacerbator’ phenotype.93 The interval between exacerbations decreases 
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with each sequential episode, being around five years between the first and 
second episode, and declining to less than four months between the ninth 
and tenth episodes. The risk of subsequent exacerbations also increases, 
being three-fold after the second severe exacerbation and 24-fold after the 
tenth severe exacerbation. Additionally, mortality appears to peak in the first 
week after a severe exacerbation (estimated at 40 deaths per 10 000/day), 
and decreases gradually over three months (estimated at five deaths per  
10 000/day).83 Interestingly, in the ECLIPSE study there was no association 
between exacerbations and smoking status.  
 
2.8.4. Phenotyping based on imaging 
The increasing use of CT scanning in COPD and the development of 
quantitative techniques for analysis has resulted in phenotyping based on 
imaging, or in which imaging forms a major component. 
2.8.4.1. Emphysema 
Increasing emphysema scores quantitated on CT scan are associated with 
both a worse health status and increased mortality.73,101 The NETT (National 
Emphysema Treatment Trial) investigators found increased mortality if 
emphysema was homogeneous, or if subjects had a greater proportion of 
emphysema in the lower lung zones, compared with the upper zones. These 
patients had worse outcomes with lung volume reduction surgery than 
subjects with predominantly upper lobe emphysema.76,102 These observed 
differences in mortality and therapeutic options, based on the presence and 
location of radiological emphysema, validate the use of this phenotype.  
2.8.4.2. Bronchiectasis 
Bronchiectasis is an abnormal, permanent dilation of the airways and causes 
a cycle of inflammation, infection and repair, which leads to permanent 
damage and destruction to the bronchial walls; it is not uncommon in COPD. 
In a prospective Spanish cohort, 57.2% (115 of 201 subjects) of patients with 
moderate-to-severe COPD (GOLD stage 2 or higher) were found to have 
bronchiectasis on CT scan of the chest. In addition, bronchiectasis was 
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independently associated with all-cause mortality (HR 2.54, 95% CI 1.16-
5.56, p=0.02).82 Patel et al found bronchiectasis in 50% (27 of 54 subjects) of 
their cohort, and showed an association between lower lobe bronchiectasis 
and more severe exacerbations, as well as increased bacterial colonisation 
and inflammatory cytokines in the sputum.103 The presence of bronchiectasis 
on CT scan has been suggested as an additional phenotype, or poor 
prognostic marker in COPD.73 
 
 2.8.5. Systemic disease and inflammation 
Systemic inflammation is not present in every patient with COPD. In the 
ECLIPSE cohort, 16% of subjects had persistent, systemic inflammation, 
defined on the basis of six inflammatory biomarkers: white blood cell count, 
CRP, IL-6, IL-8, fibrinogen and TNFα. These ‘inflamed’ subjects exhibited 
increased all-cause mortality and exacerbation frequency compared with 
‘non-inflamed’ subjects, despite similar lung function impairment.84 The 
authors were able to characterise the systemic inflammatory network pattern 
(inflammome) in patients with COPD, and contrasted it with the inflammome 
in smokers with normal lung function, as well as non-smokers. Additionally, 
they were able to show that systemic inflammation is not invariable in COPD, 
being absent in approximately a third of subjects. The mechanisms 
responsible for the presence and severity of inflammation and appropriate 
therapies are not yet known.73,86 Despite this, Augusti et al proposed the 
‘systemic inflammatory’ as a phenotype for future research.  
 Comorbid (systemic) disease is often found in subjects with COPD, 
and includes cardiovascular disease, metabolic syndrome, osteoporosis, 
depression and muscle wasting.73 It is debated whether systemic 
comorbidity should be considered in all patients with COPD, or whether it 
should be considered as different phenotypes.86 Vanfleteren et al, using the 
CIROCO (CIRO CO-morbidity) cohort, examined 13 comorbidities in 213 
patients. A total of 98% of all subjects had at least one comorbidity, while 
54% had more than three comorbidities. These authors identified five 
comorbidity clusters: less comorbidity, cardiovascular, cachectic, metabolic 
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and psychological. Despite disease severity being similar among the clusters, 
there were marked differences in health status, suggesting that comorbidity 
clusters may provide information additional to usual measured parameters 
(e.g. FEV1, exercise capacity and BODE index). Additionally, increased levels 
of TNF-receptors were found in the metabolic cluster, while increased levels 
of IL-6 were found in the cardiovascular cluster.104 
 
 2.8.6. Future direction 
The field of phenotyping in COPD is still emerging, and for candidate 
phenotypes to be adopted their usefulness in predicting meaningful 
outcomes (e.g. symptoms, rates of exacerbations, response to therapy, rate 
of disease progression or death) must be confirmed. This may be achieved in 
longitudinal validation studies. Thereafter, biological or molecular 
characterisation may be attempted, with the hope of developing therapies 
appropriate for that phenotype.73 Thus, phenotyping in COPD is likely to be a 
dynamic field in the foreseeable future, with numerous candidate phenotypes 
being presented, some which may endure, while others will be discarded as 
irrelevant.  
 
2.9. Causation between TB and COPD 
 
Although there is a strong epidemiological association between previous 
pulmonary TB and chronic airflow obstruction (CAO), this does not 
necessarily prove causation. (i.e. pulmonary TB as the cause of CAO/COPD). 
This section deals with the theory of causality and specifically focuses on 
temporality, confounders and reverse causation, with respect to the 
relationship between TB and CAO.  
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 2.9.1. Hill’s criteria for causation 
In a landmark thesis on association and causation, Sir Bradford Hill 
presented criteria for assigning causation between an environmental factor 
and disease, they are:105  
• Strength of association – the stronger the association, the greater the 
likelihood of causation. As discussed earlier in the present study, 
tuberculosis has been shown to have a strong association with CAO, 
even demonstrating a stronger association than that for smoking in 
some studies.18  
• Consistency of evidence – the association is repeatedly observed in 
different places, circumstances and times. For tuberculosis, the 
evidence appears to be consistent in a wide variety of population 
groups, as discussed above.52 
• Specificity of association – causation is suggested if an association is 
shown between a very specific population, and specific types and 
sites of disease, without another likely explanation. The more specific 
the association, the greater the likelihood of causation. However, Hill 
cautions against overemphasis of this criterion, and states that 
causation may still be assigned in the absence of specificity. This is 
because many diseases (e.g. COPD and CAO) may have more than 
one cause (e.g. smoking, biomass fuel, occupational exposure etc.).  
• Temporality – ‘which is the cart and which is the horse?’ Exposure to 
the cause must occur before the effect; this is especially important in 
diseases that develop slowly. This will be further discussed in more 
detail below. 
• Biological gradient – if the magnitude of association increases with 
increasing exposure, then causation may be present. This is not 
required in all cases, as single exposure may be enough to result in 
disease (e.g. HIV exposure resulting in AIDS). 
• Plausibility – presence of a biologically plausible mechanism linking 
cause to effect. Biological plausibility is dependent upon the biological 
knowledge of the day, and so is not always convincingly fulfilled. 
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• Coherence – in assigning causality, there should be coherence 
between the available epidemiological and laboratory/biological data, 
recognising that current basic science/laboratory data and techniques 
may be inadequate, and coherence may lag decades behind 
epidemiological observations.  
• Experiment – can an experiment prove the association? For example, 
blocking an exposure or intervening to reduce the outcome of interest. 
• Analogy – is there a similar model of disease, either in humans or 
animals, with which the current hypothesis can be compared? 
 
Hill did not believe that these criteria must be rigorously obeyed before 
accepting causality, rather he states: ‘none of my nine viewpoints can bring 
indisputable evidence for or against the cause-and-effect hypothesis and 
none can be required as a sine qua non. What they can do, with greater or 
less strength, is to help us make up our minds…’ 
 
 2.9.2. Temporality and biological gradient 
Owing to limitations of study design, the present study is unable to address 
the question of temporality in the association between previous TB and CAO. 
However, there is published evidence to support the temporal hypothesis 
that incident TB predates the onset of airflow obstruction.  
 A number of studies conducted on patients with active TB have 
demonstrated airflow obstruction. Estimates of airflow obstruction among 
subjects with active disease have ranged from 11%-51%.55,106–112 In addition, 
combined obstruction and restriction (defined as FEV1:FVC <0.7 and FVC 
<80% predicted) in PTB is high. 
 However, there is less data on the development of airflow obstruction 
during the treatment of TB. In a hospitalised cohort of patients with first 
episode pulmonary TB (n=74), Plit et al, found at diagnosis that 11% (n=8) of 
subjects had airflow obstruction. This had increased to 28% (n=21) at 
treatment completion, thus implying 62% of airflow obstruction developed 
during treatment.55 Interestingly, restriction on lung function declined from 
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57% at diagnosis to 24% after completion of treatment. Snider et al reported 
obstruction at treatment completion in 23%, and mixed 
obstruction/restriction in a further 19% of 1 403 subjects discharged from a 
TB sanatorium.54 In an Indian study, Brashier et al found obstruction in 46% 
of 100 patients at treatment completion.56 Unfortunately, neither of the last 
two studies stated the prevalence of obstruction at treatment initiation, 
making it difficult to determine when in the course of disease and treatment 
airflow obstruction developed.  
 There is some evidence that decline in lung function and obstruction 
may continue after successful treatment of pulmonary TB. Hnizdo et al 
conducted a retrospective review of 27 660 gold miners and found that lung 
function declined after completion of treatment for pulmonary TB. They 
reported greatest loss of function at six months after the diagnosis of TB, 
which had stabilised by 12 months.113 This study, unfortunately, only 
assessed FEV1 and FVC, not FEV1:FVC, neither did it adjust for either 
smoking or silica exposure. These weaknesses limit the conclusions that can 
be drawn with regards to airflow obstruction. In another retrospective review 
of 115 subjects who had completed TB treatment, Chung et al demonstrated 
a continued decline in lung function (both FEV1:FVC and FEV1) for 18 
months following treatment completion, with some improvement 
thereafter.114 The retrospective nature of this study, lack of longitudinal data 
and potential for selection bias, again limit the conclusions drawn. Vargha 
followed up 99 patients for 15 years after hospital discharge; 35% of patients 
developed new airflow obstruction, while airflow obstruction resolved in 
12%.115 Again, there was no adjustment for smoking. Therefore, the available 
literature suggests that previous TB usually antedates the development of 
airflow obstruction, but questions regarding the timing and subsequent 
progression of airflow obstruction remain. 
 Evidence for a biological gradient in the TB-CAO association would 
require that subjects with either more extensive TB or recurrent episodes of 
TB have more-severe airflow obstruction. Biological plausibility of the 
association is discussed in more detail below [see 2.10.2.1].  
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Hnizdo et al, using a cohort of gold miners, observed in patients with 
several episodes of active PTB that lung function declined with each 
episode. The decline in FEV1 was three times greater after the third episode 
than after the first (–410 mL vs. –153 mL). The percentage of subjects with 
FEV1 impairment (FEV1 <80% predicted) in those with one, two and three 
episodes of TB was 18%, 27% and 35%.113 Although FEV1:FVC was not 
reported, the absolute loss of FEV1 (in mL) was greater than that of the FVC 
for all subjects who had TB, regardless of the number of episodes, 
confirming the development of airflow obstruction rather than restriction.  
 In summary, there is evidence of temporality in the TB-CAO 
association, adding weight to the argument for causality. It appears that 
lung-function changes may evolve over time in patients with tuberculosis. 
Restriction appears to predominate in the active phases of TB and may mask 
underlying airflow obstruction, the latter appearing as the former resolves 
with treatment.55 Thereafter, CAO may progress over months or years, and 
further episodes of TB increase the decline in lung function. 
 
2.9.3. Confounders 
Several potential confounders need to be considered when evaluating the 
association between previous TB and CAO. A confounder is defined as a 
variable/factor that is both a cause of the disease/outcome under study, as 
well as being correlated (either positively or negatively) with the exposure of 
interest.116 Two important confounders to consider in the TB-CAO 
association are cigarette smoking and HIV status.  
 Cigarette smoking fulfills the criteria as a confounder in the causal 
pathway between TB and CAO. A number of systematic reviews have 
confirmed a positive association. The pooled odds ratios for association have 
been estimated at 1.7-2.2 for TB infection; 2.0-2.6 for TB disease; and 1.3-
2.2 for TB mortality.117–119 In a local Cape Town study of 2 401 adults, den 
Boon et al found a positive association between smoking and a positive 
tuberculin skin test (TST). An odds ratio of 1.99 (95% CI 1.62-2.45) was 
observed for ever-smokers having a positive TST, compared with never 
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smokers.120 Groenewald et al estimated that 24% of pulmonary TB in South 
Africa could be attributed to cigarette smoking; 32% for men and 8% for 
women.40 More strikingly, Sitas et al have attributed 56% of deaths to TB 
among South African Coloured men to cigarette smoking, with the 
attributable fraction being 36% for White men and 14% for African men. 
Attributable fractions among South African women were: 43% for Coloured 
women, 12% for White women and 4% for African women.42 Cigarette 
smoke has been shown to impair alveolar macrophage function, by impairing 
cytokine responses and mycobacterial containment.121 However, despite the 
potential for cigarette smoking to confound, the strong positive association 
between TB and CAO persists, even after adjusting for smoking.18,25,26  
 HIV infection is another potential confounder in the association 
between TB and CAO. There is increasing recognition of HIV as a cause of 
CAO/COPD (i.e. associated with the outcome).122–125 Several mechanisms for 
the development of airflow limitation in HIV infection have been proposed, 
but this topic is beyond the scope of the present review.125,126 Additionally, 
the well-known positive association between the immune-deficient state of 
HIV and TB satisfies the requirement for potential confounding.21  
The magnitude of this confounding in the TB-CAO association is not 
known, as none of the larger epidemiological studies mentioned above have 
adjusted for HIV status, since most were conducted in low-HIV-prevalence 
countries. However, two studies conducted in South African miners found no 
differences in lung function loss between HIV-positive and HIV-negative 
subjects following TB,127,128 suggesting that the association between 
tuberculosis and CAO is independent of HIV status (i.e. no confounding 
effect). This will need to be confirmed in future studies. 
 
2.9.4. Reverse causation with smoking and tuberculosis 
It is possible that the presence of COPD may place individuals at greater risk 
of the development of PTB (i.e. reverse causation), with COPD being the 
primary event. Potential reasons and mechanisms for this occurring are 
unconvincing. Possibilities are that impaired lung immunity in COPD may 
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predispose to the development of PTB. This could include the effects of 
COPD treatment (e.g. corticosteroids). Lee et al, examining a nationwide 
Taiwanese database of 1 000 000 beneficiaries, reported COPD to be an 
independent risk factor for the development of TB [HR 2.47, 95% CI 2.21-
2.76].129 There was evidence of an association between oral corticosteroid 
and oral β-agonists use and the development of PTB, but no association was 
found for inhaled corticosteroids. The retrospective database study design 
limits interpretation of these findings, and alternative hypotheses should be 
considered. However, Shu et al, in another retrospective Taiwanese study, 
confirmed these findings. There was an association in COPD between PTB 
and oral corticosteroid use and with high-dose inhaled corticosteroid use, 
but not with medium or low doses.130 However, potential selection bias and 
the small numbers of subjects with TB equally limit interpretation of this 
study. Thus, although reverse causation is a possible explanation, given the 
data on the temporal relationship between PTB and CAO, it is unlikely that 
this mechanism plays a major role. 
 
2.10. Mechanisms of airflow obstruction 
 
In contrast to smoking-related COPD, the mechanisms responsible for 
chronic airflow limitation associated with previous TB have not been well 
studied.  
 
 2.10.1. Mechanisms of CAO in COPD 
The CAO in COPD results from a combination of both obstructive 
bronchiolitis (small airways disease) and emphysema (parenchymal disease) - 
the relative proportion of each varying from patient to patient,22,60 which 
develops over years or even decades of exposure to a causative agent, 
usually smoking. 
 Small airways, defined as those of less than 2 mm in internal diameter 
(fourth to fourteen generations), are the predominant site of airflow 
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obstruction. They have less cartilage than larger airways, a larger proportion 
of smooth muscle and fewer goblet cells. In normal lungs, these airways 
contribute little to airflow resistance, but in obstructive diseases of the lung 
(e.g. asthma and COPD) they become the major site of obstruction, because 
even minor changes in diameter result in large increases in airflow 
resistance.131 In COPD, increased wall thickness results from a combination 
of inflammation, fibrosis and mucus plugging, which narrows the lumenal 
diameter. Mucous gland metaplasia results in hypersecretion of mucus, 
which, combined with impaired mucociliary clearance caused by squamous 
metaplasia, leads to plugging of airways. In addition, the increased mucus 
viscosity influences surface tension, which results in premature airway 
collapse during expiration.81,131  
 Airway wall volume, mucus metaplasia and plugging of small airways 
are positively associated with severity and progression of COPD.132,81 
Recently, McDonough et al assessed the small airways of 78 patients using 
multidetector CT scanning and MicroCT scanning. They were able to show a 
significant reduction in the number of airways measuring 2.0-2.5 mm for all 
GOLD stages of disease. Additionally, they showed a reduction in both the 
number and total cross-sectional area of terminal bronchioles in patients with 
GOLD stage 4 disease, which suggests that small airways narrow and 
disappear before the onset of emphysema, and accounts for the large 
increase in small airway resistance.133  
 The relationship between pathology in large and small airways is 
unclear. Hogg et al proposed that inflammation of the central and peripheral 
airways occurs independently of each other.134 In support of this, the 
inflammatory profile is different in airways of differing caliber. However, the 
presence of bronchiectasis in larger airways is now recognised in patients 
with COPD and occurs in up to 57% of COPD patients, and relates to both 
and increased risk of exacerbations and mortality. 
The presence of radiological emphysema is associated with both 
lower health status and increased mortality in patients. In emphysema, loss 
of elastic recoil associated with the parenchymal destruction results in the 
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premature closure of the airways on expiration. Interestingly, there is 
additional loss of both terminal bronchiole number and area (described 
above) in both centrilobular and panlobular emphysema.133 
The chronic exposure to cigarette smoke, and other toxic gases and 
particles evokes both the early innate defense system (including the 
mucociliary escalator and epithelial barrier) and later adaptive immune 
response (with both humoral and cellular elements), with persisting chronic 
inflammation and attempts to repair and restore the tissue to its initial 
state.134 
The lungs of smokers have consistently shown increased inflammatory 
cells as well as denuded epithelium,60 with clusters of pigmented alveolar 
macrophages causing a characteristic respiratory bronchiolitis.135 
Macrophages, being five to ten times more numerous in subjects with COPD, 
appear to play a central role; being both activated and localised to areas of 
damage, as well as responsible for the recruitment of other immune cells.60 
The airways of patients with COPD additionally show increased numbers of 
neutrophils as well as lymphocytes - predominantly CD8 and B cell 
subtypes134 - which are organised into lymphoid follicles and correlate with 
the degree of airflow obstruction.131,134  
Airway inflammation in COPD is considered to be a Th1-type 
response, with high levels of IL-1, IL-6 and IFN-γ. Th17 cells, which induce 
the production of IL-6 from bronchial epithelial cells, stimulate mucin 
secretion (including both MUC5A and MUC5B). Increased levels of IL-6 and 
IL-17 have both been associated with increased risk of bronchial infections, 
exacerbations and hospitalisations.81  
Destruction of the lung parenchyma appears to be facilitated through 
the release of multiple proteinases and matrix metalloproteinases (MMPs) by 
both neutrophils and macrophages,136 with the resultant degradation of 
elastin (by neutrophil elastase) and increased excretion of desmosine (an 
elastin breakdown product). Patients with emphysema exhibit increased 
levels of MMP-1 (collagenase), MMP-2 and MMP-9 (gelatinase B).60,137  
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The action of proteolytic enzymes is normally balanced by the action 
of antiproteases (e.g. alpha-1-antitrysin, airway-epithelium-derived secretory 
leukoprotease inhibitor, and tissue inhibitors of matrix metalloproteinases - 
TIMPs). It is thought that cigarette smoke increases the production of 
proteolytic enzymes while decreasing the available antiproteases, tipping the 
protease-antiprotease balance in favour of tissue destruction. Genetic 
polymorphisms of various genes may account for the variable expression of 
disease in smokers.60 
Patients with COPD display a greater intensity pro-inflammatory state 
compared to non-smokers, with increased NF-κB and decreased HDAC2 
expression.131 Smoking-induced oxidative stress may play a role in activating 
NF-κB, in turn increasing levels of TNF-α, IL-8 and other pro-inflammatory 
factors.138 Additionally, surfactant protein-D (SP-D), a part of the innate 
immune system elevated in smokers, is associated with airway inflammation 
and may prove useful as a future biomarker.65  
Large and small airways demonstrate differences in inflammation, with 
large airways exhibiting more macrophages and small airways more CD8 
lymphocytes and neutrophils. Additionally, NF-κB expression is greater in the 
large airways, while HDAC2 expression is reduced in the small airways.131 
 The increased inflammatory reaction to cigarette smoke occurs before 
the detection of structural changes in the lung, or clinically detectable airflow 
obstruction.135,139 The inflammatory reaction initiated by cigarette smoke 
appears to be independent of smoking intensity and continues long after 
smoking cessation. The mechanism of the ongoing inflammation in the lung 
after smoking cessation is unexplained, and various authors have 
hypothesised about the persistence of either auto-antigens or micro-
organisms as perpetuating factors.22,131  
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 2.10.2. Airflow obstruction associated with tuberculosis 
  2.10.2.1. Hypothesis of bronchial tree involvement 
Endobronchial involvement in active pulmonary TB has been confirmed on 
CT scans and appears as centrilobular nodules, branching linear structures, 
(’tree-in-bud’ appearance) or poorly defined nodules, being present in almost 
all cases of active TB.140 Lesions in and around the small airways are the 
most characteristic feature of active TB, occurring in 95.0% of individuals. 
Although most lesions disappear by five months,141 the resultant 
peribronchial fibrosis may cause fixed airflow obstruction.  
 Bronchiectasis, defined as abnormal permanent dilation of bronchi, is 
common after PTB and is another recognised cause of CAO. The association 
between TB and bronchiectasis was first noted in 1819 by Laennec, and later 
confirmed in post-mortem studies.142 It is proposed that post-tuberculous 
bronchiectasis may result from endobronchial or peribronchial fibrosis, or 
stenosis leading to distal airway dilatation. Additionally, enlarged tuberculous 
or reactive lymph nodes may lead to atelectasis and post-obstructive 
bronchiectasis in lung distal to the glands. Furthermore, bronchi may 
become distorted and dilated in areas of parenchymal fibrosis and scarring, 
or following rupture of tuberculous glands into airways.54 CAO in 
bronchiectasis correlates both with extent of disease and bronchial wall 
thickness, but the mechanisms responsible are unclear. Bronchospasm, 
retention of secretions, and intrinsic narrowing of small- and medium-sized 
airways resulting in gas trapping may be involved.142 
 Lesions in or surrounding small airways (<2 mm) may result in airflow 
obstruction in post-tuberculous lungs. These airways are not easily visualised 
radiographically, even with CT scans, but their involvement is inferred from 
the presence of gas trapping on expiratory CT scans and may take the form 
of complete closure (obliterative bronchiolitis) or cicatricial narrowing. Gothi 
et al, reported a strong correlation between a mosaic pattern of gas trapping 
and a previous history of tuberculosis,143 while Long et al demonstrated the 
persistence of mosaic pattern attenuation after tuberculosis treatment, 
despite resolution of endobronchial and parenchymal changes.140 
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 There is limited and conflicting evidence on the development and role 
of bronchial hyper-responsiveness after PTB.53 
  2.10.2.2. Hypothesis of inflammatory parenchymal  
  destruction 
Another potential mechanism for CAO after PTB is that lung parenchyma 
undergoes destruction during the active phase of disease, similar to that 
seen in smoking-related emphysema. Parenchymal destruction may increase 
pulmonary compliance, resulting in dynamic airway collapse with gas 
trapping.26,142 Additionally, inflammation may persist long after treatment 
completion, resulting in ongoing chronic parenchymal destruction similar to 
that observed in smoking-related COPD. This mechanism is supported by 
similarities in the inflammatory profile observed in these conditions, with 
elevated levels of MMPs (specifically MMP-1 and MMP-9) in airways.144 In a 
recent study by Tang et al, levels of cytokines (IL-6, TNFα, IFNγ and sIL-2R) 
were elevated in both conditions compared with controls, while subjects with 
comorbid TB and COPD had higher levels of sIL-2R, IL-6 and TNFα than 
subjects with either TB or COPD alone. This evidence may suggest that the 
persisting airway inflammation after active PTB may lead to COPD, and 
secondly supports the additive inflammatory and destructive potential when 
both infection and smoking-related COPD are established, and possibly 
when smoking continues after an episode of PTB.145  
Tumour necrosis factor alpha (TNFα) is a central cytokine in the host’s 
defense against TB. In certain Taiwanese populations, polymorphisms of the 
TNFα promoter region results in increased TNFα production and a 10-fold 
increase in COPD.60.146 It is thus possible that persistently elevated levels of 
TNFα during and following PTB contribute to the development of changes 
similar to those observed in COPD. 
However, emphysema is not a usual feature in PTB. Long et al found 
no convincing CT scan evidence of emphysema in patients with active 
tuberculosis.140 In one small study, no reduction in DLCO, considered a useful 
marker of emphysema, was found in patients with post-tuberculosis airflow 
obstruction (n=11).147 Consistent with this, Martin et al found no evidence of 
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histological emphysema in a series of autopsies of subjects with acute TB 
and airflow obstruction.148 Thus, the mechanism of CAO following an episode 
of TB requires further study. 
 
2.11. Burden of Obstructive Lung Disease (BOLD) study 
methodology 
 
The population-based study of Jithoo et al provided one of the most 
accurate estimates of COPD, and current and past PTB in a South African 
community. The major strength of this study was the use of standardised 
international methodology (the BOLD methodology) for the survey, which 
included spirometry using standard spirometers, trained technologists, and 
central quality control for all tests. Patients found to have COPD according to 
BOLD criteria form the basis for the studies reported in the present study. 
First, however, it is relevant to provide details of the BOLD methodology.  
 
2.11.1. BOLD population selection and sampling 
The BOLD methodology requires sites to recruit a minimum population-
sample of 600 adults (300 men and 300 women). Subjects must be 40 years 
of age or older, non-institutionalised and living in an area with a total 
population of greater than 150 000 people. Sampling plans must be pre-
approved by the Operations Centre.14 For the Cape Town study (2005), the 
predominantly low-income urban areas of Ravensmead and Uitsig were 
chosen, with a population at the time of 36 334. These communities were 
known to have a higher prevalence of smoking, TB and, possibly, asthma 
than any other area in the country. This study followed on from a previous 
study, the Lung Health Study (LHS), carried out in the same community in 
2002 by Jithoo et al. The LHS 2002 was a cross-sectional study comprising a 
15% random sample of addresses (833 addresses), and recruiting persons 
>15 years old. The BOLD 2005 study sampled the same 833 addresses, but 
only recruited adults >40 years old. The BOLD Operations Centre approved 
this sampling methodology.29  
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2.11.2. BOLD definition of COPD  
The BOLD methodology bases COPD diagnosis strictly on lung function 
criteria without requiring documented exposure to risk factors, or the 
presence of symptoms. Chronic airflow limitation is defined as a post-
bronchodilator FEV1:FVC <0.7.5,14 The NHANES III prediction equations for 
Caucasians are used to categorise severity, again using GOLD staging 
mentioned above. The limitations of these definitions have been presented 
on page 4 above. 
 
2.11.3. BOLD spirometry 
Lung function data in BOLD was performed in participants’ homes using a 
portable spirometer: the EasyOne ndd Spirometer (ndd Medical 
Technologies, Andover, MA, USA).14 Prior to its adoption by BOLD, the 
performance of this spirometer was evaluated in the large PLATINO study, 
which made use of 70 such spirometers every day for between three and six 
months. The spirometers were calibrated daily with a three-litre calibration 
syringe and investigators found good calibration stability, which was 
maintained for the duration of the study. Almost all calibration checks were 
within the ± 90 mL (3%) required by the American Thoracic Society (ATS) 
standards, and most were within ± 50 mL. During the survey, they found one 
defective calibration syringe and one spirometer had a faulty memory.149  
 Before and 15 minutes after an inhalation of a rapid-onset beta2-
agonist bronchodilator (200 μg of salbutamol), lung function was performed 
by certified technologists. All lung function data were assessed for 
acceptability and reproducibility in accordance with the ATS and European 
Respiratory Society (ERS) standards, and was performed centrally at the 
BOLD Pulmonary Function Reading Center (PFRC). Data not meeting these 
standards were excluded from analysis.14 A review of the 9 893 spirometry 
tests in 14 countries during the BOLD study revealed that quality goals were 
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met in about 90% (i.e. FEV1 and FVC repeatable within 150 mL), thus 
confirming the reliability of the spirometer.150  
 
2.11.4. BOLD questionnaire 
The BOLD investigators developed questionnaires that included questions 
about respiratory symptoms, exposure to risk factors, health status and 
health utilisation. The questionnaires were administered in person by trained 
staff in the subject’s native language. Although some of the questionnaires 
were based on standardised instruments, there do not appear to be reports 
of the precision, accuracy and repeatability of the questionnaires used in the 
BOLD study.14,24  
 Similar to other studies, the BOLD methodology based the 
assessment of previous TB status on responses to questions in the 
questionnaire only. For obvious reasons, more accurate methods like reports 
of microbiology, clinical records or radiology were not employed.17 It is likely, 
however, that reliance on questionnaires to assess TB exposure results in an 
underestimation of previous TB, particularly in a high-prevalence setting. This 
fact was illustrated by Lam et al in a large population survey conducted in 
China (n=8 066), in which diagnosis of previous TB by questionnaire provided 
232 cases and by chest X-ray, 1 954 cases.26 This disparity might be 
explained in part by concerns about stigmatisation if participants report 
previous TB. This is likely to vary in different cultures; thus, these findings 
should not be extrapolated to other communities. 
 
2.11.5. BOLD diagnostic reliability 
As with any definition or test, basing the diagnosis of COPD on spirometric 
criteria alone has shortcomings. Firstly, a number of other conditions, such 
as chronic asthma and bronchiectasis, can result in irreversible airflow 
obstruction and may be misdiagnosed as COPD in these prevalence 
studies.38 This question, and its likely impact on the reported results of BOLD 
studies that have now been performed in more than 30 sites globally, has not 
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been adequately addressed. Nor has an estimatation of the magnitude of this 
problem or possible correction factors that might improve the accuracy of 
the estimate of COPD when employing the BOLD criteria been proposed. In 
follow-up studies performed five and nine years after the first PLATINO Study 
in Latin America (which used methodology similar to that of BOLD Study), the 
prevalence of COPD remained relatively stable with only a small increase of 
0.9% in Montevideo (five-year follow-up), and 0.4% in both Santiago de Chile 
(six-year follow-up) and Sao Paolo (nine-year follow-up).151 However, the 
authors did not attempt to assess the accuracy of the diagnosis, and, in 
particular, the proportion that might have had asthma and other diagnoses. 
 Therefore, an important component of the present study is an attempt 
to assess the diagnostic accuracy of the BOLD methodology in diagnosing 
COPD. 
 
2.12. Radiological tools for correlating lung structural 
abnormalities with function  
 
Because radiology will be extensively utilised in the assessment of structural 
lung changes, a review of these techniques, in the context of the present 
study, is presented. 
 
 2.12.1. Radiological changes of tuberculosis 
Radiological changes of active primary TB normally appear as homogeneous 
consolidation (usually segmental or lobar, but multifocal in 12%-24%), while 
nodular, linear, patchy and mass-like lesions have also been described.152 In 
contrast, post-primary disease is characterised by parenchymal opacities, 
occurring predominantly in the apical and posterior segments of the upper 
lobes (83%-85%) and the superior segments of the lower lobes (11%-14%); 
the majority involve more than one segment, while cavitation occurs in 40%-
45% of cases.152,153 The parenchymal opacities are frequently heterogeneous 
and may be associated with nodular or linear lesions initially radiating from 
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the hilum, progressing to distortion of the bronchovascular and mediastinal 
structures. Tuberculomas, defined as round or oval, sharply marginated 
lesions, of 0.5-4.0 cm in diameter, may be either solitary or multiple, and are 
the predominant lesion in 3%-6% of post-primary disease.152 
Bronchogenic spread of TB is observed in approximately 20% of 
chest X-rays and is identified as multiple nodules (5.0-10.0 mm) in a 
segmental distribution, frequently in a dependent (lower) region of the lung, 
distal to a cavity.152 CT scanning, a far more sensitive tool, detects 
bronchogenic spread in 95% of TB cases. Centrilobular nodules (2.0-4.0 mm) 
form early in the disease, with bronchiolar caseous material being visualised 
as branching linear structures – the so-called ‘tree-in-bud’ pattern. Larger, ill-
defined nodules (5.0-8.0 mm) are also observed, which appear to partially 
resolve into ‘centrilobular nodules’ with treatment. The larger nodules consist 
of outer, ill-defined areas of non-specific inflammation, while the smaller 
centrilobular nodules consist of dense caseous necrosis,141 the majority of 
which disappear after treatment with minimal residual changes.154 Cavitation 
starts as 3.0-4.0 mm lesions, centering on the centrilobular bronchioles, 
which enlarge and coalesce to form larger air spaces and resolve with 
residual scarring damage.154 
Im et al have claimed that fibrosis and emphysema invariably result 
from bronchogenic spread of areas of caseation, with traction by adjacent 
scar tissue (so-called ‘cicitricial emphysema’) as well as bronchiolar stricture, 
being proposed as possible mechanisms for the emphysema.154 Other 
investigators have not been able to confirm these findings.140 
Radiographic areas of mosaic low-attenuation, thought to represent 
either gas trapping secondary to bronchiolar occlusion, or hypoperfusion 
secondary to arteriolar occlusion or vasoconstriction, have been 
demonstrated in active PTB. Im et al, using a similar pig model of disease, 
concluded that gas trapping was the more likely explanation and was unable 
to demonstrate a vascular contribution to the mosaic pattern.154 
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Other radiological findings that may occur in active TB include: 
bronchial wall thickening, lobular consolidation, interlobular septal thickening 
and pleural involvement.  
The residual radiological abnormalities found after active PTB are 
varied. Upper-lobe changes are most common, and comprise atelectatic and 
fibrotic areas, as well as emphysematous bullae, bronchiectasis and calcified 
nodules. The trachea and large airways may show dilation and distortion 
secondary to pulmonary fibrosis. Volume loss is common, as is residual 
pleural and diaphragmatic abnormalities, and the presence of a pleural 
cap.154,155  
Several methods have been described that assess for the presence of 
active TB on chest X-ray, as well as quantify the burden of disease. These 
methods vary from ‘expert reader’ opinion to semi-quantitative methods of 
assessment.57,155,156 One such method, The Chest Radiograph Reading and 
Recording System (CRRS), employs a semi-quantitative method for 
assessing the common abnormalities of acute TB and their distribution, 
showing a good kappa statistic between readers (k=0.63, 95%CI 0.52-
0.73).157  
In contrast, there are no well-described or validated methods for 
documenting the presence of, or quantifying the burden of, previous 
pulmonary TB on either chest X-ray or CT scan. Described methods are non-
standardised and non-quantitative, based largely on subjective descriptions 
by expert readers.26,155,158  
 
 2.12.2. Quantitative CT scanning in COPD  
2.12.2.1. Technical aspects 
Computed tomography (CT) images are captured in two-dimensional pixels, 
which when combined with the thickness of the tomogram slice (z-axis) is 
termed a voxel. A high-resolution (HRCT) protocol to visualise lung 
parenchyma involves axial slices 1.0-2.0 mm in thickness, spaced 10.0-15.0 
mm apart, and reconstructed, traditionally performed using single-slice 
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scanners. Modern multi-detector scanners contain from 4 to 320 detectors, 
and are able to generate true volumetric data from contiguous slices 0.5-1.0 
mm apart in a single breath hold, thus improving image resolution with 
reduced exposure times.159 Image density is expressed as Hounsfield units 
(HU) and is visually displayed using a gray scale. Human tissue varies from  
–1 000 HU (density of air) to approximately +1 000 HU (density of cortical 
bone), with the density of water being 0 HU and blood being 40 HU.160 The 
total radiation dose during CT scanning is a combination of the tube current 
(in mA), total exposure time and maximum voltage (kVp). Current lung 
imaging methods used in clinical research involve exposures of 1.0-3.0 
millisievert (mSv) per scan, compared with 5.0-8.0 mSv per scan for standard 
protocols, which is similar or lower than an expected natural background 
radiation dose for an individual per annum (3.0 mSv).160,161 
 Images can be acquired at total lung capacity (TLC), functional 
residual capacity (FRC) or residual volume (RV), which yield different 
densities for lung parenchyma due to differences in aeration. Inability to 
perform full inspiratory/expiratory manoeuvres, adequately breath hold, or lie 
still (resulting in movement artifact) affect image capture. The use of 
concomitant spirometry (through the use of a volume controller), or careful 
coaching of subjects prior to scanning, may be used to ensure optimal lung 
volumes; the former being more precise, while the later is more practical. Use 
of the shortest possible scan time increases the probability of an adequate 
breath-hold, thus minimising movement artifact. This is achieved by using a 
fast gantry rotation time, the maximum number of channels available and the 
highest pitch.160,162 
 Insufficient radiation dose can result in excessive ‘noise’ on acquired 
images, resulting in error in density analysis. The ‘signal-to-noise’ ratio can 
be improved by increasing the radiation dose administered; however, the 
need for attaining meaningful attenuation values needs to be balanced with 
the risks of exposing subjects to increased radiation doses. However, an 
insufficient radiation dose results in excessive ‘noise’ on acquired images, 
leading to error in density analysis. Regular calibration against a 
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manufacturer-supplied ‘phantom’ is required to ensure both accuracy and 
precision. Varying CT slice thickness can introduce variation into density 
measurements (see below).162,160,161 
2.12.2.2. Assessment of emphysema 
Pulmonary emphysema is histologically defined as the permanent dilation of 
air spaces distal to the terminal bronchiole, with destruction of the 
intervening airspace walls. Emphysema is visualised on CT scan as low 
attenuation areas (LAA); however, the measurement of such LAA and the 
thresholds density cut-off that should be used to define radiological 
emphysema has been much debated.163,164 Initially, a lung parenchymal 
density threshold of –910 HU or less was proposed using a single-slice 
scanner and 10.0 mm thick slices. This threshold correlates well with 
histological emphysema in resected lung tissue.165 Subsequently, using 
HCRT protocols (1.0 mm slices), Gevenois et al reported that a threshold of  
–950 HU or less showed the strongest correlation with pathology 
specimens.166 More recently, Madani et al found that the extent of 
emphysema was estimated best by using thresholds of –960 HU or –970 HU 
when using multi-detector CT (MDCT) protocols.167 With automated 
quantitative techniques, the extent of emphysema is usually expressed at a 
percentage of lung parenchyma with low attenuation areas (e.g. %LAA –950 
for the –950 HU cut-off). Normal lung parenchyma has a density of 
approximately –850 HU. It is important to remember that although %LAA 
correlates moderately well with histological emphysema, it is not specific, as 
other pathology may also yield low attenuation readings (e.g. cavities).168,163 
Currently, the <–950 HU threshold is most-widely used.168 
As emphysema is not uniformly distributed throughout the lungs, most 
current computational software provides estimates of %LAA on either a 
zonal (upper, middle and lower zones) or a lobar basis.163,164 Recently, 
Castaldi et al, using the large COPDGene cohort, used algorithms to estimate 
proportions of various radiological phenotypes of emphysema (centilobular, 
panlobular and pleural-based emphysema), and were able to show better 
correlation with physiological parameters using these methods.169 
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 An alternative approach for detecting and quantitating emphysema is 
percentile densitometry, which provides a mean density value for the lung at 
a defined centile. This method may be preferable for longitudinal evaluation 
of emphysema, as it is less affected by changes in lung volume, but is less 
reproducible than the threshold method (i.e. density <–950 HU). Both the first 
and fifteenth percentile have been proposed; the former percentile shows 
better histological correlation when using MDCT, while the latter appears 
more robust if image artifact is present, and is more frequently quoted in 
current literature.164,162,168,170 
 Important sources of variation in measurement of %LAA exist. First, 
sub-maximal inspiration results in under-aeration of lung, which falsely 
increases parenchymal density measurement. Although these differences in 
density measures are marginal at 100% and 90% of TLC, differences 
became significant at lower levels of inspiration (e.g. 80%, 70% and 50% of 
TLC).168,171 Additionally, CT slice thickness influences estimates of %LAA; 
thinner slices demonstrate a greater extent of emphysema. Thicker slices, 
although giving better resolution, have been made obsolete with the advent 
of MDCT protocols. Furthermore, a low signal-to-noise ratio also results in 
increased %LAA, although the mean parenchymal density is little affected.162 
Interestingly, recent smoking cessation has been shown to increase the 
%LAA,172 which is thought to result from rapid clearing of soot, tar and, 
possibly, inflammation upon cessation, revealing underlying low-attenuation 
areas.162,168 Despite these limitations, quantitative assessments of 
emphysema are more reproducible than visual assessments performed by 
experienced radiologists.173 Barr et al, in the COPDGene workshop, 
demonstrated inter-reader agreement on manual quantification in COPD to 
be moderate to poor, while the concordance between visual and quantitative 
measures was 75% for emphysema.174 Furthermore, radiologists tend to 
underestimate disease extent in less-severe emphysema, and overestimate 
disease in more-severe disease.168 
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2.12.2.3. Assessment of airways 
A number of techniques have been developed to measure and assess airway 
anatomy in COPD, with a number of parameters being measured. Focus has 
traditionally been on airway remodelling, and in particular, thickening – which 
is often expressed as a percentage of bronchial wall area.160 Initially, methods 
of airway quantification used manual tracing methods to assess single or a 
few predominantly large airways.175 With the advent of MDCT, manual 
methods were replaced by automated techniques. Most common among 
these is the ‘full-width-at-half-maximum’ (FWHM) technique. This method is 
performed by placing a point at the bronchial lumen centre, with software 
calculating the CT attenuation values along lines radiating outwards from this 
point. In this way, airway wall boundaries are defined at the point where 
attenuation is halfway to the maximum on the lumen side, and halfway to the 
minimum on the parenchymal side.176 Other parameters can then be 
calculated: airway wall thickness (AWT); luminal area; wall area percentage; 
and airway perimeters. However, the FWHM method is known to 
systematically overestimate airway wall thickness, and underestimate luminal 
area. This overestimation increases as airway size decreases.177,162,159,178 To 
improve accuracy, a number of different quantitative algorithms have been 
developed, examples of these include: maximum-likelihood algorithms on the 
grey level; ellipse fitting to the lumen; and score-guided erosion algorithm 
methods. Currently, there is no consensus on a ‘gold-standard’ for this 
method.176,177  
 Multiplanar reconstruction using MDCT data permits the tracing of 
airway diameter down to the segmental and sub-segmental levels. The 
software algorithms are designed to extract airway centerlines through these 
reconstructions, then re-sample images perpendicular to the airway direction 
at intervals equally spaced along the airway.179 These measurements may be 
used in summary measures of bronchial wall area. For example, Pi10, which 
is the square root of the wall area of a hypothetical bronchus with an internal 
perimeter of 10.0 mm; this measure is a calculated value obtained from linear 
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regression models, using data obtained from all measured bronchi within an 
individual.179,168  
 There are a number of sources of variation in quantitative assessment 
of airways. Foremost among these is the algorithm used, as values obtained 
from the algorithm are not merely density measures, but rather require the 
division and interpretation of voxels into ‘airway lumen’ and ‘surrounding 
tissue’. Detection and measurement of the airway lumen is relatively simple 
because of the high degree of density contrast between the intraluminal air 
and surrounding tissue. More complicated is the outer delineation of the 
airway wall, especially when the surrounding lung parenchyma or 
bronchovascular bundle density is similar to that of the airway wall.162 Thus, it 
is important that the same algorithm be used for all subjects within a study, 
while comparisons of values obtained by different algorithms should be 
discouraged.  
 In addition to the algorithm used, airway caliber and resolution of the 
CT scan may affect airway assessment. Small airways have been shown to 
have a higher error rate in measurement compared with larger airways (as 
discussed above). This has resulted in investigators frequently focusing 
primarily on the analysis of larger airways. Over time, the ever-increasing 
scanner resolution will improve airway assessment. Additionally, biological 
factors such as lung volume may affect assessment, with larger lung volumes 
being shown to result in larger airway lumen diameter.162  
 Small airways (<2.0 mm in diameter) are of particular interest in COPD, 
as they are the most important sites of airflow obstruction. However, they are 
normally below the resolution of CT scan detection, unless their walls 
become thickened due to inflammation or filled with exudates. Detection of 
these airways is limited by the resolution of the scanner (i.e. the size of the 
voxel), which is normally 0.5 mm, and reliable airway measurements have 
only been consistently demonstrated down to an airway diameter of 2.0 
mm.180,159,131 However, indirect evidence of small airway dysfunction is the 
presence of gas trapping on expiratory CT scans. Gas trapping is defined as 
a ‘less than normal increase in lung attenuation and lack of volume reduction 
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after expiration’.164 On expiration, normal lung density increases, thus, areas 
of lung where gas trapping is present appear less dense than the 
surrounding lung, which provides useful information on lung structure below 
the resolution of CT images. Quantification of gas trapping on expiratory 
scans in COPD is relatively new, and a threshold of <–856 HU on expiration 
has been proposed. The value –856 HU is derived from a conversion of 6.0 
mL/g of lung inflation on inspiration (i.e. approximately normal lung density 
on inspiration). Expiration manoeuvres to both RV and FRC have been used 
to determine gas trapping, and optimal respiratory manoeuvres have not yet 
been defined.168,164,160,162 
The interpretation of radiological findings of gas trapping is difficult 
due to the lack of a pathological reference for comparison. Furthermore, in 
COPD, quantitative measurement of gas trapping is complicated by the need 
to separate areas of true gas trapping from residual air in emphysematous 
areas. Several different techniques have been proposed to overcome this, 
with some authors using ‘voxel-by-voxel ventilation maps’, which calculate 
the change in density of voxels between inspiration and expiration.168 Glaban 
et al used this approach and defined voxels with a density <–950 HU on 
inspiration to have ‘emphysema’, while those with a density of >–950 HU on 
inspiration but <–856 HU on expiration were considered to have ‘functional 
gas trapping’.181 Despite the lack of a pathological ‘gold-standard’ 
comparator, CT measures of gas trapping have been shown to correlate well 
with physiological measures of airflow obstruction (e.g. FEV1:FVC).168,182  
 An alternative measure of gas trapping is the expiratory:inspiratory 
mean lung density ratio (E/I ratio). This ratio, which is not yet widely adopted, 
compares the mean lung density at FRC (expiration) to the mean lung density 
at TLC (full inspiration), and has been proposed as a potentially better 
measure than the –856 HU threshold mentioned above, as it demonstrates 
better ROC curves compared with other measures.160,176 
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2.12.2.4. Correlation between imaging and lung function 
 and other clinical features  
Quantitative CT measurements of both emphysema (%LAA) and airway wall 
thickness (AWT) correlate with lung function measures. Nakano et al 
demonstrated correlation between AWT (using FWHM methods) and peak 
expiratory flow rate (PEFR), percentage predicted FVC and RV:TLC ratio, but 
not FEV1:FVC or diffusion capacity.183 Washko et al, in a cohort of 224 
subjects, found that airway wall attenuation added additional information and 
was independently associated with FEV1.184 Nakano et al reported that in 
COPD, radiological assessment of intermediate-airway wall area correlated 
well with histological measurement of small-airway wall area, suggesting that 
intermediate-sized airway wall assessment could be used as a surrogate 
measure for small-airway pathology.185 However, Hasegawa et al 
demonstrated that correlation of AWT with percentage predicted FEV1 
improved as airway caliber declined.186 Dijkstra et al found AWT to be a 
better predictor of FEV1 than the emphysema component; however, 
combined emphysema scores and AWT only predicted 40.0% of the 
variance in percentage-predicted FEV1. These authors suggested that 
obtaining values on expiration may be better predictors of FEV1 than those 
performed at TLC.179 Other authors have been unable to show a relationship 
between airway dimensions and FEV1.187 Coxson et al and others postulated 
that poor resolution of the all-important small airways may be responsible for 
the relative insensitivity of CT scanning to predict changes in FEV1.180,186 In 
support of this theory, a remarkable correlation has been shown between 
measures of gas trapping and spirometry (FEV1:FVC and predicted FEV1 
percentage),182 as well as with residual volume.131 Some authors reported that 
measures of gas trapping (i.e. %LAA –856) have a stronger association than 
measures of emphysema (i.e. %LAA –950), with both FEV1 and FEV1:FVC.188  
Radiological measures of emphysema have been associated with both 
lung function and lung function decline. Mohamed Hoesein et al showed in a 
cohort of 2 085 men, an association between extent of emphysema and both 
a lower FEV1 and a greater decline in FEV1 on follow-up.189 Castaldi et al 
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showed that patterns of emphysema were more predictive of FEV1, 
dyspnoea scores and six-minute walk distance, than %LAA –950. Pleural-
based and panlobular emphysema patterns were found to have a larger 
impact on physiological measures than centrilobular patterns.169 
In terms of symptomatology, Grydeland et al found that both %LAA 
and Pi10 were independently associated with dyspnoea in COPD, while Pi10 
was additionally associated with both cough and wheezing.190 Other authors 
have confirmed these findings, demonstrating the association of AWT with 
respiratory symptoms (dyspnoea, wheezing and bronchitic symptoms).179,187 
Han et al reported that AWT and severity of emphysema were independently 
associated with exacerbation frequency; furthermore, that in subjects with 
low levels of emphysema, AWT exerted greater influence than the 
emphysema component. Interestingly, these authors found AWT, not wall 
area percentage, was predictive of exacerbation frequency, and postulated 
that airway wall percentage area may mask underlying airway wall thickening 
and pathology when bronchi are dilated.178 In terms of mortality, the 
Norwegian GenKOLS study found CT measures of emphysema to be a 
strong independent predictor of mortality, where subjects having moderate-
to-severe emphysema scores had a 19-month shorter survival than other 
subjects. Airway wall thickness did not independently predict mortality, but 
demonstrated a positive additive interaction in the presence of 
emphysema.191  
 These observations provide support for further use of CT scans to 
phenotype patients with COPD. Classifying COPD as either airway-
predominant or emphysema-predominant disease may, in future, allow more 
focused research and guide selection of therapies.192 
 
 2.12.3. Emphysema estimates from other cohorts 
Emphysema is a histological diagnosis and is common in the general 
population, occurring in 30%-50% of cigarette smokers, 8% of cigar 
smokers and 3% of never-smokers at post-mortem. Pathological subtypes 
are: centrilobular, with loss of the respiratory bronchioles; panlobular, with 
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uniform destruction of the secondary lobule; and paraseptal emphysema, 
characterised by multiple peripheral bullae or septae.193 
 Recently, the large MESA Lung/SHARe Study population-based 
cohort study, used quantitative CT to assess 7 914 adults subjects. They 
found that the percentage of emphysema (at a threshold of –950 HU) varied 
from 2.2% (in African Americans) to 3.6% (in Whites).193 
 In a different study of 463 COPD patients matched with controls, 
Grydeland et al demonstrated the median %LAA –950 to be 8.9% in male 
COPD cases, and 4.7% in females, while the corresponding median values in 
the control group were 0.7% and 0.3%, respectively.194 The %LAA increased 
with the number of pack-years smoked.  
In another study, conducted among 1 140 male lung-cancer screening 
participants, Mets et al reported median quantified emphysema of 0.8% 
(IQR: 0.4%-1.5%) and median air-trapping values of 0.8% (0.8%-0.9%) for 
the whole population, while the average Pi10 was 2.4 ± 0.5 mm. A total of 
437 participants (38%) had COPD on lung function testing. Using a 
diagnostic model, comprising: emphysema scores; air-trapping scores; body 
mass index (BMI); pack-years; and smoking status, they were able to identify 
274 of these 437 participants as having COPD, with 85 false positives. This 
equated to a sensitivity of 63% (95% CI 58%-67%) and a specificity of 88% 
(95% CI 85%-90%), with a PPV of 76% (95% CI 72%-81%) and NPV of 79% 
(95% CI 76%-82%).195,196  
 As part of the COPDGene cohort, 4 062 subjects had CT scans and 
spirometry. Of these, 2 145 (53%) had COPD on spirometry (GOLD stage 1 
or higher), and 1 917 (47%) served as smoking controls. In this study, 
quantitative CT measurements correlated well with spirometry. The mean 
%LAA –950 (sd) on inspiratory CT scans was: 2.5% (2.8) for controls; 6.0% 
(6.0) for GOLD stage 1 COPD; 8.4% (8.6) for GOLD stage 2 COPD; 18.2% 
(12.7) for GOLD stage 3 COPD; and 28.1% (14.0) for GOLD stage 4 COPD. 
Mean measurements of gas trapping on expiratory scans (%LAA –856) were: 
11.7% (9.6) for controls; 20.6% (12.0) for GOLD stage 1 COPD; 28.9% (15.2) 
for GOLD stage 2 COPD; 48.2% (16.9) for GOLD stage 3 COPD; and 63.3% 
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(12.8) for GOLD stage 4 COPD. The Pi10 (sd) was reported as: 3.6 mm (0.1) 
for controls; 3.6 mm (0.1) for GOLD stage 1 COPD; 3.7 mm (0.1) for GOLD 
stage 2 COPD; 3.7 mm (0.1) for GOLD stage 3 COPD; and 3.8 mm (0.1) for 
GOLD stage 4 COPD. The corresponding AWT at the fourth generation 
airways (in mm) was: 5.5 mm (0.7) for controls; 5.4 mm (0.7) for GOLD stage 
1 COPD; 5.0 mm (0.6) for GOLD stage 2 COPD; 4.9 mm (0.6) for GOLD stage 
3 COPD; and 4.8 mm (0.6) for GOLD stage 4 COPD. Regional differences in 
early small-airways disease were seen, with disease being predominant, in 
upper lobes in mild and moderate COPD (GOLD stage 1 and 2). Regional 
differences were not prominent in severe COPD (GOLD stage 4 disease).188 
 Using a retrospective cohort of 1 272 adults with chronic airflow 
obstruction, Kurashima et al used visual CT assessment to show that 40.6% 
(517) of subjects had COPD with emphysema, while 8.2% (104) had COPD 
without emphysema, 14.0% (178) had asthma with emphysema, 13.3% (169) 
had asthma without emphysema, 10.0% (128) had other respiratory disease 
with emphysema, and 13.8% (176) had other respiratory disease without 
emphysema. CT-diagnosed emphysema was associated with increased 
mortality in both asthma and COPD patients.197 
 The pattern of emphysema appears to vary according to overall 
burden of disease. Subjects with lower %LAA (<10%) have more mild 
centrilobular disease, whereas higher %LAA (>10%) is associated with more 
panlobular and pleural-based emphysema, as well as moderate- and severe-
centrilobular disease.169 Using visual assessment of emphysema pattern, 
investigators of the Multi-Ethnic Study of Atherosclerosis (MESA) study 
assessed CT scans from smokers with COPD and controls aged between 
50-79 years, with >10 pack-years of smoking. Of the 318 included subjects, 
113 (36%) showed the presence of emphysema (14% centrilobular 
predominant; 9% paraseptal predominant; and 4% panlobular predominant). 
Subjects with centrilobular or panlobular emphysema exhibited greater 
dyspnoea, reduced six-minute walk distance (6MWD), and a lower diffusion 
capacity. A total of 17% of smokers without COPD on spirometry had 
radiological evidence of emphysema.198 
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  In summary, evidence of emphysema on CT scans appears to 
antedate detectable spirometric airflow obstruction in smokers, but 
detectable radiological changes (emphysema scores, airway measurements 
and gas trapping) do not fully account for observed airflow obstruction in all 
patients with COPD. The evidence to date suggests that small-airways 
disease initially develops in the upper lobes, and becomes more diffuse as 
the disease worsens. The centrilobular pattern of disease is more common in 
early COPD, while panlobular and paraseptal disease increases as the 
disease worsens. 
 In conclusion, CT scans provide a useful method for examining the 
extent and nature of emphysema, correlate with clinical features, and may be 
used as a component of assessments for COPD phenotyping. The relevance 
of phenotyping in treatment selection is currently under investigation. The 
sensitivity of the method makes it suitable for the evaluation of TB-
associated airflow limitation, particularly for examining the extent and 
regional distribution of emphysema (in relation to post-TB lung scarring). 
However, problems of resolution might limit its usefulness for studying the 
site of disease in small airways, and disease in this location may have to be 
inferred from other measures. 
 
Chapter 3. Hypothesis 
 
The central hypothesis for this work is that chronic airflow obstruction in 
patients with a history of previous TB differs in terms of pathophysiology, 
natural history and responsiveness to treatment from patients without this 
risk factor for COPD. The three specific objectives are: 
 
Objective 1 (main objective) 
To compare cohorts of subjects with chronic airflow obstruction, with and 
without evidence of previous pulmonary TB, for differences in structural 
abnormalities, pathophysiology, natural history and response to treatment 
that might support considering patients with a past history of pulmonary TB 
as a distinct phenotype of COPD. 
 
Objective 2 
To examine the diagnostic performance and limitations of the Burden of 
Obstructive Lung Disease (BOLD) methodology as an estimate for the 
prevalence of COPD in communities. 
 
Objective 3 
To examine the natural history and predictors of mortality of COPD in a 
cohort of adults over 40 years of age identified using the BOLD methodology, 
in 2005, in an area with high-prevalence of TB. 
 
Chapter 4. Methodology 
 
This chapter describes the methodology utilised to meet the research 
objectives; it covers the study design, study population, inclusion and 
exclusion criteria, and discusses all tests performed and their sequence, and 
both the statistical and radiological analyses that were undertaken.  
 
4.1. Study design 
 
These specific objectives were addressed by studies performed on a cohort 
of subjects diagnosed with COPD in a community survey in 2005.  
 
4.2. Study population 
 
The study population comprised all subjects identified as having COPD in 
2005 in a community-based previous prevalence study performed by 
researchers at the University of Cape Town Lung Institute, in collaboration 
with the Desmond Tutu TB Centre (Stellenbosch University), using the Burden 
of Obstructive Lung Disease (BOLD) methodology.  
 This study identified 196 people (101 females, 95 males) as having 
COPD (GOLD stage 1 or higher). Thirty-four people fulfilled spirometric 
criteria for GOLD stage 1, 109 for GOLD stage 2, 48 for GOLD stage 3, and 5 
for GOLD stage 4. 
 
4.3. Sampling methods and background to study population 
 
The BOLD study enrolled subjects that had previously participated in the 
Lung Health Study 2002 (LHS2002); a burden of lung disease study 
performed by the same investigators. 
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4.3.1. Study site: description of the populations of Ravensmead 
and Uitsig  
Ravensmead and Uitsig are two adjacent, predominantly low-income 
suburbs of Cape Town, which in 2001 had an estimated population of 36 334 
living in 5 592 households. The estimated mean household income was  
R2 732 per month, and the number of persons per address ranged from 6.63 
to 13.83 for flats, and 5.5 to 12.9 for houses. Only 36% of adults were 
employed in the formal sector, and 47% had an education level of less than 
Grade 7. The prevalence of smoking and alcohol use were high: 33% of men 
and 30% of women were defined as ‘risky drinkers’ (i.e. >4 drinks per day for 
men, and >3 drinks per day for women). Tuberculosis incidence was also 
high, estimated at 776/100 000, with 6% of new TB cases being HIV positive. 
The background HIV prevalence among local antenatal clinic attendees in 
2001 was 7.9%. All homes in these areas were electrified, which limited 
biomass fuel exposure.29 
 
4.3.2. Lung Health Study 2002: sampling methods and findings 
The LHS2002 was a cross-sectional study comprising a 15% random sample 
of addresses (833 addresses). The adult population survey was conducted in 
persons >15 years of age. The sample design was a random cluster survey, 
with an address forming the sampling unit/cluster. If the household head did 
not consent to the survey, that dwelling was replaced by the house to the 
right, and, failing that, the house to the left of the originally selected 
residence. A sample size of 3 500 participants was required to meet power 
calculations.  
  The final sample comprised 3 483 adults, of whom 38.3% >40 years 
reported at least one respiratory symptom, and 18.2% Grade 2 or higher 
dyspnoea (scored using the modified MRC Dyspnoea Score). Symptomatic 
chronic bronchitis was reported in 7.2% of adults >15 years, 49.9% of 
participants were current smokers, and 7.6% were ex-smokers. A total of 
9.7% of subjects reported a ‘doctor-diagnosed’ episode of TB, 7.0% 
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reported healthcare-worker (usually doctor) diagnosed asthma, and 5.5% 
reported emphysema. 
 
4.3.3. BOLD 2005 study: sampling methods 
The BOLD study used the original LHS2002 enumeration lists, and 
resampled all 833 addresses surveyed in that study. However, as required by 
the BOLD method, only adults >40 years were recruited. Approximately two 
thirds of the adults sampled had participated in the LHS2002. The remaining 
third were either LHS2002 non-responders or new residents at the selected 
addresses.   
 Of the 1 377 eligible persons, 958 consented (69.6%) to participate, 
and 419 declined (30.4%). All provided questionnaire data, and 896 
attempted spirometry, with 62 being excluded on medical grounds. 
Spirometry of acceptable quality was obtained in 847 subjects (61.5% of  
1 377). Spirometry data from 49 subjects was of poor quality and not 
analysable. The major findings of the BOLD 2005 study have been discussed 
in the Literature Review [see page 21]. 
 
4.4. Ethical approval 
 
Ethical approval to conduct the current (2010) follow-up study was obtained 
from the Human Research Ethics Committee of the Faculty of Health 
Sciences, University of Cape Town, the Stellenbosch University Ethics 
Committee, and the local health authority (the City of Cape Town). 
Participation was voluntary and informed written consent was obtained from 
all participants prior to enrolment. Information was provided and consent 
was obtained in each participant’s preferred language. After appropriate 
counselling, consent for HIV testing was also obtained.  
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4.5. Inclusion/exclusion criteria 
  
Inclusion criteria:  
• Subjects diagnosed with COPD (GOLD stage 1 or higher) in the BOLD 
study in Ravensmead/Uitsig in 2005.  
• Written informed consent to participate and willingness to undergo all 
test procedures. 
 
Exclusion criteria: 
• Subjects in the BOLD study that could not be traced. 
• Subjects who did not consent to participate.  
• Subjects who were unable to perform spirometry or had a contra-
indication to bronchodilator testing including: 
o A myocardial infarct within the last three months. 
o A resting pulse rate of more than 120 beats/minute. 
o Cataract surgery, or a major surgical procedure in the last 
month. 
o Any other co-morbidity (e.g. unstable angina or pneumonia) 
that, in the judgment of the investigators, might affect the 
performance of the test or place the subject at risk. 
o Chest or abdominal surgery in the past three months. 
• Pregnancy (of any gestational age). 
• Respiratory tract infection with unresolved symptoms in the four 
weeks prior to the visit (subjects with ‘temporary exclusion criteria’, 
e.g. recent surgery, could be rescheduled once recovered). 
• Active TB, on treatment or with symptoms requiring investigation. 
• Subjects with known advanced or untreated malignancy.  
• All HIV-positive subjects.  
 
The rationale for excluding HIV-positive persons was the high probability for 
the presence of confounding factors in these subjects, for example: altered 
immune status and increased risk of respiratory and opportunistic infections. 
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The sample size was considered too small to adequately adjust for such 
confounders.  
 
4.6. Examinations and study procedures 
 
All subjects underwent all investigations, and were required to attend the 
University of Cape Town Lung Institute on three separate occasions. With the 
exception of chest CT scans, all tests were performed at the University of 
Cape Town Lung Institute (Mowbray, Cape Town). The CT scans were 
performed at Vincent Pallotti Hospital (Pinelands, Cape Town), a local, 
private (non-government) hospital. 
 
4.6.1. Questionnaires 
Study personnel were trained to administer the questionnaires in a 
standardised manner. The study co-ordinator performed quality control for 
both method of administration and completeness of data. Three 
questionnaires were administered in the follow-up study in 2010: 
4.6.1.1. The BOLD Questionnaire 
The first questionnaire administered was the BOLD Core Questionnaire that 
had previously been administered in 2005. This questionnaire records data 
on demographics, respiratory symptoms, risk factors and respiratory 
diagnoses [see Appendix 1 – BOLD Core Questionnaire]. Both English and 
Afrikaans versions were available to participants - the translation to Afrikaans 
had been performed by the Stellenbosch University Language Centre in 
preparation for the previous BOLD study and involved translation, back-
translation and piloting in the vernacular of the test community.  
 4.6.1.2. Additional Tuberculosis Questionnaire 
A second questionnaire was the Additional Tuberculosis Questionnaire 
(ATbQ), which was intended to gather more details of reported episodes of 
TB, including: their number and date; method of diagnosis; location of 
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treatment administration; hospitalisations; treatment duration; and resolution 
of symptoms following treatment completion [see Appendix 2 – Additional 
Tuberculosis Questionnaire]. 
  4.6.1.3. St George’s Respiratory Questionnaire 
The St George’s Respiratory Questionnaire (SGRQ) is a tool designed to 
measure impact of respiratory symptoms on overall health, daily life, and 
perceived wellbeing in subjects with fixed and reversible airway obstruction 
(i.e. COPD and asthma).199 It is comprised of two parts: the first assesses 
symptoms and the second assesses activity and impact; these are combined 
to form a total score. The questionnaire was originally designed for self-
administration; however, due to low levels of literacy in the study population, 
and to improve the consistency of the results, the questionnaire was 
administered by the study personnel to all participants, regardless of 
functional literacy [see Appendix 3 - St George’s Respiratory Questionnaire] 
Permission to use the SGRQ was obtained prior to commencement of the 
study.  
 
4.6.2. Lung physiology 
Participant’s weight and height were measured at the first visit. Height was 
recorded as the average of measurements, using a Stadiometer (Holtain 
Limited, Britain), which was calibrated daily with a 600 mm metal rod. Weight 
was measured on a standing scale (SecaTM, Seca Ltd, United Kingdom), 
which was calibrated annually by the manufacturer. The following tests of lung 
physiology were also performed: 
4.6.2.1. Spirometry 
Spirometry was performed at all three visits as follows: 
At Visit 1, spirometry was performed with the same ndd EasyOneTM 
Spirometer (ndd Medical Technologies, Andover, MA, USA) used in the 
BOLD study of 2005 [see p46]. 
At Visit 2, spirometry was performed using both the ndd EasyOneTM 
and an office-based spirometer – the nSpire Spirometer® (FerrarisTM, 
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Columbia, USA). Both spirometers were calibrated daily using a three-litre 
syringe, and at least monthly with biological controls (staff at the Lung 
Institute).  
At Visit 3, spirometry was performed using the nSpire Spirometer® 
(details above).  
 All spirometry was performed before and after administration of both a 
rapid-acting beta2-agonist and an anti-cholinergic bronchodilator. First, 
ipratropium bromide anhydrous 80 μg (100 µl) (Atrovent manufactured by 
Boehringer IngelheimTM) was administered via a pressurised metered dose 
inhaler (pMDI), followed immediately by four puffs (100 μg each) of 
salbutamol via a pMDI device (Ventolin GlaxoSmithKlineTM). Spirometry was 
repeated after 45 minutes.  
 The following spirometric variables were measured: forced expiratory 
volume in 1 second (FEV1); forced vital capacity (FVC); FEV1:FVC ratio; and 
peak expiratory flow rate (PEFR). 
 Prior to Visit 2, all subjects were requested to withhold all respiratory 
medication (i.e. a wash-out period) as follows: theophylline and 
aminophylline-containing preparations for one week; long-acting beta2-
agonists and anti-cholinergics for 48 hours; and short-acting bronchodilators 
(beta2-agonists and anti-cholinergics) for six hours prior to testing.  
4.6.2.2. Diffusing capacity for carbon monoxide 
The diffusing capacity for carbon monoxide (DLCO) was performed at Visit 2 
using VMAX 2130® (made by SensormedicsTM,, Yorba Linda, CA, USA), which 
was calibrated daily. The single breath method of DLCO determination was 
used.  
4.6.2.3. Whole body plethysmography 
Whole body plethysmography was performed at Visit 3, to allow for 
comparison of lung volumes measured by this method and results of the CT 
scan. The Eagle & Bodybox Pulmonary System® (FerrarisTM, Columbia, USA) 
was used and calibrated daily with a three-litre syringe, and at least monthly 
with biological controls. The following variables were measured: functional 
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residual capacity (FRC); vital capacity (VC); total lung capacity (TLC); 
inspiratory capacity (IC); vital capacity (VC); residual volume (RV); and 
RV:TLC ratio.  
4.6.2.4. Reference equations 
As in the BOLD survey of 2005, the NHANES III prediction equations for 
Caucasians [see Table 1] were used: Lower Limit of Normal (LLN) values use 
the lower fifth Percentile, or –1.645* Standard Error of Estimate.  
 
Table 1: NHANES III prediction equations for Caucasians. 
	   Intercept	   Age	   Age2	   Height	  (Pred)2	   Height	  (LLN)2	   Intercept	  (LLN)	   R2	  
White	  Males	  >20	  yr	   	   	   	   	   	   	  
FEV1	   	  	  0.5536	   –0.01303	   –0.000172	   0.00014098	   0.00011607	   	   0.8510	  
FVC	   –0.1933	   	  	  0.00064	   –0.000269	   0.00018642	   0.00015695	   	   0.8668	  
FEV1:FVC	   	  	  87.340	   –0.2066	   	   	   	   78.372	   0.1538	  
White	  Females	  >18	  yr	   	   	   	   	   	   	  
FEV1	   	  	  0.4333	   –0.00361	   –0.000194	   0.00011496	   0.00009283	   	   0.7494	  
FVC	   –0.3560	   	  	  0.01870	   –0.000382	   0.00014815	   0.00012198	   	   0.7344	  
FEV1:FVC	   	  	  90.809	   –0.2125	   	   	   	   81.015	   0.3955	  
Reference:	  Hankinson	  et	  al	  AJRCCM	  199;159:179-­‐197	  
 
Because there are no NHANES III reference equations for static lung volumes 
obtained by plethysmography, the European Community of Coal and Steel 
(ECCS) reference equations were used200 in chapters where analysis of 
plethysmography is reported. 
 
4.6.3. Assessment of responses to systemic glucocorticosteroids 
and a long-acting beta2-agonists 
At Visit 2, after a washout period, all subjects were given a therapeutic trial of 
oral glucocorticosteroids and a long-acting beta2-agonist (LABA) for a 
minimum of two but not more than four weeks (beginning at Visit 2 and 
ending at Visit 3). The treatment comprised prednisone tablets in a dose of 
20 mg per day and formoterol 24 mcg twice daily administered via a pMDI. 
Subjects were instructed and coached in the use of a pMDI to ensure optimal 
Methodology 
 71 
delivery of the inhaled formoterol. At Visit 3, spirometry was repeated at least 
12 hours after the last (evening) dose of formoterol.  
 Participants with the following conditions were not administered 
glucocorticosteroids: uncontrolled diabetes, peptic ulcer disease or any 
condition that, in the view of the investigators, might place the subject at risk 
of a serious adverse event from oral corticosteroid use. Similarly, the LABA 
was not administered to subjects at risk of side effects (e.g. tachyarrthymias).  
To monitor adherence, subjects were asked to return all unused 
prednisone tablets, and a pill count was performed. No adherence tests were 
applied to inhaler use.  
 
4.6.4. Skin prick allergy testing 
Skin prick tests were performed at Visit 1, to establish the presence and 
nature of allergies, on subjects with any of the following risk factors: 
reversibility on spirometry (i.e. an increase of FEV1 of ≥12.0% and ≥200 mL 
after administration of bronchodilator); a family history of atopy; or symptoms 
suggestive of asthma or allergic rhinitis/hay fever [see Appendix 4 – Atopic 
Questionnaire]. 
Trained personnel, using allergens supplied by Lab SpecTM (Randburg, 
South Africa) performed the skin prick testing. The following were tested: 
negative control (diluent); positive control (Histamine 10 mg/mL); mould mix; 
cat dander; house dust mite (HDM) (Dermatophagoides pteronyssinus and 
Dermatophagoides farinae); grass mix; and Bermuda grass. 
 
4.6.5. Chest imaging 
Lung imaging comprised of chest X-rays and high-resolution CT scans.  
4.6.5.1. Chest X-ray 
Chest X-rays were performed at Visit 2, at the University of Cape Town Lung 
Institute, using the Odelca DR chest radiology apparatus (Delft Imaging 
Systems, The Netherlands). Posterior-anterior (PA) views were obtained on 
all subjects and were reported independently by two pulmonologists 
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experienced in chest radiology. A further description of the reporting 
methods and analysis is provided on page 130.  
4.6.5.2. CT scanning of chest 
A high-resolution CT scan of the chest (HRCT) without contrast medium was 
performed on all subjects at Visit 3. Images were captured at full inspiration 
and full expiration.  
CT images were obtained by a single experienced radiographer using 
a standardised image acquisition protocol. The same 64-channel Siemens 
Sensation 64 Multidetector scanner (Munich, Germany) was used for all 
studies. The tube current was 140 kVp and 40-60 mAs (effective), and beam 
collimation was a minimum of 64 x 0.6 mm. Images were reconstructed using 
a smooth kernel, which were standardised following baseline phantom 
evaluations, thus giving similar noise characteristics across all scans. 
Subjects were examined in the supine position, and CT scans were 
performed from the apex to the base of the lungs during breath-holding at full 
suspended inspiration (i.e. TLC) for the inspiratory scans, and full expiration 
(i.e. RV) for expiratory scans. Breath-holding at both lung volumes was 
rehearsed with each subject prior to the CT examination to ensure minimal 
respiratory motion during scanning. The scanning procedure required 
approximately 15-20 minutes of the scanner time. Full details of the scanning 
procedure, scanner techniques and breath-holding manoeuvres are in 
Appendix 5 – TOPD image acquisition protocol. 
Quantitative analysis of the scans was performed at the Department of 
Radiology, David Geffen School of Medicine, University of California Los 
Angeles, USA by Dr Jonathan Goldin and his colleagues. The CT scan 
images were transferred electronically to Los Angeles after removal of all 
information that might reveal participants’ clinical identity or clinical status, 
and analysis was performed using MedQIA software (Los Angeles, CA, USA). 
Similarly, assessment of bronchial anatomy was performed in a blinded 
manner by collaborators at Radboud University Medical Center, Nijmegen, 
Netherlands, using software previously developed for this purpose.  
The following quantitative parameters were calculated:  
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On Inspiratory CT scans: 
• Lung and lobar volumes 
• Total lung and lobar densities 
• Percentage low attenuation areas <–950 HU (emphysema score)  
• Percentage area attenuation <200 HU (fibrosis score). 
On expiratory scans: 
• Total lung and lobar densities 
• Percentage low attenuation areas <–860 HU (gas trapping score).  
Bronchial anatomy: 
• Pi10. 
The cut-point of –860 HU was chosen as the measure of gas trapping after 
discussion with the collaborators in UCLA. This measure is almost identical 
to the more traditional –856 HU cut-point, and the 4 HU difference between 
the two definitions is within the scanner limits of resolution and repeatability, 
and, thus, unlikely to influence findings [see page 54]. 
 
4.6.6. Blood tests 
Finger prick blood specimens were obtained from each subject for: 
4.6.6.1. HIV testing 
At Visit 1, subjects were counselled by an experienced Voluntary Testing 
Counsellor or physician, and were tested for HIV status after obtaining full 
written consent. The protocol required that HIV-positive subjects be provided 
with post-test counselling, immediate referral to the nearest appropriate HIV 
treatment centre, but they were to be excluded from the study. 
4.6.6.2. Blood glucose 
As a safety precaution, a random blood glucose test was performed at Visit 
2, prior to commencement of the trial of prednisone; subjects with elevated 
levels were not administered prednisone.  
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4.6.7. Schedule of study visits 
Initial Contact 
The Community Health Workers employed by the Desmond Tutu TB Centre 
traced subjects in the community, and the purpose and details of the study 
were explained to all potential participants. If subjects agreed to participate, 
they were provided with a date to attend for Visit 1. All visits took place at the 
University of Cape Town Lung Institute. See Figure 1 below. 
 
Visit 1 
At Visit 1, the following were performed: 
1. Written consent was obtained. 
2. HIV consent and counselling, bedsides HIV-ELISA testing followed by 
post-test counselling. 
3. BOLD questionnaire. 
4. The Additional Tuberculosis Questionnaire. 
5. The St George’s Respiratory Questionnaire 
6. Physical Examination. 
7. Spirometry (pre and post bronchodilator) using the ndd EasyOneTM 
spirometer.  
8. Allergy tests. 
 
Visit 2  
At Visit 2, the following were performed: 
1. MRC dyspnoea score. 
2. Pre and post bronchodilator spirometry using: 
• The ndd EasyOneTM spirometer  
• The nSpire spirometerr®. 
3. Diffusing capacity for carbon monoxide (DLCO). 
4. Chest X-ray. 
5. Blood sugar testing (finger prick). 
6. Education and administration of medication for corticosteroid and 
bronchodilator trial.  
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Visit 3  
At Visit 3 the following were performed: 
1. MRC dyspnoea score. 
2. Repeat spirometry (pre and post bronchodilator) using the nSpire 
spirometer. 
3. Whole body plethysmography. 
4. Subjects were transported to Vincent Pallotti Hospital (Pinelands, 
Cape Town), for an HRCT scan.  
Where necessary, subjects were transported back to the UCT Lung Institute 
for follow-up and referral for management of any identified medical problems.  
 
 
Figure 1: Schedule of visits and procedures. 
 
Rationale for visit schedule 
The repeated Easyone ndd spirometry (pre- and post-bronchodilator) on 
Visits 1 and 2, allowed opportunity to assess both the impact of respiratory 
medication withdrawal on lung physiology, and the repeatability of spirometry 
performed with this spirometer in subjects not using medication. Pairing of 
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the two different spirometers at Visit 2 allowed direct comparison of the two 
instruments against each other. Whole body plethysmography was performed 
at Visit 3, to compare values of lung volumes obtained with the 
plethysmography with those based on quantitative CT scan imaging at the 
same Visit. Whole body plethysmography was not additionally performed at 
Visit 2, for reasons of cost and practicality, diffusing capacity for carbon 
monoxide (DLCO) was performed at Visit 2 for logistical reasons, Due to the 
chronic nature of the disease, changes in DLCO at Visit 3 was not anticipated.  
  
 
4.7. Determination of cause of death 
 
For subjects reported as having died since the 2005 BOLD study, attempts 
were made to determine the causes of death. This involved questioning the 
nearest living relatives or suitable alternatives. Additionally, two data 
bases/death registers (the South African Medical Research Council and the 
City of Cape Town databases) were scrutinised for information on causes of 
death. Searches involved using name, surname and date of birth to confirm 
identities. Identity numbers were not available and could thus not be used.  
4.8. Subject transport and remuneration 
 
Since many participants were of advanced age and in relatively poor health, 
transportation for each visit to the Lung Institute and the Vincent Pallotti 
Hospital was provided in Lung Institute vehicles. In accordance with UCT 
Faculty of Health Sciences Human Research Ethics Committee guidelines, 
subjects were provided with R40.00 per visit for expenses relating to their 
attendance. Visits lasted between three and four hours. When participants 
used their own or public transport, they were reimbursed with R120.00 per 
visit. 
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4.9. Data management 
 
All completed questionnaires, data forms and reports were printed, dated 
and signed by the team member concerned, and placed in each subject’s 
research folder. Data capturers performed double-entry data capture, and 
data was entered onto databases, without personal subject information to 
ensure subject anonymity. A unique subject study number was used to 
identify subjects. On completion of the data capture, the raw data was data-
locked.  
 
4.10. Statistical methods 
 
Grouping of study population by previous tuberculosis status  
The study population was divided into three groups: subjects without any 
evidence of previous pulmonary TB (no previous TB or NPTB group); 
subjects with definite evidence of previous pulmonary TB (definite previous 
TB or DPTB group); and subjects with some evidence for previous pulmonary 
TB (probable previous TB or PrPTB group). The latter two groups were 
combined to form the previous TB (PPTB) group.  
 Because the correct classification of subjects into the above groups 
was pivotal to the study hypothesis, a separate chapter is devoted to this 
classification [see Chapter 7]. 
 Once categorised, the two groups, NPTB and PPTB, were compared 
by univariate analysis, comprising Student’s t-tests and Wilcoxon tests for 
continuous variables, and Chi-squared tests for categorical data. Thereafter, 
three-way comparisons were made between the groups: NPTB, DPTB and 
PrPTB. Univariate analysis comprised Analysis of Variance and Kruskal-
Wallis Test for continuous variables, and Chi-squared tests for categorical 
data. 
 Multivariate analysis was performed for variables found to be 
significantly different between the groups, adjusting for potential 
confounders. Linear and logistic regression modelling was performed using 
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forward, backward and stepwise model building, where appropriate. 
Inclusion and exclusion confidence thresholds are included in the 
appropriate text.  
 Analysis of predictors of mortality was performed using original data 
from the initial BOLD study (2005), with univariate and multivariate analysis 
being performed in a similar manner to the above. 
 To assess the accuracy of the BOLD methodology, the results 
obtained with the same questionnaire and spirometer used in the BOLD 2005 
survey were compared with those obtained in 2010. Additionally, results from 
the handheld spirometer (EasyOne ndd) were compared at sequential visits, 
as well as to office-based spirometry. Where relevant, correlation coefficients 
and Bland-Altman analysis were performed. Statistical analysis was 
performed using the statistical software package Stata version 12 (Statacorp, 
Texas, USA). 
 
4.11. Patient safety, benefits and harms 
 
No serious risk to the subjects was anticipated. With the exception of finger-
prick blood sampling and allergy skin prick testing, the investigations were 
non- or minimally invasive, and the lung function testing and CT scans 
involved minor discomfort.  
 Risks associated with the trial of treatment using oral 
glucocorticosteroids was reduced by using only half the 40 mg dose of 
prednisone recommended in the South African Thoracic Society Guidelines4 
(20 mg was administered). Concerns were the possibility of reactivation of 
latent TB infection, and increased susceptibility to community-acquired and 
opportunistic infections. Subjects were assessed for adverse effects of 
treatment at the relevant visits.  
 The CT scans and chest X-rays exposed the subjects to radiation; 
however, the total amount of radiation each subject received from the CT 
scans was equivalent to that of background radiation from living in Cape 
Town for 18 months (estimated at between 5-8 mSv per subject). To reduce 
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risks, additional scans following contrast were not performed. The dose of 
radiation from the chest X-ray (0.1 mSv) is approximately 1/100th the radiation 
dose of a CT scan, and is equivalent to living in Cape Town for 12 days. 
Pregnant women were excluded from the study.  
 Benefits to the subjects for participation in the present study were the 
review of their lung disease (and co-morbidities), with referral for appropriate 
further investigation and management, as well as optimisation of treatment 
for their obstructive lung disease.  
 
4.12. Funding 
 
This study was investigator-initiated and funded by the host institution – the 
University of Cape Town Lung Institute, and supported by three research 
scholarships awarded to the lead investigator: 
• AstraZeneca/South African Thoracic Society Respiratory Research 
Fellowship (2009) 
• South African Medical Research Council (MRC) Grant for Self-initiated 
Research (2010) 
• Discovery Foundation Academic Fellowship Award (2011) 
• MRC PhD Scholarship – National Health Scholars Programme – 2013.  
 

 Chapter 5. Results of Follow-up of the BOLD 2005 
Cohort: Overview of Demographic and Clinical 
Characteristics, Death and Spirometry Changes 
 
5.1. Introduction 
 
This chapter describes the results of the follow-up study of subjects 
identified as having COPD in the BOLD 2005 survey, including their 
subsequent clinical course, and predictors of mortality (Objective 3 page 62) 
 
5.2. The BOLD 2005 cohort 
 
The BOLD 2005 study included 847 subjects with analysable spirometry 
results. Of these, 196 subjects (23.1%) had evidence of airflow obstruction 
defined as FEV1:FVC <0.7, and 651 (76.9%) did not. Of the former, 34 (4.0%) 
were in GOLD stage 1 disease; 109 (12.9%) in GOLD stage 2; 48 (5.7%) 
GOLD stage 3, and 5 (0.6%) GOLD stage 4 disease.  
 
5.3. The BOLD 2010 Follow-up study enrollment 
 
Repeated attempts to contact all 196 subjects to request their participation in 
the Follow-up study yielded the following [see Figure 2]: 19 subjects (9.7%) 
declined participation, 11 subjects (5.6%) had moved from the 
community/area and were uncontactable, and 45 subjects (23.0%) had died. 
A further 14 subjects (7.1%) were excluded on various grounds: 13 (6.6%) on 
medical grounds such as dementia (5); substance abuse (alcoholism and/or 
drug addiction (3); bronchial carcinoma (2); carcinoma of larynx (1); heart 
disease (1); and ‘collapsed lung’ (1). One subject was excluded after study 
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completion, as he was enrolled in error (having the same name and address 
as the intended subject). The correct subject was later confirmed to have 
been alive at the time of the Follow-up study, but died shortly after at the age 
of 93. 
 One hundred and seven subjects (54.6%) participated in the study, 
but three withdrew after Visit 1, and one was unable to perform acceptable 
spirometry. Therefore, analysable lung function was obtained in 103 (52.6%) 
subjects, and 104 (53.1%) underwent chest imaging (chest X-ray and CT 
scan). 
 
 
 
5.4. Mortality in BOLD 2005 cohort 
 
In 2005, the mean age of all subjects identified with COPD was 59.0 years 
(sd=10.9, range 40.8-92.5 years). The mean age of the 45 subjects who died 
was 63.3 years (sd=11.2, range 41.1-91.6 years); 24 were men (53.3%) and 
Figure 2: Disposition of subjects in the BOLD 2005 Follow-up 
study. 
Identified with COPD in 
BOLD study (2005) 
n=196 
Enrolled 
n=107 (54.6%)  
Included 
n=103 (52.6%) 
Withdrew  3 
Unable to perform spirometry 1 
Died  45 (23.0%) 
Respiratory 8 
Cardiovascular 10 
Cancer 3 
Other cause 3 
Unknown 21 
Moved   11 (5.6%) 
Declined  19 (9.7%) 
Excluded  14 (7.1%) 
Dementia 5 
Malignancy 3 
Substance abuse 3 
Other 3 
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21 women (46.7%). Of the original cohort, 25.3% of the men (24 of 95) and 
20.8% of the women (21 of 101) had died. Of the subjects that died: 6 
(13.3%) had been classified in 2005 as GOLD stage 1; 20 (44.4%) as GOLD 
stage 2; 15 (33.3%) as GOLD stage 3; and 4 (8.9%) as GOLD stage 4. Thus, 
between 2005 and 2010: 17.7% (6 of 34) of GOLD stage 1 had died; 18.3% 
(20 of 109) of GOLD stage 2 had died; 31.3% (15 of 48) of GOLD stage 3 had 
died; and 80.0% (4 of 5) of GOLD stage 4 had died [see Figure 3]. 
 
  
Figure 3: Mortality by GOLD stage in 2005. 
 
5.4.1. Causes of mortality 
Suspected cause of death was determined, based of analysis of two death 
registry databases (the South African Medical Research Council and the City 
of Cape Town databases) [see page 76]. Table 2 shows the suspected 
causes of death.  
4 
1 
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Table 2: Suspected cause of death in BOLD 2005 subjects. 
Cause Number (%) 
Respiratory Cause 8 (17.8%)  
COPD  5 (11.1%) 
Respiratory Disease  1 (2.2%) 
Asthma  2 (4.4%) 
Malignancy 3 (6.7%)  
Colon Carcinoma  2 (4.4%) 
Metastatic Liver Cancer   1 (2.2%) 
Cardiovascular 10 (22.2%)  
Heart Failure  4 (8.9%) 
Hypertension  2 (4.4%) 
Myocardial Infarction  1 (2.2%) 
Cerebrovascular accident  3 (6.7%) 
Other 3 (6.7%)  
Renal Failure  1 (2.2%) 
Septicaemia  1 (2.2%) 
Alcohol abuse  1 (2.2%) 
Unknown / Uncertain 21 (46.7%)  
Total  45 
(100.0%) 
 
 
5.4.2. Risk factors for mortality in the BOLD 2005 cohort  
5.4.2.1. Univariate analysis 
The univariate analysis of associations with mortality included the following 
independent variables: age; gender; smoking status; smoking burden; GOLD 
stage of COPD in 2005; history of previous TB; pipe/cigar smoking; dusty 
job; heart disease; hypertension; diabetes; and years of schooling. Results 
are shown in Table 3. 
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Table 3: Univariate analysis of risk factors for mortality.  
 
On univariate analysis, only increasing age, GOLD stage in 2005, and years 
of schooling showed a significant association with mortality. Burden of 
smoking (i.e. number of pack-years) showed a trend towards a positive 
 Alive  Died  p-value Test 
Total 151  45    
Age       
Mean 57.8  63.3    
Median 57.5  63.4  0.0033 Wilcoxon 
Min  40.8  41.1    
Max 92.5  91.6    
IQR 49.3 - 65.1  55.4 - 70.7    
       
Male 71 47.0% 24 53%   
Female 80 53.0% 21 47% 0.457 Chi2 
       
Smoking        
Never smoker 22 15% 5 11%   
Ever smoker 129 85% 40 89% 0.588 Chi2 
Current 89  34    
Ex-smoker 40  6  0.3445 Chi2 (trends) 
       
Smoking Burden       
Median pack-years 11.3  17.7    
(IQR) (4.84 – 22)  (7.87 - 27.30) 0.0575 Wilcoxon 
       
BOLD status 2005      
GOLD 1  28  6    
GOLD 2  89  20    
GOLD 3  33  15    
GOLD 4  1  4  0.0062 Chi2 (trends) 
       
Tuberculosis       
Previous TB 50 33.1% 13 28.9%   
No Previous TB 101 66.9% 32 71.1% 0.594 Chi2 
Pipe/Cigar smoking# 30 20.1% 8 17.8% 0.727 Chi2 
Dusty Job 90 59.6% 21 46.7% 0.124 Chi2 
Heart Disease 9 6.0% 5 11.1% 0.239 Chi2 
Hypertension 46 30.5% 17 37.8% 0.356 Chi2 
Diabetes 13 8.6% 5 11.1% 0.610 Chi2 
Years of Schooling* n=150  n=45    
Years 7  6    
IQR 6-8  3-8  0.048 Wilcoxon 
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association (Wilcoxon p=0.0575). The remaining independent variables 
showed no association with death. 
5.4.2.2. Multivariate analysis  
Multivariate analysis was performed using logistic regression, and 
included the following as variables: age; gender; burden of smoking; previous 
TB; GOLD stage in 2005; and years of schooling [see Table 4]. 
 
Table 4: Multivariate analysis of risk factors for mortality. 
Variable OR p-value 95% CI 
Age  1.05 0.003 1.02-1.09 
Gender  
(males as reference) 
0.64 0.256 0.29-1.38 
GOLD 1 Ref Ref Ref 
GOLD 2  1.11 0.845 0.38-3.29 
GOLD 3  2.47 0.140 0.74-8.23 
GOLD 4  29.16 0.006 2.61-325.22 
Pack years 1.01 0.332 0.99-1.02 
Years of schooling 0.90 0.106 0.80-1.02 
Tuberculosis 1.92 0.137 0.81-4.58 
 
In the multivariate analysis, only increasing age (p=0.003) and GOLD stage 4 
disease (compared with GOLD stage 1 disease, p=0.006) showed a 
statistically significant association with mortality.  
 
5.5. Follow-up cohort: demographics 
 
Of the 107 subjects enrolled for Visit 1, 49 were men (45.8%) and 58 were 
women (54.2%). Three women withdrew and one man was unable to perform 
spirometry. The mean and median ages were 63.0 and 63.1 years, 
respectively (range 46.4-82.7 years, IQR 55.2-69.8 years) [see Figure 4 and 
Table 5]. All enrolled subjects described themselves as ‘coloured’ (i.e. mixed 
race). 
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Table 5: Age group ranges. 
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Figure 4: Age group distribution. 
 
5.5.1. Smoking status 
Smoking status was assessed with two questionnaires.  
The standard BOLD Core Questionnaire, contained the following questions: 
• Have you ever smoked cigarettes? 
• How old were you when you first started regular cigarette smoking? 
• How old were you when you last stopped? 
• On average, over the entire time that you smoked, about how many 
cigarettes per day did you smoke? 
• Have you ever smoked a pipe or cigar? 
• Do you now smoke a pipe or cigar? 
 
The Additional Smoking Questionnaire was developed to identify and 
quantify all forms of smoking, and captured variation in amount smoked at 
various stages of life [see Appendix 6 – Additional Smoking Questionnaire]. 
The results obtained with the BOLD (2010) and Additional Smoking 
Questionnaire (2010) are presented below [Table 6 and Table 7 respectively]: 
 
Table 6: Smoking status: results obtained with the BOLD questionnaire (2010). 
 
(n=107) 
 
n 
 
% 
Pack  
Year 
(mean) 
Pack 
Year  
(sd) 
Pack 
Year 
(min) 
Pack  
Year 
(max) 
Never Smoked 13 12.2% 0 0 0 0 
Ex-Smoker 34 31.8% 26.9 24.7 0.1 94 
Current Smoker 60 56.1% 24.8 20.7 3.1 104 
 
 
Age groups by decade 
 
n 
 
% 
40 to 49 9 8.4% 
50 to 59 38 35.5% 
60 to 69 34 31.8% 
70 to 79 21 19.6% 
>80 5 4.7% 
Total 107 100.0% 
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Table 7: Smoking status: results obtained with Additional Smoking 
Questionnaire (2010). 
 
Cigarette 
smoking 
 
n 
 
% 
Pack  
Year 
(mean) 
Pack  
Year 
(sd) 
Pack 
Year 
(min) 
Pack 
Year 
(max) 
Never  12 11.4% - - - - 
Ex-smoker 38 36.2% 24.6 21.7 0.2 90.3 
Current Smoker 55 52.4% 27.7 22.3 0.95 119 
       
 
Cannabis 
smoking 
  Joint Year# 
(mean) 
Joint Year 
(sd) 
Joint 
Year 
(min) 
Joint Year 
(max) 
Never 74 70.5% - - - - 
Ex-user 24 22.9% 62.6 82.6 0.3 310 
Current-User 7 6.7% 457.5 600.6 2 1760 
       
 
‘Other’ smoking 
  Pipeξ/Unitϕ 
Year (mean) 
Pipe/Unit 
Year (SD) 
Pipe/Unit 
Year 
(Min) 
Pipe/Unit 
Year 
(Max) 
Never 71 67.6% - - - - 
Pipe  27 25.7% 151.63 236.9 0 1180 
Methaqualone 
(Mandrax)  
7 6.6% 116.4 132.2 3 379 
Other 
 (Opium x1, Tik i.e. 
Methylamphetamine x 1)  
2 1.9%     
*Only 105 completed the Additional Smoking Questionnaire 
# ‘Joint Year’ is defined as one joint per day, daily for 1 year.  
 ξ ‘Pipe Year’ is defined as one pipe per day, daily for 1 year 
ϕ ‘Unit Year’ is defined as one pill, pipe or button per day, daily for 1 year 
 
 
5.5.2. History of previous tuberculosis 
Of the original 196 subjects from the BOLD study (2005), 63 (32.1%) reported 
a previous episode of TB. Previous TB status (PPTB) in the TOPD study was 
assessed in two different questionnaires: 
• The BOLD questionnaire 
• An Additional Tuberculosis Questionnaire [discussed in Chapter 4: 
Methodology – page 67]. 
5.5.2.1. Results obtained with the BOLD Questionnaire 
At follow-up, 41 subjects (38.3%) reported one or more episodes of PPTB. 
One subject who reported PPTB in 2005 failed to report this in 2010, while 
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seven subjects who reported PPTB in 2010 did not report this in 2005 [see 
Table 8]. 
 
Table 8: Comparison of previous tuberculosis status using the BOLD 
questionnaires 2005 and 2010. 
 TB status in 2010  
 PPTB No PPTB  Total 
TB status in 2005    
PPTB 34 1 35 
No PPTB 7 65 72 
Total 41 66 107 
5.5.2.2. Results obtained with the Additional Tuberculosis 
Questionnaire 
With the Additional Tuberculosis Questionnaire, 36.5% (n=39) reported 
PPTB, and 63.6% (n=68) of subjects had no PPTB [see Table 9]. 
 
Table 9: Previous tuberculosis status using the Additional TB Questionnaire. 
 Number of episodes of PPTB   
 (0) (1) (2) (3) Total % 
No PPTB 68 - - - 68 63.6% 
PPTB  - 26 12 1 39 36.5% 
 
Significantly more men than women reported PPTB: 23 (46.9%) versus 16 
(27.6%), respectively (Chi2: p=0.038). The median age of subjects with PPTB 
was 4.1 years younger than those without, but this difference was not 
statistically significant (Wilcoxon p=0.242) [see Table 10]. 
 
Table 10: Previous tuberculosis status by age. 
 n Mean  Median Min Max IQR 
No previous TB 68 63.8 63.9 46.4 82.7 55.4 - 71.5 
Previous TB 39 61.6 59.8 47.9 81.9 53.1 -68.6 
     (Wilcoxon: p=0.242) 
 
The mean age of subjects’ first episode of TB was 39.4 years (sd=16 years, 
range 6-77 years). One subject was unable to recall the year of their first 
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episode, and for the remainder, 20 subjects (52.6%) reported that their first 
episode occurred before the age of 40 years [see Figure 5 and Table 11]. 
 
Table 11: Age of first episode of 
tuberculosis. 
	   n	   %	   Cum	  %	  
Age	  <	  10	   1	   2.6%	   2.6%	  
Age	  10	  -­‐19	   2	   5.3%	   7.9%	  
Age	  20	  -­‐29	   10	   26.3%	   34.2%	  
Age	  30	  -­‐	  39	   7	   18.4%	   52.6%	  
Age	  40	  -­‐	  49	   9	   23.7%	   76.3%	  
Age	  50	  -­‐	  59	   5	   13.2%	   89.5%	  
Age	  60	  -­‐	  69	   3	   7.9%	   97.4%	  
Age	  70	  -­‐	  79	   1	   2.6%	   100.0%	  
Total	  	   38	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Figure 5: Age of first episode of 
tuberculosis. 
 
The 39 positive responders suffered a total of 53 episodes of PPTB [details in 
Table 12]. Twenty-six subjects (66.7%) reported one episode of PPTB, 12 
subjects (30.8%) reported two, and one subject (2.6%) reported three 
episodes of PPTB. A new episode of PPTB occurring subsequent to the 
BOLD study (2005) was reported in 10 subjects. Of these, seven occurred in 
2005 (two retreatment cases, and five new cases), one in 2007 (new case) 
and two occurred in 2008 (one retreatment, one new case). One of these 
subjects reported two episodes of TB in 2005.  
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Table 12: Description of episodes of previous TB, using the Additional TB 
Questionnaire. 
 Number  
Total number of subjects with Prev TB  39     
Total number of episodes of TB   53    
Hospitalisations for TB   9    
 
 
 
n 
Mean 
(months) 
 
sd 
 
Min 
 
Max 
1st Episode TB (n=39)      
Treatment duration unknown 7 - - - - 
Treatment duration known 32 6.25 1.74 2 12 
2nd Episode (n=12)        
Treatment duration unknown 1 - - - - 
Treatment duration known 11 6.45 2.16 3 12 
3rd Episode (n=1)        
Treatment duration unknown 1 - - - - 
Total TB treatment duration (n=39)       
Treatment duration “unknown” 7 - - - - 
Treatment duration known 32 8.47 3.78 2 18 
 
5.5.3. HIV status 
All subjects were tested for HIV at enrollment. HIV was an exclusion criterion 
for the study, but no subjects screened positive and, thus, no subjects were 
excluded on this basis.  
 
5.5.4. Comorbidity 
Of the 107 included subjects, 73 (68.2%) reported at least one comorbid 
condition, with hypertension (48.6%) and diabetes (12.1%) being the most 
common. Full details of comorbidities are presented in Table 13 below. 
 
 
 
 
 
 
 
Chapter 5  
 92 
Table 13: Comorbid medical conditions. 
(n=107) n % 
No medical comorbidity 34 31.8% 
     
Cardiovascular disease    
Hypertension 52 48.6% 
Heart disease 15 14.0% 
ASD repair 1 0.9% 
High cholesterol 10 9.3% 
Endocrine    
Diabetes 13 12.1% 
Thyroid disease 1 0.9% 
Arthritis 18 16.8% 
CNS disease    
CVA 1 0.9% 
Epilepsy 1 0.9% 
Bell's Palsy  1 0.9% 
Glaucoma 1 0.9% 
Anxiety 2 1.9% 
GIT disease   
GORD 1 0.9% 
PUD 1 0.9% 
Cancer 2 1.9% 
Injury   
Head 1 0.9% 
Spinal 1 0.9% 
Motor Accident 1 0.9% 
Allergic Rhinitis 2 1.9% 
Skin     
Eczema 1 0.9% 
Psoriasis 1 0.9% 
 
5.5.5. Atopy Questionnaire: respiratory symptoms and atopic 
disease 
A questionnaire on respiratory symptoms and atopic respiratory diseases 
was administered to all subjects [see Appendix 4 – Atopic Questionnaire]. 
The results are presented in Table 14. A total of 28.0% subjects (30 of 107) 
reported a physician-based diagnosis of asthma; 20.8% (22 of 106, with 1 no 
response) a personal history of asthma; 50.5% (n=54) periodic wheezing; 
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57.9% (n=62) a periodic cough; and 59.8% (n=64) periodic dyspnoea. Sixty 
seven percent of subjects (71 of 106, 1 no response) reported periodic 
cough, wheezing or dyspnoea in the last 12 months. 
Ten percent (n=11) reported a physician diagnosis of allergic rhinitis, 
while 22.6% (24 of 106, 1 no response) reported a personal history of allergic 
rhinitis, and 33.6% (n=36) bouts of nasal blockage, rhinorrhea and sneezing 
not associated with common cold symptoms. 
 
Table 14: Responses to administered Atopic Questionnaire. 
  
n 
Positive 
responses 
 
% 
Asthma Diagnosis    
Diagnosed by physician 107 30 28.0% 
Personal history 106 22 20.8% 
Periodic wheezing 107 54 50.5% 
Periodic cough 107 62 57.9% 
Periodic dyspnoea 107 64 59.8% 
Periodic symptoms in last 12 
months 
106 71 67.0% 
Allergic Rhinitis    
Diagnosed by physician 107 11 10.3% 
Personal history 106 24 22.6% 
Bouts of Nasal Symptoms 107 36 33.6% 
 
5.5.6. Skin prick allergy tests  
Skin prick tests were performed on all subjects who responded positively to 
any question in the Atopic Questionnaire, or who demonstrated reversibility 
on lung function testing [discussed in the methodology on page 71]. On this 
basis, 93 of 107 (86.9%) subjects underwent skin prick tests. Positive results 
to antigen, defined as a wheal of 3 mm or greater in diameter, were obtained 
in 39.8% (37 of 93) of those tested, and one had an uninterpretable result 
[see Table 15 below]. Of the subjects with positive results, 25 (67.6%) were 
positive to Dermatophagoides pteronyssinus antigen, 27 (73.0%) were 
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positive to Dermatophagoides farinae antigen, 16 (43.2%) were positive to 
grass mix, 7 (18.9%) to each of mould and Bermuda grass, and 8 (21.6%) to 
cat antigen.  
 
Table 15: Skin prick allergy test results. 
(n=107) n % 
Test results   
Negative 55 51.4% 
Positive 37 34.6% 
Not performed 14 13.1% 
Un-interpretable 1 0.9% 
   
 
Positive results (n=37) 
 
n 
 
% 
House dust mite  
(Dermatophagoides	  pteronyssinus) 
25 67.6% 
House dust mite 
(Dermatophagoides farinae) 
27 73.0% 
Mould mix 7 18.9% 
Cat 8 21.6% 
Grass-mix 16 43.2% 
Bermuda grass 7 18.9% 
 
5.5.7. Health status: St George’s Respiratory Questionnaire 
Results with the SGRQ are presented in Table 16. One hundred and six of 
107 subjects completed the SGRQ, but two failed to respond to all questions 
due to comorbid disease. The median values (and IQR) for the total, 
symptom, activity and impact domain scores were: 33.4 (IQR 14.1-54.1); 37.8 
(IQR 14.1-59.5); 53.6 (IQR 29.3-73.2) and 19.1 (IQR 4.5-40.1) respectively 
[see Figure 6 and Table 16].  
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Table 16: St Georges Respiratory Questionnaire scores at Visit 1.  
 n Mean Median sd Min Max IQR 
Symptom score 106 38.06 37.81 25.35 0 83.38 14.07 - 59.53 
Activity score 106 49.25 53.62 31.33 0 100 29.26 - 73.21 
Impact score 104 24.67 19.05 23.38 0 99.28 4.45 - 40.12 
Total score 104 34.73 33.4 24.35 0 90.61 14.12 - 54.09 
 
0
20
40
60
80
10
0
St George's Respiratory Questionnaire Score
Total Score Symptom Score
Activity Score Impact Score
 
Figure 6: SGRQ scores at Visit 1 for all subjects. 
 
5.5.8. Respiratory medication 
Thirty-nine subjects (36.5%) reported use of at least one respiratory 
medication, the most common being short-acting beta-agonist use (SABA) in 
29.9% of subjects [see Table 17]. Only 16.8% reported inhaled corticosteroid 
(ICS) use and 3.7% use of a LABA, while 35 (32.7%) reported use of 
respiratory medication for more than six months of the previous year.  
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Table 17: Use of respiratory medication in enrolled subjects. 
(n=107) n % 
Subjects not using respiratory 
medication 
68 63.6% 
Subjects using respiratory medication 39 36.5% 
Number of concurrent medications:   
1 17 15.9% 
2 11 10.3% 
3 9 8.4% 
4 2 1.9% 
5 0 0.0% 
Medication use   
SABA 32 29.9% 
SAMA 10 9.4% 
LABA 4 3.7% 
(LAMA) 0 0.0% 
ICS 18 16.8% 
Theophylline 10 9.4% 
   
Subjects using medication on most days 24 22.4% 
In last year, number of months of 
medication use 
  
0 months 68 64.2% 
0 - 3 months 1 0.9% 
4 - 6 months 2 1.9% 
7 - 9 months 1 0.9% 
10 - 12 months 34 32.1% 
unknown 1 0.9% 
SABA – short-acting beta agonist 
SAMA – short-acting antimuscarinic agent 
LABA – long-acting beta agonist 
LAMA – long-acting antimuscarinic agent 
ICS – inhaled corticosteroid 
 
5.6. Follow-up cohort: spirometry 
 
A total of 106 of 107 subjects provided spirometry of acceptable quality at 
Visit 1. NHANES III reference equations and lower limit of normal (LLN) for 
Caucasians were applied. 
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5.6.1. FEV1:FVC  
Of the 106 subjects, 94 (88.7%) demonstrated airflow obstruction (defined as 
FEV1:FVC <0.7) before administration of a bronchodilator (BD). This 
persisted after the bronchodilator in 90 subjects (84.9%). The mean post-BD 
FEV1:FVC was 0.58 (sd 0.140; range 0.27-0.90) [see Table 18 and Figure 7]. 
 
Table 18: Pre- and post-bronchodilator FEV1:FVC <0.70. 
 Pre-BD  
No Obstruction 
Pre-BD 
Obstruction 
 
Total 
Post-BD  
No Obstruction 
8 8 16 
Post-BD  
Obstruction 
4 86 90 
Total 12 94 106 
Obstruction defined as FEV1:FVC <0.7 
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Figure 7: Distribution of post-bronchodilator FEV1:FVC. 
.  
Using NHANES-III prediction equations, and a definition of airflow 
obstruction (AFO) as a post-BD FEV1:FVC less than the lower limit of normal 
(LLN) for age, 79 of 106 (74.5%) subjects had AFO and 27 (25.5%) hadn’t. 
Thus, the LLN definition resulted in 11 subjects being reclassified as not 
having AFO [see Table 19]. Nine of these 11 (81.8%) subjects were older than 
65 years of age, 7 (63.6%) were over 70 years, and 5 (45.5%) were over 75 
years.  
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Table 19: Comparison of airflow obstruction (AFO) using the fixed ratio and 
lower limit of normal (LLN) definitions. 
 LLN definition  
Fi
xe
d 
ra
tio
 
de
fin
iti
on
  AFO –ve AFO +ve Total 
AFO –ve 16 0 16 
AFO +ve 11 79 90 
Total 27 79 106 
 
5.6.2. FEV1 and FVC 
The post bronchodilator values obtained at Visit 1 for FEV1 and FVC (in litres 
and percentage predicted) are presented in Table 20, Figure 8, Figure 9, 
Figure 10 and Figure 11. FEV1 and FVC reported in litres were not normally 
distributed. There was no significant difference in FVC (as percentage 
predicted) between those with AFO and those without, using either the lower 
limit of normal (t-test p=0.8135) or the fixed ratio definition for AFO (t-test 
p=0.3288).  
 
Table 20: Post bronchodilator FEV1 and FVC of all subjects at Visit 1. 
 n Mean Median sd Min Max IQR 
Post BD FEV1          
FEV1 (in litres) 106 1.63 1.51 0.662 0.61 3.57 1.12 - 2.13 
         
FEV1 (% pred) 106 62.73 64.8 18.94 23.1 101.9 46.2 - 77.2 
AFO by LLN 79 57.08 55.8 17.63 23.1 101.9 41.2 - 70.9 
AFO by fixed ratio 90 59.76 60.8 18.42 23.1 101.9 42.3 - 73.1 
 No AFO (by fixed ratio) 16 79.45 79.3 12.10 61.5 99.9 69.2 - 88.7 
Post BD FVC          
FVC (in litres) 106 2.86 2.66 0.983 1.21 5.7 2.09 - 3.45 
         
FVC (% pred) 106 82.64 82.64 15.36 48.17 128.86 71.82 - 94.21 
AFO by LLN 79 82.85 83.18 16.01 48.17 128.86 71.34 - 94.49 
AFO by fixed ratio 90 83.26 83.52 15.58 48.17 128.86 71.88 - 94.49 
No AFO (by fixed ratio) 16 79.17 79.10 14.00 54.56 104.55 69.15 - 87.83 
BD = bronchodilator 
AFO = Airflow obstruction 
LLN = lower limit of normal 
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Figure 8: Visit 1 post-bronchodilator 
FEV1 for all subjects (litres). 
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Figure 9: Visit 1 post-bronchodilator 
FEV1 for all subjects (% predicted). 
 
4
18
21
22
15
10
8
6
1 1
(n=106)
0
5
10
15
20
Nu
m
be
r
1 2 3 4 5 6
Post Brochodilator FVC (in litres)
Visit 1
FVC in litres (all subjects)
 
Figure 10: Visit 1 post-
bronchodilator FVC for all subjects 
(litres). 
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Figure 11: Visit 1 post-
bronchodilator FVC for all subjects 
(% predicted).
 
5.6.3. FEV1 reversibility 
Reversibility, which is defined as an increase in FEV1 following bronchodilator 
administration of more than 200 mL and more than 12.0%, was found in 
32.1% subjects, in 34.4% with AFO (31 of 90 subjects) and 18.8% without 
AFO (3 of 16 subjects) [see Table 21, Figure 12 and Figure 13]. 
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Table 21: Reversibility of FEV1 in subjects with and without post-
bronchodilator airflow obstruction.  
 No Obstruction % Obstruction % Total % 
No Reversibility  13 81.3% 59 65.6% 72 67.9% 
Reversibility 3 18.8% 31 34.4% 34 32.1% 
Total 16 100.0% 90 100.0% 106 100.0% 
Reversibility = >200 mL and 12% increase in FEV1 
Obstruction = FEV1:FVC <0.7 
1 1 1 2
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Figure 12: Change in FEV1 (litres) 
postbronchodilator (all subjects). 
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5.6.4. Comparison of GOLD staging in BOLD 2005 and Follow-up 
study  
The GOLD staging (in 2005) included (n=106) and not included in the Follow-
up study (n=90) is presented in Table 22 and Table 23, together with a 
comparison of staging in 2005 and 2010 for subjects included in both studies 
(n=106). 
 During BOLD 2005, of the 106 subjects included in the lung function 
analysis at Visit 1, 17 were GOLD stage 1 (16.0%), 65 were GOLD stage 2 
(61.3%), 23 were GOLD stage 3 (21.7%) and 1 was GOLD stage 4 (0.9). 
Twenty-one subjects (19.8%) deteriorated by a GOLD stage, 27 subjects 
(25.5%) improved, and 58 subjects (54.7%) remained in the same GOLD 
stage. Change in staging was as follows: 
• Deterioration in GOLD staging was seen in: 
o 29.4% (5 of 17) of those previously in GOLD stage 1  
o 20.0% (13 of 65) of GOLD stage 2 
o 13.0% (3 of 23) of GOLD stage 3. 
Figure 13: Percentage change in 
FEV1 post bronchodilator (all 
subjects). 
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• Improvement in GOLD staging was seen in: 
o 35.3% (6 of 17) of those previously in GOLD stage 1  
o 23.1% (15 of 65) of GOLD stage 2  
o 21.7% (5 of 23) of GOLD stage 3 
o and 100.0% (1 of 1) of GOLD stage 4. 
• No Change in GOLD staging between the studies was observed in:  
o 35.3% (6 of 17) of those in GOLD stage 1  
o 56.9% (37 of 65) of GOLD stage 2 
o 65.2% (15 of 23) of GOLD stage 3 
o none of GOLD stage 4. 
In addition, 16 subjects no longer had AFO in 2010 (i.e. FEV1:FVC was 
≥0.70). Six of these (37.0%) had previously been in GOLD stage 1 in 2005, 
nine (56.3%) in GOLD stage 2, and one (3.7%) in GOLD stage 3 in 2005. 
Of the 90 subjects who remained obstructed at the GOLD stage: 
o 21 subjects deteriorated (23.3%) 
o 11 subjects improved (12.2%) 
o 58 subjects remained the same (64.4%). 
 
Table 22: GOLD stage in 2005 for subjects not included in the Follow-up 
study. 
  
Died 
 
Moved 
 
Excluded 
 
Declined 
Unable 
to 
perform 
spirometry 
 
Total 
GOLD stage (in 2005)       
1 6 3 2 5  16 
2 20 5 7 11 1 44 
3 15 3 5 3  26 
4 4 0 0 0  4 
Total  45 11 14 19 1 90 
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Table 23: Comparison of GOLD stage in 2005 (BOLD study) with 2010 (Follow-
up study) for included subjects. 
  GOLD stage at Follow-up study (2010)  
GOLD stage at  
BOLD Study (2005) 
Not 
Obstructed 
 
1 
 
2 
 
3 
 
4 
 
Total 
1 6 6 
(54.6%) 
5 
(45.5%) 
0 
(0.0%) 
0 
(0.0%) 
11 
2 9 6 
(10.7%) 
37 
(66.1%) 
12 
(21.4%) 
1 
(1.8%) 
56 
3 1 1 
(4.6%) 
3 
(13.6%) 
15 
(68.2%) 
3 
(13.6%) 
22 
4 0 0 
(0.0%) 
0 
(0.0%) 
1 
(100%) 
0 1 
Total  16 13 45 28 4 90 
Highlighted cells demonstrate  
no interval change in GOLD stage  Percentage = % of 2005 GOLD stage  (for subjects with obstruction only, n=90) 
 
 
5.6.5. Longitudinal change in lung function  
5.6.5.1. Change in FEV1 between BOLD and Follow-up 
study 
The post-bronchodilator FEV1 values (in litres) and changes between studies 
were not parametrically distributed. Results are presented in Table 24, Figure 
14 and Figure 15. There was a significant decline in FEV1 (litres) between the 
BOLD and Follow-up studies (Wilcoxon p<0.0001), with a median decline of 
0.155L.  
 
Table 24: Comparison of FEV1 (litres) between BOLD and Follow-up studies (all 
subjects). 
 n Mean Median sd Min Max (IQR)  
BOLD FEV1 106 1.78 1.64 0.655 0.65 4.01 (1.28 - 2.27) Wilcoxon  
p<0.0001 Follow-up FEV1 106 1.63 1.51 0.662 0.61 3.57 (1.12 - 2.13) 
Change in FEV1 106 -0.149 -0.155 0.324 -1.37 1.8 (-0.30 - 0.00)  
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Figure 14: Comparison of FEV1 
(litres) between BOLD and Follow-
up studies (all subjects). 
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Figure 15: Change in FEV1 (litres) 
between BOLD and Follow-up 
studies (all subjects).
 
Comparison of the changes in FEV1 (as percentage predicted) using the 
Student’s t-test for parametrically distributed variables [Table 25, Figure 16 
and Figure 17], showed no difference in the FEV1 (% predicted) between the 
studies (t-test for paired samples: p=0.316). 
 
Table 25: Comparison of FEV1 (% predicted) between BOLD and Follow-up 
studies. 
 n Mean Sd Min Max  
BOLD FEV1 106 0.638 0.169 0.278 1.058 t-test for paired 
samples; 
p=0.316 Follow-up FEV1 106 0.627 0.189 0.231 1.019 
Change in FEV1 
(% predicted) 
106 -0.011 0.110 -0.334 0.476  
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Figure 16: Comparison of FEV1 (% 
predicted) between BOLD and 
Follow-up studies. 
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Figure 17: Change in FEV1 (% 
predicted) between BOLD and 
Follow-up studies.
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The decline in FEV1 (L) was assessed according to GOLD stage at the BOLD 
2005 study – a non-parametric variable. Although the mean decline in FEV1 
appeared to be larger in the higher GOLD staging groups, when the 
appropriate non-parametric tests (i.e. Kruskal-Wallis test) were used to 
compare median values, no significant difference was found (Kruskal-Wallis; 
p=0.479). As GOLD stage 4 only comprised of one subject at follow-up, this 
stage was omitted from the analysis [see Table 26, Figure 18 and Figure 19]. 
 
Table 26: Change in FEV1 (mL) between the studies, grouped according to 
GOLD stage at BOLD study (2005). 
 n Mean Median sd Min Max IQR 
GOLD 1 17 -202 -210 191 -440 140 -378: -60 
GOLD 2 65 -177 -120 282 -1 370 470 -300: -40 
GOLD 3 23 55 -170 464 -700 1 800 -250: 50 
GOLD 4 1 370 370 - - - - 
Overall 106 -149 -155 324 -1 370 1 800 -300: -000 
 
 
1
2
3
4
FE
V1
 in
 L
itr
es
Stage 1 Stage 2 Stage 3 Stage 4
(grouped by GOLD Status at BOLD 2005)
FEV1 (in litres) at BOLD & TOPD Studies
BOLD 2005 TOPD 2010
GOLD Staging
 
Figure 18: FEV1 (litres) at BOLD and 
Follow-up studies, grouped 
according to GOLD stage in 2005. 
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Figure 19: Change in FEV1 (mL) 
between studies, grouped 
according to GOLD stage in 2005. 
 
The median rate of change in FEV1 (mL per year), a non-parametrically 
distributed variable, was 28.93 mL/yr [see Table 27 and Figure 20]. No 
significance difference in rate of decline was found between subjects in the 
different GOLD stages assessed at the BOLD 2005 study (Kruskal-Wallis; 
p=0.247). 
Follow-up Study 
 105 
 Table 27: Rate of change in FEV1 (mL per year) between BOLD and Follow-up 
studies. 
(n=106) Mean Median sd IQR Min Max 
Rate of FEV1 Change 
(mL/yr) 
-28.29 -28.93 59.71 (-54.76 – 0.00) -246.26 317.15 
 
1 2
4
20
36
14
1 1
0
10
20
30
40
Nu
m
be
r
-300 -200 -100 0 100 200 300
Rate of Change in FEV1 (ml/year)
Between BOLD (2005) and TOPD (2010)
Rate of Change in FEV1
 
Figure 20: Rate of change in FEV1 (mL/ yr) between BOLD and Follow-up 
studies. 
To examine the potential effect of treatment of airflow limitation on the results 
of spirometry in the Follow-up study, the association between rate of change 
in FEV1 and use of respiratory medication was assessed. No association 
between the use of any respiratory medication, LABA or ICS use alone; and 
rate of change of FEV1 was found (Wilcoxon p=0.168, p=0.868 and p=0.614, 
respectively). However, subjects who used SABAs showed a greater rate of 
decline in FEV1 (Wilcoxon p=0.0467) [see Table 28]. However, this is likely to 
be reverse causation, with SABAs being dispensed for subjects with 
worsening lung function. 
 
Table 28: Rate of change of FEV1 according to use of short-acting beta2-
agonist (SABA). 
 n Mean Median IQR Min Max 
No SABA use 74 -21.33 -21.21 -49.41: 5.65 -246.26 317.15 
SABA use 32 -44.39 -35.05 -71.10: -12.54 -172.57 68.08 
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5.6.5.2. Change in FVC between the BOLD and Follow-up 
study 
 
Between the BOLD and Follow-up studies, there was a significant decline in 
FVC (in litres) (Wilcoxon p=0.0419), but not FVC (% predicted) (Wilcoxon 
p=0.773) [see Table 29, Figure 21 and Figure 22]. 
 
Table 29: Comparison of FVC between BOLD and Follow-up studies. 
(n=106) Mean Median sd Min Max IQR  
FVC (litres)         
At BOLD 2005 2.97 2.77 0.943 1.2 5.75 2.22: 3.54 Wilcoxon 
p=0.0419 At TOPD 2010 2.86 2.66 0.983 1.21 5.7 2.09: 3.45 
Change in FVC -92.45 -75.00 564.04 1820 2730 -420.00: 200.00  
FVC (% Predicted)         
At BOLD 2005 82.54 82.29 17.29 42.86 147.40 69.08: 92.08 Wilcoxon  
p=0.773 At TOPD 2010 82.64 82.64 15.36 48.17 128.86 71.82: 94.21 
Change in FVC (%) 0.104 2.478 16.287 -61.263 52.352 -9.384: 10.423  
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Figure 21: Comparison of FVC (in 
litres) between BOLD and Follow-up 
studies. 
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Figure 22: Comparison of FVC (% 
predicted) between BOLD and 
Follow-up studies. 
 
A significant difference in the change in FVC, in both millilitres (Kruskal-Wallis 
p=0.0073) and % predicted (Kruskal-Wallis p=0.0101), was observed when 
analysing according to GOLD stage at the BOLD 2005 study [see Table 30, 
Figure 23 and Figure 24]. 
Subjects in GOLD stage 1 at BOLD 2005 had a significantly greater 
decline in FVC compared to subjects in both GOLD stages 2 and 3 (p=0.0171 
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and p=0.0025, respectively). However, there was no significant difference in 
the change in FVC between subjects in GOLD stages 2 and 3 (p=0.136). 
GOLD stage 4 comprised of only one subject, and was therefore excluded 
from the analysis. 
 
Table 30: Change in FVC between studies, grouped according to GOLD stage 
at BOLD 2005 study. 
 n Mean Median sd Min Max IQR  
Change in FVC (in mL) 
GOLD 1 17 -386 -350 406.9 -1160 500 -520:  -190  
GOLD 2 65 -99 -80 510.1 -1820 1540 390:  190 Kruskal-
Wallis  
GOLD 3 23 119 140 714.9 -1050 2730 -160: 270 p=0.0073 
GOLD 4 1 510 510 - - - - -  
Total 106 -92 -75 564 -1820 2730 -420:  200  
Change in FVC (% predicted) 
GOLD 1 17 10.09 -8.49 17.159 -61.26 16.00 -16.98:  1.43  
GOLD 2 65 0.39 2.12 14.746 -33.45 52.35 -8.47:  10.42  
GOLD 3 23 6.16 8.02 17.02 -23.89 52.14 -3.31:  15.50 Kruskal-
Wallis 
GOLD 4 1 15.45 15.45 - - - - - p=0.0101 
Total 106 0.10 2.48 16.29 -61.26 52.35 -9.38:  10.42  
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Figure 23: Change in FVC (mL) 
between studies, grouped 
according to GOLD stage in 2005. 
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Figure 24: Change in FVC (% 
predicted) between studies, 
grouped according to GOLD stage 
in 2005. 
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5.6.5.3. Change in FEV1:FVC between BOLD and Follow-up 
study  
The absolute FEV1:FVC, a non-parametric variable, was found to be 
significantly lower in the Follow-up study compared with the BOLD study 
(Wilcoxon p=0.0047). The mean change in FEV1:FVC, a parametric variable, 
decreased by 2.5% (mean) [see Table 31]. 
When comparing the change in FEV1:FVC between GOLD stage groups in 
BOLD 2005, only a trend to significance was observed, with GOLD stages 2 
and 3 demonstrating a greater decline (ANOVA; p=0.091). GOLD stage 4 
(n=1) was excluded from this analysis. 
 
Table 31: Comparison of FEV1:FVC between BOLD & TOPD studies. 
 n Mean sd IQR Min Max  
BOLD 2005 106 60.0 9.00 (55.86 - 67.22) 35.44 70.21 Wilcoxon  
TOPD 2010 106 57.5 13.96 (46.13 -  66.20) 27.01 89.60 p=0.0047 
 n Mean sd Min Max    
Change in FEV1:FVC         
Overall 106 -2.50 9.76 -25.45 22.33    
By GOLD stage (2005)         
GOLD 1 17 1.98 8.871 -9.52 19.23    
GOLD 2 65 -3.08 9.659 -25.45 22.33   ANOVA 
GOLD 3 23 -4.52 10.116 -21.17 19.18   p=0.091 
GOLD 4 1 5.20 - - -    
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Figure 25: Comparison of FEV1:FVC 
between BOLD and TOPD studies. 
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Figure 26: Comparison of FEV1:FVC 
between studies, grouped 
according to GOLD stage in 2005. 
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5.7. Change in symptoms between BOLD and Follow-up studies 
 
The change in two reported symptoms between the two studies was 
assessed: dyspnoea, according to the MRC Dyspnoea Scale; and presence 
or absence of chronic cough. When comparing the MRC Dyspnoea scores 
[see Table 32]: 35 (32.7%) of 107 subjects reported the same dyspnoea 
score in both studies, while 58 (54.2%) reported worsening, and 14 (13.1%) 
had improved.  
 
Table 32: Comparison of MRC Dyspnoea scores between the BOLD 2005 and 
Follow-up study. 
 
 
 
Follow-
up 
study 
(2010) 
 BOLD study (2005) 
 MRC 1 MRC 2 MRC 3 MRC 4 MRC 5 Total 
 MRC 1 21 5 3 1 0 30 
MRC 2 10 2 1 0 0 13 
MRC 3 10 1 5 0 1 17 
MRC 4 5 6 8 4 3 26 
MRC 5 6 1 6 5 3 21 
Total 52 15 23 10 7 107 
 
The presence of a chronic cough [see Table 33] was reported by 48 subjects 
(44.9%) in 2005 and 63 (58.9%) in 2010. Twenty-five subjects (23.4%) 
reported the development of a chronic cough, while 10 subjects (9.3%) 
previously reporting a chronic cough, reported no chronic cough in the 
Follow-up study. 
 
Table 33: Comparison of presence of chronic cough between the BOLD 2005 
and Follow-up study. 
 
Follow-up 
study 
(2010) 
  BOLD study (2005) 
 Cough No cough Total 
Cough  38 25 63 
No cough 10 34 44 
Total 48 59 107 
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5.8. Summary of Findings 
 
Mortality 
The mortality among subjects identified with CAO was high. Almost a quarter 
of all subjects identified with CAO in the BOLD 2005 study had died by the 
five-year follow-up, 57.7% of whom had only mild or moderate airflow 
obstruction (i.e. GOLD stage 1 or 2 disease) in 2005. On multivariate analysis, 
only age and GOLD stage 4 disease was significantly associated with 
mortality. The commonest causes of death were cardiovascular (22.2%) and 
respiratory (17.8%) in nature; however, the cause of death was unknown in 
46.7% of subjects.  
 
Risk factors for CAO 
The prevalence of a previous history of pulmonary TB was high. A total of 
38.3% of subjects in the Follow-up study reported a previous episode of TB; 
in 52.6% this occurred before the age of 40 years.  
 
Presence of CAO and decline in lung function and GOLD stage at 
Follow-up  
At follow-up, only 84.9% of subjects had CAO defined by FEV1:FVC <0.70 
and 74.5% when defined by LLN. The median decline in FEV1 between the 
studies was 155 mL (29 mL/yr), but this was not greater than the calculated 
age-related decline (i.e. when expressed as FEV1 % predicted). The decline 
in FEV1 did not appear to differ by GOLD stage of severity. By contrast, the 
decline in FVC (expressed in both litres and % predicted) was significantly 
greater in subjects with milder stages of disease.  
In subjects with CAO, the GOLD stage had deteriorated between the 
studies in 23.3%, improved in 12.2% and was unchanged in 64.4%. 
However, this must be interpreted in the light of fact that a significant 
proportion of subjects had died. 
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Change in symptoms of COPD 
A majority of subjects reported worsening of dyspnoea, and more subjects 
reported chronic cough at follow-up. However, some reported improvement 
and/or disappearance of a chronic cough.  
 

 Chapter 6. Results of the Assessment of the 
Diagnostic Accuracy of the BOLD Methods 
 
The BOLD methodology involves use of questionnaires and a handheld 
spirometer suitable for use in participants’ homes. This method, though 
highly suited for community-based surveys, of necessity involves 
compromise in terms of quality of spirometry and diagnostic precision. 
Specifically, compared with laboratory-based testing, it is not possible to 
standardise the time of day, washout of bronchodilators, and, possibly, of the 
quality of the spirometer used. However, in developing the BOLD 
methodology, the co-ordinators went to lengths to ensure that the spirometry 
results were of high quality, by careful assessment of the specifications and 
performance of the spirometer (the EasyOne ndd spirometer was selected); 
standardisation of test conditions, and the training and accreditation of those 
performing spirometry and providing centralised quality control and data 
entry [see page 46]. These measures make the data obtained suitable for 
making comparisons between different sites and countries. However, in 
common with most epidemiologic methods, the interests of field-use took 
precedence over diagnostic precision; to date, the impact of this has not 
been examined. This chapter provides detailed clinical evaluation by an 
experienced clinician, aided by comprehensive tests of lung physiology and 
imaging, of all participants considered to have COPD on the basis of the 
BOLD 2005 survey. Because the assessment was performed five years after 
the initial survey, in each subject, the clinical course served as an additional 
diagnostic feature. In this way, the diagnostic performance of the BOLD 
methods (both questionnaires and spirometry) was evaluated, in order to 
inform the interpretation of data obtained with this method.  
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6.1. Accuracy of diagnosis of Chronic Airflow Obstruction 
 
A total of 106 subjects (54.1% of the original BOLD 2005 cohort of 196 
subjects) were enrolled and underwent spirometry at Visit 1, and 103 (52.6%) 
at Visit 2 (there were three withdrawals before Visit 2). Using the fixed ratio 
definition of CAO (i.e. FEV1:FVC <0.70), 90 (84.9%) subjects had CAO, and 
16 subjects (15.1%) did not. With the LLN definition, 79 subjects (74.5%) 
were defined as having CAO and 27 subjects (25.4%) were not. As expected, 
evidence of over-diagnosis of CAO in the elderly with the fixed-ratio methods 
was found; 9 of the 11 subjects (81.8%) with CAO by the fixed-ratio 
definition, but not the LLN-definition, were aged over 65 years. Seven of 
these were older than 70 years, and a further five were aged over 75 years. 
 
6.2. Misdiagnosis: inclusion of subjects with asthma  
 
Distinguishing between asthma and COPD on the basis of clinical features 
and spirometry is challenging, even for an experienced clinician, because the 
conditions lack pathognomonic clinical features and symptoms, and in many 
patients features of both may be present, the so-called Asthma COPD 
Overlap Syndrome (ACOS).201 Thus, it is not surprising that the BOLD method 
does not attempt to exclude asthma in subjects with CAO, other than by 
excluding subjects under that age of 40 years when asthma is the more likely 
diagnosis. 
 To address the problem of distinguishing subjects with asthma from 
those with other causes of CAO, the approach adopted in the present study 
was to develop several categories of diagnosis, based on combinations of 
clinical features that are associated with increased likelihood of an asthma 
diagnosis. Thus, subjects were classified according to probability of an 
asthma diagnosis, ranging from highly likely (asthma) to probable (termed 
probable asthma). This approach also required consideration of features 
strongly associated with the diagnosis of COPD, that is, exposure history 
(smoking) and absence of reversibility after bronchodilator. In addition, as a 
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sensitivity assessment of these categories, all clinical data on each subject 
was reviewed by two pulmonologists and a ‘clinician’s diagnosis’ on the 
presence or not of asthma was made on the balance of probabilities rather 
than strictly defined criteria. Additional points in the history of clinical 
presentation were also considered.  
 
6.2.1. Definition of asthma 
In the present study, the definition of asthma with a strong likelihood of 
asthma (here called asthma) required that participants fulfilled the following 
criteria: never a smoker (or light smoking history of less than five pack-years) 
AND a previous physician’s diagnosis of asthma. 
 By this definition, a total of 11 out of 106 subjects (10.4%) had 
asthma. The results of spirometry, and association of an asthma diagnosis 
with CAO and reversibility are presented in Table 34: 
• One subject with asthma had no airflow obstruction (FEV1:FVC 
>0.70) or reversibility. This participant was one of the 13 subjects 
in the whole study cohort with no CAO and no reversibility.  
• Seven had airflow obstruction and no reversibility. These 
comprised seven of 59 (11.9%) subjects in the whole study cohort 
with this spirometry. 
• Three had both airflow obstruction and reversibility; 10.7% (3 of 28) 
of subjects in the whole cohort with this pattern of spirometry.  
 
Table 34: Association between asthma, chronic airflow obstruction and 
reversibility to bronchodilator. 
 No CAO CAO   
 No  
Revers 
 
Revers 
No 
Revers 
 
Revers 
 
Total 
 
No asthma  12 3 52 28 95 (89.6%) 
Asthma  1 0 7 3 11  (10.4%) 
Total 13 3 59 31 106 106 
Revers = reversibility to bronchodilator 
CAO = chronic airflow obstruction (i.e. FEV1:FVC<0.7) 
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 6.2.2. Definition of probable asthma 
A scoring method was used to define probable asthma: one point was 
allocated for each of the following: 
• Never a smoker (or light smoking history of less than five pack-
years) 
• OR previous physician’s diagnosis of asthma 
• AND any two of the following three criteria: 
o positive skin prick test [defined on page 93] 
o history suggestive of allergic rhinitis 
o seasonal variations in symptoms. 
A score of two or more was used to define the presence of probable asthma. 
Probable asthma was diagnosed in 19 of 106 subjects (17.9%). Of these 
subjects [see Table 35]:  
• two had neither airflow obstruction (FEV1:FVC <0.70) nor 
reversibility; 2 of 13 subjects with this spirometry (15.4%). 
• nine had airflow obstruction and no reversibility; 9 of 59 (15.3%) 
subjects in the whole study cohort with this spirometry. 
• eight had both airflow obstruction and reversibility; 8 of 31 (25.8%) 
of subjects in the whole cohort with this pattern of spirometry. 
 
 
Table 35: Association between probable asthma, chronic airflow obstruction 
and reversibility to bronchodilator. 
 No CAO CAO   
 No  
Revers 
 
Revers 
No 
Revers 
 
Revers 
 
Total 
 
No asthma  11 3 50 23 87 (82.1%) 
Asthma  2 0 9 8 19 (17.9%) 
Total 13 3 59 31 106 106 
Revers = reversibility to bronchodilator 
CAO = chronic airflow obstruction (i.e. FEV1:FVC<0.7) 
 
6.2.3. Clinician’s review of asthma diagnosis 
Any subject, who exhibited reversibility to bronchodilator, did not have post-
bronchodilator obstruction, or who had three or more suggestive features on 
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history, was submitted for manual review of asthma diagnosis by two 
pulmonologists. The suggestive features on history were: a non-smoker (or 
smoking history of less than five pack-years); a history suggestive of allergic 
rhinitis; seasonal variation in symptoms; a positive skin prick test; and a 
previous physician’s diagnosis of asthma. 
 On this basis, a clinician’s diagnosis of asthma was made in 18 of 106 
subjects (17.0%). Of the 90 subjects with CAO, 15 (16.7%) were identified as 
asthmatic, while three of the remaining 16 subjects (18.8%) without CAO had 
asthma [see Table 36]. 
 
Table 36: Association between clinician’s diagnosis of asthma, chronic airflow 
obstruction and reversibility to bronchodilator. 
 No CAO CAO  
 No 
Revers 
 
Revers 
No 
Revers 
 
Revers 
Total 
No asthma  11 2 50 25 88 
Asthma  2 1 9 6 18 
Total 13 3 59 31 106 
Revers = reversibility to bronchodilator 
CAO = chronic airflow obstruction (i.e. FEV1:FVC<0.7) 
 
6.3. Assessment of BOLD Instruments 
 
6.3.1. Repeatability of questionnaires 
In order to assess the repeatability of the BOLD questionnaire, two questions 
were selected where the responses were unlikely to have changed in the five 
years between studies. These were: 
• How many years of formal education did you receive? (‘years of 
schooling’) 
• What was the highest level of formal education that your father 
attained? (‘years of fathers schooling’) 
A number of other questions were selected, for which a change from a 
positive response in BOLD 2005 to a negative response (in 2010) would 
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indicate an error of recall, either in the first or the second survey. These 
questions were: 
• Have you ever smoked? 
• Have you ever been told by a healthcare professional that you have 
had: 
o Heart attack? 
o Hypertension? 
o Diabetes? 
o Tuberculosis? 
6.3.1.1. Concordance of answers to questions in 2005 and 
Follow-up 
6.3.1.1.1 Years of schooling 
One of 107 subjects had missing data for this question. In the remaining 106 
subjects, 56 (52.8%) reported the same number of years of schooling in both 
studies [see Table 37], 24 (22.7% overall) reported a difference of two or 
more years, and five (4.7%) reported a difference of five years or more. The 
total reported number of years of schooling was similar between the studies 
(one sample median test, p=0.119). Using Bland-Altman analysis, a mean 
difference of –0.35 years in the reported number of years of schooling 
between the questionnaires is observed (sd = 2.06; 95% CI –4.48- +3.77) 
[see Figure 27 and Figure 28]. 
 
Table 37: Comparison of reporting number of years of schooling between 
BOLD and Follow-up studies. 
Years of schooling  n % 
Same between studies  56 52.8% 
Reported more years schooling in 2005 study 30 28.3% 
Reported more years schooling in 2010 study 20 18.9% 
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0
5
10
15
TO
PD
 (2
01
0)
0 5 10 15 20
BOLD (2005)
(n=106)
reported at BOLD and TOPD studies
Comparison of reported years of schooling
 
Figure 27: Scatter plot of the 
number of years of schooling 
reported in both studies. 
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Figure 28: Bland- Altman plot of 
difference in reported number of 
years of schooling against the 
average number of years. 
6.3.1.1.2. Fathers years of schooling 
Possible responses to this question included: ‘primary school’, ‘middle 
school’, ‘high school’, ‘college’, ‘technicon/university’, ‘none’ or ‘unknown’. 
Of the 107 subjects, 61 (57.0%) reported the same finding in both studies. Of 
the remaining 46 subjects (43.0%), 43 (93.5%) reported ‘not knowing’ at one 
of the two visits, but gave a definitive (discordant) response at the other. Of 
these 43 subjects, 33 reported ‘not knowing’ in the BOLD 2005 study, while 
only 10 reported ‘not knowing’ in the Follow-up study. This yields a kappa 
value of 0.238 [expected agreement 43.6%; actual agreement 57.0%; 
p<0.0001). The large number of discrepancies points to systematic error in 
this population. This may reflect a genuine lack of knowledge of the correct 
answer to this question, resulting in guesses that varied between visits.  
6.3.1.1.3. Smoking status change 
Of the 107 subjects analysed in 2005, 92 (86.0%) were classified on the basis 
of the questionnaire as smokers or ex-smokers. None of these reported 
being never smokers in 2010, confirming good repeatability of this question 
[see Table 38]. However, two additional subjects reported being smokers at 
the second study, possibly because they had begun to smoke. This was not 
interrogated further.  
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Table 38: Comparison of reporting of smoking status in 2005 and 2010. 
  BOLD 2005 study  
 
Follow-up  
in 2010 
 Smoker Never-smoker Total 
Smoker 92 2 94 
Never-smoker 0 13 13 
Total 92 15 107 
6.3.1.1.4. History of comorbidity 
The comparison of subjects reporting comorbidities (heart disease, 
hypertension, diabetes or TB) in 2005 and 2010 is presented in Table 39. 
Two of the five subjects who reported heart disease in 2005 failed to report 
this in 2010, but an additional 13 reported this condition in 2010. Similarly, no 
subject who reported hypertension in 2005 changed their response in 2010, 
but an additional 23 reported hypertension in 2010. For diabetes, all but one 
continued to report diabetes in 2010, and an additional five subjects reported 
having this condition. Finally, only one of 34 subjects who reported a history 
of TB in 2005 gave a negative response to this question in 2010, but an 
additional seven subjects reported this disease in 2010.  
 An estimate of the repeatability of the above questions was performed 
using kappa values; however, incident pathology (i.e. developing disease 
between 2005 and 2010) had to be considered. When the incident disease 
was re-coded as ‘no change’, the resultant kappa values provided a 
conservative estimate of the repeatability of the questions. The kappa values 
(and 95% CIs) are presented below in Table 40. 
 
Table 39: Comparison of reporting of disease between the BOLD 2005 and 
Follow-up study. 
 
 
 
 
 
 
 
 
Follow-up  
study  
(2010) 
 BOLD study (2005)  
 Heart disease No heart disease Total 
Heart disease 3 13 16 
No heart disease 2 89 91 
Total 5 102 107 
    
 Hypertension No hypertension Total 
Hypertension 30 23 53 
No hypertension 0 54 54 
Total 30 77 107 
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 Diabetes No Diabetes Total 
Diabetes 9 5 14 
No Diabetes 1 91 92 
Total 10 96 106 
    
 Tuberculosis No tuberculosis Total 
Tuberculosis 34 7 41 
No tuberculosis 1 65 66 
Total 35 72 107 
 
Table 40: Estimates of kappa values for question repeatability (excluding 
incident disease). 
 kappa value 95% CI 
For smoking 
status 
1.00 (0.81 – 1.19) 
For heart disease 0.74 (0.56 – 0.92) 
For hypertension 1.00 (0.81 – 1.19) 
For diabetes 0.94 (0.75-1.13) 
For tuberculosis 0.98 (0.79 -1.17) 
   
* incident pathology was recoded as “no change” (i.e. negative) in 2010 
  
6.3.2. Assessment of spirometry  
6.3.2.1. Reproducibility 
The term reproducibility refers to a test performed on the same subjects, but 
under different conditions (e.g. different time, position of subject, observer 
etc.) When a test is performed on a subject under the same conditions, the 
term repeatability is used, and is not appropriate here.202  
The reproducibility of the EasyOne ndd spirometer was considered by 
comparison of results obtained at Visit 1 and Visit 2 in two ways: first by 
direct comparison of the spirometric volumes and second by comparing the 
designation of subjects as having CAO or not, according to the FEV1:FVC.  
 A total of 56 subjects were included in this analysis. Of the 107 
subjects at Visit 1, three had withdrawn by Visit 2, two were unable to 
perform spirometry, and one had missing data. Additionally, to limit the 
potential for confounding, subjects with more than 30 days between the 
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visits (n=4), and subjects that were required to withhold respiratory 
medication prior to Visit 2 (n=41), were omitted. Thus, the included subjects 
were stable on treatment that could affect airway caliber. The mean time 
between the visits was 10.8 days (median 10.5 days, sd=3.41 days, range 2-
24 days).  
 For FEV1 measured with the EasyOne ndd spirometer, the correlation 
coefficient between values at Visits 1 and 2 was 0.9471 [see Figure 29]. 
However, using the Bland-Altman analysis, the mean difference was 0.0180 
litres (sd=0.220, 95% CI –0.422- +0.458) [see Figure 30]. Thus, on a 
subsequent visit, the variation in FEV1 measurement ranged from 422 mL 
below or 458 mL above the initial measurement. Sixteen of 56 subjects 
(28.6%) had FEV1 values that differed by more than 150 mL between the 
visits. 
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Figure 29: Comparison of FEV1 at 
Visit 1 & Visit 2 using EasyOne ndd 
spirometer. 
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Figure 30: Bland-Altman plots for 
FEV1 reproducibility using EasyOne 
ndd spirometer. 
 
The correlation coefficient for the FVC between Visits 1 and 2 was 0.9153 
[see Figure 31], and in the Bland-Altman analysis, the mean difference was  
–0.003 litres (sd=0.448 litres, 95% CI –0.899- +0.894) [see Figure 32]. A total 
of 37 subjects (66.1%) had FVC measurements that differed by more than 
150 mL between the visits. 
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Figure 31: Comparison of FVC at 
Visit 1 and 2 using EasyOne ndd 
spirometer. 
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Figure 32: Bland-Altman plots for 
FVC reproducibility using EasyOne 
ndd spirometer. 
 
The classification of subjects according to the presence or absence of CAO 
(defined as FEV1:FVC <0.70) at two visits (less than 30 days apart) using the 
same spirometers, was assessed. Discordance in classification of CAO 
status was found in 11 of 56 subjects (19.6%), but neither reading had a 
higher likelihood of diagnosing CAO [see Table 41] 
 
Table 41: Correlation between assessments of CAO at Visit 1 and Visit 2 (less 
than 30 days apart) performed with the EasyOne nnd spirometer in subjects 
not receiving treatment for airways disease. 
 
 
Visit 2 
 Visit 1  
 No CAO CAO Total 
No CAO 6 5 11 
CAO 6 39 45 
Total 12 44 56 
 
6.3.2.2. Comparison of results of spirometry performed with 
the EasyOne ndd with Nspire office spirometers  
Pre- and post-bronchodilator spirometry was performed at Visit 2 using two 
different spirometers: the handheld EasyOne ndd and the Nspire office 
spirometer [see page 68]. 
 Of the possible 107 eligible subjects, three withdrew before Visit 2, 
one was unable to perform acceptable spirometry, and one had missing 
data. In the remaining 102 subjects, the correlation coefficient for FEV1 
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between the spirometers was 0.979 [see Figure 33], and on Bland-Altman 
analysis the mean difference was 0.0415 litres (sd 0.146, 95% CI –0.251-
+0.333). Thus, difference in FEV1 measured by the handheld EasyOne ndd 
spirometer ranged from 250 mL lower to 333 mL higher than that measured 
by the Nspire spirometer [see Figure 34]. Twenty-three subjects (22.5%) had 
FEV1 values that differed by more than 150 mL between spirometers at the 
same visit [see Figure 35]. 
 
(Correlation coeff : 0.9791)
0
1
2
3
4
Ea
sy
on
e 
nd
d 
FE
V1
0 1 2 3 4
Nspire FEV1
(n =102)
between Easyone ndd and Nspire (office) spirometers
Comparison of Spirometry (visit 2) : FEV1
 
Figure 33: Comparison of FEV1 at 
Visit 2 using two different 
spirometers. 
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Figure 34: Bland-Altman plot 
comparing FEV1 using two different 
spirometers at Visit 2. 
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Figure 35: Difference in 
measurement of FEV1 at Visit 2 
using two different spirometers.
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The assessment for the presence of CAO by the two spirometers at Visit 2 
differed in 17 subjects (16.7%) [see Table 42], but neither spirometer was 
associated with a greater tendency to diagnose CAO. 
 
Table 42: Classification in the assessment of CAO made with two spirometers 
at Visit 2. 
  EasyOne Spirometer  
 
Nspire 
Spirometer 
 No CAO CAO Total 
No CAO 7 10 17 
CAO 7 78 85 
Total 14 88 102 
 
6.4. Summary of findings  
 
In the assessment of the methodology used during the Cape Town BOLD 
2005 study, approximately 15.0% of subjects no longer had evidence of 
airflow obstruction. This discrepancy was higher (25.0%) when the LLN 
definition was applied. Apart from the well-described over-diagnosis in the 
elderly, the reasons for the high numbers of non-obstructed individuals is not 
clear, but could include: misdiagnosis and inclusion of asthmatic subjects; 
systematic measurement error in either the first or second study (e.g. 
variability in spirometry measurement or inadequate FVC manoeuvre at 
second visit); or the effect of treatment in some subjects. However, this last 
explanation is unlikely as no association between the use of respiratory 
medication and change in FEV1 was observed [see page 102]. 
Estimates of the prevalence of asthma in the Follow-up cohort ranged 
from 6.3%-18.8% in subjects without airflow obstruction, and from 11.1%-
18.9% for those with airflow obstruction: 10.4% and 17.9% overall.  Of 
these, a number with both CAO and a smoking history, are likely to be 
considered as asthma-COPD overlap syndrome (ACOS). However lack of 
definitive diagnostic criteria for this condition makes formal conclusions 
difficult, and even if the diagnosis is adopted, treatment approaches different 
to those for COPD and more similar to asthma, should be employed.98 
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Large variation in the reproducibility of FEV1, and especially FVC, 
between visits less than 30 days apart, were observed with the same 
handheld EasyOne ndd spirometers. This difference resulted in a change in 
the diagnosis of CAO in up to 19.6% of subjects.  
Additionally, there was a large variation in FEV1 measurement 
between those obtained with the EasyOne ndd and the Nspire office 
spirometer used on the same occasion. In up to 16.7% of subjects this 
difference resulted in discordant assessment of CAO status. 
However, these differences between the spirometer results appeared 
to be random (i.e. neither systematic nor unidirectional). Despite the 
discordant results, the total numbers of subjects with and without CAO 
remained similar. These results suggest that the EasyOne ndd provides a 
reasonably reliable estimate of the prevalence of CAO for epidemiological 
population-level research, but for clinical diagnosis and management results 
of spirometry need to be viewed with caution and, if necessary, repeated, as 
results from a single-test may be misleading. The use of additional tests with 
more accurate office equipment, and other lung function tests will further 
improve the accuracy of diagnosis in individual patients.  
 Chapter 7. Classification of Subjects according to 
Previous Pulmonary Tuberculosis Status 
 
7.1. Introduction 
 
The central hypothesis examined in the present study is whether chronic 
airflow limitation in patients with a history of previous pulmonary tuberculosis 
(PPTB) differs in terms of pathophysiology, natural history and 
responsiveness to treatment to that in patients without this risk factor for 
COPD. It is therefore crucial to correctly assign subjects as having had 
pulmonary tuberculosis or not. There is, however, no agreed or standardised 
method of retrospectively assessing PPTB status. This chapter compares 
different methods of investigating PPTB status and the approach adopted in 
the present study.  
 
7.2. Measurement of PPTB status by questionnaire 
 
To assess the potential of using a more detailed questionnaire with which to 
assign subjects correctly, two questionnaires, the second being more 
comprehensive, were administered and compared.  
 
7.2.1. BOLD Questionnaire 
The BOLD Questionnaire, which was used in both the BOLD 2005 and 
Follow-up Study in 2010, contained the following questions [see Figure 36]: 
• Has a doctor or other health care worker ever told you that you have 
had tuberculosis? (Question 26F) 
o (If yes) Are you currently taking medicine for tuberculosis? 
(Question 26F1) 
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o (If no) Have you ever taken medicine for tuberculosis? (Question 
26F2) 
 
 
Figure 36: BOLD Questionnaire questions ascertaining previous tuberculosis 
status. 
 
Results from the BOLD questionnaire have been presented on page 88 and 
Table 8. In brief, of the 107 subjects included in the study at Visit 1, 41 
subjects (38.3%) provided a positive response to question 26F (above) and 
reported a previous history of TB, whereas 66 subjects (61.7%) did not. One 
subject provided no data on past treatment received for PTB, but all of the 
remaining 40 subjects reported having received medication for tuberculosis 
previously, and none were currently on treatment. 
 
7.2.2. Additional Tuberculosis Questionnaire 
At follow-up in 2010, an Additional Tuberculosis Questionnaire (ATbQ) was 
developed and administered, and the results were compared with the BOLD 
questionnaire [see Appendix 2 – Additional Tuberculosis Questionnaire]. The 
ATbQ contained the following questions: 
1. Were you ever diagnosed with tuberculosis? 
2. (If yes) How many times were you treated for tuberculosis? 
 
For every episode of tuberculosis, the subject was asked, if possible, to 
provide the following information: 
• Date of diagnosis 
• Site of infection  
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• Certainty or assurance that the diagnosis was communicated by the 
diagnosing healthcare worker 
• Method of diagnosis 
• Hospitalisation for treatment 
• Duration of hospitalisation (if appropriate) 
• Site of treatment (i.e. clinic) 
• Duration of treatment 
• Completion of treatment 
• Resolution of symptoms 
• Assessment as ‘cured’ by healthcare worker 
• Failure to complete treatment. 
Based on responses to this questionnaire, a specialist pulmonologist 
provided an opinion as to whether a diagnosis of PPTB could be made with 
certainty. The results of this questionnaire have been presented on page 89 
and Table 9, Table 10,Table 11 and Table 12. In short, with the ATbQ, 39 
subjects (36.4%) reported having had at least one episode of PPTB, while 68 
subjects (63.6%) did not.  
 
7.2.3. Comparison of questionnaires 
Agreement of the PPTB status between the two questionnaires was 98.1% 
(expected agreement 53.2%), kappa value of 0.96 (95% CI 0.91-1.00).  
In the two subjects lacking agreement between questionnaires: 
• One subject reported having being treated for tuberculosis for three 
months as an outpatient before the diagnosis was changed to asthma. 
• For the other subject, there was no obvious reason for the discrepant 
responses and it was considered by the study team to be an error of 
data entry in the BOLD questionnaire. 
The concordance between the two questionnaires is reassuring. Potentially 
the wording of the BOLD questions is likely to record trials of PTB treatment 
(empiric short-term use of TB treatment), as a ‘positive history of PTB’ – even 
when treatment is stopped following evidence of a wrong diagnosis of TB. 
This did not appear to be a significant problem in the present study.  
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7.3. Assessment of PPTB status using chest X-ray  
 
7.3.1. Description of method 
Two experienced pulmonologists reported the chest X-rays of the 104 
subjects (taken at Visit 2) of whom these were available. The readers were 
blinded to the subject information, including history of previous TB, and were 
asked to respond to the following questions: 
- Is the chest X-ray completely normal? (Y/N) 
- Is the chest X-ray consistent with previous tuberculosis? (Y/N)  
- Is there hyperinflation on chest X-ray? (Y/N) 
- Is there volume loss on chest X-ray? (Y/N) (Volume loss of both 
single lobes and of the whole lung was considered to be volume 
loss.)  
In view of the wide variety of radiological changes that may be found after an 
episode of TB, such as: fibro-cavitatory changes; apical fibrosis and bands; 
cavitation; granulomas (which may or may not be calcified); bronchiectasis; 
lymph node calcification; and pleural fibrosis, the term ‘consistent with 
previous tuberculosis’ could not not defined. Instead, the two readers were 
asked to use their experience and clinical judgment to answer the questions. 
Lack of agreement between the two readers after their first read was 
resolved during a consensus read, which was held on a different occasion, at 
which readers were blinded to their original responses, and a consensus 
decision was reached. 
 
7.3.2. Findings 
Of the 104 subjects with chest X-rays, both readers judged 47 subjects 
(45.2%) to have had PPTB, while 57 subjects (54.8%) were considered to 
have no evidence of PPTB. However, these were not always the same 
subjects. In 14 subjects, there was lack of concordance (i.e. lack of 
agreement into which category a subject fell). Thus, the overall kappa value 
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was 0.72 (95% CI 0.60-0.86), with an agreement between the readers of 
86.5% (expected agreement = 50.5%). 
 At the consensus read, Reader 1 changed six results, and Reader 2 
changed eight results, giving a consensus categorisation of 45 subjects 
(43.3%) as having chest X-ray evidence of PPTB, and 59 subjects (56.7%) 
without such evidence [see Table 43 and Figure 37]. 
 
Table 43: Results of the assessment of chest X-rays for features compatible 
with PPTB by two independent readers. 
 Reader 1  % Reader 2  % Consensus % 
Previous TB 47 45.2% 47 45.2% 45 43.3% 
No Previous TB 57 54.8% 57 54.8% 59 56.7% 
Total 104 100.0% 104 100.0% 104 100.0% 
 
 
Figure 37: Results of the assessment of chest X-rays for features compatible 
with PPTB by two independent readers. 
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7.4. Measurement of PPTB status using CT scans 
7.4.1. Description of method  
Two consultant radiologists (one from UCLA and one from UCT) were 
blinded to all subject information and asked to review all 104 CT scans for 
evidence of PPTB. They were asked to comment on the following: 
• Presence of the following changes, and likelihood that they were due 
to previous TB: 
o Apical changes 
o Nodules 
o Calcification 
o Lymph nodes 
o Pleural abnormalities 
o Other (not specified) 
• Whether the CT scan showed evidence of PPTB (yes/no) 
• A rating of their confidence that the radiological abnormalities reported 
were due to PPTB. 
For estimation of likelihood, a Likert scale of 0 to 5 was used, with: 0, no 
evidence; 1, highly unlikely; 3, equivocal; and 5, highly likely due to PTB. 
Where there was disagreement between Reader 1 and 2 on PPTB status, a 
third reader (a pulmonologist) was asked to review and report on the scan. 
This arbitrating reader was blinded to both subject information and previous 
radiological assessments. Blinding was ensured by randomly including 
among the images, 26 CT scans on which the first two readers had agreed. 
 
7.4.2. Findings 
Reader 1 identified 62 subjects (59.6%) with and 42 subjects (40.4%) without 
CT changes consistent with PPTB. Reader 2 reported changes consistent 
with PPTB in 84 subjects (80.8%) and no changes in 20 subjects (19.2%) 
(kappa value: 0.43, 95% CI 0.27-0.60). There was 75.0% agreement between 
the readers (expected agreement 55.9%), representing discordance on 26 
scans. The arbitrating reader differed with and changed 17 results from 
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Reader 2, and 9 results from Reader 1. Thus, the final categorisation of CT 
scans was: 71 subjects (68.3%) exhibited changes consistent with PPTB, 
and 33 (31.7%) did not [see Table 44 and Figure 38]. 
 
Table 44: Assessment of PPTB status, using CT scans, by two readers. 
   CT 
Reader 1 
% CT 
Reader 2 
% CT 
Consensus 
% 
Previous TB 62 59.6% 84 80.8% 71 68.3% 
No Previous 
TB 
42 40.4% 20 19.2% 33 31.7% 
Total 104 100.0% 104 100.0% 104 100.0% 
 
 
Figure 38: Assessment of PPTB status, using CT scans, by two readers. 
The level of confidence of Readers 1 and 2 in their assignment of PPTB are 
presented in Table 45 and Figure 39. 
 
Table 45: Reader confidence that changes observed on CT scan were due to 
PPTB. 
 Reader 1 % Reader 2 % 
No Evidence 37 35.6% 5 35.6% 
Highly 
Unlikely 
4 3.9% 8 3.9% 
Unlikely 2 1.9% 1 1.9% 
Equivocal 8 7.7% 6 7.7% 
Likely  7 6.7% 3 6.7% 
Highly Likely 46 44.2% 81 44.2% 
Total 104 100.0% 104 100.0% 
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Figure 39: Reader confidence that changes observed on CT scan were due to 
PPTB. 
 
7.5. Comparison of different methods of assigning PPTB status 
 
Agreement between the different methods of assigning PPTB status was 
compared as follows: 
 
7.5.1. Comparison of Additional TB Questionnaire and chest X-ray 
read 
Of the 104 subjects with chest X-rays, there was concordance between the 
questionnaire and chest X-ray results in assigning TB status in 84 (80.8%), 
and discordance in 20 subjects (19.2%) with questionnaire, yielding a kappa 
value of 0.60 (95% CI 0.45-0.76; expected agreement 51.7) [see Table 46].  
 
Table 46: Comparison of Additional TB Questionnaire (ATbQ) and chest X-ray 
read for assessing PPTB status. 
  Chest X-ray  
 
 
ATbQ 
 No Previous TB Previous TB Total 
No Previous TB 52 13 65 
Previous TB 7 32 39 
Total 59 45 104 
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7.5.2. Comparison of Additional TB Questionnaire and CT scan 
read 
There was poor agreement between questionnaire and CT scan in assigning 
PPTB status, with concordance in 68 (65.4%), and discordance in 36 of 104 
subjects (34.6%), yielding a kappa value of 0.37 (95% CI 0.23-0.51; expected 
agreement 45.43%) [see Table 47]. 
 
Table 47: Comparison of Additional TB Questionnaire (ATbQ) and CT scan read 
for assessing PPTB status. 
  CT Scan   
 
 
ATbQ 
 No Previous TB Previous TB Total 
No Previous TB 31 34 65 
Previous TB 2 37 39 
Total 33 71 104 
 
7.5.2.1. Inter-reader concordance of CT scan assessment in 
subjects with a history of PPTB on questionnaire 
Thirty-nine subjects gave a history of PPTB on ATbQ. In four of these 
subjects (10.3%), CT scan assessment of their PPTB status was discordant 
on the initial read by the two readers, the remainder (n=35) was concordant 
(i.e. assessed as evidence of PPTB). Two of the four discordant scans were 
ultimately adjudged to be consistent with PPTB, and two were adjudged to 
be inconsistent with PPTB.  
7.5.2.2. Inter-reader concordance of CT scan assessment in 
subjects with no history of PPTB but CT scan evidence of PPTB 
There were 34 subjects assessed as having PPTB on CT scan but not 
reporting a history of PPTB. Twenty-five of these CT scans (73.5%) were 
assessed by both readers as having evidence of PPTB (i.e. concordance), 
with the remaining nine CT scans (26.5%) yielding discordant assessment. 
The confidence with which PPTB was assessed by each of the readers for 
these 34 subjects is shown below in Table 48 and Figure 40. 
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Overall, the readers were confident or very confident (assigning high 
likelihood of PPTB) for the majority of CT images viewed.  
 
Table 48: Reader confidence that observed CT scan changes were due to 
PPTB, in subjects with no history, but CT scan evidence for PPTB.  
  Reader 1  % Reader 2 % 
 
 
 
Confidence 
of PPTB 
None 6 17.65% 0 0% 
Very low 2 5.88% 0 0% 
Low 1 2.94% 0 0% 
Moderate 3 8.82% 1 2.94% 
High 5 14.71% 2 5.88% 
Very high 17 50.0% 31 91.18% 
Total 34 100.0% 34 100.0% 
 
 
Figure 40: Reader confidence that observed CT scan changes were due to 
PPTB, in subjects with no history, but CT scan evidence for PPTB. 
 
7.5.3. Comparison of chest X-Ray and CT scan reads  
Assignment of PPTB status by chest X-ray and CT scans was concordant in 
70 (67.3%) and discordant in 34 of 104 subjects (32.7%), yielding a kappa 
value of 0.38 (95% CI 0.23-0.53, expected agreement 47.5%) [see Table 49]. 
This lack of agreement was chiefly due to the greater sensitivity of CT scans.  
Classification of PPTB Status 
 137 
Table 49: Comparison of chest X-ray and CT scan reads for assessing of PPTB 
status. 
  CT scan  
 
Chest 
X-ray 
 No Previous TB Previous TB Total 
No Previous TB 29 30 59 
Previous TB 4 41 45 
Total 33 71 104 
 
7.6. Analysis of grouping 
 
The overlap of results of the three methods (ATbQ, chest X-ray and CT scan) 
for assessing PPTB status is presented in Table 50 and Figure 41. 
 
Table 50: Grouping of subjects after assessment of PPTB status by Additional 
TB Questionnaire (ATbQ), chest X-ray and CT scan reads. 
n=104 
 
 Group 
1 
Group 
2 
Group 
3 
Group 
4 
Group 
5 
Group 
6 
Group 
7 
Group 
8 
Evidence 
for PPTB 
ATbQ +ve +ve +ve -ve +ve -ve -ve -ve 
Chest 
X-ray 
+ve +ve -ve +ve -ve +ve -ve -ve 
CT 
Scan 
+ve -ve +ve +ve -ve -ve +ve -ve 
 Number 31 1 6 10 1 3 24 28 
 % 29.8% 1.0% 5.8% 29.8% 1.0% 2.9% 23.1% 26.9% 
 
The majority of subjects showed agreement between the three methods of 
establishing PPTB status (i.e. 31 of 104 subjects were positive for PPTB by 
all three methods, and in 28, all three tests were negative). CT scan adjudged 
24 subjects as PPTB alone, while a further six were assessed as PPTB by 
both CT scan and questionnaire, but not by chest X-ray. An additional 10 
were assessed as PPTB by CT scan and chest X-ray, but not by 
questionnaire. Five subjects were adjudged as having PPTB by either 
questionnaire or chest X-ray, but not by CT scan. Their details are as follows: 
• Two subjects were considered false negatives for PPTB assessed by 
CT scan, as both gave convincing histories for fully treated PPTB, and 
one had chest X-ray assessment supporting PPTB. 
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• Three subjects were adjudged as being true negatives for PPTB, as 
chest X-rays were thought to show evidence for PPTB, but both 
history and CT scans were negative.  
 
 
Figure 41: Assignment of PPTB status by questionnaire (ATbQ), chest X-ray 
and CT scan (n=104). 
 
Thus, CT scanning misclassified two subjects as false negatives, and chest 
X-ray misclassified three subjects as false positives. 
7.7. Composite definition of PPTB status for use in the TOPD  
 
To assess the role of PPTB in CAO, it was important that only subjects with a 
very low likelihood of PPTB be included in a no PPTB group. A high negative 
predictive value (‘rule out test’) was therefore required to minimise potential 
for type II statistical error. For this reason, the categorisation employed in this 
study was a composite of both the Additional TB Questionnaires and CT 
scan assessments. Categories of subjects were defined as follows:  
 
• Definite Previous Tuberculosis (DPTB)  (n=39, 37.5%)  
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Subjects with a positive history in the Additional TB Questionnaire 
as having PPTB.  
• Probable Previous Tuberculosis (PrPTB) (n=34, 32.7%) 
Subjects without a history of PPTB, but having CT scan evidence 
of PPTB.  
• No Previous Tuberculosis (NPTB)  (n=31, 29.8%) 
Subjects with neither a history of PPTB according to the ATbQ, nor 
evidence of PPTB on CT scan. 
In some analyses, subjects in the DPTB and PrPTB groups were combined in 
the category Previous Pulmonary Tuberculosis (PPTB) (n=73). 
 
7.7.1. Performance of questionnaire alone for ruling out PPTB 
In this analysis, the performance of questionnaire alone using the ATbQ was 
compared to the above composite definition of PPTB. The ATbQ categorised 
39 of 104 subjects as having PPTB, with the remaining 65 as not. Thus, 
compared to the above definition, the ATbQ incorrectly categorised 34 
subjects (32.7%) as not having PPTB (i.e. false negatives), yielding a 
sensitivity of 53.4% (95% CI 42.1-64.4%); and negative predictive value 
(NPV) of 47.7% (95% CI 36.0-59.6%) (by definition, specificity and PPV were 
100.0%) [see Table 52]. 
 
7.7.2. Performance of chest X-ray alone for ruling out PPTB 
Similarly, the performance of chest X-ray alone was compared with the 
history and CT scan-based composite definition above, and yielded a 
sensitivity of 57.5% (95% CI 46.1-68.2%) and specificity of 90.3% (95% CI 
75.1-96.7%), with three (2.9%) false positives and 31 (29.8%) false negatives 
[see Table 52].  
7.7.3. Performance of alternative definition of PPTB status using 
questionnaire and chest X-ray  
An alternative classification for PPTB using questionnaire and chest X-ray 
(but not CT scan) was compared with the questionnaire/CT scan-based 
composite definition described above.  
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This alterative classification categorised subjects as follows:  
• Definite Previous Tuberculosis (n=39, 37.5%) 
Subjects with a history of PPTB regardless of chest X-ray findings.  
• Probable Previous Tuberculosis (n=13, 12.5% ) 
Subjects without a history of previous PTB but radiological 
evidence of PPTB on chest X-ray. 
• No Previous Tuberculosis (n=52, 50.0%) 
 
Subjects with neither a history nor chest X-ray evidence of PPTB. 
Comparisons of the preferred composite and above alternative definitions of 
PPTB are shown in Table 51.  
 
Table 51: Comparison of CT-based composite definition of PPTB status with 
the alternative classification using chest X-ray and questionnaire. 
  Chest X-ray-based definition 
  NPTB 
 
PrPTB 
 
DPTB 
 
Total 
CT-based 
composite 
definition 
NPTB 28 3 0 31 
PrPTB 24 10 0 34 
DPTB 0 0 39 39 
Total 52 13 39 104 
 
The alternative history/chest X-ray-based classification mischaracterised 24 
subjects (23.1%) as NPTB, when they had PrPTB by the preferred 
classification (i.e. false negatives), while three subjects (2.9%) were 
misclassified as PrPTB when they had NPTB (i.e. false positives). Thus, the 
overall misclassification rate was 26.0% (27 of 104 subjects). 
 Using the alternative questionnaire/chest X-ray classification and 
combining the Definite and Probable PPTB groups into a Previous TB (PPTB) 
group, the performance of this classification had a sensitivity of 67.1% (95% 
CI 55.7-76.8%), specificity of 90.3% (75.1%-96.6%), PPV of 94.2% (95% CI 
84.4-98.0%) and NPV of 53.9% (95% CI 40.5-66.7%) [see Table 52]. 
Therefore, this method performs well as a rule-in test, but not as a rule out 
when the presence of previous PTB needs to be determined with a high-
degree of certainty.  
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Table 52: Comparison of the composite definition of PPTB with questionnaire 
alone, chest X-ray alone, or combined questionnaire and chest X-ray 
(alternative definition). 
  Composite Definition of PPTB*    
  PPTB NPTB Total Sn Sp PPV NPV 
Questionnaire       
 PPTB 39 0 39     
 NPTB 34 31 65     
 Total 73 31 104 53.4% - # 100.0% 47.7% 
Chest X-ray       
 PPTB 42 3 45     
 NPTB 31 28 59     
 Total 73 31 104 57.5% 90.3% 93.3% 47.5% 
Alternative definition using questionnaire and chest X-ray 
 PPTB 49 3 52     
 NPTB 24 28 52     
 Total 73 31 104 67.1% 90.3% 94.2% 53.9% 
*Composite Definition used both questionnaire and CT scan (as defined in text) 
# Specificity not calculated as formed part of Composite Definition (therefore would be 100%) 
 
7.8. Conclusion 
 
Determining whether a patient has had, or has a strong likelihood of having 
had, pulmonary tuberculosis (PTB) is important in several clinical and 
research settings. Both epidemiological and immunological research require 
the correct classification of PPTB status to isolate the effects attributable to 
TB, while in clinical practice and drug research it remains important to 
establish PPTB status prior to commencing therapy that may impair the 
immune host-response to mycobacterial infection, for example, when using 
biological agents. There is, however, no gold-standard test for PPTB and 
commonly used methods have limitations. 
 The undisputed method for confirming PPTB is historical evidence 
(preferably in contemporaneous clinical reports) that infection with 
Mycobacterium tuberculosis (Mtb) has been confirmed bacteriologically. 
However, this information is seldom available, particularly in cross-sectional 
epidemiologic studies. Thus, although highly specific, this method lacks 
sensitivity and has a low negative predictive value. Reasons for the low yield 
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include: limited access to or incomplete clinical records, population mobility, 
and the limitations of sputum examination (smear-negative cases).  
 Self-reporting, the usual method in cross-sectional surveys14,17,18 is 
subject to recall and reporting bias. A markedly lower prevalence of PPTB 
using history, as compared to chest X-ray findings, is common, as recently 
reported in the large BIOBANK cohort study.26 In theory, both the questions 
used and the method of administration (i.e. self vs. investigator-administered) 
may influence the results. For example, the question ‘have you ever been 
diagnosed with TB?’ differs from ‘have you ever been given TB treatment?’. 
The latter assumes a correct and bacteriological diagnosis, which may not be 
the case, particularly in high-burden settings where a trial of treatment is 
commonly used. In spite of these potential sources of imprecision, in the 
present study the kappa value for the comparison of the BOLD and more 
comprehensive ATbQ was 0.96, differing by only two subjects.  
 Other methods for assessing previous infection with Mtb (although not 
specifically PPTB) are the tuberculin skin test (TST) and Interferon Gamma 
Release Assays (IGRA). Although useful in developed countries, with a low-
burden of TB, for diagnosing latent TB infection (with a high negative-
predictive value), these tests are positive in the majority of adults in high-
burden settings, regardless of TB status, and are therefore unhelpful as a 
rule-out test.203 For this reason, neither TST nor IGRAs were used in the 
present study.  
 Radiology, predominantly chest X-ray, has been used in a number of 
studies to assess whether subjects have had PPTB.26,158 Although the 
radiological changes of active TB are well known,152 identifying and correctly 
attributing abnormalities to a previous bout of PTB is more difficult and no 
validated criteria for this have been proposed. The usual clinical question is 
whether a lesion represents active rather than healed disease, with the 
question of whether the change is compatible with healed PTB as a 
secondary consideration. However, in settings where even healed PTB needs 
to be excluded, even subtle changes may be significant and, as 
demonstrated in the current study, a CT scan identifies such abnormalities in 
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almost twice as many patients as a chest X-ray. Recognised lesions 
suggesting healed PTB include: fibrotic scars, nodules (with discrete borders 
or calcified), upper lobe changes with volume loss, and blunting of the 
costophrenic angles.155,204 Applying strict and limited diagnostic criteria may 
increase the specificity of the diagnosis, but reduces sensitivity. 
 When developing an approach to using composites of evidence of 
PPTB to provide an accurate method for ruling out PPTB it was necessary to 
compare the yields and concordance between the different tests, and 
combinations thereof. Various methods were considered. 
 Discrepant Analysis compares two tests (e.g. questionnaire and chest 
X-ray) and employs a third test as the ‘resolver test’ to distinguish, in this 
instance, true positives (PPTB) from true negatives. However, among other 
weaknesses of the method, the resolver test is required to be a gold 
standard test and preferably independent of both initial tests. Additionally, 
this method most likely leads to upward bias in the sensitivity and specificity 
of the initial test, as not all subjects are exposed to the resolver test.205. 
An alternate approach is Latent Class Analysis, which models 
imperfect tests, called manifest variables, to identify different subtypes of 
cases, which are defined by the unobservable outcome, called latent 
variables (i.e. the true diagnosis). Results from the imperfect tests can be 
used to estimate true diagnostic status, sensitivity, specificity and 
prevalence. In the current study, the conditions required were not met, 
including the lack of adequate numbers of test (here only two tests) and lack 
of independence of the tests.205 
For the present study, a Composite Reference Standard was used, 
which combined different and imperfect tests using pre-specified rules to 
determine disease status (e.g. presence of PPTB).205 As the objective was a 
rule-out test, the most sensitive test (CT scan-based) was combined with the 
most specific test (clinical history of PPTB). Partial validation of the results of 
CT scan was the fact that all but two subjects with a history of PPTB had CT 
features compatible with this.  
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 Thus, the use of a CT-based classification system that includes clinical 
history was adopted for the present study and is proposed as the best option 
in high-prevalence TB areas as a rule-out test for PPTB. History alone 
resulted in a misclassification rate of up to 32.7%, with a sensitivity of only 
53.4%, and when combined with chest X-ray had a sensitivity of 67.1% and 
specificity of 90.3%, but misclassified 26.0% of subjects. In the absence of a 
better gold standard, the use of a history plus CT-based classification 
system described above is advised as the reference standard if PPTB needs 
to be excluded with a degree of certainty.  
 In the light of the above findings, the following composite was used in 
the study of TOPD: 
1. Definite Previous Tuberculosis (DPTB):  Subjects with a history of 
PPTB, based on the Additional Tuberculosis Questionnaire, almost all 
of who had CT scan evidence of PPTB. 
2. Probable Previous Tuberculosis (PrPTB): Subjects without a history of 
PPTB, but with changes on CT scan compatible with PPTB. 
3. No Previous Tuberculosis (NPTB): Subjects with neither a history of 
PPTB, nor evidence of PPTB on a CT scan of the chest.  
In some analyses, DPTB and PrPTB groups were combined as Previous 
Pulmonary Tuberculosis (PPTB), for two-way comparison with NPTB.  
 Chapter 8. Results of Clinical Endpoints: 
Symptoms and Lung Physiology 
 
8.1. Introduction  
 
This chapter presents an analysis of the lung physiology data and clinical 
endpoints, comparing and contrasting the results for subjects with and 
without evidence of previous pulmonary tuberculosis (PPTB). 
 The data for this analysis was obtained at Visits 2 and 3. Prior to Visit 
2, subjects who were on respiratory medications were required to observe a 
‘washout’ period [see page 68]. Between Visits 2 and 3, subjects were 
administered oral prednisone (20 mg daily) and formoterol (long-acting beta2-
agonist) (24 mcg pMDI twice daily), as discussed on page 70. The interval 
between Visit 2 and 3 was a minimum of two and a maximum of four weeks.  
The results obtained with the Nspire (office) spirometry were used for 
this analysis. A comparison of results obtained with the EasyOne ndd 
(handheld spirometer) and Nspire spirometers at Visit 2 are presented in 
Chapter 6 (page 123). For the present study subjects were classified as 
having Previous Pulmonary TB (PPTB) – either Definite Previous TB (DPTB) 
or Probable Previous TB (PrPTB) – or No Previous TB (NPTB), as defined in 
the previous chapter.  
 
8.2. Analysis of the full cohort 
 
A total of 104 subjects participated in both Visits 2 and 3. One subject was 
unable to perform acceptable spirometry, but measurements of DLCO and 
whole body plethysmography were acceptable. Of these subjects, 31 
(29.8%) were classified as having NPTB, 39 (37.5%) as DPTB and 34 (32.7%) 
as PrPTB [see Figure 42]. 
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Figure 42: Classification of subjects according to PPTB status, used in the 
analysis of lung physiology. 
 
8.2.1. Smoking status and chronic bronchitis 
8.2.1.1. Smoking status 
Smoking status, being both a major confounder and potential effect-modifier, 
was assessed using data collected in the Additional Smoking Questionnaire.
 The smoking status of subjects according to the PPTB status is 
presented in Table 53. A significantly greater proportion of subjects with 
PPTB were smokers (either ex- or current smokers) compared to subjects 
without TB (93.2% vs. 77.4%, respectively, Chi2: p=0.022). The proportion of 
subjects who were smokers was 94.9% (37 of 39) of the DPTB group, 91.2% 
(31 of 34) of the PrPTB group, compared with 77.4% (24 of 31) of the NPTB 
group – a finding of borderline significance (Fisher’s Exact: p=0.078, Chi2: 
p=0.063). 
 Of those with PPTB, 34.2% were ex-smokers (25 of 73) and 58.9% 
were current smokers (43 of 73). In those without PPTB, 41.9% were ex-
smokers (13 of 31) and 35.5% were current smokers (11 of 31), which is a 
significant difference (Chi2: p=0.026). Of those with DPTB, 35.9% were ex-
smokers (14 of 39) and 59.0% were current smokers (23 of 39). In the PrPTB 
group, 32.4% reported being ex-smokers (11 of 34) and 58.8% current 
smokers (20 of 34). On three-group analysis, the difference between groups 
was not statistically significant (Fisher’s Exact Test p=0.125, Chi2: p=0.108). 
 
Analysis of Lung Physiology 
 147 
Table 53: Comparison of smoking status according to PPTB status. 
 
 
NPTB PPTB p-value Test NPTB DPTB PrPTB p-value Test 
Never  
smokers  
7 5   7 2 3   
Ever 
smokers  
24 68 0.022 Chi2 24 37 31 0.078 
(0.063 
Fisher's 
Chi2) 
Ex-smokers 13 25   13 14 11   
Current 11 43 [0.026 Chi2] 11 23 20 0.125 
[0.108 
Fisher's 
Chi2] 
Total 31 73   31 39 34   
 
In contrast to the above, comparison of the number of pack-years smoked 
(burden of smoking) was not significantly different between those with or 
without PPTB (Wilcoxon p=0.131), or on three-group analysis of those in the 
NPTB, DPTB and PrPTB groups (Kruskal-Wallis p=0.270) [see Table 54 and 
Table 55]. 
 
Table 54: Burden of smoking (pack-years) according to PPTB status: NPTB vs. 
PPTB. 
Pack years  NPTB sd PPTB sd p-value test 
 Mean 20.83 23.36 24.70 22.066 n/a n/a 
 Median 13.05  21.20  0.131 Wilcoxon 
 
Table 55: Burden of smoking (pack-years) according to PPTB status: three-
group analysis. 
Pack years NPTB sd DPTB sd PrPTB sd p-value test 
Mean 20.83 23.36 26.27 24.208 22.91 19.528 n/a n/a 
Median 13.05  22.00  19.86  0.270 Kwallis 
8.2.1.2. Chronic bronchitis 
In subjects with previous TB, chronic bronchitis (British MRC definition) was 
reported in 34.2% of subjects (25 of 73) with PPTB compared with 16.1% of 
those with NPTB (5 of 31) (Chi2: p=0.062). In the three-group analysis, 41.0% 
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of those with DPTB (16 of 39) reported chronic bronchitis, 26.5% with PrPTB 
(9 of 34) and 16.1% with NPTB (Chi2: p=0.069) [see Table 56 and Table 57] 
 
Table 56: Presence of chronic bronchitis according to PPTB status: NPTB vs. 
PPTB. 
 NPTB % PPTB % p-value test 
No Chronic Bronchitis 26 83.9% 48 65.8%   
Chronic Bronchitis 5 16.1% 25 34.3% 0.062 Chi2 
Total  31  73    
 
Table 57: Presence of chronic bronchitis according to PPTB status: three-
group analysis. 
 NPTB % DPTB % PrPTB % p-value test 
No Chronic Bronchitis 26 83.9% 23 59.0% 25 73.5%   
Chronic Bronchitis 5 16.1% 16 41.0% 9 26.5% 0.069 Chi2 
TOTAL  31  39  34    
 
8.2.2. Physiology tests at Visit 2  
For Visit 2, 103 subjects were able to perform spirometry. The following 
variables were not normally distributed and required analysis using non-
parametric statistical tests: 
• Post-bronchodilator FEV1 (litres)  
• Post-bronchodilator FVC (litres) 
• Post-bronchodilator FEV1:FVC. 
Findings of Visit 2 data and analysis are presented in Table 58. 
8.2.2.1. Post-bronchodilator FVC 
There was no significant difference in the median post bronchodilator FVC 
(litres) between those with or without PPTB (Wilcoxon p=0.398). Similarly, no 
difference was found in the comparison of the three subgroups: NPTB, DPTB 
and PrPTB (Kruskal Wallis p=0.368).  
 There was also no difference in the mean post-bronchodilator FVC (as 
% predicted) between those with and without PPTB (Satterthwaite’s t-test for 
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unequal variances p=0.917). No difference was found between the three 
subgroups (ANOVA p=0.990).  
8.2.2.2. Post-bronchodilator FEV1 
There was no significant difference in the median post-bronchodilator FEV1 
(litres), between those with or without PPTB (Wilcoxon p=0.440), and no 
significant difference on three-group analysis of the NPTB, DPTB and PrPTB 
groups (Kruskal Wallis p=0.617).  
FEV1 (% predicted) was both normally distributed and had equal 
variance. Thus, one sample t-test and ANOVA tests were used. The 
difference in the FEV1 (% predicted) between those with NPTB (mean FEV1 
75.1%) and those with PPTB (mean FEV1 67.0%) was not significant (t-test 
p=0.090) [see Figure 43]. On three-group analysis, the difference between the 
NPTB (mean 75.1% predicted), DPTB (mean 63.0%) and PrPTB groups 
(mean 71.8%) was also not significant (ANOVA p=0.0529) [see Figure 44]. 
Using the Bonferroni correction, the difference between each pair of means 
was as follows: 
• Difference between NPTB and DPTB: p=0.065 
• Difference between NPTB and PrPTB: p=1.000 
• Difference between DPTB and PrPTB: p=0.250. 
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Figure 43: Post-bronchodilator 
FEV1 (% predicted) at Visit 2 
according to PPTB status: NPTB vs. 
PPTB. 
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Figure 44: Post-bronchodilator 
FEV1 (% predicted) at Visit 2 
according to PPTB status: three-
group analysis. 
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Table 58: Comparison of the results of lung physiology at Visit 2 according to previous PTB status: PPTB vs. NPTB and by subgroups. 
 
 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (31)  (72)    (31)  (39)  (33)    
               
Post BD FVC (L) - mean 2.76 0.849 3.00 1.051 n/a  2.76 0.849 3.11 1.049 2.87 1.053 n/a  
Post BD FVC (L) - median 2.80 - 2.83 - 0.398 Wilcoxon 2.80 - 3.22 - 2.65 - 0.368 Kwallis 
Post BD FVC (%) - mean 96.29 11.335 95.99 17.490 0.917 Satterthwaite 
t-test 
96.29 11.335 95.79 19.195 96.21 15, 532 0.990 ANOVA 
               
Post BD FEV1 (L) -mean 1.74 0.638 1.67 0.746 n/a n/a 1.74 0.638 1.64 0.797 1.70 0.693 n/a n/a 
Post BD FEV1 (L) - median 1.68 - 1.44 - 0.440 Wilcoxon 1.68 - 1.41 - 1.49 - 0.617 Kwallis 
Post BD FEV1 (%) -mean 75.06 18.282 67.04 23.126 0.090 t-test 75.06 18.282 62.95 24.880 71.88 20.172 0.053 ANOVA 
               
Post BD FEV1:FVC - mean 0.63 0.131 0.56 0.141 n/a n/a 0.63 0.131 0.52 0.133 0.60 0.138 n/a n/a 
Post BD FEV1:FVC - median 0.67 - 0.60 - 0.012 Wilcoxon 0.67 - 0.54 - 0.63 - 0.002 Kwallis 
               
Reversibility               
Litres - median 0.20 0.156 0.19 0.168 0.730 Wilcoxon 0.20 0.16 0.16 0.148 0.19 0.190 0.879 Kwallis 
% change 11.76 13.708 11.99 16.708 0.994 Wilcoxon 11.76 13.71 11.77 18.148 12.63 15.106 1.000 Kwallis 
Significant reversibility*               
Number of subjects 13 - 26 -   13 - 12 - 14 -   
% (0.42) - (0.36) - 0.576 Chi2 0.42 - 0.31 - 0.42 - 0.511 Chi2 
               
DLCO (mL/min/mmHg) 18.06 5.483 15.16 4.954 0.010 t-test 18.06 5.483 14.93 4.754 15.44 5.242 0.033 ANOVA 
DLCO (%) 79.52 23.659 64.85 19.553 0.002 t-test 79.52 23.659 61.72 15.285 68.55 23.341 0.003 ANOVA 
*Significant reversibility = change in FEV1 of >200mL & >12%        
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8.2.2.3. Rate of decline in FEV1 
The rate of decline in FEV1 between the BOLD 2005 study and Visit 1 
spirometry of the Follow-up study (2010) are presented in Table 60. No 
difference in either the absolute decline in FEV1 or the rate of decline was 
found between subjects with and without PPTB. The FEV1 declined by a 
median of 119 mL (16.8 mL/yr) in those with NPTB and by 170 mL (32.7 
mL/yr) in those with PPTB (Wilcoxon p=0.283). There was also no difference 
in the rate of decline between the subgroups.  
8.2.2.4. FEV1:FVC  
The median FEV1:FVC was significantly lower in subjects with PPTB (median 
ratio 0.60) compared with those subjects with NPTB (median ratio 0.67) 
(Wilcoxon p=0.012) [see Figure 45]. 
 Additionally, on three-group analysis, there was a significant difference 
in median FEV1:FVC between those with NPTB (median ratio 0.67), those 
with DPTB (median ratio 0.54) and those with PrPTB (median ratio 0.63) 
(Kruskal-Wallis Test p=0.002) [see Figure 46]. 
 Comparing the median FEV1:FVC between the individual groups using 
the Wilcoxon test yielded the following results: 
• Difference between NPTB and DPTB: p=0.0006 
• Difference between NPTB and PrPTB: p=0.4011 
• Difference between DPTB and PrPTB: p=0.0098. 
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Figure 45: Post-bronchodilator 
FEV1:FVC at Visit 2 according to 
PPTB status, NPTB vs. PPTB. 
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Figure 46: Post-bronchodilator 
FEV1:FVC at Visit 2 according to 
PPTB status: three-group analysis.
8.2.2.4. Bronchodilator responsiveness 
Bronchodilator responses (change in FEV1 45 minutes after administration of 
400 μg salbutamol and 80 μg ipratropium bromide anhydrous) were similar in 
those with and without PPTB, whether expressed in litres or percentage 
change. Additionally, there was no significant difference when three-group 
analysis was performed. Neither was there a difference in the proportion of 
subjects with significant reversibility (defined as a change in FEV1 of more 
than 200 mL and 12.0%) between subjects with and without PPTB, or in 
three-group analysis [see Table 58]. 
8.2.2.5. Diffusing capacity (DLCO) 
A significantly higher mean DLCO (ml/min/mmHg) was found in subjects with 
NPTB (18.06 mL/min/mmHg, sd=5.483) compared with PPTB (15.16 
mL/min/mmHg, sd=4.954) (t-test p=0.0097) [see Figure 47]. The difference 
between DPTB (14.93 mL/min/mmHg, sd=4.754), PrPTB (15.44 
mL/min/mmHg, sd=5.242) and NPTB groups (18.06 mL/min/mmHg, 
sd=5.483) was also significant (ANOVA p=0.003) [see Figure 48]. However, 
on Bonferroni correction only the difference between those with NPTB and 
DPTB remained (p=0.033). 
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Figure 47: Diffusing capacity 
(mLl/min/mmHg) according to 
PPTB status : NPTB vs. PPTB. 
 
(n=31)
(n=39) (n=33)
5
10
15
20
25
30
Di
ffu
sio
n 
ca
pa
cit
y (
m
L/
m
in/
m
m
Hg
/L
,st
pd
)
No Previous TB Definite TB Probable TB
(n=103)
ANOVA: 0.033
at Visit 2
Diffusion Capacity
 
Figure 48: Diffusing capacity 
(mL/min/mmHg) according to PPTB 
status: three-group analysis. 
DLCO, expressed as percentage of predicted, was also higher in subjects with 
NPTB (79.5%, sd=23.7%) vs. those with PPTB (64.9%, sd=19.6%)  
(t-test p=0.002) [see Figure 49]. It was also significantly different in three-
group analysis between those with NPTB (79.5%, sd=23.7%), DPTB (61.7%, 
sd=15.3%) and PrPTB (68.6%, sd=23.3%) (ANOVA p=0.003) [see Figure 50]. 
The Bonferroni correction confirmed a significant difference only between 
those with NPTB and those with DPTB (p=0.002). 
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Figure 49: Diffusing capacity 
(%predicted) according to PPTB 
status: NPTB vs. PPTB. 
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Figure 50: Diffusing capacity 
(%predicted) according to PPTB 
status: three-group analysis. 
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8.2.3. Lung physiology tests at Visit 3 
 
The mean time interval between Visit 2 and 3 was 16.4 days (median 15 
days, sd=3.605 days, min 11 days, max 29 days). The result of the 
spirometry on 103 subjects tested at Visit 3 is presented in Table 59. 
8.2.3.1. Post-bronchodilator FVC 
There was no significant difference in the medians of FVC (litres) at Visit 3 
between those with PPTB and those without (Wilcoxon p=0.256). Moreover, 
there was no significant difference between the three groups (NPTB, DPTB 
and PrPTB) in the median FVC (litres) at Visit 3 (Kruskal-Wallis p=0.309).  
Similarly, values for FVC expressed as percentage of predicted 
between those with and without PPTB were not significantly different 
(Wilcoxon p=0.846) (three-group analysis, Kruskal-Wallis p=0.954). 
8.2.3.2. Post-bronchodilator FEV1 
There was no significant difference in the median FEV1 (liters) at Visit 3 
between those with PPTB and those without (Wilcoxon p=0.421). 
Additionally, there was no significant difference in the median FEV1 (litres) on 
three-group analysis (Kruskal-Wallis p=0.522). 
 Similarly, values for FEV1 expressed as percentage of predicted were 
not significantly different between those with and without PPTB (t-test 
p=0.159), nor on three-group analysis (ANOVA p=0.058). Application of the 
Bonferroni correction confirmed no significant difference between the three 
groups.  
8.2.3.3. FEV1:FVC  
FEV1:FVC (a non-parametric variable) was significantly lower in subjects with 
PPTB (median ratio 60.9%) compared to those with NPTB (median ratio 
65.4%) (Wilcoxon p=0.021) [see Figure 51]. Additionally, on subgroup 
analysis, there was a significant difference in the median FEV1:FVC between 
those with NPTB (median ratio 65.4%), DPTB (median ratio 54.6%) and 
PrPTB (median ratio 62.1%) (Kruskal-Wallis p=0.002) [see Figure 52]. 
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 Comparing the median FEV1:FVC between the individual groups using 
the Wilcoxon test yielded the following results: 
• Difference between NPTB and DPTB: p=0.0012 
• Difference between NPTB and PrPTB: p=0.5278 
• Difference between DPTB and PrPTB: p=0.0066. 
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Figure 51: FEV1:FVC by PPTB status 
at Visit 3: NPTB vs. PPTB. 
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Figure 52: FEV1:FVC by PPTB status 
at Visit 3: three-group analysis. 
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Table 59: Comparison of results of lung physiology at Visit 3 according to previous PTB status: PPTB vs. NPTB and by subgroups. 
 
(n = 103) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (31)  (72)    (31)  (39)  (33)    
               
Post BD FVC (L) -mean 2.75 0.890 3.05 1.086 n/a n/a 2.75 0.890 3.14 1.062 2.95 1.121 n/a n/a 
Post BD FVC (L) -median 2.61 - 2.89 - 0.256 Wilcoxon 2.61 - 3.05 - 2.64 - 0.309 Kwallis 
Post BD FVC (%) - mean 95.65 16.881 97.25 18.646 n/a n/a 95.65 16.881 96.67 19.130 97.94 18.328 n/a n/a 
Post BD FVC (%) - 
median 
95  97  0.846 Wilcoxon 95  97 - 98 - 0.954 Kwallis 
               
Post BD FEV1 (L) -mean 1.73 0.632 1.69 0.754 n/a n/a 1.73 0.632 1.66 0.787 1.74 0.723 n/a n/a 
Post BD FEV1 (L) - 
median 
1.71 - 1.38 - 0.421 Wilcoxon 1.71 - 1.36 - 1.55  0.522 Kwallis 
Post BD FEV1 (%) -mean 75.03 22.016 67.52 25.679 0.159 t-test 75.03 22.016 62.40 27.074 73.58 22.865 0.058 ANOVA 
               
Post BD FEV1:FVC - mean 63.12 12.992 55.84 14.086 n/a n/a 63.12 12.992 51.87 13.004 60.52 14.058 n/a n/a 
Post BD FEV1:FVC - 
median 
65.37 - 60.89 - 0.021 Wilcoxon 65.37 - 53.63 - 62.07 - 0.002 Kwallis 
 
Table 60: Rate of decline in FEV1 between BOLD 2005 and Follow-up studies, according to PPTB status (using Visit 1 data). 
 
(n = 103) 
 
NPTB 
 
sd 
Prev 
TB 
 
sd 
 
Test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
Test 
(n) (30)  (73)   (30)  (39)  (34)   
Change in FEV1 (mL)             
mean -119 201 -160 367 p=0.283 -119 201 -139 432 -183 278 p=0.561 
median -95  -170  (Wilcoxon) -95  -170  -165  (Kwallis) 
Rate of Change (mL per year)             
mean -22.5 37.8 -30.3 67.5 p=0.273 -22.6 37.8 -26.4 77.9 -34.7 54.1 p=0.545 
median -16.8  -32.7  Wilcoxon) -16.8  -34.3  -31.2  (Kwallis) 
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8.2.3.4. Whole body plethysmography 
Of the 104 subjects with Visit 3 data, four were unable to perform 
reproducible manoeuvres and one subject was older than 80 years, for whom 
no ECCS predicted values are available; these five subjects were excluded. 
The results for the remaining subjects are presented in Table 61  
 There was no significant difference between subjects with and without 
PPTB for the following volumes: 
• Total Lung Capacity (TLC) - in litres and as a percentage of predicted. 
• Vital Capacity (VC) – in litres and as a percentage of predicted values. 
Similarly, on three-group analysis, there was no significant difference in TLC 
or VC between subjects with DPTB, PPTB and NPTB. 
Mean inspiratory capacity (IC in litres) was significantly lower in subjects with 
PPTB compared to those with NPTB (2.04 L vs. 2.40 L, t-test p=0.006). 
Additionally, a significantly lower median percentage-predicted IC was found 
in those with PPTB (93% vs. 120%, Wilcoxon p<0.0001). Analysis of the 
three subgroups confirmed significantly lower IC in subjects with DPTB 
(mean 2.03 L, median 92% pred) and PrPTB (mean 2.06 L, median 99.5% 
pred) compared to subjects with NPTB (mean 2.40 L, median 120% pred) 
[see Table 61]. 
Functional residual capacity (FRC in litres) was significantly higher in 
subjects with PPTB compared to those without (median 3.45 L vs. 2.78 L, 
Wilcoxon p=0.0018), with the median percentage predicted FRC also 
significantly higher (median 116% vs. 103%, Wilcoxon p=0.0022). Three-
group analysis confirmed higher values for FRC in both DPTB (median 3.72 
L, median 121.5% pred) and PrPTB groups (median 2.93 L, median 110.0% 
pred) compared with subjects in the NPTB group (median 2.78 L, median 
103% pred). 
Similarly, the expiratory reserve volume (ERV in litres and as 
percentage of predicted) was higher in subjects with PPTB compared to 
those with NPTB (median 0.57 L vs. 0.19 L, Wilcoxon p=0.0001, and 63.5% 
vs. 22%, Wilcoxon p<0.0001, respectively). The ERV was also higher in 
subjects with DPTB (median 0.685 L, median 73% pred) and PrPTB  (median 
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0.445 L, median 51.5% pred) than in subjects with NPTB (median 0.19 L, 
median 22% pred). Residual Volume (RV in litres) was higher in subjects with 
PPTB than in those without (median 2.785 L vs. 2.49L, Wilcoxon p=0.0517), 
but not when expressed as a percentage of predicted (median 133.5% vs. 
133%, Wilcoxon p=0.244). Similarly, in three-group analysis, the significant 
difference in the RV expressed in litres was not found when expressed as a 
percentage predicted.  
 Values for RV:TLC between subjects with and without PPTB were not 
found to be significantly different (mean 0.54 vs. 0.51, t-test p=0.0598). 
Similarly, values for the three subgroups were not significantly different 
(ANOVA p=0.1093). 
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Table 61: Comparison of results of whole body plethysmography at Visit 3 according to previous TB status: PPTB vs. NPTB and by 
subgroups 
 
(n=99) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (29)  (70)    (29)  (38)  (32)    
               
TLC (L)- mean* 5.40 1.250 5.800 1.519 0.2074 t-test 5.40 1.250 6.02 1.350 5.54 1.683 n/a n/a 
TLC (L)- median 5.43 - 5.615 - n/a n/a 5.43# - 5.97# - 4.74# - 0.0943 Kwallis 
TLC (%)- mean# 102.9 15.18 105.2 18.47 n/a n/a 102.9 15.18 107.4 21.03 102.5 14.77 n/a n/a 
TLC (%)- median 102  102.5 - 0.6555 Wilcoxon  102  102 - 103 - 0.795 Kwallis 
               
VC (L)- mean# 2.70 0.691 2.72 0.885 n/a n/a 2.70 0.691 2.77 0.874 2.66 0.907 n/a n/a 
VC (L)- median 2.74 - 2.64 - 0.8717 Wilcoxon  2.74 - 2.77 - 2.5 - 0.8531 Kwallis 
VC (%)- mean* 88.97 12.724 83.73 14.411 0.0922 t-test 88.97 12.724 81.89 13.830 85.91 14.998 0.1192 ANOVA 
VC (%)- median 90 - 85 - n/a n/a 90 - 84 - 88  n/a n/a 
               
IC (L)- mean* 2.40 0.544 2.04 0.589 0.0064 t-test 2.40 0.544 2.03 0.521 2.06 0.669 0.024 ANOVA 
IC (L)- median 2.39 - 2.05 - n/a n/a 2.39 - 2.075 - 2.035 - n/a n/a 
IC (%)- mean# 119.1 21.51 96.2 27.36 n/a n/a 119.1 21.51 93.1 29.00 99.8 25.23 n/a n/a 
IC (%)- median 120 - 93 - <0.0001 Wilcoxon  120 - 92 - 99.5 - 0.0001 Kwallis 
               
FRC (L)- mean# 2.96 0.913 3.76 1.230 n/a n/a 2.96 0.913 3.99 1.139 3.48 1.293 n/a n/a 
FRC (L)- median 2.78 - 3.45 - 0.0018 Wilcoxon  2.78 - 3.72 - 2.925 - 0.0005 Kwallis 
FRC (%)- mean# 103.5 27.00 124.2 32.91 n/a n/a 103.5 27.00 130.5 35.02 116.8 28.99 n/a n/a 
FRC (%)- median 103 - 116 - 0.0022 Wilcoxon  103 - 121.5 - 110 - 0.002 Kwallis 
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(n=99) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (29)  (70)    (29)  (38)  (32)    
ERV (L)- mean# 0.31 0.314 0.68 0.510 n/a n/a 0.31 0.314 0.75 0.510 0.6 0.506 n/a n/a 
ERV (L)- median 0.19 - 0.57 - 0.0001 Wilcoxon  0.19 - 0.685  0.445 - 0.0002 Kwallis 
ERV (%)- mean# 33.5 26.82 70.1 43.58 n/a n/a 33.5 26.82 73.0 41.69 66.8 46.16 n/a n/a 
ERV (%)- median 22 - 63.5 - <0.0001 Wilcoxon  22 - 73  51.5 - 0.0001 Kwallis 
               
RV (L)- mean# 2.69 0.782 3.08 0.988 n/a n/a 2.69 0.782 3.25 1.000 2.88 0.952 n/a n/a 
RV (L)- median 2.49 - 2.785 - 0.0517 Wilcoxon 2.49 - 2.995 - 2.555 - 0.0234 Kwallis 
RV (%)- mean# 134.6 34.11 148.5 48.47 n/a n/a 134.6 34.11 156.9 55.56 138.6 36.84 n/a n/a 
RV (%)- median 133 - 133.5 - 0.244 Wilcoxon 133 - 139 - 130.5 - 0.2478 Kwallis 
               
RV:TLC – mean* 49.7 6.62 53.1 8.62 0.0598 t-test 49.7 6.62 54.0 10.04 52.1 6.56 0.1093 ANOVA 
RV:TLC - median 51 - 53.5  n/a n/a 51 - 55.5  51.5 - 0.1606 Kwallis 
               
 (n=28)  (n=70)    (n=28)  (n=38)  (n=32)    
TV – mean# 0.65 0.211 0.74 0.323   0.65 0.211 0.70 0.208 0.8 0.418 - - 
TV- median 0.65 - 0.67    0.65 - 0.68 - 0.665  - - 
* Parametric data 
# Non-parametric data  
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8.2.4. Response to two-week trial of oral glucocorticosteroid and 
long acting B-agonist 
8.2.4.1. Trial medication usage 
The trial medication usage is described on page 70. Of the 103 subjects with 
spirometry at Visit 3, seven (6.8%) were not given prednisone for medical 
reasons: five had diabetes mellitus, one had poorly controlled hypertension, 
and one had a recent history of anaemia and GIT symptoms. Thus, 96 
(93.2%) subjects received prednisone. The usage and duration of treatment 
are summarised in the Table 62 below. Of the 103 subjects, only two were 
not issued with formoterol (for medical reasons), while an additional five 
subjects reported non-use of formoterol (two because it caused dizziness; 
three gave no reason). Ninety-six subjects (93.2%) claimed compliance with 
formoterol use [see Table 62].  
Table 62: Trial medication use and adherence between Visits 2 and 3. 
 Prednisone Formoterol 
Subjects given medication n=96 (93.2%) n=101 (98.1%) 
Subjects not given medication n=7 (6.8%) n=2 (1.9%) 
Days between visits (n=96)  
Mean 16.25  
SD 3.45  
Min-Max (13 - 29)  
Tablets used    
Unknown (n) n=8 (8.3%) n/a 
Known (n) n=88 (91.7%) n/a 
Mean number of tablets used 55.67 n/a 
SD 19.32 n/a 
Min-Max (7 - 108) n/a 
Percentage compliance*   
(Adherence unknown) n=8 (8.3%) n=0 (0%) 
Adherence known n=88 (91.7%) n=96 (93.2%) 
Mean percentage adherence(%) 87.50 n/a 
SD (%) 26.94 n/a 
Min-Max (%) (12 - 133) n/a 
   
n >75% adherence n=68  
n > 80% adherence n=65  
*Percentage adherence= (number of tablets taken)÷(number of tablets prescribed) 
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8.2.4.2. Changes in spirometry between Visit 2 and 3 
In order to eliminate the effect of poor adherence, the analysis was limited to 
subjects with more than 75% adherence to prednisone treatment, which was 
68 subjects. 
 Overall, the median improvement in pre-bronchodilator FEV1 from 
baseline after the two-week trial of prednisone and formoterol was 70 mL for 
subjects with PPTB (110 mL for DPTB and 60 mL for PrPTB) and 90 mL for 
NPTB.  
Comparing the NPTB and PPTB groups, there was no significant difference 
in any of the following measures [see Table 63]: 
• Pre-bronchodilator FEV1 (litres and % predicted) 
• Post-bronchodilator FEV1 (litres and % predicted) 
• Pre-bronchodilator FVC 
• Post-bronchodilator FVC 
• FEV1:FVC (both pre- and post-bronchodilator). 
Additionally, there was no significant difference in the above variables 
on three-group analysis (i.e. DPTB, PrPTB and NPTB) [see Table 64]. 
 When the above analysis was performed using all subjects who were 
prescribed prednisone and formoterol, no difference was found between 
groups or subgroups – regardless of adherence (n=92).  
 
Table 63: Change in spirometry after two-week medication trial, in subjects 
with greater than 75% adherence. 
 All 
subjects 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
Test* 
(n) (68)  (16)  (52)    
Change in PreBD FEV1        
litres: mean  
(median) 
0.118  
(0.08) 
0.222 0.138  
(0.09) 
0.278 0.112  
(0.07) 
0.205 0.79 Wilcoxon 
% predicted: mean  
(median) 
4.67  
(2.5) 
12.985 8.06  
(4) 
20.111 3.625  
(2) 
9.890 0.94 Wilcoxon 
Change in Post BD FEV1        
litres: mean  
(median) 
0.031  
(0.04) 
0.239 0.0088  
(-0.025) 
0.353 0.038  
(0.055) 
0.195 0.52 Wilcoxon 
% predicted: mean  
(median) 
1.56  
(1.5) 
13.121 0.625 
 (-1) 
22.671 1.846  
(2) 
8.640 0.35 Wilcoxon 
Change in PreBD FVC        
litres: mean  
(median) 
0.157  
(0.105) 
0.327 0.159  
(0.07) 
0.384 0.156  
(0.12) 
0.311 0.74 Wilcoxon 
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 All 
subjects 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
Test* 
Change in PostBD FVC        
litres: mean  
(median) 
0.0587  
(0.06) 
0.354 0.0463  
(0.03) 
0.530 0.0625 
(0.06) 
0.286 0.62 Wilcoxon 
Change in PreBD FEV1:FVC        
litres: mean  
(median) 
0.0128  
(0.0113) 
0.044 0.0199  
(0.00974) 
0.050 0.0106 
 (0.0113) 
0.04 0.82 Wilcoxon 
Change in PostBD FEV1:FVC        
litres: mean  
(median) 
0.00234 
(0.00137) 
0.045 -0.00611  
(-0.00136) 
0.054 0.00494 
 (0.00231) 
0.04 0.82 Wilcoxon 
*All variable measured were non-parametrically distributed 
BD = bronchodilator 
 
Table 64: Change in spirometry after two-week medication trial in subjects 
with greater than 75% adherence: three-group analysis. 
 NPTB sd DPTB sd PrPTB sd p-value Test* 
(n) (16)  (27)  (25)    
Change in PreBD FEV1       
litres: mean 
(median) 
0.138 
(0.09) 
0.278 0.0874 
(0.11) 
0.193 0.139 
(0.06) 
0.218 0.919 Kwallis 
% predicted:mean 
(median) 
8.06 
(4) 
20.111 1.723 
(2) 
10.959 5.68 
(2) 
8.325 0.689 Kwallis 
Change in Post BD FEV1       
litres 0.0088 
(-0.025) 
0.353 0.0130 
(0.05) 
0.184 0.065 
(0.06) 
0.207 0.713 Kwallis 
% 0.625 (-1) 22.671 0.926 (1) 8.241 2.84 (3) 9.114 0.568 Kwallis 
Change in PreBD FVC       
litres: mean 
(median) 
0.159 
(0.07) 
0.384 0.130 
(0.13) 
0.29 0.185 
(0.1) 
0.339 0.924 Kwallis 
Change in PostBD FVC       
litres: mean 
(median) 
0.0463 
(0.03) 
0.530 0.0133 
(-0.02) 
0.25 0.116 
(0.08) 
0.316 0.684 Kwallis 
Change in PreBD FEV1:FVC       
litres: mean 
(median) 
0.0199 
(0.00974) 
0.050 0.00350 
(-0.00429) 
0.05 0.0183 
(0.0200) 
0.0299 0.246 Kwallis 
Change in PostBD FEV1:FVC       
litres: mean 
(median) 
-0.00611 
(-0.00136) 
0.054 0.00517 
(-0.00054) 
0.05 0.00468 
(0.00626) 
0.0328 0.528 Kwallis 
*All variable measured were non-parametrically distributed 
BD = bronchodilator 
8.2.4.3. MRC Dyspnoea score at Visits 2 and 3 
Self-reported dyspnoea (MRC Dyspnoea score) was recorded before and 
after the two-week medication trial (i.e. Visits 2 and 3, respectively).  
There were no significant differences between the groups or 
subgroups in MRC Dyspnoea scores at either Visit 2 or Visit 3 [Visit 2 MRC 
Dyspnoea scores presented in Table 65]. Additionally, there was no 
significant difference between the groups in the change in MRC Dyspnoea 
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score between visits [see Table 66]. No difference between the groups, 
regarding change in MRC score, was observed when analysis was restricted 
to subjects with >75% adherence with medication trial (Wilcoxon p=0.330, 
Kruskal-Wallis p=0.585). 
 
Table 65: Baseline MRC Dyspnoea scores at commencement of two-week trial 
of medication (Visit 2). 
 All NPTB PPTB p-value NPTB DPTB PrPTB p-value 
(n) (102) (31) (71)  (31) (38) (33)  
Average MRC score      
Mean  2.93 2.87 2.96  2.87 3.03 2.88 0.547 
ANOVA 
Median 2.5 2.00 3.00 0.842 
Wilcoxon 
2.00 3.00 2.00  
Number of subjects in MRC group     
MRC 1 21 6 15  6 5 10  
MRC 2 30 10 20  10 12 8  
MRC 3 15 5 10  5 8 2  
MRC 4 7 2 5  2 3 2  
MRC 5 29 8 21  8 10 11  
Total 102 31 71 0.792 
Chi2 (for trends) 
31 38 33 0.770 
Kwallis 
 
Table 66: Change in MRC Dyspnoea score after two-week medication trial. 
 All NPTB Prev 
TB 
p-value NPTB DPTB PrPTB p-value 
(n) (102) (31) (71)  (31) (38) (33)  
Mean -0.52 -0.48 -0.54  -0.48 -0.45 -0.64 0.961 
Kwallis 
Median 0 0 0 0.818 
Wilcoxon 
0 0 0  
 
8.2.5. St George’s Respiratory questionnaire  
 
The Subjects’ baseline symptoms and performance status were assessed at 
their first visit (Visit 1) using the St George’s Respiratory Questionnaire 
(SGRQ) [see Appendix 3 - St George’s Respiratory Questionnaire]. The 
median total score was 34.6 and 32.6 for subjects with and without PPTB, 
respectively. These values exceed the total scores for healthy adults, which 
range from 5 to 7. No difference in the Symptom, Activity or Total SGRQ 
scores was found between PPTB and NPTB [see Table 67]; however, there 
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was a trend towards worse symptoms (a higher score) in the Impact Domain 
of subjects with PPTB (Wilcoxon p=0.076). Analysis of subgroups revealed 
no significant between-group differences for any of the SGRQ domains [see 
Table 67]. 
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Table 67: St George’s Respiratory Questionnaire (SGRQ) scores according to PPTB status. 
 NPTB sd PPTB sd p-value Test* NPTB sd DPTB sd PrPTB sd p-value Test* 
Symptom Score  
(n) 
 
(31) 
  
(72) 
    
(31) 
  
(38) 
  
(34) 
   
Mean  37.15 24.783 28.59 25.518 n/a n/a 37.15 24.783 37.16 24.317 40.19 27.074 n/a n/a 
Median 42.27 - 37.59 - 0.714 Wilcoxon 42.27 - 33.69 - 43.16 - 0.836 Kwallis 
Activity Score 
(n) 
 
(31) 
  
(72) 
    
(31) 
  
(38) 
  
(34) 
   
Mean  48.92 30.496 49.39 31.441 n/a n/a 48.92 30.496 50.90 30.174 47.69 33.172 n/a n/a 
Median 59.457 - 53.62 - 0.888 Wilcoxon 59.457 - 56.54 - 53.57 - 0.944 Kwallis 
Impact Score 
(n) 
 
(31) 
  
(70) 
    
(31) 
  
(36) 
  
(34) 
   
Mean  17.50 15.663 28.20 25.713 n/a n/a 17.50 15.663 27.86 23.473 28.57 28.246 n/a n/a 
Median 16.52 - 21.12 - 0.076 Wilcoxon 16.52 - 21.12 - 20.68 - 0.199 Kwallis 
Total Score 
(n) 
 
(31) 
  
(70) 
    
(31) 
  
(36) 
  
(34) 
   
Mean  30.62 20.478 36.75 25.693 n/a n/a 30.62 20.478 36.87 24.176 36.61 27.574 n/a n/a 
Median 32.60 - 34.59 - 0.324 Wilcoxon 32.60 - 34.59 - 35.09 - 0.607 Kwallis 
* All variable were non parametrically distributed 
# St George’s Respiratory Questionnaire - performed at Visit 1 
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8.3. Analysis of subjects with chronic airflow obstruction only 
 
As a sensitivity analysis, the analysis of group and subgroup differences in 
lung function tests was performed including only subjects in whom CAO was 
confirmed on post-bronchodilator spirometry at Visit 2. Seventeen of 103 
subjects (16.5%) were excluded on this basis: nine from the NPTB (29.0%), 
seven from the PrPTB (21.2%), and one from the DPTB group (2.5%). 
Thereafter, results from 86 (83.5%) of the full cohort were analysed. Of those 
analysed, 22 (25.6%) were classified as NPTB, 38 (44.2%) as DPTB and 26 
(32.7%) as PrPTB.  
 The results of this further analysis were similar to those for the full 
cohort. These results are presented in Appendix 7 – Results of Clinical and 
Physiological Endpoints only for Subjects with Chronic Airflow Obstruction. 
Only the post-bronchodilator FEV1:FVC, which was previously noted to be 
higher in subjects with NPTB, was no longer found to be statistically different 
in subjects with PPTB (Wilcoxon p=0.135). 
The mean DLCO (both as absolute values and % predicted) was 
significantly lower in subjects with PPTB compared to those without (t-test 
p=0.027 and p=0.005, respectively), including in three-group analysis of 
NPTB, DPTB and PrPTB (ANOVA p=0.0126). 
Similarly, the inspiratory capacity was significantly lower in subjects 
with previous TB, compared to both subjects without previous TB (Wilcoxon 
p=0.0002), and in three-group analysis (Krusal-Wallis p=0.0004).  
 
8.4. Summary of findings 
 
Significantly more subjects with previous pulmonary TB reported being an 
ex- or current smoker, but this difference was not seen on three-way analysis 
between the subgroups: NPTB, DPTB and PrPTB. Additionally, there was no 
difference in the number of pack-years smoked between those with and 
without PPTB. Chronic bronchitis was not found to be more common in 
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subjects with PPTB, when both the full cohort and only those with CAO was 
assessed. Thus, there is lack of association between these two confounders 
and PPTB status. 
 Prior to the medication trial (Visit 2), the median FEV1:FVC was 
significantly lower in subjects with PPTB, and the FEV1 (% predicted) was 
numerically lower (borderline significance), but the FVC was similar. When 
subjects without CAO were excluded, no differences in FEV1:FVC, FEV1 or 
FVC between subjects with PPTB and NPTB were observed. This is likely 
due to over-representation of subjects without CAO in the NPTB group 
(29.0% of the NPTB group (9 of 31) did not have airflow obstruction, 
compared with 11.1% of the PPTB group (8 of 72), 2.5% of the DPTB group 
and 21.2% of the PrPTB group). Similarly, the lower FEV1:FVC observed at 
Visit 3 in subjects with PPTB was absent when subjects with no CAO were 
excluded from analysis.  
 The gains in pre-bronchodilator FEV1 after a two-week trial of 
prednisone and formoterol were small, being merely 70 mL for subjects with 
PPTB and 90 mL for NPTB. Importantly, there were no between-group 
differences in outcomes of FEV1, FVC, FEV1:FVC or MRC dyspnoea score 
after this short trial of medication.  
 Subjects with PPTB consistently showed a significantly lower DLCO 
compared to subjects without PPTB, including on three-group analysis, with 
subjects in the DPTB group having a 17.8% lower DLCO (% predicted) 
compared to subjects with NPTB.  
 Additionally, subjects with PPTB consistently showed a significantly 
lower inspiratory capacity (IC) than those without, as well as a higher 
functional residual capacity and Expiratory Reserve volume; there were no 
differences in the Total Lung Capacity, Vital Capacity and RV:TLC between 
those with and without PPTB. The median IC (% predicted) was 27.0% lower 
in subjects with PPTB. 
 There were no differences in baseline symptoms (MRC Dyspnoea 
score) and health status (SGRQ) between subjects with and without PPTB.  
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In the majority of three-group analyses, the PrPTB group was found to have 
values intermediate between those of the DPTB and NPTB groups, 
supporting the correct characterisation of subjects, described in the previous 
chapter. 

 Chapter 9. Results of Lung Imaging  
9.1. Introduction  
 
This chapter presents the results of the CT imaging performed on subjects in 
the BOLD cohort who were followed up in 2010. The purpose of the imaging 
was to improve the accuracy of clinical diagnosis, to confirm the presence of 
changes attributable to PPTB, and to examine differences in the relationships 
of structure (imaging findings) and function (lung function measurements) 
between subjects with and without a history of PPTB. The overall aim of 
these investigations was to establish whether there are grounds for 
considering tuberculosis-associated chronic obstructive pulmonary disease 
(TOPD) as a distinct phenotype of COPD. 
 The CT scans were performed at Visit 3, on the same day as whole 
body plethysmography, and quantitative analysis of the whole lung and all 
lobes as well as the bronchial tree was performed [see page 72]. 
As in the previous chapter, subjects were classified as having Previous 
Pulmonary TB (PPTB) – either Definite Previous TB (DPTB) or Probable 
Previous TB (PrPTB) - or No Previous TB (NPTB), as defined in Chapter 7. 
 
9.2. Missing data 
 
Chest CT scans were performed on 104 subjects, but in nine, the inspiratory 
images were unsuitable for analysis due to poor image quality, movement 
artifact and other technical reasons. One further scan was excluded due to 
previous right lobectomy for lung cancer. Two of the excluded subjects were 
in the NPTB group, four in the DPTB and three in the PrPTB groups. 
 The PPTB status of the remaining 94 scans are shown in Figure 53. Of 
these subjects, two did not have evaluable plethysmography data and 92 
subjects had both analysable imaging and plethysmography data.  
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Figure 53: Classification of subjects according to PPTB status, for the analysis 
of CT scan images. 
For technical reasons, quantification of residual volume scans was 
incomplete in a further three subjects. In two, the mean density scores for the 
right lung (right upper, middle and lower lobes) was missing, and in one, both 
these and the mean density scores for the left lower lobe were missing.  
 
9.3. Imaging analysis of the full cohort  
 
9.3.1. Lung volumes 
9.3.1.1. Comparison with whole body plethysmography 
There was strong correlation between total lung volumes measured by 
quantitative CT scan (at full inspiration) and plethysmography (Pairwise 
deletion correlation coefficient 0.9101, p<0.0001) [see Table 68, Table 69 and 
Figure 54]. 
 
Table 68: Comparison of total lung volume measurement by whole body 
plethysmography and quantitative CT scan in all subjects: NTPB vs. PPTB 
groups. 
 
(volume in litres) 
 
 
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
(n) (92)  (27)  (65)  
Plethysmography 5.71 1.440 5.50 1.223 5.81 1.152 
(n) (94)  (28)  (66)  
CT volume 5.15 1.467 4.91 1.189 5.24 1.568 
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Table 69: Comparison of total lung volume measurement by whole body 
plethysmography and quantitative CT scan: three-group analysis. 
 
(volume in litres) 
 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
(n) (27)  (35)  (30)  
Plethysmography 5.50 1.223 5.94 1.376 5.65 1.677 
(n) (28)  (35)  (31)  
CT volume 4.91 1.189 5.32 1.505 5.16 1.658 
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Figure 54: Comparison of total lung capacity measured by whole body 
plethysmography and CT scan. 
9.3.1.2. Assessment of lobar volumes 
A comparison was made of the each lung and lobe, expressed as a 
percentage of total lung volume at full inspiration (TLC) according to PPTB 
status. The total percentage volume occupied by the lower lobes, as well as 
that of the individual right and left lower lobes, was not significantly different 
between subjects with and without PPTB (Wilcoxon p=0.447, p=0.350 and 
p=0.785, respectively). Similarly, an analysis of volumes according to the 
three groups - DPTB, PrPTB and NPTB - revealed no differences (Kruskal-
Wallis p=0.614 (both LL), p=0.632 (RLL) and ANOVA p=0.376 (LLL)) [see 
Table 70]. 
The median volume of the right upper lobe (RUL) (percentage of whole 
lung) was significantly lower in subjects with PPTB (20.7% vs. 22.6%, 
Wilcoxon p=0.035), than those with NPTB, but not when analysed according 
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to the three subgroups: DPTB (19.5%), PrPTB (21.9%) and NPTB (22.6%, 
Kruskal-Wallis p=0.107). However, a significantly lower median RUL volume 
was found, when subjects with DPTB were compared directly to those with 
NPTB, excluding subjects with PrPTB (Wilcoxon p=0.0332). In contrast, there 
was no significant difference left upper lobes (LUL) volumes of subjects with 
and without PPTB (Wilcoxon p=0.928), nor between the three subgroups 
(Kruskal-Wallis p=0.804). 
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Table 70: Comparison of lung and lobar volumes (as percentage of total lung volume) according to PPTB status. 
 
(units = % of  
total lung volume) 
 
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-
value 
 
test 
(n) (n=94)  (n=28)  (n=66)    (n=28)  (n=35)  (n=31)    
Lower Lobe Volume                
Total of both Lower Lobes #               
mean 47.32 7.321 45.84 6.044 47.96 7.755 n/a n/a 45.84 6.044 48.79 9.424 47.03 5.288 n/a n/a 
median 46.76 - 46.96 - 46.28 - 0.4469 WIlcoxon 46.96 - 48.8 - 45.89 - 0.6139 Kwallis 
RLL#                 
mean 24.42 5.078 23.33 3.566 24.88 5.558 n/a n/a 23.33 3.566 25.09 6.319 24.64 4.643 n/a n/a 
median 24.1 - 23.78 - 24.54 - 0.3502 WIlcoxon 23.78 - 24.85 - 24.14 - 0.6318 Kwallis 
                 
LLL#                 
mean 22.91 4.183 22.51 3.495 23.08 4.457 n/a n/a 22.51* 3.495 23.69* 5.290 22.38* 3.223 0.3762 ANOVA 
median 22.52 - 22.4 - 22.5232 - 0.785 WIlcoxon 22.4 - 22.85 - 22.33 - 0.6714 Kwallis 
                 
Individual Lobes (%) (n=94)  (n=28)  (n=66)    (n=28)  (n=35)  (n=31)    
RUL#                 
mean 20.78 5.065 22.79 3.848 19.93 5.3 n/a n/a 22.79 3.848 19.75 5.656 20.12 4.951 n/a n/a 
median 21.78 - 22.55 - 20.72 - 0.035 WIlcoxon 22.55 - 19.48 - 21.91 - 0.1021 Kwallis 
RML*                 
mean 7.77 2.660 7.14 2.062 8.04 2.849 0.1368 t-test 7.14 2.062 8.15 3.485 7.9 1.95 0.3088 ANOVA 
median 7.63 - 6.97 - 8.14 - n/a n/a 6.97 - 8.04 - 8.19 - 0.28 Kwallis 
LUL#                 
mean 24.12 5.007 24.23 3.023 24.08 5.663 n/a n/a 24.23 3.023 23.31 5.63 24.95 5.67 n/a n/a 
median 24.17 - 23.42 - 24.34 - 0.9275 WIlcoxon 23.42 - 24.3 - 24.37 - 0.8041 Kwallis 
*Parametic variables 
#Non-parametric variables 
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9.3.2. Bronchial wall measurement 
Use of the Pi10 as a measurement of bronchial wall thickness is described on 
page 54. The Pi10 is the square root of the wall area of a hypothetical 
bronchus with an internal perimeter of 10 mm, calculated from linear 
regression models and using data from all measured bronchi in the scan.  
 Two of the 104 scans were not analysed due to inability of the software 
algorithm to process these scans.  
 There was no significant difference in the median Pi10 values between 
subjects with and without PPTB (2.44 and 2.36, respectively, Wilcoxon 
p=0.87) [see Table 71]. Additionally, no significant difference in the Pi10 was 
found between those with DPTB (Pi10=2.35), PrPTB (Pi10=2.38) and NPTB 
(Pi10=2.44, Kruskal-Wallis p=0.76) [see Table 72]. 
Table 71: Bronchial wall area (Pi10) according to PPTB status: NPTB vs PPTB. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
(n) (102)  (30)  (72)    
Pi10         
Mean  2.45 0.56 2.46 0.55 2.44 0.57 n/a n/a 
Median 2.4  2.44  2.36  0.87 Wilcoxon 
 
Table 72: Bronchial wall area (Pi10) according to PPTB status: three-group 
analysis. 
 
(n=102) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (30)  (39)  (33)    
Pi10         
Mean  2.46 0.55 2.44 0.64 2.45 0.48 n/a n/a 
Median 2.44  2.35  2.38  0.76 Kwallis 
9.3.3. Lung density (average Hounsfield Units) measured at total 
lung capacity 
The average density of the lungs was assessed at full inspiration (i.e. TLC).  
 The average (median) total density of the lungs was significantly lower 
in subjects with PPTB compared to subjects with NPTB (-852HU vs. -835HU; 
Wilcoxon p=0.04). Analysed according to the three subgroups this difference 
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was of borderline significance: DPTB -854HU, PrPTB -846HU and NPTB -
835HU (Kruskal-Wallis: p=0.0666) [see Table 73]. 
 The density scores were lower in subjects with PPTB than in those with 
NPTB for the following: Whole left lung (p=0.0505); whole right lung 
(p=0.0322); left lower lobe (LLL) (p=0.189); right middle lobe (RML) (p=0.006) 
and right lower lobe (RLL) (p=0.024). No differences in density in the right 
upper lobe (RUL) (p=0.298) and left upper lobes (LUL) (p=0.116) between 
subjects with PPTB and NPTB were observed [see Table 73]. 
 On three-group comparison the following was found: a trend to lower 
densities for the whole left and right lungs (p=0.0596 and p=0.0654, 
respectively); and significantly lower densities for the LLL (p=0.0241), RML 
(p=0.0188) and RLL (0.0076) [see Table 73]. 
 
9.3.4. Lung density (average Hounsfield Unit) measured at residual 
volume 
The mean density of both lungs (combined) measured at full expiration was 
significantly lower in subjects with PPTB compared to those without (–754HU 
vs. –701HU, t-test 0.0005), as well on three-group analysis: DPTB –762 HU, 
PrPTB –745 HU and NPTB –701 HU (ANOVA p=0.0014), when measured at 
full expiration [see Table 74]. 
 The mean densities were significantly lower in subjects with PPTB for 
both left and right lungs (p=0.0019 and p=0.0003 respectively), as well as for 
all lobes individually. This finding was repeated on three-group analysis [see 
Table 74].  
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Table 73: Lung and lobar density (average Hounsfield Units - HU) at total lung capacity, according to PPTB status. 
 
 
 
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
(test) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
(test) 
(n) (94)  (28)  (66)   (28)  (35)  (31)   
Total Lung#               
mean HU -845.22 33.47 -833.7 35.3 -850.1 31.68 0.04 
Wilcoxon 
-833.7 35.3 -853.09 31.46 -846.74 32.1 0.0666 
Kwallis 
median HU -848.44  -835.17  -851.95   -835.17  -853.77  -846.16   
Left Lung #               
mean HU -844.96 36.47 -833.94 37.09 -849.64 35.46 0.0505 
Wilcoxon 
-833.94 37.09 -853.05 35.92 -845.78 35.12 0.0596 
Kwallis 
median HU -850.43  -835.74  -853.42   -835.74  -859.64  -844.63   
LUL#               
mean HU -849.04 38.15 -840.7 36.62 -852.58 38.51 0.1162 
Wilcoxon 
-840.7 36.62 -855.2 39.05 -849.63 38.32 0.1986 
Kwallis 
median HU -855.95  -844.6  -858.23   -844.6  -857.64  -858.82   
LLL#                
mean HU -838.42 38.38 -824.58 39.71 -844.29 36.54 0.0189 
Wilcoxon 
-824.58 39.71 -847.94 36.55 -840.17 36.68 0.0241 
Kwallis 
median HU -844.33  -825.98  -848.64   -825.98  -851.69  -844.28   
Right Lung#                
mean HU -845.24 32.13 -833.34 34.02 -850.28 30.17 0.0322 
Wilcoxon 
-833.34 34.02 -852.92 30.33 -847.31 30.19 0.0654 
Kwallis 
median HU -849.75  -837.32  -853.51   -837.32  -854.94  -845.77   
RUL#                
mean HU -846 32.75 -839.63 36.81 -848.69 30.78 0.2975 
Wilcoxon 
-839.63 36.81 -851.77 28.38 -845.23 33.42 0.5211 
Kwallis 
median HU -850.48  -844.67  -853.15   -844.67  -851.23  -853.48   
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All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
(test) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
(test) 
RML #               
mean HU -856.75 31.9 -843.04 31.73 -862.57 30.37 0.006 
t-test 
-843.04* 31.73 -864.95* 31.25 -859.89* 29.63 0.0188 
ANOVA 
median HU -857.65  -836.7  -864.61   -836.7  -865.66  -857.97   
RLL #               
mean HU -837.36 40.73 -821.2 35.65 -844.22 41.06 0.024 
Wilcoxon 
-821.2 35.65 -845.2 45.79 -843.12 35.69 0.0076 
Kwallis 
median HU -840.39  -824.62  -849.59   -824.62  -851.62  -843.32   
# - nonparametric variables 
* -parametric variables 
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Table 74: Lung and lobar density (average Hounsfield Units - HU) at residual volume, according to PPTB status. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
(test) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
(test) 
(n) (94)  (28)  (66)   (28)  (35)  (31)   
Total Lung*               
mean HU -738.61 69.032 -701.54 76.95 -754.33 59.29 0.0005 
t-test 
-701.54 76.95 -762.25 57.71 -745.39 60.72 0.0014 
ANOVA 
Left Lung *               
mean HU -733.61 72.28 -698.75 75.97 -748.39 65.82 0.0019 
t-test 
-698.75 75.97 -755.89 66.27 -739.94 65.34 0.0054 
ANOVA 
LUL*               
mean HU -751.15 73.36 -716.3 81.23 -765.94 64.92 0.0023 
t-test 
-716.3 81.23 -772.93 64.2 -758.04 65.86 0.0067 
ANOVA 
LLL#  (n=93)  (n=27)  (n=66)   (n=27)  (n=35)  (n=31)   
mean HU -712.7 72.96 -682.9 69.18 -724.89 71.42 n/a -682.9* 69.18 -732.89* 74.23 -715.85* 68.16 0.025 
ANOVA 
median HU -706.86  -671.72  -712.67  0.0119 
WIlcoxon 
       
               
Right Lung*  (n=91)  (n=27)  (n=64)   (n=27)  (n=35)  (n=29)   
mean HU -745.84 62.84 -710.31 67.9 -760.83 54.5 0.0003 
t-test 
-710.31 67.9 -767.37 53.62 -752.95 55.43 0.001 
ANOVA 
RUL*  (n=91)  (n=27)  (n=64)   (n=27)  (n=35)  (n=29)   
mean HU -753.56 64.74 -725.07 71.2 -765.58 58.31 0.0057 
t-test 
-725.07 71.2 -774.61 55.99 -754.68 60.15 0.01 
ANOVA 
RML * (n=91)  (n=27)  (n=64)   (n=27)  (n=35)  (n=29)   
mean HU -784.4 56.93 -753.53 64.9 -797.42 48.07 0.0006 
t-test 
-753.53 64.9 -800.22 51.45 -794.05 44.3 0.0025 
ANOVA 
RLL * (n=91)  (n=27)  (n=64)   (n=27)  (n=35)  (n=29)   
mean HU -714.78 78.31 -669.49 73.76 -733.89 72.56 0.0002 
t-test 
-669.49 73.76 -738.74 74.85 -728.04 69.24 0.001 
ANOVA 
# - nonparametric variables 
* -parametric variables 
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9.3.5. Emphysema score  
Emphysema scores are the percentage of the whole lung volume at full 
inspiration with a lung density of –950 HU or lower [see page 52]. 
 There was no observed difference in the emphysema score for both 
lungs (combined) between subjects with and without PPTB (t-test p=0.1952). 
Similarly, no difference was found between the left lung alone, right lung 
alone, LUL, LLL, RUL and RML [see Table 75]. However, the RLL showed 
numerically more emphysema in subjects with PPTB compared to those 
without (25.6% vs. 21.4%), but this was of borderline statistical significance 
(Wilcoxon p=0.055). On three-group analysis, subjects with DPTB had higher 
emphysema scores than those with PrPTB and NPTB, for the whole left lung 
(p=0.032), the right lung (p=0.044), LUL (p=0.018) and RUL (p=0.034). A 
similar trend was observed for both lungs combined (p=0.062), the RML 
(p=0.098) and RLL (p=0.059). There was no difference in emphysema scores 
between the three subgroups only in the LLL (p=0.11) [see Table 75]. 
 
9.3.6. Gas trapping score 
Gas trapping scores are the percentage of the whole lung volume at full 
expiration (RV) with a lung density of –860 or less [see page 72]. 
Gas trapping scores were significantly higher for both lungs combined 
(36.0% vs. 26.7%, t-test p=0.0062) in subjects with PPTB than in those 
without, and in comparisons of the three subgroups: DPTB 38.9%, PrPTB 
32.8% and NPTB 26.7% (ANOVA p=0.0061) [see Table 76]. Subjects with 
PPTB had significantly higher gas trapping scores for both the left and right 
lungs alone (p=0.016 and p=0.0019), the LUL (p=0.006), RUL (p=0.0047), 
RML (p=0.0041) and RLL (p=0.001). This finding was also highly significant in 
the analysis of the three subgroups, with intermediate values for the PrPTB 
group [see Table 76]. Only in the LLL was the gas trapping score not 
statistically different in those with PPTB.  
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Table 75: Comparison of emphysema scores (using –950 HU cut-point), according to PPTB status. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (94)  (28)  (66)    (28)  (35)  (31)    
Total*                 
mean 25.8 8.78 23.99 7.14 26.57 9.33 0.1952 t-test 23.99 7.14 28.56 8.1 24.32 10.22 0.062 ANOVA 
Left Lung*                 
mean 25.78 9.03 24.21 7.45 26.44 9.6 0.2767 t-test 24.21# 7.45 28.4# 8.33 24.23# 10.56 0.0318 Kwallis 
median 26.1  23.41  26.29    23.41  28  21.5    
LUL*                 
mean 27.32 9.49 25.64 7.69 28.03 10.13 0.2679 t-test 25.64# 7.69 30.45# 9.12 25.29# 10.66 0.0179 Kwallis 
median 27.05  25.09  28.7    25.09  29.9  23.69    
LLL#                 
mean 23.67 9.58 22 8.43 24.38 10.01 0.3171 Wilcoxon 22# 8.43 25.83# 8.93 22.75# 11.02 0.1101 Kwallis 
median 22.36  22.18  22.83    22.18  25.72  19.92    
Right Lung*                  
mean 25.86 8.94 23.77 6.97 26.75 9.56 0.1395 t-test 23.77 6.97 28.81 8.77 24.42 10.02 0.0441 ANOVA 
RUL*                 
mean 26.9 9.24 25.32 7.78 27.58 9.78 0.2809 t-test 25.32 7.78 30.09 9.53 24.74 9.4 0.0335 ANOVA 
RML*                  
mean 27.22 9.69 24.86 7.62 28.22 10.34 0.1246 t-test 24.86 7.62 29.91 10.46 26.32 10.02 0.098 ANOVA 
RLL*                  
mean 24.23 10.43 21.12 7.29 25.55 11.3 0.0599 t-test 21.12 7.29 27.28 10.43 23.58 12.08 0.0594 ANOVA 
median 23.4  21.42  24.78  0.0551 Wilcoxon 
non equal 
variances 
21.42  26.98  20.94    
(values indicate the % of lung parenychyma below -950HU) 
# - nonparametric variables 
* -parametric variables 
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Table 76: Comparison of gas trapping scores (using –860 HU cut-point), according to PPTB status. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (94)  (28)  (66)    (28)  (35)  (31)    
Total*                 
mean 33.24 15.31 26.69 13.02 36.02 15.44 0.0062 t-test 26.69 13.02 38.86 15.05 32.82 15.49 0.0061 ANOVA 
Left Lung#                 
mean 31.99 16.1 25.8 13.03 34.61 16.63 0.0158 Wilcoxon 25.8 13.03 37.31 16.88 31.57 16.08 0.025 Kwallis 
median 27.27  22.5  30.73    22.5  35.07  28.77    
LUL*                 
mean 35.63 16.86 28.38 13.81 38.71 17.19 0.006 t-test 28.38 13.81 41.72 17.39 35.3 16.57 0.0065 ANOVA 
LLL# (n=93)  (n=27)  (n=66)    (n=27)  (n=35)  (n=31)    
mean 26.98 16.95 22.23 13.84 28.92 17.8 0.1194 Wilcoxon 22.23 13.84 31.2 18.75 26.35 16.58 0.205 Kwallis 
median 21.71  19.64  22.24    19.64  25.76  21.75    
                 
Right Lung*  (n=91)  (n=27)  (n=64)    (n=27)  (n=35)  (n=29)    
mean 34.65 15.25 27.16 13.37 37.81 14.97 0.0019 t-test 27.16 13.37 40.29 14.81 34.82 14.87 0.0027 ANOVA 
RUL* (n=91)  (n=27)  (n=64)    (n=27)  (n=35)  (n=29)    
mean 36.61 16.36 29.26 14.64 39.71 16.15 0.0047 t-test 29.26 14.64 42.77 16.73 36.03 14.87 0.0044 ANOVA 
RML*  (n=91)  (n=27)  (n=64)    (n=27)  (n=35)  (n=29)    
mean 42.25 16.28 34.81 15.57 45.38 15.65 0.0041 t-test 34.81 15.57 46.76 16.43 43.72 14.76 0.0123 ANOVA 
RLL#  (n=91)  (n=27)  (n=64)    (n=27)  (n=35)  (n=29)    
mean 28.63 17.23 20.28 13.03 32.15 17.65 0.001 Wilcoxon 20.28 13.03 34.33 17.77 29.52 17.46 0.0022 Kwallis 
median 24.11  18.47  27.84    18.47  28.55  24.73    
(values indicate the % of lung parenychyma below -860HU) 
# - nonparametric variables 
* -parametric variables 
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9.3.7. Corrected gas trapping scores at residual volume 
Areas of emphysematous lung have the potential to increase the gas 
trapping scores in CT scans performed at residual volume. For this reason, 
gas trapping scores may be corrected for areas of emphysema. This is 
performed by subtracting a subject’s emphysema score (which is measured 
at TLC) from the gas trapping score (measured on RV). These corrected gas 
trapping scores are presented in Table 77, and the distribution for the right 
and left lungs are seen in Figure 55 and Figure 56, respectively.  
Subjects with PPTB had significantly higher corrected gas trapping 
scores than those with NPTB (median 9.5% vs. 2.7%, Wilcoxon p=0.0036). 
Moreover, subjects with DPTB had significantly higher corrected gas 
trapping scores (median 10.3%), compared with subjects with PrPTB 
(median 8.5%) or NPTB (median 2.7%) (Kruskal-Wallis p=0.011) [see Table 
77}. 
Similarly, both right and left lungs individually, as well as all-individual 
lobes (except the LLL) demonstrated significantly greater corrected gas 
trapping scores in subjects with PPTB, compared to those without. On three-
group analysis, higher corrected gas trapping scores were observed in 
subjects with DPTB compared with NPTB, for both lungs and all lobes 
(except the LLL), while subjects with PrPTB had intermediary values [see 
Table 77]. 
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Figure 56: Distribution of corrected 
gas trapping scores - left lung. 
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9.3.8. Fibrosis scores 
Fibrosis was defined as percentage area of lung parenchyma with density 
scores of –200 HU or greater on CT scans performed at full inspiration. 
There was no significant difference in the fibrosis scores between 
those with and without PPTB (2.3% vs. 2.1%, respectively, Wilcoxon 
p=0.370). In subjects with PPTB, only the RUL showed a significantly greater 
fibrosis score than in those with NPTB (Wilcoxon p=0.0336), and no 
difference was observed between these groups for the right and left lung 
overall, or in other individual lobes [see Table 78]. 
However, on analysis of the three groups, subjects with DPTB showed 
significantly greater fibrosis scores for both lungs combined (p=0.0547), for 
the right lung (0.0175) and RUL (0.0014) compared with those with PrPTB 
and NPTB, while the LUL and RLL also demonstrated a trend toward higher 
fibrosis scores [see Table 78]. 
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Table 77: Comparison of corrected gas trapping scores§, according to PPTB status. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (94)  (28)  (66)    (28)  (35)  (31)    
Total#                   
mean 7.44 10.7 2.69 8.69 9.45 10.89 0.0036 Wilcoxon 2.69 8.69 10.3 11.7 8.49 10 0.0105 Kwallis 
median 5.73  1.71  7.6     1.71  9.08  6.14     
Left Lung*                    
mean 6.21 11.35 1.59 9.27 8.17 11.64 0.0094 t-test 1.59 9.27 8.92 13.06 7.34 9.95 0.0294 ANOVA 
LUL*                   
mean 8.31 12.33 2.73 9.99 10.68 12.53 0.0038 t-test 2.73# 9.99 11.27# 13.65 10.01# 11.32 0.0112 Kwallis 
median 7.52  0.88  9.16     0.88  10.7  6.59     
LLL#                   
mean 3.23 11.73 0.029 9.01 4.54 12.5 0.1116 Wilcoxon 0.029 9.01 5.37 14.48 3.6 9.97 0.2799 Kwallis 
median 0.9  -3.18  3.21     -3.18  5.12  3.06     
                 
Right Lung*  (n=91)  (n=27)  (n=64)     (n=27)  (n=35)  (n=29)     
Mean 8.5 10.64 3.23 8.84 10.72 10.61 0.018 t-test 3.23 8.84 11.48 10.93 9.81 10.34 0.0063 ANOVA 
RUL*  (n=91)  (n=27)  (n=64)     (n=27)  (n=35)  (n=29)     
Mean 9.42 11.66 3.79 9.44 11.8 11.75 0.0023 t-test 3.79 9.44 12.68 11.86 10.74 11.73 0.0078 ANOVA 
RML*  (n=91)  (n=27)  (n=64)     (n=27)  (n=35)  (n=29)     
mean 14.78 11.97 9.73 10.89 16.91 11.84 0.0082 t-test 9.73 10.89 16.85 12.47 16.97 11.24 0.031 ANOVA 
RLL#  (n=91)  (n=27)  (n=64)     (n=27)  (n=35)  (n=29)     
mean 4.08 11.47 -0.99 9.04 6.22 11.76 0.0022 Wilcoxon -0.99 9.04 7.04 12.68 5.23 10.69 0.0086 Kwallis 
median 1.94  -2.11  3.38     -2.11  3.68  3.28     
§- Corrected gas trapping score = (860 HU score at RV – 950HU score at TLC)  
(values indicate the adjusted % of lung parenchyma below threshold) 
# - nonparametric variables 
* -parametric variables 
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Table 78: Comparison of fibrosis scores (using –200 HU cut-point), according to PPTB status. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
Prev 
TB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (94)  (28)  (66)    (28)  (35)  (31)    
Total#                 
mean 2.25 0.59 2.13 0.45 2.3 0.64 0.3697 Wilcoxon 2.13 0.45 2.44 0.63 2.15 0.62 0.0547 Kwallis 
median 2.14  2.08  2.15    2.08  2.28  2.11    
Left Lung#                  
mean 2.22 0.71 2.1 0.49 2.26 0.78 0.6434 Wilcoxon 2.1 0.49 2.35 0.71 2.17 0.86 0.254 Kwallis 
median 2.09  2.03  2.11    2.03  2.2  2.09    
LUL#                 
mean 2.2 1.08 1.95 0.46 2.31 1.24 0.3853 Wilcoxon 1.95 0.46 2.49 1.09 2.11 1.39 0.0616 Kwallis 
median 1.97  1.88  2.01    1.88  2.31  1.94    
LLL#                 
mean 2.29 0.73 2.29 0.57 2.29 0.79 0.4568 Wilcoxon 2.29 0.57 2.3 0.72 2.27 0.87 0.6999 Kwallis 
median 2.21  2.29  2.18    2.29  2.17  2.18    
Right Lung#                  
mean 2.3 0.63 2.16 0.44 2.36 0.69 0.4568 Wilcoxon 2.16 0.44 2.54 0.7 2.16 0.63 0.0175 Kwallis 
median 2.17  2.18  2.16    2.18  2.33  2.05    
RUL#                 
mean 2.44 1.23 1.97 0.47 2.63 1.39 0.0336 Wilcoxon 1.97 0.47 2.86 1.19 2.38 1.56 0.0014 Kwallis 
median 2.09  1.91  2.18    1.91  2.4  1.9    
RML#                 
mean 1.89 0.7 1.94 0.56 1.87 0.76 0.2149 Wilcoxon 1.94 0.56 1.98 0.92 1.74 0.5 0.2322 Kwallis 
median 1.85  2.03  1.8    2.03  1.88  1.63    
RLL#                 
mean 2.47 0.82 2.45 0.52 2.46 0.93 0.5517 Wilcoxon 2.45 0.52 2.68 1.12 2.22 0.56 0.0988 Kwallis 
median 2.31  2.4  2.28    2.4  2.3  2.1    
(values indicate the % of lung parenychyma above -200HU) 
# - nonparametric variables 
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9.3.9. Correlation between gas trapping and fibrosis scores 
An analysis of the correlation between the fibrosis scores (–200 HU or higher 
on TLC scans) and gas trapping (–860 HU or lower on RV scans) was 
performed. Spearman’s rank correlation coefficient (rho) was used to 
estimate level of correlation, and the coefficient of determination (R2) was 
calculated using simple linear regression.  
A significant correlation was found between the gas trapping and the fibrosis 
scores for all subjects when combined (Spearman’s correlation coefficient); 
both lungs combined (rho=0.256, p=0.0128), left and right lungs alone, LUL, 
LLL and RLL. However the coefficients of determination (R2) were small for 
most of the comparisons, ranging from 0.0026 to 0.068 [see Table 79]. 
This relationship between gas trapping and fibrosis scores was 
present for subjects in the NPTB and PrPTB groups, but not the DPTB group 
- the correlation coefficients and coefficients of determination (R2) being 
greater for subjects in the former group. The R2 values ranged from 0.117 to 
0.300 for the NPTB group, and from 0.0121 to 0.289 for the PrPTB group 
[see Table 80]. 
In contrast, there was no significant relationship between gas trapping 
and fibrosis scores for the DPTB group (rho for both lungs 0.1905, p=0.273), 
and R2 values ranged from –0.0179 to 0.0784. Spearman correlation 
coefficients were approximately zero for the right lung, RUL, and LUL, 
implying no association [see Table 80 and Figure 57]. 
Thus, the association between gas trapping and fibrosis scores was 
limited to the group with NPTB, but the group with PrPTB demonstrated 
intermediate levels of correlation.  
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Table 79: Correlation of gas trapping scores with fibrosis scores, according to 
PPTB status: NPTB vs. PPTB. 
  
All 
 
p-value 
 
NPTB 
 
p-value 
 
PPTB 
 
p-value 
Total (n=94)  (n=28)  (n=66)  
Spearman’s Coefficient 0.2558 0.0128 0.5479 0.0025 0.2061 0.0969 
R-squared 0.048 0.0339 0.2383 0.0084 0.0467 0.0813 
Left Lung  (n=94)  (n=28)  (n=66)  
Spearman’s Coefficient 0.3375 0.0009 0.5047 0.0062 0.3004 0.0143 
R-squared 0.0657 0.0127 0.1984 0.0175 0.0698 0.0321 
LUL (n=94)  (n=28)  (n=66)  
Spearman’s Coefficient 0.2115 0.0407 0.5528 0.0023 0.1476 0.2369 
R-squared 0.035 0.0711 0.271 0.0045 0.0471 0.0799 
LLL (n=93)  (n=27)  (n=66)  
Spearman’s Coefficient 0.3333 0.0011 0.3187 0.1052 0.325 0.0077 
R-squared 0.0551 0.0235 0.1911 0.0226 0.0415 0.101 
Right Lung  (n=91)  (n=27)  (n=64)  
Spearman’s Coefficient 0.207 0.049 0.5598 0.0024 0.145 0.2531 
R-squared 0.0125 0.2915 0.2452 0.0086 0.0112 0.4048 
RUL  (n=91)  (n=27)  (n=64)  
Spearman’s Coefficient 0.1189 0.2617 0.5446 0.0033 0.0587 0.6447 
R-squared 0.0026 0.6292 0.3 0.0031 0.0013 0.7738 
RLL (n=91)  (n=27)  (n=64)  
Spearman’s Coefficient 0.32 0.002 0.254 0.2011 0.339 0.0061 
R-squared 0.0677 0.0128 0.1173 0.0803 0.0743 0.0293 
 
Table 80: Correlation of gas trapping scores with fibrosis scores, according to 
PPTB status: three-group analysis.  
  
NPTB 
 
 
p-value 
 
DPTB 
 
p-value 
 
PrPTB 
 
p-value 
Total (n=28)  (n=35)  (n=31)  
Spearman’s Coefficient 0.5479 0.0025 0.1905 0.2731 0.3835 0.0332 
R-squared 0.2383 0.0084 0.0359 0.2755 0.1341 0.0427 
Left Lung        
Spearman’s Coefficient 0.5047 0.0062 0.2336 0.1768 0.4907 0.0051 
R-squared 0.1984 0.0175 0.075 0.1115 0.0963 0.0892 
LUL       
Spearman’s Coefficient 0.5528 0.0023 0.0527 0.7638 0.4583 0.0095 
R-squared 0.271 0.0045 0.0277 0.3392 0.1161 0.0607 
LLL (n=27)  (n=35)  (n=31)  
Spearman’s Coefficient 0.3187 0.1052 0.2499 0.1477 0.4375 0.0138 
R-squared 0.1911 0.0226 0.0784 0.1034 0.0186 0.4639 
Chapter 9  
 190 
  
NPTB 
 
 
p-value 
 
DPTB 
 
p-value 
 
PrPTB 
 
p-value 
Right Lung  (n=27)  (n=35)  (n=29)  
Spearman’s Coefficient 0.5598 0.0024 0.0653 0.7095 0.3635 0.0526 
R-squared 0.2452 0.0086 0.0024 0.7787 0.1012 0.0925 
RUL        
Spearman’s Coefficient 0.5446 0.0033 -0.0179 0.9186 0.2389 0.212 
R-squared 0.3 0.0031 0.0125 0.522 0.0121 0.5704 
RLL (n=27)  (n=35)  (n=29)  
Spearman’s Coefficient 0.254 0.2011 0.2714 0.1147 0.5448 0.0022 
R-squared 0.1173 0.0803 0.0599 0.1564 0.2893 0.0015 
0
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Figure 57: Correlation of fibrosis scores with gas trapping scores, for the right 
lung. 
 
9.4. Imaging analysis only in subjects with chronic airflow 
obstruction  
 
In an attempt to limit a type 1 error, an analysis restricted to subjects who 
were confirmed to have CAO at Visit 2 (i.e. confirmed CAO in the Follow-up 
study) was performed for the variables described above. On this basis 17 of 
94 subjects (18.1%) were excluded: nine (52.9%) from the NPTB group, one 
(5.9%) from DPTB and seven (41.1%) from the PrPTB group. In one 
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additional subject, whole body plethysmography was unsuccessful, and of 
the remainder, two subjects had incomplete CT scan quantification data.  
Selected results of this analysis are presented in Appendix 8 - Results 
of Lung Imaging, only for Subjects with Chronic Airflow Obstruction. 
 Results of the lung and lobar volume assessment were consistent with 
the previous analysis of all subjects and showed only reduced percentage 
volume of the RUL in subjects with PPTB, compared to subjects with NPTB. 
 Similarly, the analysis of bronchial wall measurements was consistent 
with that of the full cohort, and the Pi10 was not significantly different 
between subjects with and without PPTB, nor on three-group analysis [see 
Appendix 8]. 
 In contrast to the full cohort analysis, after removal of subjects with 
CAO, the average lung density at TLC (inspiratory scan) was no longer 
significantly different between subjects with and without PPTB, for either 
lungs or the lobes. This finding was consistent on three-group analysis. The 
RLL displayed a trend to less dense lungs (p=0.0527) on comparison of 
NTPB and PPTB, but not on three-group analysis [see Appendix 8].  
 The findings of re-analysis of the average lung density at residual 
volume (expiratory scan) were consistent with analysis of the whole cohort, 
and showed lower mean densities in subjects with PPTB compared to those 
with NPTB for: both lungs combined, right and left lungs alone, RML, RLL 
and LUL (trend to significance). Three-way analysis reduced the statistical 
significance of some of these findings [see Appendix 8]; however, when the 
DPTB and NPTB groups were compared directly with exclusion of the PrPTB 
group, the DPTB group showed significantly lower densities for: both lungs 
combined, right lung, left lung, RML, RLL and LUL (trend to significance).  
 In contrast to the analysis of the full cohort, when analysing only 
subjects with CAO, the emphysema scores were not found to be statistically 
significantly different between those with and without PPTB, for both lung 
combined, right and left lungs individually, as well as all lobes. This 
observation was confirmed on three-group analysis [see Appendix 8]. 
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 Re-analysis of gas trapping scores in subjects with PPTB showed a 
trend towards significantly greater scores in those with PPTB compared to 
those with NPTB, for both lungs combined. However, there were significantly 
greater scores for the right lung alone, RML and RLL in subjects with PPTB, 
as well as a trend towards greater scores for the LUL. Three-way analysis 
demonstrated significant differences in only the RLL gas trapping scores. 
However, on direct comparison of the DPTB and NPTB groups, with 
exclusion of PrPTB group, significantly higher gas trapping scores were 
observed for subjects with DPTB in: both lungs combined, the right lung, 
RUL, RLL and LUL, while the left lung and RML demonstrated a trend to 
significance [see Appendix 8].  
The corrected gas trapping score for both lungs was higher in 
subjects with PPTB than those with NPTB, however did not attain statistical 
significance (p=0.0583). The values for the right lung alone and the RLL were 
significantly higher in those with PPTB, while a trend to higher values was 
also seen in the left lung alone, the LUL, RUL and RML. Three-group analysis 
was unable to confirm these findings, but direct comparison of subjects in 
the DPTB and NPTB groups, showed significantly higher values in the DPTB 
in keeping with the above [see Appendix 8]. The analysis of the fibrosis 
scores only in subjects with CAO yielded results entirely consistent with the 
analysis of the full cohort [see Appendix 8]. 
 
9.4.1. Comparison of subjects with and without CAO in the NPTB 
group (sensitivity analysis)  
In the above analysis, 17 subjects without CAO were excluded, nine of whom 
were from the NPTB group, and one from the DPTB group. Thus, a sensitivity 
analysis was performed to determine if differences within the NPTB group 
between subjects with and without CAO could account for some of the 
observed discrepancies with the full cohort analysis [see Table 81]. 
A trend towards greater emphysema scores in the subjects with NPTB 
and CAO was found, compared to those without CAO (for both lungs 25.7% 
vs. 20.4%, t-test p=0.0617). The gas trapping scores were significantly 
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greater in subjects with CAO compared to those without (for both lungs 
30.1% vs. 19.6%, t-test p=0.0437). But, there was no significant difference in 
the corrected gas trapping scores between subjects with and without CAO 
(t-test p=0.147) [see Table 81]. 
 
Table 81: Comparison of imaging findings between subjects in the NPTB 
group, with and without CAO. 
 NO COPD sd COPD sd p-value test 
(n) (9)  (19)    
Emphysema  
(-950HU) 
      
Total*       
mean  20.35 7.22 25.72 6.6 0.0617 t-test 
median 21.46  28.19    
Left Lung*       
mean  20.48 7.69 25.98 6.83 0.0668 t-test 
median 21.35  28.43    
Right Lung*       
mean  20.21 6.84 25.45 6.53 0.0614 t-test 
median 21.55  26.35    
Gas Trapping  
(-860HU) 
(n=9)  (n=19)    
Total*       
mean  19.55 9.04 30.07 13.43 0.0437 t-test 
median 19.97  27.1    
Left Lung#       
mean  19.06 9.14 29 13.57 0.0463 Wilcoxon 
median 19.35  25    
Right Lung* (n=9)  (n=18)    
mean  19.96 9.04 30.76 13.91 0.0455 t-test 
median 19.55  27.35    
Corrected Gas Trapping  
(Gas trapping score – emphysema score) 
      
Total* (n=9)  (n=19)    
mean  -0.78 6.86 4.35 9.14 0.1468 t-test 
median -3.75  4.08    
Left Lung*       
mean  -1.42 7.47 3.01 9.87 0.2442 t-test 
median -4.46  2.36    
Right Lung# (n=9)  (n=18)    
mean  -0.25 6.43 4.97 9.5 0.1358 Wilcoxon 
median -3.22  3.854    
# - nonparametric variables 
* -parametric variables 
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9.5. Summary of findings 
 
The quantitative assessment of the CT lung images provided the following 
results: 
The volume of the RUL but not the LUL was reduced in subjects with 
PPTB and especially with DPTB in both the full cohort, and only subjects with 
CAO. This result is a useful sensitivity indicator as the RUL is the most 
frequent and severely involved lobe in PTB.  
 A slightly higher emphysema score found in subjects with PPTB was 
not confirmed when subjects without CAO were excluded. In contrast, gas 
trapping (measured at full expiration) was greater in both lungs and in the 
majority of lobes in subjects with PPTB, even when corrected by excluding 
areas with emphysema detected at TLC (the corrected gas trapping score). 
These results were similar when subjects without CAO were excluded 
although reduced numbers reduced the statistical significance of the 
observation.  
Apart from the RUL, fibrosis scores in the remaining lobes were not 
significantly different between subjects with and without PPTB. Although 
increased fibrosis scores were found in analysis of the whole right lung and in 
both lungs combined, these were presumed to reflect RUL fibrosis. 
No association was demonstrated between fibrosis scores and gas 
trapping scores in DPTB, but a significant correlation was seen in subjects 
with NPTB, the reason for which is not apparent.  
Finally, the thickness of the airway walls, measured as the Pi10, was 
similar in subjects with and without PPTB.  
  
 Chapter 10. Results of the Multivariate Analysis of 
the Relationship between Demographic and Clinical 
Features, Lung Physiology and Structural 
Abnormalities in Subjects with COPD and TOPD  
10.1. Introduction 
 
The relationship between structural changes observed on CT imaging and 
abnormalities in lung physiology were examined by multivariate analysis. A 
particular focus was to explore differences between subjects with and 
without previous pulmonary TB (PPTB). The dependent variables analysed 
were: diffusing capacity (DLCO - expressed as percentage of predicted value) 
and inspiratory capacity (IC - percentage of predicted), and CT scores for 
emphysema, corrected gas trapping and fibrosis. These were examined for 
both lungs (combined) and, for simplicity, only the right lung, right upper and 
lower lobes were included as part of this analysis. 
The independent variables used in the multivariate analysis were [see 
Table 82]:  
• Age 
• Gender 
• Cigarette usage (pack-years)  
• Cannabis usage (joint-years) 
• Asthma status, defined previously [see page 116] 
• Previous Tuberculosis status, [presented on page 141] as 
o No previous TB (NPTB)  
o Probable Previous TB (PrPTB) 
o Definite Previous TB (DPTB) 
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Table 82: Summary of independent variables. 
Age (n=107)  
 Mean=63.01yrs sd=9.719 
Gender (n=107)  
Male 49 (45.8%) 
Female 58 (54.2%) 
   
Cigarette (pack-years) (n=105)  
 Mean=23.413 sd=22.351 
 Median=18.7  
Cannabis (joint-years) (n=105)  
 Mean=44.813 sd=187.84 
   
Asthma status (n=106)  
No asthma  88  
Asthma 18  
   
Previous TB status (n=104)  
No previous TB (NPTB)  31  
Probable Previous TB (PrPTB) 34  
Definite Previous TB (DPTB) 39  
(withdrew) (3)  
 
The right upper and right lower lobes were selected because relationships on 
univariate analysis between structural changes and physiology in these lobes 
were more consistent than those from the upper and lower lobes of the left 
lung. 
 For all dependent variables, two methods of multivariate analysis were 
performed. A full model with all independent variables included, as well as 
backward stepwise regression, where variables were removed from the 
model if their significance was p>0.10, and were allowed to re-enter the 
model if their significance became p<0.08. Additionally, as a sensitivity 
measure, regression modelling was performed for all dependent variables 
using simple backward regression, simple forward regression and then 
stepwise forward regression. The results obtained from these analyses were 
not materially different, and consequently they are not presented here.   
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10.2. Multivariate analysis for diffusing capacity (percentage of 
predicted)  
 
[See Table 83 and Table 84] 
 
 10.2.1. Full model 
Table 83: Multivariate analysis for diffusing capacity using a full model. 
   Coef SE t P>|t| 95% CI 
Number of Obs 102 Age 0.142 0.217 0.650 0.516 -0.290 0.573 
F 3.21 Gender -2.777 4.418 -0.630 0.531 -11.548 5.995 
Prob > F 0.0043 Cig Pack Yr -0.175 0.106 -1.660 0.101 -0.386 0.035 
R-squared 0.1927 Can Joint Yr 0.024 0.012 1.960 0.053 0.000 0.049 
Adj R-sq 0.1326 Asthma 10.794 5.728 1.880 0.063 -0.579 22.167 
Root MSE 20.405 PrPTB -10.859 5.178 -2.100 0.039 -21.141 -0.578 
  DPTB -17.740 5.120 -3.460 0.001 -27.906 -7.574 
  Constant 73.202 14.462 5.060 0.000 44.487 101.917 
 10.2.2. Backward stepwise regression  
Table 84: Multivariate analysis for diffusing capacity using backward stepwise 
regression. 
Number of Obs 102  Coef SE t P>|t| 95% CI 
F 5.71 PrPTB -10.362 5.185 -2.000 0.048 -20.651 -0.074 
Prob > F 0.0012 DPTB -16.279 5.035 -3.230 0.002 -26.272 -6.286 
R-squared 0.1487 Asthma 11.493 5.511 2.090 0.040 0.556 22.430 
Adj R-sq 0.1227 Constant 76.818 3.961 19.390 0.000 68.957 84.679 
Root MSE 20.522        
. 
DLCO (% predicted) was significantly lower in subjects with DPTB and PrPTB, 
compared with NPTB. In subjects with DPTB, the mean DLCO was 16.3% 
lower (p=0.002), and in subjects with PrPTB it was 10.4% lower (p=0.048) 
than in those with NPTB. 
 Using the full model, cannabis use and the presence of asthma was 
associated with a trend towards a higher DLCO [see Table 83]. However, on 
backward stepwise regression, a significant association persisted only in 
asthma, with an 11.5% increase in DLCO (p=0.04).  
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When asthma was removed from the regression modeling, both 
cigarette smoking and cannabis smoking showed significant associations 
with DLCO [see Table 85]. The likely explanation is confounding between 
‘smoking’ and ‘asthma’, as a minimal or negative smoking history was a 
criterion used in the diagnosis of subjects as having asthma. 
Table 85: Multivariate analysis for diffusing capacity using backward stepwise 
regression, with asthma not included in the model. 
 Coeff SE T P>|t| 95% CI 
Probable TB -10.975 5.108 -2.15 0.034 -21.112 -0.839 
Definite TB -18.688 4.987 -3.75 0.000 -28.584 -8.791 
Cig Pack Yr -0.203 0.101 -2.01 0.047 -0.403 -0.003 
Can Joint Yr 0.0245 0.0121 2.02 0.046 0.005 0.049 
Constant 83.535 4.201 19.88 0.000 75.198 91.872 
 
10.3. Multivariate analysis for inspiratory capacity (percentage of 
predicted) 
 
Data on 99 subjects were included in this analysis, as four subjects in the 
cohort of 104 subjects were unable to perform reproducible manoeuvres and 
one subject was older than 80 years. Asthma status could not be imputed in 
one subject (owing to missing information). The models are show in Table 86 
and Table 88. 
 10.3.1. Full model 
Table 86: Multivariate analysis for inspiratory capacity using a full model. 
   Coef SE t P>|t| 95% CI 
  Age 0.721 0.264 2.730 0.008 0.196 1.246 
Number of Obs 98	   Gender 16.862 5.197 3.240 0.002 6.538 27.187 
F 6.74	   Cig Pack Yr -0.036 0.124 -0.290 0.774 -0.282 0.210 
Prob > F 0	   Can Joint Yr 0.003 0.014 0.230 0.815 -0.025 0.032 
R-squared 0.3438	   Asthma 8.739 6.707 1.300 0.196 -4.585 22.063 
Adj R-sq 0.2927	   PrPTB -20.748 6.099 -3.400 0.001 -32.866 -8.631 
Root MSE 23.437	   DPTB -21.528 5.990 -3.590 0.001 -33.428 -9.628 
  Constant 63.209 17.191 3.680 0.000 29.057 97.361 
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10.3.2. Backward stepwise regression 
 
Table 87: Multivariate analysis for inspiratory capacity using, backward 
stepwise regression. 
Number of Obs 98  Coef SE t P>|t| 95% CI 
F 11.42 Age 0.673 0.258 2.610 0.010 0.161 1.185 
Prob > F 0 Gender 18.339 4.831 3.800 0.000 8.746 27.931 
R-squared 0.3294 Probable TB -20.873 6.056 -3.450 0.001 -32.899 -8.847 
Adj R-sq 0.3005 Definite TB -22.201 5.876 -3.780 0.000 -33.870 -10.532 
Root MSE 23.307 Constant 66.460 16.549 4.020 0.000 33.597 99.323 
 
In both the full and backward stepwise regression models: age, gender and 
PPTB status were associated with IC (% predicted). On backward stepwise 
regression analysis, subjects with PPTB had an IC 20.9% lower (95% CI –
32.9- –8.8%, p=0.001), and subjects with DPTB an IC 22.2% lower (95% CI –
33.9%- –10.5%, p<0.001) than subjects with NPTB. In this model, for every 
10 years of age, the IC was 6.7% higher (p=0.008). Females had an 18.3% 
higher IC compared to males (p<0.001). 
 
10.4. Multivariate analysis for CT emphysema score 
 
Ninety-three of 94 subjects with quantitative CT scan data were included in 
analysis. In one subject asthma status could not be imputed.  
 
10.4.1. Analysis of both lungs combined 
Multivariate analysis results for the emphysema score of both lungs 
combined are presented in Table 88 and Table 90. 
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10.4.1.1. Full model 
Table 88: Multivariate analysis of emphysema score for both lungs, using a full 
model. 
 Coef SE t P>|t| 95% CI 
Age 0.022 0.091 0.240 0.807 -0.159 0.203 
Gender -7.822 1.769 -4.420 0.000 -11.338 -4.305 
Cig Pack Yr -0.010 0.043 -0.230 0.820 -0.095 0.076 
Can Joint Yr 0.001 0.005 0.290 0.769 -0.008 0.011 
Asthma 0.511 2.291 0.220 0.824 -4.044 5.067 
PrPTB -0.073 2.106 -0.030 0.973 -4.260 4.115 
DPTB 3.483 2.079 1.680 0.098 -0.651 7.617 
Constant 27.341 5.934 4.610 0.000 15.544 39.139 
10.4.1.2. Backward stepwise regression 
Table 89: Multivariate analysis of emphysema score for both lungs, using 
backward stepwise regression. 
 Coef SE t P>|t| 95% CI 
DPTB 3.515 1.665 2.110 0.038 0.207 6.823 
Gender -7.710 1.616 -4.770 0.000 -10.920 -4.500 
Constant 28.565 1.370 20.850 0.000 25.844 31.286 
 
In both full and backward stepwise regression analyses, female gender was 
negatively associated with CT emphysema score. Female subjects had a 
7.7% lower score than males (p<0.001). On backward stepwise regression 
analysis, DPTB was positively associated with emphysema score; DPTB 
subjects had a 3.5% higher score than subjects with NPTB (p=0.038).  
 
10.4.2. Analysis of right lung 
Multivariate analysis results for the emphysema score of the right lung alone 
are presented in Table 90 and Table 91. 
 As in the analysis of both lungs with the full model, gender was 
negatively associated with emphysema score, and subjects in the DPTB 
group showed a trend towards a positive association. However, using 
backward stepwise regression, the association with DPTB was positive: a 
3.8% higher emphysema score compared with subjects with NPTB 
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(p=0.026). Female subjects demonstrated a 7.5% lower emphysema score 
compared to males (p<0.001). 
10.4.2.1. Full model 
Table 90: Multivariate analysis of emphysema score for right lung, using a full 
model. 
 Coef SE t P>|t| 95% CI 
Age 0.052 0.093 0.560 0.575 -0.132 0.237 
Gender -7.672 1.804 -4.250 0.000 -11.258 -4.086 
Cig Pack Yr -0.021 0.044 -0.470 0.638 -0.108 0.067 
Can Joint Yr 0.004 0.005 0.710 0.481 -0.006 0.014 
Asthma 0.696 2.337 0.300 0.766 -3.950 5.342 
PrPTB 0.186 2.148 0.090 0.931 -4.085 4.456 
DPTB 3.914 2.120 1.850 0.068 -0.302 8.129 
Constant 25.325 6.051 4.190 0.000 13.294 37.356 
10.4.2.2. Backward stepwise regression 
Table 91: Multivariate analysis of emphysema score for right lung, using 
backward stepwise regression.  
 Coef SE t P>|t| 95% CI  
DPTB 3.847 1.705 2.26 0.026 0.461 7.234 
Gender -7.538 1.654 -4.56 0.000 -10.824 -4.252 
Constant 28.413 1.402 20.26 0 25.628 31.199 
10.4.3. Analysis of right upper lobe 
Multivariate analysis results for the emphysema score of the right upper lobe 
alone are presented in Table 92 and Table 93. 
10.4.3.1. Full model 
Table 92: Multivariate analysis of emphysema score for right upper lobe, using 
a full model. 
 Coef SE t P>|t| 95% CI 
Age 0.046 0.098 0.470 0.641 -0.148 0.240 
Gender -7.012 1.895 -3.700 0.000 -10.780 -3.245 
Cig Pack Yr 0.014 0.046 0.310 0.759 -0.078 0.106 
Can Joint Yr 0.001 0.005 0.280 0.782 -0.009 0.012 
Asthma 0.820 2.455 0.330 0.739 -4.061 5.701 
PrPTB -1.146 2.257 -0.510 0.613 -5.632 3.341 
DPTB 3.670 2.228 1.650 0.103 -0.759 8.099 
Constant 26.239 6.358 4.130 0.000 13.598 38.880 
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10.4.3.2. Backward stepwise regression 
Table 93: Multivariate analysis of emphysema score for right upper lobe, using 
backward stepwise regression. 
 Coef SE t P>|t| 95% CI 
DPTB 4.238 1.790 2.370 0.020 0.682 7.794 
Gender -7.094 1.737 -4.080 0.000 -10.544 -3.643 
Constant 29.095 1.472 19.760 0.000 26.170 32.021 
 
A negative association was again shown between female gender and 
emphysema score in both models, being 7.1% less than males (p<0.001). 
Only on backward stepwise regression was the emphysema score of the 
RUL shown to be significantly higher (4.2%) in subjects with DPTB, 
compared to the NPTB group (p<0.001). 
 
10.4.4. Analysis of right lower lobe 
Multivariate analysis results for the emphysema score of the right lower lobe 
alone are presented in Table 94 and Table 95. 
Multivariate analysis of the emphysema score of the right lower lobe 
showed similar associations to those of the right lung, an association with 
gender, and a trend toward association for subject with DPTB. Subjects with 
DPTB had a 3.9% higher (p=0.056), and females had 8.4% lower 
emphysema scores (p<0.001) than NPTB and male gender, respectively. 
10.4.4.1. Full model 
Table 94: Multivariate analysis of emphysema score for right lower lobe, using 
a full model. 
 Coef SE t P>|t| 95% CI 
Age 0.080 0.109 0.730 0.466 -0.137 0.296 
Gender -8.581 2.115 -4.060 0.000 -12.785 -4.377 
Cig Pack Yr -0.061 0.052 -1.180 0.243 -0.163 0.042 
Can Joint Yr 0.008 0.006 1.380 0.172 -0.004 0.020 
Asthma 0.130 2.740 0.050 0.962 -5.317 5.577 
PrPTB 1.968 2.518 0.780 0.437 -3.038 6.975 
DPTB 4.740 2.486 1.910 0.060 -0.203 9.682 
Constant 22.352 7.094 3.150 0.002 8.246 36.457 
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10.4.4.2. Backward stepwise regression 
Table 95: Multivariate analysis of emphysema score for right lower lobe, using 
backward stepwise regression. 
 Coef SE t P>|t| 95% CI 
DPTB 3.929 2.027 1.940 0.056 -0.097 7.955 
Gender -8.432 1.966 -4.290 0.000 -12.339 -4.526 
Constant 27.208 1.667 16.320 0.000 23.896 30.520 
 
10.5. Multivariate analysis of CT corrected gas trapping score  
The derivation and significance of the corrected gas trapping score is 
discussed on page 184.  
10.5.1 Analysis of both lungs combined 
[See Table 96 and Table 97] 
10.5.1.1. Full model 
Table 96: Multivariate analysis of corrected gas trapping scores for both lungs, 
using a full model. 
 Coef SE t P>|t| 95% CI 
Age 0.114 0.115 0.990 0.326 -0.115 0.342 
Gender -0.637 2.233 -0.290 0.776 -5.077 3.803 
Cig Pack Yr 0.063 0.054 1.160 0.251 -0.045 0.171 
Can Joint Yr 0.002 0.006 0.370 0.709 -0.010 0.015 
Asthma -5.941 2.893 -2.050 0.043 -11.693 -0.190 
PrPTB 4.777 2.659 1.800 0.076 -0.511 10.064 
DPTB 6.194 2.625 2.360 0.021 0.975 11.413 
Constant -3.689 7.492 -0.490 0.624 -18.584 11.206 
10.5.1.2. Backward stepwise regression 
Table 97: Multivariate analysis of corrected gas trapping scores for both lungs, 
using backward stepwise regression.  
 Coef SE t P>|t| 95% CI 
PrPTB 5.232 2.637 1.980 0.050 -0.008 10.472 
DPTB 6.473 2.582 2.510 0.014 1.342 11.604 
Asthma -7.184 2.772 -2.590 0.011 -12.692 -1.676 
Constant 4.653 2.023 2.300 0.024 0.632 8.673 
 
There was an association with corrected gas trapping score of lungs 
(combined) and both asthma status (negative association), and DPTB 
Chapter 10  
 204 
(positive association), and a trend toward a positive association with PrPTB 
was seen in the full model.  
 However, on backward stepwise regression modeling, both subjects 
in the DPTB and PrPTB groups had significantly higher corrected gas 
trapping scores compared to subjects with NPTB (6.5% and 5.2% greater 
scores, respectively, p=0.014 and p=0.050). Subjects with asthma had a 
7.2% lower score (p=0.011).  
 
10.5.2. Analysis of right lung 
[See Table 98 and Table 99] 
10.5.2.1. Full model 
Table 98: Multivariate analysis of corrected gas trapping scores for right lung, 
using a full model. 
 Coef SE t P>|t| 95% CI 
Age 0.096 0.116 0.830 0.408 -0.134 0.327 
Gender -0.647 2.220 -0.290 0.772 -5.064 3.770 
Cig Pack Yr 0.062 0.054 1.160 0.248 -0.044 0.169 
Can Joint Yr 0.002 0.006 0.320 0.749 -0.010 0.014 
Asthma -6.483 2.865 -2.260 0.026 -12.182 -0.784 
PrPTB 5.531 2.689 2.060 0.043 0.182 10.880 
DPTB 6.759 2.599 2.600 0.011 1.588 11.929 
Constant -1.912 7.447 -0.260 0.798 -16.726 12.902 
10.5.2.2. Backward stepwise regression 
Table 99: Multivariate analysis of corrected gas trapping scores for right lung, 
using backward stepwise regression.  
 Coef SE t P>|t| 95% CI 
Asthma -7.758 2.722 -2.850 0.005 -13.169 -2.347 
DPTB 7.013 2.553 2.750 0.007 1.938 12.087 
PrPTB 6.061 2.643 2.290 0.024 0.807 11.314 
Constant 5.350 2.019 2.650 0.010 1.337 9.363 
 
Analysis of the corrected gas trapping scores for the right lung confirmed an 
association with asthma (negative) and a significant positive association with 
both DPTB and PrPTB in both models. 
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 Subjects with DPTB had a 7.0% higher (p=0.007) and subjects with 
PrPTB a 6.1% higher corrected gas trapping score (p=0.024) than subjects 
with NPTB. Asthma was associated with a 7.8% lower corrected gas 
trapping score (p=0.005) compared to those without asthma.  
10.5.3. Analysis of right upper lobe 
[See Table 100 and Table 101] 
10.5.3.1. Full model 
Table 100: Multivariate analysis of corrected gas trapping scores for right upper lobe, 
using a full model. 
 
 Coef SE t P>|t| 95% CI 
Age 0.119 0.127 0.940 0.352 -0.134 0.371 
Gender -1.760 2.433 -0.720 0.471 -6.599 3.079 
Cig Pack Yr 0.080 0.059 1.370 0.176 -0.037 0.197 
Can Joint Yr -0.001 0.007 -0.190 0.847 -0.015 0.012 
Asthma -6.588 3.139 -2.100 0.039 -12.831 -0.344 
PrPTB 5.776 2.946 1.960 0.053 -0.085 11.637 
DPTB 7.440 2.848 2.610 0.011 1.776 13.105 
Constant -2.413 8.159 -0.300 0.768 -18.644 13.818 
10.5.3.2. Backward stepwise regression 
 
Table 101: Multivariate analysis of corrected gas trapping scores for right 
upper lobe, using backward stepwise regression. 
 Coef SE t P>|t| 95% CI 
PrPTB 6.405 2.909 2.200 0.030 0.621 12.189 
DPTB 7.568 2.810 2.690 0.009 1.982 13.154 
Asthma -8.312 2.996 -2.770 0.007 -14.269 -2.356 
Constant 6.058 2.222 2.730 0.008 1.640 10.476 
 
A significant association was again found between corrected gas trapping 
scores of the RUL and both PPTB status and asthma. Subjects with DPTB 
having a 7.6% higher (p=0.009), and PrPTB a 6.4% higher score (p=0.030) 
than NPTB subjects. Subjects with asthma had an 8.3% lower score 
(p=0.007) than those without asthma.  
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10.5.4. Analysis of right lower lobe 
[See Table 102 and Table 103] 
10.5.4.1. Full model 
Table 102: Multivariate analysis of corrected gas trapping scores for right 
lower lobe, using a full model. 
 Coef SE t P>|t| 95% CI 
Age 0.024 0.129 0.190 0.850 -0.232 0.281 
Gender 1.441 2.474 0.580 0.562 -3.481 6.362 
Cig Pack Yr 0.032 0.060 0.540 0.590 -0.087 0.151 
Can Joint Yr 0.006 0.007 0.910 0.364 -0.007 0.020 
Asthma -6.517 3.192 -2.040 0.044 -12.866 -0.167 
PrPTB 5.451 2.996 1.820 0.072 -0.509 11.412 
DPTB 6.463 2.896 2.230 0.028 0.702 12.223 
Constant -2.202 8.297 -0.270 0.791 -18.708 14.304 
Age 0.024 0.129 0.190 0.850 -0.232 0.281 
10.5.4.2. Backward stepwise regression 
Table 103: Multivariate analysis of corrected gas trapping scores for right 
lower lobe, using backward stepwise regression. 
 Coef SE t P>|t| 95% CI 
DPTB 6.835 2.823 2.420 0.018 1.223 12.447 
PrPTB 5.664 2.923 1.940 0.056 -0.147 11.475 
Asthma -6.901 3.010 -2.290 0.024 -12.886 -0.916 
Constant 0.998 2.233 0.450 0.656 -3.440 5.437 
 
Analysis of the right lower lobe revealed similar results on both models, with 
the corrected gas trapping score being 6.8% higher in subjects with DPTB 
(p=0.018) and 5.7% higher in PrPTB (trend p=0.056) compared to NPTB. In 
subjects with asthma, the score was 6.9% lower than those without asthma 
(p=0.024). 
10.6. Multivariate analysis for CT fibrosis score 
 
The fibrosis score was defined as a value of –200 HU or higher. 
 
 
10.6.1. Analysis of both lungs combined 
[See Table 104 and Table 105] 
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10.6.1.1. Full model 
Table 104: Multivariate analysis of fibrosis scores for both lungs, using a full 
model. 
 Coef SE t P>|t| 95% CI 
Age 0.008 0.006 1.220 0.224 -0.005 0.021 
Gender 0.347 0.125 2.770 0.007 0.097 0.596 
Cig Pack Yr 0.004 0.003 1.220 0.225 -0.002 0.010 
Can Joint Yr -0.000 0.000 -0.590 0.560 -0.001 -0.000 
Asthma -0.071 0.162 -0.440 0.663 -0.394 0.252 
PrPTB 0.016 0.149 0.110 0.914 -0.280 0.313 
DPTB 0.357 0.147 2.420 0.017 0.064 0.650 
Constant -98.631 0.420 -234.680 0.000 -97.795 -99.466 
10.6.1.2. Backward stepwise regression 
Table 105: Multivariate analysis of fibrosis scores for both lungs, using a 
backward stepwise regression.  
 Coef SE t P>|t| 95% CI 
DPTB 0.331 0.121 2.750 0.007 0.092 0.571 
Gender 0.321 0.117 2.740 0.007 0.089 0.554 
Constant -98.041 0.099 -988.260 0.000 -98.238 -97.844 
 
The CT fibrosis score was significantly higher in subjects with DPTB but not 
in PrPTB, compared to subjects with NPTB (0.33% higher score, p=0.007). 
Females had a 0.32% higher score than males (p=0.007). 
 
10.6.2. Analysis of right lung 
[See Table 106 and Table 107] 
CT fibrosis scores for the right lung alone were also higher in subjects with 
DPTB, but not PrPTB, compared with subjects with NPTB (0.41% greater 
score, p=0.002). Females showed a trend towards higher scores for the right 
lung alone compared with males (p=0.099). 
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10.6.2.1. Full model 
Table 106: Multivariate analysis of fibrosis scores for right lung, using a full 
model. 
 Coef SE t P>|t| 95% CI 
Age 0.009 0.007 1.300 0.197 -0.005 0.023 
Gender 0.250 0.134 1.860 0.067 -0.018 0.517 
Cig Pack Yr 0.003 0.003 1.060 0.290 -0.003 0.010 
Can Joint Yr -0.000 0.000 -0.180 0.856 -0.001 0.001 
Asthma -0.128 0.174 -0.730 0.464 -0.474 0.218 
PrPTB -0.014 0.160 -0.080 0.933 -0.332 0.305 
DPTB 0.408 0.158 2.580 0.012 0.094 0.722 
Constant -98.599 0.451 -218.800 0.000 -99.495 -97.703 
10.6.2.2. Backward Stepwise Regression 
Table 107: Multivariate analysis of fibrosis scores for right lung, using backward 
stepwise regression. 
 Coef SE t P>|t| 95% CI 
DPTB 0.408 0.129 3.150 0.002 0.151 0.665 
Gender 0.209 0.126 1.670 0.099 -0.040 0.459 
Constant -97.961 0.106 -920.010 0.000 -98.172 -97.749 
 
10.6.3. Analysis of right upper lobe 
[See Table 108 and Table 109] 
In both methods of analysis for the RUL, only subjects with DPTB 
demonstrated higher fibrosis scores than those in the NPTB group (0.68% 
increase, p=0.010). 
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10.6.3.1. Full model 
Table 108: Multivariate analysis of fibrosis scores for right upper lobe, using a 
full model. 
 Coef SE t P>|t| 95% CI 
Age 0.014 0.014 0.980 0.329 -0.014 0.041 
Gender 0.043 0.268 0.160 0.874 -0.491 0.576 
Cig Pack Yr -0.002 0.007 -0.360 0.716 -0.015 0.011 
Can Joint Yr 0.001 0.001 0.850 0.398 -0.001 0.002 
Asthma -0.361 0.347 -1.040 0.302 -1.052 0.330 
PrPTB 0.376 0.319 1.180 0.243 -0.259 1.011 
DPTB 0.839 0.315 2.660 0.009 0.212 1.466 
Constant -98.787 0.900 -109.780 0.000 -100.577 -96.998 
10.6.3.2. Backward stepwise regression 
Table 109: Multivariate analysis of fibrosis scores for right upper lobe, using 
backward stepwise regression. 
	   Coef	   SE	   t	   P>|t|	   95%	  CI	  
DPTB	   0.676	   0.256	   2.650	   0.010	   0.168	   1.184	  
Constant	   -­‐97.817	   0.157	   -­‐623.910	   0.000	   -­‐98.129	   -­‐97.506	  
 
10.6.4. Analysis of Right Lower Lobe 
[See Table 110 and Table 111] 
10.6.4.1. Full Model 
Table 110: Multivariate analysis of fibrosis scores for right lower lobe, using a 
full model. 
 Coef SE t P>|t| 95% CI 
Age 0.012 0.009 1.380 0.171 -0.005 0.029 
Gender 0.353 0.169 2.090 0.040 0.017 0.689 
Cig Pack Yr 0.013 0.004 3.080 0.003 0.004 0.021 
Can Joint Yr -0.001 0.000 -2.350 0.021 -0.002 -0.000 
Asthma 0.030 0.219 0.140 0.890 -0.405 0.466 
PrPTB -0.249 0.201 -1.240 0.220 -0.648 0.151 
DPTB 0.324 0.199 1.630 0.106 -0.071 0.719 
Constant -98.770 0.567 -174.290 0.000 -99.897 -97.643 
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10.6.4.2. Backward Stepwise Regression 
Table 111: Multivariate analysis of fibrosis scores for right lower lobe, using 
backward stepwise regression. 
	   Coef	   SE	   t	   P>|t|	   95%	  CI	  
DPTB	   0.441	   0.165	   2.660	   0.009	   0.112	   0.770	  
Can	  Joint	  Yr	   -­‐0.001	   0.000	   -­‐2.700	   0.008	   -­‐0.002	   -­‐0.000	  
Gender	   0.379	   0.167	   2.280	   0.025	   0.048	   0.711	  
Cig	  Pack	  Yr	   0.013	   0.004	   3.260	   0.002	   0.005	   0.021	  
Constant	   -­‐98.157	   0.174	   -­‐564.120	   0.000	   -­‐98.502	   -­‐97.811	  
 
Multivariate analysis of the right lower lobe, using both the full and backward 
stepwise models, confirmed significant associations of fibrosis scores with 
gender and smoking of both cigarettes and cannabis. In addition, in the 
backward stepwise regression analysis definite PPTB was also found to be 
significantly associated with fibrosis. Subjects with definite PPTB had 0.44% 
higher fibrosis scores compared with subjects with no PPTB (p=0.009).  
Females had a 0.38% higher score than males, and in cigarette smokers an 
increase of 0.13% for every 10-pack-years smoked was observed (p=0.002). 
By contrast, cannabis smokers had a 0.01% lower fibrosis score for every 10 
‘joint-years’ smoked (p=0.008).  
 
10.7. Summary of findings  
 
These analyses of subjects with CAO confirm associations of PPTB (DPTB 
and in some instances PrPTB also) with both physiological and radiological 
features of COPD, suggesting that CAO associated with PPTB is different 
from usual COPD in several important respects. PPTB-associated CAO is 
associated with a lower diffusing capacity for carbon monoxide (DLCO) and 
inspiratory capacity (IC) and higher CT emphysema, corrected gas trapping 
and fibrosis scores. The associations of some of these features with gender 
and asthma serve as sensitivity indicators to the significance of the findings. 
As expected, asthma was associated with a higher DLCO without an increase 
in emphysema score. Cigarette smoking was associated with a lower DLCO 
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and had higher fibrosis scores in the right lower lobe (possibly related to 
‘dirty’ lungs from smoke particulates). However, for all physiological and 
radiological features assessed, namely DLCO, IC, CT emphysema, gas 
trapping and fibrosis scores, the strength of association with PPTB was 
dominant over even cigarette smoking. In addition, the finding of both 
increased emphysema and gas trapping corrected for emphysema suggest 
airways disease with gas trapping as an important component of disease. 
Taken together with the absence in significant differences in other 
physiological measures between COPD and PPTB-associated CAO (FEV1, 
TLC and RV/TLC), these differences are not explained by differences in the 
severity of CAO of subjects with PPTB and suggest different structural 
changes. This is further explored in the next chapter. 

 Chapter 11. Discussion 
 
11.1. Introduction  
 
The aim of this research was to interrogate tuberculosis-associated 
obstructed pulmonary disease (TOPD), with the purpose of defining its 
physiology and radiology, and to compare it with the usual forms of chronic 
obstructive pulmonary Disease (COPD). The research question arose from 
the Burden of Obstructive Lung Disease (BOLD) study performed in Cape 
Town in 2005, which reported a very high prevalence of COPD, higher than 
sites in other countries, and a high prevalence of a history of previous 
tuberculosis among the subjects diagnosed with COPD. Another significant 
observation was the low number of pack-years among smokers, which is 
further evidence that factors other than tobacco smoking might be important 
in the pathogenesis of COPD in that community, the most obvious of which 
are the long-term effects of previous pulmonary tuberculosis (PPTB).  
 Although this research centered on the description of TOPD as a 
potential distinct phenotype of COPD, access to the original BOLD study site 
permitted the design of a follow-up study of some of the original BOLD 
cohort to address important additional questions. First, to confirm the 
diagnosis of COPD in subjects who previously fulfilled the diagnostic criteria 
for COPD in 2005. In conjunction, it afforded the opportunity to perform a 
critical appraisal of the BOLD method, and its performance in estimating the 
burden of COPD in communities in the setting of a high prevalence of TB, 
including the reliability of the specified spirometer. Second, to examine the 
natural history of COPD in this community, and determine the role, if any, 
played by PPTB. 
 Through a process of repeated home visits and contact tracing, a 
satisfactory response rate was obtained. A total of 107 (54.6%) of the original 
196 subjects considered to have COPD in the BOLD 2005 study, (from a total 
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community-based sample of 847 subjects) were available for study, and vital 
status was obtained on the remainder. The first task was to correctly 
categorise subjects according to whether they had suffered at least one 
episode of pulmonary TB. Since history alone was likely to be insensitive, a 
method combining history and chest CT scans was developed, which is 
discussed in detail below. On the basis of this assessment, two categories 
could be confidently established: definite previous tuberculosis (DPTB) and 
no previous tuberculosis (NPTB). Another category, probable previous 
tuberculosis (PrPTB), comprised subjects with CT-scan features compatible 
with PPTB but no history of this infection. In some analyses, DPTB and 
PrPTB were combined, and are referred to as PPTB.  
 
11.2. Major findings: mechanism of airflow obstruction and 
structure-function relationships 
 
The analyses of lung physiology and its relationship to quantitative lung 
imaging for the three categories of subjects provided evidence of significant 
differences not attributable to severity of COPD, and insights into potential 
mechanisms of disease.  
 Subjects with PPTB did not differ in terms of smoking history, MRC 
dyspnoea score, health status measured by the St George’s Respiratory 
Questionnaire, presence of chronic bronchitis, mean FEV1, FVC or 
FEV1:FVC, or bronchodilator responsiveness. Additionally, their mean total 
lung capacity, vital capacity, residual volume and RV:TLC was similar to that 
in usual COPD.  
  However, despite these similarities, subjects with PPTB had a lower 
inspiratory capacity (IC), and a higher functional residual capacity (FRC) and 
expiratory reserve volume (ERV) than usual COPD, which suggests more 
static gas trapping – the median IC as a percentage of predicted, was 22.2% 
lower. Other physiological evidence of hyperinflation did not accompany 
these changes. The TLC in subjects with PPTB was no different from that in 
NPTB (median of 102.0% predicted in both), and RV and RV:TLC were 
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elevated to a similar extent in both (median RV 139.0% predicted median 
RV:TLC 55.5% for DPTB; and 133.0% predicted and 51.0% respectively for 
NPTB). These values also confirm that the presence of PPTB did not result in 
a restrictive defect, as might be expected with widespread or diffuse fibrosis. 
Indeed, the overall fibrosis score on CT scan was not increased, and volume 
loss and increased fibrosis score was only present in the right upper lobe 
(RUL). This volume loss, expressed as percentage of whole lung, reflects the 
known tendency for PTB to affect this lobe, and was not seen in the left 
upper lobe (LUL).  Although pulmonary fibrosis is a hallmark of healed 
tuberculosis, apart from the RUL, none of the other lobes showed increased 
fibrosis scores in PPTB. 
 Compatible with the physiology findings, lung imaging revealed 
important differences between subjects with and without PPTB. First, more 
gas trapping was found in PPTB, while increases in emphysema score were 
of questionable significance. The gas trapping score corrected for the 
presence of emphysema was approximately 6.5% higher in subjects with 
DPTB, and 5.6% higher in PrPTB. Consistent with this; total lung density at 
full expiration was significantly lower in PPTB than in NPTB. In contrast, 
although emphysema score in subjects with DPTB was 3.5% higher, no 
increase was seen in PrPTB, which suggests that this finding should be 
interpreted with caution. Thus, on balance, gas trapping, which is usually a 
feature of pathology in bronchi and bronchioles, is the major functional 
abnormality. It is, however, important to note that the only imaging 
measurement of the bronchial tree, the Pi10, failed to confirm differences 
between subjects with and without PPTB. Potential reasons for this are 
discussed below. 
 A further difference in the lung physiology was the lower diffusing 
capacity (DLCO) observed in subjects with PPTB (16.3% predicted lower for 
DPTB). This novel observation was evident in both univariate and multivariate 
analyses, and for both DPTB and PrPTB. The values for DLCO were 61.7% 
predicted and 68.6% predicted for DPTB and PrPTB, respectively, compared 
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with 79.5% predicted for NPTB. The reasons for the lower DLCO in subjects 
with PPTB require explanation. 
 A reduction in DLCO is a feature of emphysema, and is negatively 
associated with the presence of low attenuation areas on HRCT. Putative 
responsible mechanisms are: ventilation perfusion abnormalities and loss of 
alveolar-capillary interface (gas-exchanging areas) in the lungs. Emphysema 
is unlikely to be the dominant mechanism of reduced DLCO in the subjects in 
the present study, as the emphysema scores were generally low, and the 
higher emphysema scores seen in DPTB but not in PrPTB were inconsistent 
in various analyses. Moreover, the quantitative algorithm used to assess low-
attenuation areas includes abnormal air spaces and cavities, which are 
common in healed PPTB, with the potential of falsely elevating emphysema 
scores in DPTB. 
 A more likely cause of reduced DLCO is involvement of either the 
pulmonary vasculature, or bronchioles with resultant ventilation:perfusion 
mismatch. Pulmonary TB is known to cause profound changes in the 
pulmonary vasculature, and unlike usual COPD, post-tuberculous scarring is 
more frequently associated with the development of pulmonary hypertension 
and cor pulmonale.206,207 Although vascular involvement (attenuation of 
pulmonary vasculature) could account for both the reduction in DLCO and 
lower lung density observed on expiratory CT scans in PPTB, this 
mechanism does not explain the presence of CAO and reduced IC. These 
are best explained by gas trapping due to narrowing and obliteration of small 
and medium airways, typical of a bronchocentric process. This explanation is 
compatible with the site of disease described during the active phase of TB, 
where 95% of individuals display lesions in and around the small airways 
(e.g. ‘tree-in-bud’ or centrilobular nodules).141 Although most of these lesions 
disappear after five months of treatment, healing may result in cicatricial 
fibrosis and narrowing or obliteration of bronchi or bronchioles. In this 
scenario, the reduced DLCO may be the result of ventilation:perfusion 
mismatching, analogous to that observed in other diseases (e.g. idiopathic 
pulmonary fibrosis). It is also plausible that, after an episode of tuberculosis, 
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the peri-bronchiolar cicatricial fibrosis involves not only the airways, but also 
the adjacent vessels, with resultant loss of vascular bed. Thus, the combined 
involvement of smaller airways and vasculature, and subsequent obliteration 
of these structures that are below the limits of detection of even high-
resolution CT scans, are proposed as the major site of disease in CAO 
following PPTB and the cause of the observed functional abnormalities.  
 Bronchiectasis in large airways is another feature of healed PTB. 
Although associated with CAO, the mechanisms responsible for this are 
unclear.54 The results of the present study suggest that abnormalities in 
airways distant from the most scarred lobes are responsible for the functional 
abnormality. On lung imaging, no relationship between fibrosis scores and 
gas trapping was observed. Most gas trapping was seen in the lower lobes, 
while the highest fibrosis score was in the RUL. This is also supported, albeit 
weakly, by the negative findings of the Pi10 analysis. As discussed earlier, 
the Pi10 is based on measurements from the first few generations of airways, 
while the likely small airways are located more distally to the measured 
bronchi. A further limitation of the measurement is that the Pi10 references 
wall thickness to bronchial lumen area; thus, airways that are both dilated 
and thickened may appear to be ‘normal’.  
 It is thought that this is the first study to report the differences in lung 
physiology and radiology between subjects with COPD and those with CAO 
associated with PPTB, which have been termed tuberculosis-associated 
obstructive pulmonary disease (TOPD).  
 
11.3. The efficacy of treatment in TOPD 
 
To determine the potential effect, if any, of medication on the lung physiology 
of subjects with PPTB and CAO, a two-week trial of prednisone and 
formoterol (LABA) was administered. No significant differences in the 
improvement of lung physiology parameters were demonstrated, including: 
pre-bronchodilator FEV1, or symptoms of dyspnoea (MRC Dyspnoea score) 
between subjects with PPTB or usual COPD. Both groups showed no 
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improvement in median dyspnoea scores, and only small changes in pre-
bronchodilator FEV1 (70 mL for PPTB and 90 mL for NPTB). These findings 
accord with previous COPD studies that have demonstrated non-significant 
increases in FEV1 after administration of prednisone (20 mg/day for four 
weeks),208 and, unlike asthma, the underlying pathological mechanisms of 
CAO associated with PPTB do not appear to respond to such short courses 
of therapy. Whether subjects with PPTB will demonstrate responses to 
longer-term medication, similar to those observed in usual COPD, is 
unknown and requires further investigation.  
 
11.4. Diagnosing previous pulmonary tuberculosis 
 
Central to the evaluation of the relationship between PPTB and CAO was the 
need to establish whether subjects had had pulmonary TB in the past. It was 
recognised that patient history would provide a falsely low estimate of this,26 
the effect of which would be to reduce the likelihood of detecting differences 
between COPD and TOPD. Thus, in this study, additional methods were 
used to attempt a more accurate estimation of PPTB. Chest X-rays proved to 
be of little additional value and the comparison with history was inconsistent; 
many with a history of TB had no radiographic changes, and others with 
changes on chest X-ray suggestive of PPTB gave no compatible history. On 
the other hand, CT imaging confirmed changes compatible with PPTB in 
almost all subjects with a positive history but, in addition, suggested PPTB in 
a further significant number of subjects. For the purposes of the present 
study, these were labelled as probable PPTB (PrPTB). 
  The high proportion of subjects in the PrPTB group may at first seem 
to be improbable, and this requires further discussion. Were the CT 
abnormalities in these subjects correctly assigned as PPTB, or did they 
represent other pathology such as: previous pneumonia, post-infectious 
bronchiectasis, pneumoconiosis, or the ‘dirty lungs’ (respiratory bronchiolitis) 
associated with heavy tobacco usage? First, it should be noted that the 
prevalence of PPTB in the Ravensmead and Uitsig suburbs has been well 
Discussion 
 219 
studied and is known to be very high. For example, the self-reported history 
of PPTB in the Lung Health Study in 2002 was around 10% of the total adult 
population, and the incidence of PTB estimated at 776/100 000.29 
Furthermore, in this community, between 70% and 84% of people over the 
age of 15 years have a positive tuberculin test.120 Thus, it is plausible that the 
majority of subjects has more than merely latent TB, but in fact has had at 
least a primary infection, with some resultant CT evidence of a node or scar. 
If this is true, it is also worth noting that in the majority of subjects with 
PrPTB that the abnormalities seen on CT scan were fairly minor. Thus, the 
differences in structure and function between PPTB groups and usual COPD 
may not be entirely due to the lesions of pulmonary TB directly, but due to a 
more subtle relationship between PTB and the development of CAO. A 
possibility is that there is potentiation or synergy between the effects of 
cigarette smoke and PPTB in the development of CAO, owing to persistence 
of antigen or organisms in healed or latent TB infection. Such mechanisms 
might result in the development of COPD in parts of the lung indirectly 
affected by TB. The present study was not able to address this possibility, 
which would require demonstration that CAO associated with PPTB is more 
severe and extensive than that in patients with similar smoking profiles. This 
deserves further study, and may cast light upon the poorly understood issue 
in COPD research – that of varying susceptibility. It remains unclear why 
some smokers develop COPD, but that the majority does not; it is plausible 
that persistent lung or airway inflammation from latent or PPTB may serve as 
a progression factor in this process.  
The alternative explanation for the CT changes not associated with a 
history of PPTB is the lack of specificity of images obtained. This is likely in 
at least a proportion of the subjects in the PrPTB group, but there are several 
reasons for suggesting that this proportion may be small. First, the CT 
appearance of the alternative lung diseases mentioned above tend to be 
distinctive, and are unlikely to be confused with those of PPTB. Second, the 
radiologists who viewed the CT scans were experienced in the assessment 
of PTB (great experience in high-prevalence regions), and their concordance 
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for these 34 subjects with PrPTB was high (74%), as was their individual 
rating of confidence in their own assessments [see page 135 and Table 48].  
Another explanation for the absence of a history of PTB in subjects 
with CT changes compatible with PPTB include: failure to recall a disease 
event, particularly if it occurred in childhood, or thorough denial (deliberate or 
instinctive), potentially because of stigma or embarrassment. Furthermore, 
episodes of subclinical disease may have healed spontaneously or following 
the use of mildly tuberculostatic antibiotics (e.g. fluoroquinolones), or may 
have been considered at the time to be pneumonia or a different chest 
disease.  
In support of the accuracy of the PPTB classification system 
developed for the present research is the fact that, for most 
structure/function endpoints, the PrPTB group was intermediary to the NPTB 
and DPTB groups, which implies a gradation of disease severity.   
 
11.5. Assessment of the BOLD method: questionnaires 
 
To date, the BOLD method has been used to estimate and compare the 
prevalence of COPD in 31 sites on five continents, and studies in more 
countries are currently underway.209 The present study is the first to 
interrogate the accuracy and diagnostic performance of the BOLD method. It 
was assessed in several ways: first, a measure of the performance of the 
BOLD questionnaires was assessed by comparing responses to selected 
questions in 2010 with those obtained five years earlier. Second, the 
performance of handheld spirometry using the EasyOne ndd spirometer was 
evaluated by comparing results of two assessments with the same 
spirometers at visits approximately two weeks apart. Additionally, these 
spirometer results were compared with those obtained concurrently (i.e. the 
same visit), using office spirometry equipment with accepted accuracy. 
Finally, the accuracy of the BOLD method for diagnosing COPD was 
evaluated by individual assessment of patients diagnosed with COPD in 
2005.  
Discussion 
 221 
 The assessment of the BOLD questionnaire involved using questions, 
the responses to which should not have changed between the 2005 and 
2010 studies. The correlation between responses to the questions on 
medical conditions and smoking status obtained in 2005 and 2010 appeared 
to be good (kappa values ranged from 0.74-1.00). However, there was 
surprising variability in the reporting of the subjects’ own, as well as their 
fathers’ levels of education. The reasons for this are unclear, but might 
simply reflect poor knowledge or recall of this detail. The general levels of 
education in the study community were very low, and these questions may 
have been regarded as unimportant. 
The performance of questions related to PPTB was also assessed in 
the present study by comparison of results obtained using a more-
comprehensive set of questions. As discussed above [page 141], the 
conclusion was that the current BOLD questions performed adequately for 
confirming the presence of PPTB. 
 
11.6. Assessment of the BOLD method: spirometry 
  
The BOLD method prescribes a handheld spirometer (i.e. EasyOne 
ndd spirometer, Medical Techonologies, Andover, USA) to assess lung 
function because of its suitability for use in subjects’ homes, thus avoiding 
the need for attendance to study sites or clinics. Concerns could be raised 
about the performance of portable handheld spirometers, with possible 
sources of inaccuracy being: the performance of the equipment, the subject 
and the operator. In both the 2005 and 2010 study, experienced, fulltime 
pulmonary technologists with years of experience performed the spirometry, 
observed all guideline requirements for optimal performance of spirometry 
and recorded the reproducible values. A minority of potential subjects was 
unable to provide acceptable quality flow volume loops; therefore, their 
spirometry was not included in the analysis. In the 2010 survey, the same 
technologists, using the same spirometers that were used in 2005, performed 
the tests. However, large differences in the results for both FEV1 and FVC 
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were found between visits conducted a mean of 10.8 days apart, but no 
consistent pattern suggesting a systematic error was evident. For FEV1, 
differences of more than 150 mL in either direction were observed in 28.6% 
of subjects, and FVC differed by more than 150 mL in 66.1% of subjects. 
Using these values, the presence or absence of CAO changed between visits 
in 19.6% (11 of 56) of subjects. 
 As a further check of the EasyOne ndd performance, at Visit 2, 
spirometry was performed first with the EasyOne ndd and then, within 
minutes, with an office (Nspire, Ferraris, Columbia, USA) spirometer; this 
revealed a similar inconsistency of results. The FEV1 differed by more than 
150 mL between the spirometers in 22.5% of subjects (23 of 102), with 
handheld values differing by up to 250 mL below or 333 mL above 
corresponding office spirometer measurements, and the designation of CAO 
(presence or absence) changed in 16.7% of subjects (17 of 102). 
Thus, there was considerable variation in the reproducibility of 
handheld spirometer measurements, and large differences when compared 
to office spirometry; these differences appeared to be random (i.e. not 
systematic or unidirectional). Since the performance of the Nspire was not 
tested in a similar manner, comparison of the performance of the two 
spirometers was not possible. However, the results of these assessments 
support concerns about the accuracy of the assessment of CAO using the 
EasyOne nnd spirometer, and basing the diagnosis of COPD on a single 
measurement performed with this equipment. Possible solutions might be to 
ensure that the measurement is repeated at a second visit to the subject’s 
home, or simply to accept and allow for uncertainty in the estimates of COPD 
diagnosed using the BOLD criteria. While suitable for 
epidemiological/population-level research, the EasyOne ndd performance 
may not be acceptable for use in clinical practice for the diagnosis and 
management of individual patients.  
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11.7. Assessment of the BOLD method: misdiagnosis 
 
A second concern regarding the BOLD method is the assumption that all 
subjects with CAO have COPD. This assumption is based on the likelihood 
that COPD is the most prevalent cause of post-bronchodilator CAO (as 
opposed to reversible airflow obstruction seen in asthma) in adults aged 40 
years and older. However, there is no correction for potential 
misclassification, nor have there been studies that estimate the prevalence of 
misdiagnosis. It is well recognised in adult patients that asthma and other 
less-common diseases, like bronchiectasis, may also be associated with 
chronic fixed airflow obstruction. Therefore, although the risk of misdiagnosis 
is reduced by restricting surveys to persons aged 40 years and older, and, in 
the case of asthma, by measuring spirometry after bronchodilator, 
misdiagnosis is inevitable. The BOLD method does not provide a 
recommendation concerning the need to identify possible asthma by other 
means (e.g. trial of treatment), nor to estimate the magnitude of 
misdiagnosis. As a result, BOLD estimates of burden of COPD are likely to be 
falsely high, which when applied to large populations, may result in serious 
exaggerations of the extent of the problem. The present study provided a 
unique opportunity to assess the diagnostic accuracy of the BOLD method 
by retrospectively confirming the diagnosis of COPD, and by determining the 
prevalence of asthma. 
 Five years after the initial Cape Town BOLD 2005 study, it was found 
that 15.1% of subjects (16 of 106) no longer demonstrated CAO, when using 
the fixed-ratio definition (i.e. FEV1:FVC ratio <0.7). When the lower limit of 
normal (LLN) definition was employed, this increased to 25.5% (27 of 106), 
which confirmed the well-described tendency of the fixed ratio to over-
diagnose CAO in the elderly. Of the 11 subjects having CAO, as defined by 
fixed-ratio but not LLN definition, nine were over 65 years (82.0%), seven 
over 70 years (64.0%) and five over 75 years of age (46.0%). 
 The possibility that the improvement seen in some subjects in 2010 
was the result of treatment for COPD received between surveys is unlikely for 
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several reasons. First, although commencing COPD long-acting 
bronchodilators such as tiotropium and long-acting beta2-agonists improves 
airflow limitation, the ratio of FEV1:FVC improves in only a small proportion, 
as improvements in both FEV1 and FVC occur together in most. Second, 
improvements in CAO tend to last for only a few months or years, but by five 
years CAO should again be evident.68,69 Third, only a minority of subjects in 
this cohort had received long-acting bronchodilators (3.7%). Furthermore, a 
drug-withhold period was observed before Visit 2 and, in spite of this, there 
was no increase in the proportion of subjects with CAO at this visit.  
 After developing and applying different definitions for asthma and 
specialist review, the confidence limits for a diagnosis of asthma in the 
Follow-up cohort was estimated to be between 10.4%-17.9%. When only 
subjects with post-bronchodilator airflow obstruction at Visit 1 were included 
(n=90), the estimates of asthma prevalence were between 11.1%-18.8%, 
and that for subjects without obstruction (n=16) was between 6.3%-18.8%. It 
should be noted that, in the whole Follow-up cohort, the proportion of 
subjects with clinical asthma was similar (approximately 15.0%) in those with 
CAO to those without. Thus, the presence of asthma did not account for the 
over-diagnosis of CAO in BOLD 2005. Of those labelled as asthma, and 
having both CAO and a smoking history, some may be considered as 
asthma-COPD overlap syndrome (ACOS). However, even if this diagnosis is 
made, these subjects will require a treatment approach different to COPD 
without features of asthma.98 
This estimate of 15.0% (with confidence limits from 10.0%-18.0%) 
may prove useful as a correction to apply to results obtained in BOLD 
studies in other sites, recognising that the prevalence of asthma in adults 
might vary in different populations surveyed, and additionally, that asthma 
with CAO may be higher in populations where asthma is under-diagnosed 
and poorly treated, which will apply in some, but not all, BOLD sites.  
 Importantly, as the entire BOLD 2005 cohort was not studied, the 
analysis only considered potential over-diagnosis in the BOLD method, and 
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does not inform on those falsely designated as normal (i.e. no airflow 
obstruction) during that survey. 
 
11.8. Natural history of COPD 
 
Bearing in mind the above findings and limitations, follow-up of the BOLD 
cohort permitted an assessment of the natural history and outcome of 
patients diagnosed as COPD in 2005. Of the 196 eligible subjects diagnosed 
as COPD in 2005, almost a quarter (23.0%) died in the subsequent five 
years. More than half (58.0%) of these deaths occurred in subjects with only 
mild or moderate COPD in 2005 (i.e. GOLD stage 1/2 disease). The cause of 
death was cardiovascular in 22.0% and respiratory in 18.0%, but unknown in 
47.0%. On multivariate analysis, only older age and severe COPD (GOLD 
stage 4 disease) predicted mortality. Previous pulmonary TB was not 
identified as a risk factor for mortality. These results are consistent with 
known associations in COPD, namely: a high five-year mortality due not only 
to respiratory disease, but also to cancer and cardiovascular causes.210 
However, the small size of the present cohort and limited details of causes of 
death do not permit meaningful comparisons. 
 Significantly, particularly in the African context, it can be confirmed 
that none of the patients who were screened or enrolled tested positive for 
HIV (an exclusion criteria). This may be attributable to several factors: first, 
the cohort comprised of older subjects (>40 years in 2005), in which HIV is 
less common. Second, Ravensmead/Uitsig is a relatively stable community, 
which may be a barrier to the usual drivers of HIV transmission, namely 
multiple concurrent and sequential sexual partners. Third, a selection bias 
may have occurred, with subjects who were HIV positive in 2005 (HIV status 
was not assessed during that survey) more likely to have died. However, the 
analysis of causes of death from the death registry gave no indication of this.  
 COPD is considered to be a progressive disease, with lung function 
declining at rates higher than that associated with normal aging, even after 
smoking cessation. The 2010 study provided the opportunity to study 
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change in lung function (FEV1, FVC and FEV1:FVC ratio) over five years. The 
median decline in FEV1 in the whole 2005 cohort was 28.9 mL/yr, but this did 
not exceed the predicted age-related decline. Moreover, there was no 
difference in the rate of decline between the four GOLD stages of severity. 
Similarly, no difference was observed between those with and without a 
previous history of TB. However, these results should be viewed with 
circumspection, as the numbers in each group were small and heterogeneity 
was large.  
 The decline in FVC was similar to that of the FEV1: in the whole 
cohort, a median decline over five years was 75 mL (or 15 mL/yr), which, 
expressed as percentage of predicted, was not greater than the age-related 
decline. However, the decline in FVC was greater in subjects with GOLD 
stage 1 disease, both expressed in ml and as percentage of predicted, 
compared to GOLD stage 2 and 3 disease (–80 mL and –140 mL, 
respectively, p<0.01 versus stage 1). This finding is in keeping with other 
studies demonstrating more rapid lung function decline (both FEV1 and FVC) 
in earlier stages of COPD.64 
The analysis of changes in stage of GOLD severity revealed that the 
majority (55.0%) of subjects remained in the same stage, 20.0% (16 subjects) 
worsened and 26.0% (27 subjects) improved to a milder stage. Some, but 
not all, of the improvement was accounted for by those who were no longer 
obstructed at follow-up. Together, these findings suggest a rather more 
benign course of chronic airflow obstruction in this cohort, bearing in mind 
that this was a ‘survivor’ population and that many, possibly with more 
aggressive disease, may have died, as well as the small numbers studied. 
 
11.9. Strengths and limitations of this study 
 
The design of the present study has several strengths and unique features. 
First, the study population represented the whole cohort of subjects found to 
have CAO in a well-structured community-based survey and, therefore, 
reflects the spectrum and prevalence of CAO in that community, including 
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disease severity and risk factors. Second, its longitudinal nature, employing 
the same methods (questionnaires, lung function tests and apparatus) as in 
the initial survey ensured a level of accuracy and permitted analyses not 
possible in cross-sectional surveys. Third, to our knowledge this is one of the 
first follow-up studies of patients identified with CAO in BOLD studies. Thus 
it provides a comprehensive evaluation of both the BOLD methods and a 
detailed assessment of the subjects identified with CAO resulting in accurate 
diagnoses. In the analysis of risk factors for CAO, and particularly the role of 
PPTB, the relative homogeneity of the population with respect to 
environmental exposures, living conditions and socioeconomic status, 
removed some variables. Thus, although not of case-control design, 
multivariate analyses could be used to identify determinants of disease. 
Further, the fortuitous division of the cohort into three groups of interest: no 
PPTB, probable PPTB and definite PPTB, permitted meaningful analyses in 
spite of the relatively small numbers. 
 Several limitations of the study are acknowledged: first, the small size 
of the study cohort. Second, the limited response rate: only 107 of 196 
potential participants (54.6%) were included, but limited information was 
available on the 45 (23.0%) that had died. The deaths are assumed to have 
had a significant impact on the assessment of decline in lung function. 
However, as far as could be ascertained, with the exception of those that had 
died, the subjects studied were representative of those not included. A further 
weakness of the study is the method used to decide the presence of PPTB; 
this is fully discussed above. Additionally, the studies were conducted in 
persons not co-infected with HIV, and it is unclear whether PTB in HIV will be 
associated with the development of COPD. Finally, the significant 
methodological limitations of the measures of wall thickness and in the 
assessment of gas trapping (the corrected gas trapping score) may have 
influenced the results and conclusions concerning structure/function 
relationships in COPD and TOPD. 
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11.10. Application of research findings and recommendations 
 
The research presented has several important potential applications: 
1. The development of the BOLD method, which for the first time has 
enabled comparisons of the burden of COPD in different countries, 
has provided valuable information concerning this disease. These are 
described in more than 40 publications in the scientific literature. To 
date, criticism of the BOLD method has focused on the use of 
FEV1:FVC ratio <0.7 rather than the more scientifically correct ‘lower 
limit of normal’ definition to identify CAO. However, this study has 
identified additional and significant sources of error in the BOLD 
estimates. First, in the non-reproducibility of a single measurement of 
post-bronchodilator FEV1 and the confounding influence of asthma. It 
is suggested that estimates of COPD based on BOLD should assume 
over-diagnosis and adjust the estimates downward by approximately 
15.0%. This adjustment may be relevant to planners of health 
services, recognising that asthma treatments are highly effective and 
that the prognosis is better than in COPD. 
2. Tuberculosis-associated obstructive pulmonary disease (TOPD) 
should be recognised as a distinct phenotype of COPD. This 
recognition would have several potential benefits: 
a. It would increase the urgency of controlling TB and tobacco-
use as public health priorities. 
b. It would encourage recognition of this condition in other 
countries. Since TB remains common not only in Africa but also 
in India, China and other countries with large populations, 
TOPD is highly relevant and may prove to be the most common 
chronic lung disease in adults. It is likely to be responsible for 
considerable global morbidity and mortality.  
c. It would lead to trials of treatment for this condition. Preliminary 
data from the present research failed to confirm short-term 
benefit of either formoterol (bronchodilator) or oral 
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corticosteroids on lung function or symptoms. Other COPD 
treatments require formal evaluation for this indication. 
d. It would focus attention on the mechanisms of disease and the 
potential for developing treatments that target these 
mechanisms. Phenotyping patients with COPD is being 
proposed as a means of guiding selection of treatment and the 
development of novel treatments that target relevant 
mechanisms of disease. This may be done for TOPD. 
e. It would lead to further research on how to arrest disease 
progression, as the effect of PPTB may not be temporary and 
limited. The concept of persisting tuberculosis antigen or 
inflammation influencing the development of COPD in those 
who smoke and/or are exposed to other risk factors, such as 
environmental or workplace atmospheric pollution, warrants 
further study. 
f. Relevant to countries with high prevalence of HIV infection, 
research is required on the long-term effects on the lungs of 
combined infection with TB and HIV. Preliminary research has 
confirmed impaired gas transfer and, possibly, also the 
premature development of CAO in HIV. It is likely that PTB may 
be an aggravating factor in such populations. 
 
Despite intense research and public health efforts, the TB epidemic in South 
Africa continues unabated, and the lifetime risk of infection remains high. The 
finding that even unrecognised infection with Mycobacterial tuberculosis, 
with minimal evidence of residual abnormality on lung imaging, is a risk factor 
for physiological consequences (impaired lung function) raises the prospect 
of a heavy burden of chronic lung disease being attributable to TB infection. 
This is the likely explanation for the record levels of CAO observed in the 
Cape Town BOLD cohort. Although the burden of TOPD in other provinces of 
South Africa has yet to be established, the findings described in this study 
are sufficient to cause alarm and be translated into practice and policy. 
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Table 112: Comparison of the results of lung physiology at Visit 2 according to PPTB status, only in subjects in CAO. 
 
(n=86) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (22)  (64)    (22)  (38)  (26)    
               
Post BD FVC (L) - mean 2.86 0.864 3.05 1.073 0.464 t-test 2.86 0.864 3.12 1.062 2.95 1.102 0.619 ANOVA 
Post BD FVC (%) - mean 97.00 12.653 96.89 17.796 0.978 t-test 97.00 12.653 96.21 19.274 97.88 15.703 0.9255 ANOVA 
               
Post BD FEV1 (L) -mean 1.66 0.621 1.63 0.760 n/a n/a 1.66 0.621 1.63 0.804 1.63 0.707 n/a n/a 
Post BD FEV1 (L) - median 1.56 - 1.37 - 0.6242 Wilcoxon 1.56 - 1.40 - 1.31 - 0.85 Kwallis 
Post BD FEV1 (%) -mean 69.55 17.896 65.08 23.383 0.4165 t-test 69.55 17.896 62.71 25.170 68.54 20.477 0.4232 ANOVA 
               
Post BD FEV1:FVC - mean 0.58 0.112 0.53 0.128 n/a n/a 0.58 0.112 0.51 0.130 0.56 0.121 n/a n/a 
Post BD FEV1:FVC - median 0.59 - 0.58 - 0.135 Wilcoxon 0.59 - 0.54 - 0.60 - 0.1126 Kwallis 
               
Reversibility               
Litres - median 0.19 0.172 0.19 0.163 0.7103 Wilcoxon 0.19 0.172 0.15 0.150 0.20 0.183 0.7168 Kwallis 
% change 12.22 12.583 12.63 16.696 0.9055 Wilcoxon 12.22 12.583 11.85 18.374 14.97 14.237 0.8573 Kwallis 
Significant reversibility*               
Number of subjects (9) - (24) -   (9) - (12) - (12) -   
% 0.41 - 0.38 - 0.0805 Chi2 0.42 - 0.31 - 0.46 - 0.48 Chi2 
               
DLCO (mL/min/mmHg) 17.92 6.21 14.99 4.93 0.0274 t-test 17.92 6.21 14.91 4.82 15.11 5.18 0.088 ANOVA 
DLCO (%) 78.3 24.35 63.9 18.96 0.0053 t-test 78.3 24.35 61.7 15.49 67.0 23.10 0.0126 ANOVA 
*Significant reversibility = change in FEV1 of >200 mL & >12%        
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Table 113: Comparison of the results of lung physiology at Visit 3 according to PPTB status, only in subjects in CAO. 
 
(n=86) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (22)  (64)    (22)  (38)  (26)    
               
Post BD FVC (L) -mean 2.81 0.957 3.08 1.104 n/a n/a 2.81 0.957 3.15 1.075 2.97 1.158 n/a n/a 
Post BD FVC (L) -median 2.72 - 2.90 - 0.4198 Wilcoxon 2.72 - 3.09 - 2.76 - 0.4935 Kwallis 
Post BD FVC (%) - mean 93.95 17.214 97.19 18.227 0.4689 t-test 93.95 17.214 97.03 19.253 97.42 16.985 0.7676 ANOVA 
Post BD FVC (%) - median 96.00  97.00  n/a n/a 96.00  97.00 - 97.50 - n/a n/a 
               
Post BD FEV1 (L) -mean 1.63 0.637 1.63 0.746 n/a n/a 1.63 0.637 1.64 0.793 1.62 0.687 n/a n/a 
Post BD FEV1 (L) - median 1.47 - 1.34 - 0.6704 Wilcoxon 1.47 - 1.36 - 1.32  0.8704 Kwallis 
Post BD FEV1 (%) -mean 67.55 18.441 65.45 23.340 n/a n/a 67.55 18.441 63.45 25.446 68.38 19.986 n/a n/a 
Post BD FEV1 (%) -median 68.50  65.00  0.5861 Wilcoxon 68.50  60.50  68.00  0.4816 Kwallis 
               
Post BD FEV1:FVC - mean 57.72 11.273 53.36 12.870 n/a n/a 57.72 11.273 51.30 12.679 56.38 12.792 n/a n/a 
Post BD FEV1:FVC - median 58.84 - 56.81 - 0.2408 Wilcoxon 58.84 - 53.32 - 61.71 - 0.1338 Kwallis 
*Significant reversibility = change in FEV1 of >200 mL & >12% 
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Table 114: Comparison of the results of whole body plethysmography data at Visit 3 according to PPTB status, only in subjects with 
CAO. 
 
(n=83) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (21)  (62)    (21)  (37)  (25)    
               
TLC (L)- mean* 5.64 1.31 5.93 1.53 0.4426 t-test 5.64 1.31 6.04 1.36 5.76 1.77 n/a n/a 
TLC (L)- median 5.75 - 5.89 - n/a n/a 5.75# - 6.00# - 4.90# - 0.4384 Kwallis 
TLC (%)- mean# 105.81 14.02 106.61 18.73 n/a n/a 105.81 14.02 107.97 21.06 104.60 14.79 n/a n/a 
TLC (%)- median 103.00  103.00 - 0.9916 Wilcoxon 103.00  102.00 - 106.00 - 0.9962 Kwallis 
               
VC (L)- mean# 2.77 0.76 2.77 0.91 n/a n/a 2.77 0.76 2.78 0.89 2.75 0.95 n/a n/a 
VC (L)- median 2.60 - 2.68 - 0.8463 Wilcoxon 2.60 - 2.82 - 2.50 - 0.9465 Kwallis 
VC (%)- mean* 89.00 12.07 83.97 14.15 0.1469 t-test 89.00 12.07 82.16 13.92 86.64 14.34 0.1595 ANOVA 
VC (%)- median 91.00 - 85.00 - n/a n/a 91.00 - 84.00 - 88.00  n/a n/a 
               
IC (L)- mean* 2.42 0.60 2.07 0.56 0.0172 t-test 2.42 0.60 2.04 0.52 2.11 0.63 0.0542 ANOVA 
IC (L)- median 2.36 - 2.08 - n/a n/a 2.36 - 2.08 - 2.04 - n/a n/a 
IC (%)- mean# 116.95 21.04 96.42 26.59 n/a n/a 116.95 21.04 94.00 28.86 100.00 22.91 n/a n/a 
IC (%)- median 119.00 - 93.00 - 0.0002 Wilcoxon 119.00 - 92.00 - 97.00 - 0.0004 Kwallis 
               
FRC (L)- mean# 3.17 0.94 3.86 1.24 n/a n/a 3.17 0.94 4.00 1.15 3.65 1.36 n/a n/a 
FRC (L)- median 2.80 - 3.56 - 0.0206 Wilcoxon 2.80 - 3.77 - 3.01 - 0.0174 Kwallis 
FRC (%)- mean# 109.62 23.83 127.00 33.34 n/a n/a 109.62 23.83 130.97 35.39 121.12 29.76 n/a n/a 
FRC (%)- median 105.00 - 120.50 - 0.0260 Wilcoxon 105.00 - 122.00 - 114.00 - 0.0464 Kwallis 
               
ERV (L)- mean# 0.35 0.35 0.70 0.51 n/a n/a 0.35 0.35 0.73 0.51 0.64 0.52 n/a n/a 
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ERV (L)- median 0.21 - 0.59 - 0.0023 Wilcoxon 0.21 - 0.67  0.48 - 0.0069 Kwallis 
 
(n=83) 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (21)  (62)    (21)  (37)  (25)    
ERV (%)- mean# 38.29 28.97 70.82 42.68 n/a n/a 38.29 28.97 72.11 41.92 68.92 44.58 n/a n/a 
ERV (%)- median 26.00 - 66.50 - 0.0012 Wilcoxon 26.00 - 69.00  58.00 - 0.0047 Kwallis 
               
RV (L)- mean# 2.86 0.81 3.16 1.01 n/a n/a 2.86 0.81 3.27 1.00 3.01 1.01 n/a n/a 
RV (L)- median 2.60 - 2.94 - 0.2184 Wilcoxon 2.60 - 3.04 - 2.61 - 0.2047 Kwallis 
RV (%)- mean# 141.57 34.26 152.25 50.02 n/a n/a 141.57 34.26 157.89 55.98 143.88 39.22 n/a n/a 
RV (%)- median 135.00 - 137.00 - 0.5715 Wilcoxon 135.00 - 141.00 - 135.00 - 0.6812 Kwallis 
               
RV:TLC – mean* 50.81 6.98 53.44 8.82 0.2193 t-test 50.81 6.98 54.14 10.14 52.40 6.45 0.3446 ANOVA 
RV:TLC - median 52.00 - 54.00  n/a n/a 52.00 - 56.00  52.00 - n/a n/a 
               
 (n=20)  (n=62)    (n=20)  (n=37)  (n=25)    
TV – mean# 0.66 0.20 0.76 0.32 - - 0.66 0.20 0.70 0.21 0.84 0.42 - - 
TV- median 0.65 - 0.70  - - 0.65 - 0.69 - 0.79  - - 
* Parametric data 
# Non-parametric data  
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Appendix 8 - Results of Lung Imaging, only for Subjects with Chronic 
Airflow Obstruction 
 
Table 115: Bronchial wall area (Pi10) according to PPTB status, only subjects with 
CAO: All subjects, NPTB vs PPTB. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
(n) (85)  (21)  (64)    
Pi10         
Mean  2.50 0.580 2.51 0.606 2.50 0.576 0.9756 Wilcoxon 
Median 2.49  2.49  2.49    
 
Table 116: Bronchial wall area (Pi10) according to PPTB status, only subjects with 
CAO: three-group analysis. 
 
(n=85) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (21)  (38)  (26)    
Pi10         
Mean  2.51 0.606 2.46 0.642 2.56 0.470 0.351 Kwallis 
Median 2.49  2.36  2.61    
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Table 117: Lung and lobar density (average Hounsfield Units - HU) at total lung capacity, according to PPTB status, only subjects 
with CAO. 
 
 
 
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
(test) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
(test) 
(n) (77)  (19)  (58)   (19)  (34)  (24)   
Total Lung# 	   	   	   	   	   	   	          
mean HU -­‐849.88	   32.03	   -­‐844.14	   31.94	   -­‐851.76	   32.11	   0.3629	   -­‐844.14	   31.94	   -­‐853.66	   31.75	   -­‐849.07	   33.1	   0.4813	  
median HU -­‐852.54	   	   -­‐852.41	   	   -­‐852.64	   	   Wilcoxon	   -­‐852.41	   	   -­‐856.52	   	   -­‐848.76	   	   Kwallis	  
Left Lung # 	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐849.88	   35.16	   -­‐844.5	   33.3	   -­‐851.64	   35.85	   0.4183	   -­‐844.5	   33.3	   -­‐854.01	   35.99	   -­‐848.28	   36.14	   0.3908	  
median HU -­‐859.52	   	   -­‐859.68	   	   -­‐856.89	   	   Wilcoxon	   -­‐859.68	   	   -­‐861.8	   	   -­‐847.14	   	   Kwallis	  
LUL# 	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐854.35	   35.64	   -­‐849.83	   33.42	   -­‐855.83	   36.5	   0.4857	   -­‐849.83	   33.42	   -­‐856.58	   38.76	   -­‐854.76	   33.83	   0.6818	  
median HU -­‐859.97	   	   -­‐850.12	   	   -­‐860.27	   	   Wilcoxon	   -­‐850.12	   	   -­‐859.11	   	   -­‐860.5	   	   Kwallis	  
LLL#  	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐842.69	   37.78	   -­‐835.59	   36.86	   -­‐845.02	   38.11	   0.2718	   -­‐835.59	   36.86	   -­‐848.42	   36.99	   -­‐840.2	   39.93	   0.2298	  
median HU -­‐849.66	   	   -­‐839.46	   	   -­‐850.04	   	   Wilcoxon	   -­‐839.46	   	   -­‐853.11	   	   -­‐845.95	   	   Kwallis	  
Right Lung*  	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐849.67	   30.76	   -­‐843.68	   31.02	   -­‐851.63	   30.68	   0.3692	   -­‐843.68#	   31.02	   -­‐853.18#	   30.75	   -­‐849.44#	   31.12	   0.5733	  
median HU -­‐854.27	   	   -­‐845.29	   	   -­‐854.43	   	   Wilcoxon	   -­‐845.29	   	   -­‐854.94	   	   -­‐844.85	   	   Kwallis	  
RUL*  	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐850.54	   30.22	   -­‐850.9	   34.02	   -­‐850.42	   29.19	   0.952	   -­‐850.9	   34.02	   -­‐851.72	   28.81	   -­‐848.57	   30.25	   0.9262	  
median HU -­‐853.56	   	   -­‐858.68	   	   -­‐853.29	   	   t-­‐test	   -­‐858.68	   	   -­‐850.33	   	   -­‐854.1	   	   ANOVA	  
RML * 	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All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
(test) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
(test) 
mean HU -­‐860.68	   30.64	   -­‐852.84	   28.4	   -­‐863.25	   31.14	   0.2007	   -­‐852.84	   28.4	   -­‐865.7	   31.4	   -­‐859.79	   31.1	   0.3417	  
median HU -­‐857.97	   	   -­‐850.08	   	   -­‐861.75	   	   t-­‐test	   -­‐850.08	   	   -­‐866.37	   	   -­‐857.65	   	   ANOVA	  
RLL # 	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐841.44	   41.26	   -­‐829.82	   34.54	   -­‐845.24	   42.82	   0.0527	   -­‐829.82	   34.54	   -­‐845.52	   46.44	   -­‐844.85	   38.07	   0.1318	  
median HU -­‐843.11	   	   -­‐829.47	   	   -­‐850.44	   	   Wilcoxon	   -­‐829.47	   	   -­‐852.94	   	   -­‐841.88	   	   Kwallis	  
# - non-parametric variables 
* -parametric variables 
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Table 118: Lung and lobar density (average Hounsfield Units - HU) at residual volume, according to PPTB status, only subjects with 
CAO. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
(test) 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
(test) 
(n) (77)  (19)  (58)   (19)  (34)  (24)   
Total Lung* 	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean HU -­‐747.4	   68.53	   -­‐716.33	   83.9	   -­‐757.58	   60.1	   0.0217	  
t-­‐test	  
-­‐716.33	   83.9	   -­‐763.57	   58.05	   -­‐749.11	   63.15	   0.0526	  
ANOVA	  
Left Lung * 	   	   (n=19)	   	   (n=58)	   	   	   (n=19)	   	   (n=34)	   	   (n=24)	   	   	  
mean HU -­‐742.64	   72.3	   -­‐713.69	   82.54	   -­‐752.12	   66.69	   0.0436	  
t-­‐test	  
-­‐713.69	   82.54	   -­‐757.8	   66.28	   -­‐744.09	   67.84	   0.1019	  
ANOVA	  
LUL# 	   	   (n=19)	   	   (n=58)	   	   	   (n=19)	   	   (n=34)	   	   (n=24)	   	   	  
mean HU -­‐759.13	   72.79	   -­‐730.09	   86.43	   -­‐768.72	   65.8	   0.0763	  
Wilcoxon	  
-­‐730.09	   86.43	   -­‐774.53	   64.45	   -­‐760.5	   68.19	   0.1676	  
Kwallis	  
median HU -­‐773.91	   	   -­‐766.32	   	   -­‐781.84	   	   	   -­‐766.32	   	   -­‐787.07	   	   -­‐772.52	   	   	  
LLL#  	   	   (n=18)	   	   (n=58)	   	   	   (n=18)	   	   (n=34)	   	   (n=24)	   	   	  
mean HU -­‐723.33	   71.8	   -­‐703.62	   68.7	   -­‐729.44	   72.22	   0.2172	  
WIlcoxon	  
-­‐703.62	   68.7	   -­‐735.18	   74.08	   -­‐721.32	   70.24	   0.3206	  
ANOVA	  
median HU -­‐712.67	   	   -­‐694.77	   	   -­‐713.02	   	   [0.1844]	  
[t-­‐test]	  
-­‐694.77	   	   -­‐727.97	   	   -­‐709.46	   	   	  
Right Lung*  (n=75)	   	   (n=18)	   	   (n=57)	   	   	   (n=18)	   	   (=34)	   	   (n=23)	   	   	  
mean HU -­‐755.67	   59.56	   -­‐729.04	   68.5	   -­‐764.08	   54.44	   0.0286	  
t-­‐test	  
-­‐729.04	   68.5	   -­‐768.26	   54.16	   -­‐757.9	   55.46	   0.0746	  
ANOVA	  
RUL*  	   	   (n=18)	   	   (n=57)	   	   	   (n=18)	   	   (=34)	   	   (n=23)	   	   	  
mean HU -­‐762.8	   61.28	   -­‐746.19	   70.96	   -­‐768.04	   57.59	   0.1892	  
t-­‐test	  
-­‐746.19	   70.96	   -­‐775.34	   56.66	   -­‐757.26	   58.51	   0.2332	  
ANOVA	  
RML * 	   	   (n=18)	   	   (n=57)	   	   	   (n=18)	   	   (=34)	   	   (n=23)	   	   	  
mean HU -­‐791.17	   55.96	   -­‐766.35	   68.91	   -­‐799.01	   49.35	   0.0299	  
t-­‐test	  
-­‐766.35	   68.91	   -­‐800.83	   52.1	   -­‐796.32	   45.99	   0.0918	  
ANOVA	  
RLL * 	   	   (n=18)	   	   (n=57)	   	   	   (n=18)	   	   (=34)	   	   (n=23)	   	   	  
mean HU -­‐725.46	   77.02	   -­‐685.49	   76.35	   -­‐738.09	   73.44	   0.0106	  
t-­‐test	  
-­‐685.49	   76.35	   -­‐740.03	   76.61	   -­‐735.22	   70.09	   0.0379	  
ANOVA	  
# - non-parametric variables 
* -parametric variables 
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Table 119: Comparison of emphysema scores (using -950HU cut-point) according to PPTB status, only subjects with CAO 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (77)  (19)  (58)    (19)  (34)  (24)    
Total*                 
mean 27.09 8.68 25.72 6.6 27.54 9.26 0.4308 t-test 25.72 6.6 28.91 7.95 25.6 10.74 0.2652 ANOVA 
Left Lung*                 
mean 27.06 9.01 25.98 6.83 27.41 9.64 0.5532 t-test 25.98 6.83 28.76 8.18 25.5 11.3 0.3374 ANOVA 
LUL*                 
mean 28.66 9.44 27.14 7.14 29.16 10.08 0.4232 t-test 27.14# 7.14 30.78# 9.03 26.85# 11.19 0.1356 Kwallis 
median 28.82  26.52  29.45    26.52  30.11  24.77    
LLL#                 
mean 24.78 9.81 23.7 8.61 25.13 10.22 0.5468 WilcoxonRS 23.7 8.61 26.19 8.81 23.64 11.99 0.2326 Kwallis 
median 22.95  22.44  23.27    22.44  26.02  20.31    
Right Lung*                  
mean 27.15 8.85 25.45 6.53 27.71 9.47 0.3384 t-test 25.45 6.53 29.17 8.64 25.63 10.35 0.1334 Kwallis 
 26.35  26.35  26.37    26.35  29.87  22.83    
RUL*                 
mean 28.36 9.16 27.33 7.53 28.7 9.66 0.5768 t-test 27.33 7.53 30.41 9.48 26.27 9.59 0.2049 ANOVA 
RML*                  
mean 28.26 9.72 26.11 7.55 28.97 10.3 0.2679 t-test 26.11 7.55 30.38 10.24 26.97 10.26 0.229 ANOVA 
RLL#                  
mean 25.35 10.55 22.3 7.4 26.35 11.27 0.1161 Wilcoxon 22.3 7.4 27.66 10.35 24.51 12.45 0.064 Kwallis 
median 24.14  22.26  25.5    22.26  27.29  21.21    
(values indicate the % of lung parenychyma below -950HU) 
# - non-parametric variables             * -parametric variables 
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Table 120: Comparison of gas trapping scores (using -860HU cut-point) according to PPTB status, only subjects with CAO. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (77)  (19)  (58)    (28)  (35)  (31)    
Total*         (n=19)  (n=34)  (n=24)    
mean 35.55 15.27 30.07 13.43 37.35 15.51 0.0709 t-test 30.07 13.43 39.33 15.01 34.55 16.08 0.0974 ANOVA 
Left Lung# (n=77)  (n=19)  (n=58)    (n=19)  (n=34)  (n=24)    
mean 34.21 16.3 29 13.57 35.92 16.85 0.1188 Wilcoxon 29 13.57 37.82 16.87 33.23 16.82 0.1911 Kwallis 
median 30.67  25  32.57    25  36.52  30.69    
LUL* (n=77)  (n=19)  (n=58)    (n=19)  (n=34)  (n=24)    
mean 37.77 16.76 31.59 13.5 39.79 17.32 0.0636 t-test 31.59 13.5 42.07 17.53 36.57 16.85 0.0827 ANOVA 
LLL# (n=76)  (n=18)  (n=58)    (n=18)  (n=34)  (n=24)    
mean 29.18 17.56 25.4 15.36 30.35 18.15 0.3992 Wilcoxon 25.4 15.36 31.89 18.58 28.18 17.68 0.5598 Kwallis 
median 22.5  22.64  22.5    22.64  25.84  22.01    
Right Lung*  (n=75)  (n=18)  (n=57)    (n=18)  (n=34)  (n=23)    
mean 37.11 14.94 30.76 13.91 39.12 14.8 0.0377 t-test 30.76 13.91 40.74 14.76 36.72 14.81 0.0697 ANOVA 
RUL# (n=75)  (n=18)  (n=57)    (n=18)  (n=34)  (n=23)    
mean 39.16 15.8 33.82 14.65 40.85 15.89 0.1041 Wilcoxon 33.82* 14.65 43.23* 16.76 37.34* 14.15 0.0984 ANOVA 
 38.25  30.75  39.44    30.75  44.37  38.25    
RML*  (n=75)  (n=18)  (n=57)    (n=18)  (n=34)  (n=23)    
mean 44.34 16.22 37.77 16.84 46.42 15.6 0.0478 t-test 37.77 16.84 47.21 16.46 45.25 14.51 0.129 ANOVA 
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All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
 41.72  34.41  46.5    34.41  49.05  43.53    
RLL#  (n=75)  (n=18)  (n=57)    (n=18)  (n=34)  (n=23)    
mean 30.95 17.57 22.62 14.48 33.59 17.75 0.0079 Wilcoxon 22.62 14.48 34.8 17.81 31.78 17.91 0.0212 Kwallis 
median 25.74  19.67  28.39    19.67  29.89  28.25    
(values indicate the % of lung parenychyma below 860HU) 
# - non-parametric variables 
* -parametric variables 
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Table 121: Comparison of corrected gas trapping scores§ according to PPTB status, only subjects with CAO. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-
value 
 
test 
(n) (77)  (19)  (58)    (19)  (34)  (24)    
Total* 	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
mean 8.46	   10.93	   4.35	   9.14	   9.81	   11.21	   0.0583	   t-­‐test	   4.35	   9.14	   10.42	   11.85	   8.95	   10.4	   0.1479	   ANOVA	  
median 6.14	   	   4.08	   	   8.52	   	   	   	   4.08	   	   10.19	   	   6.51	   	   (0.1197	   Kwallis)	  
Left Lung*  (n=77)	   	   (n=19)	   	   (n=58)	   	   	   	   (n=19)	   	   (n=34)	   	   (n=24)	   	   	  	   	  	  
mean 7.16	   11.67	   3.01	   9.87	   8.51	   11.97	   0.0746	   t-­‐test	   3.01	   9.87	   9.06	   13.23	   7.73	   10.15	   0.188	   ANOVA	  
 3.9	   	   2.36	   	   7	   	   	   	   2.36	   	   9.2	   	   4.33	   	   (0.1672	   Kwallis)	  
LUL* (n=77)	   	   (n=19)	   	   (n=58)	   	   	   	   (n=19)	   	   (n=34)	   	   (n=24)	   	   	  	   	  	  
mean 9.11	   12.34	   4.45	   10.18	   10.64	   12.67	   0.0572	   t-­‐test	   4.45	   10.18	   11.29	   13.86	   9.71	   11	   0.1475	   ANOVA	  
median 7.87	   	   1.45	   	   9.16	   	   	   	   1.45	   	   10.17	   	   7.5	   	   (0.1216	   Kwallis)	  
LLL* (n=76)	   	   (n=18)	   	   (n=58)	   	   	   	   (n=18)	   	   (n=34)	   	   (n=24)	   	   	  	   	  	  
mean 4.29	   12.3	   1.3	   9.73	   5.22	   12.92	   0.2399	   t-­‐test	   1.3	   9.73	   5.7	   14.56	   4.54	   10.42	   0.4733	   ANOVA	  
median 2.62	   	   -­‐0.13	   	   3.55	   	   	   	   -­‐0.13	   	   6.25	   	   3.21	   	   (0.5387	   Kwallis)	  
Right Lung*  (n=75)	   	   (n=18)	   	   (n=57)	   	   	   	   (n=18)	   	   (n=34)	   	   (n=23)	   	   	  	   	  	  
Mean 9.65	   10.8	   4.97	   9.5	   11.12	   10.84	   0.0343	   t-­‐test	   4.97	   9.5	   11.57	   11.08	   10.46	   10.68	   0.1002	   ANOVA	  
 8.9	   	   3.85	   	   10.23	   	   	   	   3.85	   	   11.91	   	   9.83	   	   (0.0755	   Kwallis)	  
RUL*  (n=75)	   	   (n=18)	   	   (n=57)	   	   	   	   (n=18)	   	   (n=34)	   	   (n=23)	   	   	  	   	  	  
Mean 10.52	   11.47	   6.15	   10.02	   11.9	   11.64	   0.0633	   t-­‐test	   6.15	   10.02	   12.82	   12	   10.54	   11.19	   0.1367	   ANOVA	  
 9.74	   	   6.03	   	   12.98	   	   	   	   6.03	   	   15.25	   	   11.14	   	   (0.1156	   Kwallis)	  
RML*  (n=75)	   	   (n=18)	   	   (n=57)	   	   	   	   (n=18)	   	   (n=34)	   	   (n=23)	   	   	  	   	  	  
mean 15.67	   12.1	   11.26	   11.99	   17.06	   11.9	   0.0759	   t-­‐test	   11.26	   11.99	   16.83	   12.66	   17.41	   10.94	   0.2058	   ANOVA	  
 16.26	   	   11.26	   	   17.1	   	   	   	   11.26	   	   17.39	   	   17.1	   	   (0.1651	   Kwallis)	  
RLL#  (n=75)	   	   (n=18)	   	   (n=57)	   	   	   	   (n=18)	   	   (n=34)	   	   (n=23)	   	   	  	   	  	  
mean 5.27	   11.94	   0.03	   9.69	   6.93	   12.17	   0.0317	   t-­‐test	   0.03	   9.69	   7.14	   12.86	   6.61	   11.36	   0.0552	   Kwallis	  
median 2.41	   	   -­‐1.54	   	   3.94	   	   	   	   -­‐1.54	   	   5.33	   	   3.94	   	   	  	   	  	  
(values indicate the adjusted % of lung parenchyma below threshold) 
§- Corrected Gas Trapping score = (860 HU score at RV – 950HU score at TLC)  
# - non-parametric variables 
* -parametric variables 
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Table 122: Comparison of fibrosis scores (using -200HU cut-point) according to PPTB status, only subjects with CAO. 
  
All 
 
sd 
 
NPTB 
 
sd 
 
PPTB 
 
sd 
 
p-value 
 
test 
 
NPTB 
 
sd 
 
DPTB 
 
sd 
 
PrPTB 
 
sd 
 
p-value 
 
test 
(n) (77)  (19)  (58)    (19)  (34)  (24)    
Total#                      
mean 2.23 0.57 2.03 0.41 2.29 0.61 0.1107 Wilcoxon 2.03 0.41 2.43 0.64 2.1 0.502 0.0312 Kwallis 
median 2.15  2  2.18      2  2.28  2.13       
Left Lung#                       
mean 2.16 0.62 2 0.45 2.21 0.67 0.277 Wilcoxon 2 0.45 2.31 0.68 2.07 0.63 0.1697 Kwallis 
median 2.06  1.91  2.11      1.91  2.14  2.11       
LUL#                      
mean 2.1 0.76 1.86 0.38 2.18 0.84 0.1978 Wilcoxon 1.86 0.38 2.41 1 1.85 0.375 0.0393 Kwallis 
median 1.9  1.84  1.99      1.84  2.21  1.88       
LLL#                      
mean 2.27 0.76 2.2 0.6 2.3 0.81 0.9717 Wilcoxon 2.2 0.6 2.3 0.73 2.29 0.93 0.9195 Kwallis 
median 2.16  2.16  2.16      2.16  2.16  2.15       
Right Lung#                       
mean 2.3 0.65 2.06 0.39 2.38 0.70 0.1161 Wilcoxon 2.06 0.39 2.56 0.7 2.13 0.625 0.0066 Kwallis 
median 2.17  2.02  2.18      2.02  2.34  2.03       
RUL#                      
mean 2.47 1.26 1.85 0.41 2.67 1.38 0.0033 Wilcoxon 1.85 0.41 2.89 1.2 2.36 1.574 0.0002 Kwallis 
median 2.1  1.8  2.2      1.8  2.45  1.93       
RML#                      
mean 1.87 0.74 1.8 0.54 1.89 0.79 0.9623 Wilcoxon 1.8 0.54 1.98 0.94 1.77 0.517 0.6817 Kwallis 
median 1.85  1.87  1.83      1.87  1.87  1.65       
RLL#                      
mean 2.46 0.87 2.4 0.53 2.48 0.96 0.8408 Wilcoxon 2.4 0.53 2.69 1.14 2.18 0.536 0.0819 Kwallis 
median 2.29  2.32  2.28      2.32  2.31  2.03       
values indicate the % of lung parenychyma above -200HU 
# - non-parametric variables 
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Table 123: Comparison of average HU at RV between NPTB and DPTB groups*, 
only in subject with CAO. 
(n=53)	   p-­‐value	   test	  
Total	  Mean	  HU	  	  	   0.0194	   t-­‐test	  
Left	  Lung	  Mean	  HU	  	   0.0384	   t-­‐test	  
LUL	  Mean	  HU	   0.0585	   Wilcoxon	  
LLL	  Mean	  HU	  	   0.1405	   t-­‐test	  
Right	  Lung	  Mean	  HU	  	   0.0279	   t-­‐test	  
RUL	  Mean	  HU	  	   0.11255	   t-­‐test	  
RML	  Mean	  HU)	   0.048	   t-­‐test	  
RLL	  Mean	  HU	   0.018	   t-­‐test	  
*(i.e. PrPTB group excluded) 
See	  above	  tables	  for	  values	  
 
Table 124: Comparison of emphysema score between NPTB and DPTB*, only in 
subjects with CAO. 
	  (n=53)	   p-­‐value	   test	  
Total	   0.1436	   t-­‐test	  
Left	  Lung	  	   0.2163	   t-­‐test	  
LUL	   0.0915	   Wilcoxon	  
LLL	  	   0.214	   Wilcoxon	  
Right	  
Lung	  	  
0.1091	   t-­‐test	  
RUL	  	   0.2305	   t-­‐test	  
RML	  	   0.1178	   t-­‐test	  
RLL	  	   0.0215	   Wilcoxon	  
*(i.e. PrPTB group excluded) 
See	  above	  tables	  for	  values	  
 
Table 125: Comparison of gas trapping scores (at -860HU cut-point) between 
NPTB and DPTB groups, only in subjects with CAO. 
(n=53)	   p-­‐value	   test	  
Total	   0.0299	   t-­‐test	  
Left	  Lung	  	   0.072	   WilcoxonRS	  
LUL	   0.0284	   t-­‐test	  
LLL	  	   0.308	   WilcoxonRS	  
Right	  Lung	  	   0.02211	   t-­‐test	  
RUL	  	   0.0501	   t-­‐test	  
RML	  	   0.0564	   t-­‐test	  
RLL	  	   0.0071	   WilcoxonRS	  
*(i.e. PrPTB group excluded) 
See	  above	  tables	  for	  values	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Table 126: Comparison of corrected gas trapping scores between NPTB and DPTB 
groups, only in subjects with CAO. 
(n=53) p-value test 
Total 0.059 t-test 
Left Lung  0.0883 t-test 
LUL 0.0653 t-test 
LLL  0.2555 t-test 
Right Lung  0.0371 t-test 
RUL  0.0495 t-test 
RML  0.1308 t-test 
RLL  0.0452 t-test 
*(i.e. PrPTB group excluded) 
See	  above	  tables	  for	  values 	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Appendix 9: Abstracts presented at conferences  
 
The following four abstracts were presented in the form of posters. Abstracts 1 
and 2 were presented at the American Thoracic Society Conference May 2014 
(San Diego); while abstracts 3 and 4 were presented at the European Respiratory 
Society Conference September 2014 (Munich).  
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1. Abstract 1 
 
Assessment of previous tuberculosis status in adults using questionnaires, chest X-rays 
and CT scans 
 
Brian Allwood1, Jonathan Goldin2, Qonita Said-Hartley1, Richard van Zyl-Smit1, Greg Calligaro1, 
Aliasgar Esmail1, Nulda Beyers3, Eric D Bateman1. 
1Division of Pulmonology, Department of Medicine, University of Cape Town & UCT Lung Institute,  
2 David Geffen School of Medicine, University of California, Los Angeles 
3 Desmond Tutu Centre for TB Research, Department of Paediatrics and Child Health, Stellenbosch 
University 
 
 
Introduction:   
Determining with certainty whether an individual has previously had pulmonary TB (PPTB) is 
important for clinicians and in research. A record of bacteriologically-confirmed PTB is often not 
available and PPTB status is based on the patient history and/or chest X-ray. We compared 
history, chest X-rays and CT scans to develop a method to establish with greatest confidence 
the absence of PPTB. 
 
Subjects and Methods:     
The study population comprised adults aged 40yrs and older diagnosed with obstructive lung 
disease in a large community-based prevalence survey in Cape Town, South Africa, performed 
using the BOLD (Burden of Obstructive Lung Disease) methodology. PPTB status was assessed 
with two administered questionnaires, standard chest X-rays and high resolution CT scans of the 
chest reported by experienced readers. 
 
Results: 
One hundred and four subjects completed the assessments. Agreement between the two 
questionnaires was excellent (kappa value 0.96), an episode of PPTB being reported in 41 of 107 
(38.3%) of subjects using the BOLD questionnaire, and in 39 of 104 (36.4%) with the PTbQ 
(Previous TB Questionnaire).  Chest X-ray reports identified evidence of PPTB in 45 of 104 of 
subjects (43.3%) and between-reader agreement was good (Kappa value 0.73). There was 
moderate concordance  between findings of questionnaires and chest X-rays (80.8%; kappa 
value 0.60). Changes compatible with PPTB were identified on chest CT scans in 68.3% of 
subjects (71 of 104) and between-reader agreement was moderate (Kappa value 0.43). 
 Using the combination of PTbQ and CT scan assessment as a composite definition, 
questionnaires alone had a sensitivity of 53.4% for PPTB and a 32.7% false negative rate. Expert 
chest X-ray read alone had a sensitivity of 57.5% and a specificity of 90.3% for PPTB. 
 
Interpretation: 
Both clinical history and chest X-ray markedly underestimate the prevalence of PPTB in patients 
with COPD. The combination of a structured questionnaire and a CT scan is more reliable for 
situations in which PPTB needs to be ruled out with relatively greater confidence. 
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2. Abstract 2 
 
Mechanism of Airflow Obstruction in Tuberculosis-associated Obstructive Pulmonary 
Disease (TOPD) 
 
Brian Allwood1, Rencia Gillespie1, Maya Galperin –Aizenberg2, Mary Bateman1, Helena Olckers1, 
Luis Taborda-Barata3, Greg Calligaro1, Qonita Said-Hartley1, Richard van Zyl-Smit1, Christopher 
B Cooper4, Eva van Rikxoort5, Jonathan Goldin4, Nulda Beyers6, Eric D Bateman1  
1Division of Pulmonology, Department of Medicine, University of Cape Town & UCT Lung Institute,  
2 University of Pennsylvania 
3 CICS – Health Sciences Research Centre, University of Beira Interior, Portugal 
4 David Geffen School of Medicine, University of California, Los Angeles 
5 Radboud University Medical Center, Nijmegen 
6 Desmond Tutu Centre for TB Research, Department of Paediatrics and Child Health, Stellenbosch 
University 
 
 
INTRODUCTION 
Epidemiological studies in populations with a high burden of pulmonary tuberculosis (PTB) 
suggest an association between PTB and the development of chronic airflow obstruction (AFO). 
The mechanisms responsible for AFO likely include airway narrowing (from bronchiolitis, 
bronchiectasis or persistent low-grade inflammation associated with healed PTB) and reduced 
lung elastic recoil from coexistent emphysema. These possibilities give rise to different opinions 
on whether Tuberculosis-associated Obstructive Pulmonary Disease (TOPD) should be viewed 
as a separate phenotype within the broad definition of Chronic Obstructive Pulmonary Disease 
(COPD). We performed dynamic quantitative CT lung imaging and measured lung physiology in 
patients with healed PTB and AFO to examine relationships between structural abnormalities and 
physiological function. 
 
METHODS 
The study population comprised subjects with chronic AFO identified during a population-based 
COPD prevalence survey performed in two low-middle-income suburbs of Cape Town, South 
Africa in 2005 using Burden Obstructive Lung Disease (BOLD) methodology. Beginning 2010, 
attempts were made to trace all subjects and invite them to participate in this follow-up study. 
Detailed questionnaires, lung physiology (including spirometry, plethysmography and CO 
diffusion capacity) as well as standardized low-dose quantitative chest CT scans were performed 
to assess bronchial anatomy and the presence of emphysema (HU<-950), gas trapping (HU<-
860) and fibrosis (HU>-200). 
 
RESULTS   One hundred and seven of 196 eligible subjects (54.6%) diagnosed with AFO in the 
2006 survey were enrolled. Lung physiology was assessed in 103 and CT scans suitable for 
quantitative analysis in 94 subjects. AFO (defined as FEV1/FVC <0.70) was confirmed in only 86 
subjects (83.5%) Based on history and CT scans, subjects were categorized as “No previous TB 
” (NPTB; n=31, 30.1%), “Probable previous TB” (PPTB; n=33, 32.0%) or “Definite Previous TB” 
(DPTB; n=39, 37.8%).  Subjects with DPTB had 16.3% lower DLCO (95 CI: -26.3 to -6.3%; 
P=0.002) and 22.2% lower IC (95% CI: -33.9 to -10.5; P<0.001) than NPTB subjects. Multivariate 
analysis confirmed that DPTB subjects had 6.5% higher gas-trapping score (95% CI: 1.34 to 
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11.60; P=0.014), and 0.33% higher fibrosis score (95% CI: 0.09 to 0.57; P=0.007), and 3.5% 
higher emphysema scores (95% CI: 0.21 – 6.82; P=0.038) than subjects with NPTB.  
 
CONCLUSION 
This structure-function evaluation of persons with TOPD, ie: chronic AFO and evidence of 
previous (healed) PTB confirms that patients with the latter risk factor should be considered a 
distinct clinical phenotype of COPD, characterized by lower DLCO, but more gas trapping 
confirmed by both lung physiology and CT scans. 
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3. Abstract 3 
 
Five-year lung function follow-up of subjects diagnosed with COPD in the South African 
Burden of Obstructive Lung Disease (BOLD) Survey 
 
Brian Allwood1 Rencia Gillespie1, Mary Bateman1 Helena Olckers1, Luis Taborda-Barata2, Greg 
Calligaro1, Richard van Zyl-Smit1, Nulda Beyers3, Eric D Bateman1 
1Division of Pulmonology, Department of Medicine, University of Cape Town & UCT 
Lung Institute, 
2CICS – Health Sciences Research Centre, University of Beira Interior, Portugal 
3Desmond Tutu Centre for TB Research, 
 
 
BACKGROUND: 
A community-based prevalence survey performed in Cape Town in 2005, using the Burden of 
Obstructive Lung Disease (BOLD) methodology estimated the prevalence of COPD to be 24% 
among adults aged 40 years and older. There is limited data on the natural history and 
progression of COPD in an African cohort.  
 
AIMS: 
To perform five-year follow-up of all subjects identified as having COPD in the previous BOLD 
study.  
 
METHODS: 
We traced all subjects previously identified COPD. Participants were invited to participate, and 
spirometry was performed using the same handheld spirometers in the BOLD study 
 
RESULTS: 
Of the 196 eligible subjects, 45 (23%) had died, 11 (6%) had moved away, 33 (17%) declined 
participation or had medical exclusions factors (e.g. dementia) and 1 was unable to perform 
spirometry. Of the 106 (54%) subjects included, the median age was 63y and 46% were men (49 
subjects). 
The cause of death was unknown in 21 subjects (47%), due to respiratory disease in 8 
(18%), cardiovascular disease in 10 (22%), and miscellaneous causes in 6 (13%). On multivariate 
analysis, only age and GOLD stage 4 COPD were significantly associated with death. 
Post-bronchodilator spirometry showed 16 of 106 (15%) had no airflow obstruction 
(FEV1:FVC ratio ≥ 0.7). The remaining 90 subjects (85%) had a median decline in FEV1 of 28.9ml 
per year (SD 59.7ml/yr), with no difference in decline between GOLD stages. The median decline 
in FVC was -75ml, and was significantly greater in GOLD stage 1 (-350ml) compared with GOLD 
stages 2 or 3 (-80ml & +140ml respectively; p<0.01).  
Of the subjects with current obstruction, 58 (64%) remained in the same GOLD stage, while 
21 (23%) had deteriorated and 11 (12%) improved a GOLD stage. 
 
CONCLUSIONS: 
Interval follow-up of the BOLD COPD cohort revealed high mortality and variable disease 
progression, but also potential diagnostic inaccuracy of BOLD spirometry in a community survey. 
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4. Abstract 4 
 
Assessment of the accuracy of Burden of Obstructive Lung Disease (BOLD) methodology 
in estimating prevalence of COPD 
 
Brian Allwood1 Rencia Gillespie1, Mary Bateman1 Helena Olckers1, Luis Taborda-Barata2, Greg 
Calligaro1, Richard van Zyl-Smit1, Nulda Beyers3, Eric D Bateman1 
1Division of Pulmonology, Department of Medicine, University of Cape Town & UCT 
Lung Institute, 
2CICS – Health Sciences Research Centre, University of Beira Interior, Portugal 
3Desmond Tutu Centre for TB Research, 
 
BACKGROUND: 
The Burden of Obstructive Lung Disease (BOLD) methodology is used widely to estimate the 
prevalence of COPD in different communities. The accuracy of these estimates remains 
uncertain but is important for policy and planning  
 
AIMS: 
To assess the BOLD methodology for accuracy of both diagnosis and spirometry, in a local 
cohort.  
 
METHODS: 
We performed a detailed five-year follow-up of all subjects labeled COPD in the Cape Town 
BOLD study (2005), assessing for possibility of asthma and performance of the EasyOne nddTM 
handheld spirometer. 
 
RESULTS: 
Of the 196 eligible subjects, 45 (23%) had died, and 45 had either moved, declined or were 
medically excluded (e.g. dementia), 106 (54%) were included. Sixteen subjects (15%) had 
FEV1:FVC ratio ≥ 0.7 (i.e. non-obstructed) after bronchodilator. Using the lower limit of normal 
definition, a further 11 subjects (10%) were non-obstructed, 7 of whom were >70years old.  
 Using both conservative and liberal definitions, the estimated overall prevalence of 
asthma ranged between 10–18%; being 6–13% for subjects without current obstruction (n=16); 
11–19% for those with current obstruction (n=90); and 10–26% for those with both obstruction 
and bronchodilator reversibility (n=31).  
 When performed concurrently with handheld spirometry, office spirometry FEV1 differed 
by more than 150ml in 22% of subjects, and resulted in misclassification of COPD status in 17%. 
[Bland-Altman: mean diff=41ml; sd 146ml; 95%CI: -250ml: +333ml] 
Between visit variability (<1 month apart) using handheld spirometry showed a change in 
COPD classification in 11 subjects (20%), with 29% having FEV1 values differing by >150ml. 
[Bland-Altman: mean diff = 18ml; sd 220ml; 95%CI: -0.422ml : +0.458ml] 
 
CONCLUSIONS: 
The BOLD methodology likely overestimates the burden of COPD due to use of the fixed-ratio 
definition of COPD; inclusion of asthmatics and variability of prescribed handheld spirometers.  
 
